Divergent synthesis of cyclopropane-containing fragments and lead-like compounds for drug discovery by Chawner, Stephen John
 
 
 1 
 
 
Divergent Synthesis of  
Cyclopropane-Containing Fragments and 
Lead-Like Compounds for Drug Discovery 
 
 
A Thesis submitted by 
 
 
Stephen John Chawner 
 
 
In partial fulfilment of the requirement for the degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
 
Department of Chemistry 
Imperial College London 
South Kensington London 
SW7 2AZ  
United Kingdom                                                                                  2017  
 
 
 2 
 
 
 
 
 
 
 
 
I confirm that the work presented within this document is my own. Clear 
acknowledgement has been made when referring to the work of others, or where 
help has been received. 
 
 
 
 
 
 
 
 
 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers 
are free to copy, distribute or transmit the thesis on the condition that they attribute it, 
that they do not use it for commercial purposes and that they do not alter, transform 
or build upon it. For any reuse or redistribution, researchers must make clear to 
others the licence terms of this work.
  3 
Acknowledgements 
Firstly, I would like to thank Imperial College London and Eli Lilly whose combined 
generosity through a CASE award made my PhD financially possible. 
 
I would like to thank my academic supervisor Dr James Bull for providing me with the 
opportunity to undertake a PhD in his group. I am grateful for the chemistry knowledge 
that he has shared, his encouragement to present at conferences and the freedom to 
follow new project ideas. 
 
In addition to funding, the CASE award provided me with the opportunity to collaborate 
with Dr Manuel Cases-Thomas at Erl Wood. Manuel was a constant source of 
enthusiasm throughout my PhD and has been a joy to work with. 
 
I would like to thank all the Bull, Armstrong and Bures groups, past and present, with 
whom I have had the pleasure to work alongside in the Heilbron lab. In particular, I 
would like to thank Dr Tom Boultwood for his early and valuable training on glovebox 
usage, Dr Owen Davis for the countless discussions on the applications and benefits 
of cyclopropanes and oxetanes within medicinal chemistry, and Dr Dominic Affron for 
sharing his extensive theoretical and practical chemistry knowledge, as well as his 
experiences with Swern reactions. In addition, I would like to thank Owen, Dom, Ethan, 
Rosie and Sahra for reading through sections of this thesis and providing valuable 
feedback. 
 
Thank you to all the scientists with whom I worked with whilst on my industrial 
placement at Erl Wood; you made my time there a fantastic experience. In addition, I 
would particularly like to thank the Eli Lilly HPLC and crystallography teams whose 
efforts are very much appreciated. 
 
I am grateful to the NMR staff at Imperial College London as well as the mass 
spectrometry staff at both Imperial College London and the EPSRC mass 
spectrometry centre. 
 
  4 
I would like to thank Lisa for being supportive over the last few years and putting up 
with all the chemistry talk. 
 
I want to thank my late grandparents James and Joan, for helping me along the 
scientific path from an early age. Finally, I wish to express my utmost gratitude to my 
parents, John and Ann, for all their love and encouragement throughout the years. 
Their support helped give me the strength to overcome the challenges that stood 
between where I was and where I wanted to be. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5 
Abstract 
The cyclopropane ring is key to a large number of medicinally-relevant compounds 
that possess a broad spectrum of biological activities. This thesis details the 
preparation of novel bifunctional cyclopropanes through a divergent functionalisation 
approach utilising two readily accessible cyclopropyl-scaffolds (Figure 1). The 
cyclopropanes generated sampled new areas of chemical space whilst being suitable  
3-dimensional fragments and lead-like compounds for drug discovery. 
 
 
Figure 1: A) General concept for a bifunctional cyclopropyl-scaffold able to undergo divergent functionalisation 
on functional handles A and B. B) Synthesis of bifunctional cyclopropyl-scaffolds 
 
A novel CoII-catalysed cyclopropanation generates two diastereoisomeric bifunctional 
cyclopropyl-scaffolds from commercially available reagents in an excellent yield and 
can be conducted on multi-gram scales. Asymmetric cyclopropanation has been 
explored with max ee = 73%. Divergent functionalisation of the ester was explored, 
utilising hydrolysis, reduction and amidation reactions to create a variety of 
functionalised cyclopropyl sulfides. The sulfide synthetic handle was oxidised to give 
the corresponding sulfoxides or sulfone selectively. Sulfoxide–magnesium exchange 
was explored and the cyclopropyl-organometallic species generated was trapped with 
a variety of electrophiles to create a diverse range of cyclopropane-containing 
products. The cyclopropyl-organometallic species was also utilised in Negishi  
cross-coupling, proving to be a versatile method to attach an aromatic or 
heteroaromatic directly onto the cyclopropane ring. 
 
 
 
Scheme 1: Divergent functionalisation of the trans-substituted cyclopropyl-scaffold via sulfoxide–magnesium 
exchange followed by either electrophilic trapping or cross-coupling. The same methodology has been used to 
functionalise the cis-substituted cyclopropyl scaffold too. 
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a) Glossary of Abbreviations, Acronyms and Symbols 
2-MeTHF       2-methyl tetrahydrofuran [𝛼]$%& specific rotation measured at 20 °C using irradiation with 
a wavelength equal to the sodium D-line (589 nm) 
D          reflux 
µmol         micromole(s) 
µM         micromolar 
µW         microwave irradiation 
®          Trademark registered with the USPTO 
™          Trademark 
nmax         infrared absorption maximum 
Å          angstrom 
Ac         acetyl group 
ADMET       absorption, distribution, metabolism, excretion, toxicology 
AlogP        atomic logP 
APCI        atmospheric pressure chemical ionisation 
aq          aqueous 
Ar          aromatic 
ASAP        atmospheric solids analysis probe 
Atm         atmosphere(s) 
Boc         t-butyloxycarbonyl 
BOX         bisoxazoline 
Bn         benzyl 
Bu         butyl 
Bz         benzoyl 
cat         catalyst 
Cb         N,N-diisopropylcarbamoyl 
clogP        compound logP 
CI          chemical ionisation 
COSY        homonuclear correlation spectroscopy 
d          doublet 
Da         Dalton 
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dba         dibenzylideneacetone 
DEPT-135      distortionless enhancement of polarisation transfer 
DIBAL        diisobutylaluminium hydride 
DIPEA        N,N-diisopropylethylamine 
DMF         N,N-dimethylformamide 
DMSO        dimethyl sulfoxide 
dr          diastereomeric ratio 
E          generic trapped electrophile 
EC50         half maximal effective concentration 
ee         enantiomeric excess 
EDA         ethyl diazoacetate 
EI          electron impact ionisation 
equiv        equivalent(s) 
ES         electrospray ionisation 
Et          ethyl 
EWG        electron-withdrawing group 
FBDD        fragment-based drug discovery 
Fsp3 The fraction of carbons in a molecule possessing 
sp3-hybridisation 
FTMS        Fourier transform mass spectrometry 
gem         geminal 
h          hour(s) 
HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo 
[4,5-b]pyridinium 3-oxid hexafluorophosphate 	 
HBA hydrogen bond acceptor 
HBD hydrogen bond donor 
hERG human ether-a-go-go-related gene 
HMPA hexamethylphosphoramide 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
HTS high throughput screening 
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Hz Hertz 
IR infrared 
i iso 
IC50 half maximal inhibitory concentration 
IP intellectual property 
J coupling constant 
Ki inhibitory constant 
L ligand 
LCMS liquid chromatography–mass spectrometry 
LDA lithium diisopropylamide 
LiTMP lithium 2,2,6,6-tetramethylpiperidine 
LOS lead-oriented synthesis 
m multiplet 
m meta 
M molar or generic transition metal 
MALDI matrix-assisted laser desorption/ionisation 
Me methyl 
min minute(s) 
mmol millimole(s) 
mM millimolar 
mp melting point 
MS molecular sieves 
MW molecular weight 
NCS         N-chloro succinimide 
nm         nanometre 
nM         nanomolar 
NMI         N-methylimidazole 
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NMR        nuclear magnetic resonance 
NSI         nanospray ionisation 
o          ortho 
p          para 
Ph         phenyl 
pKaH        acidity constant of the corresponding conjugate acid 
PMI         principal moment of inertia 
ppm         part(s) per million 
Pr          propyl 
PSA         polar surface area 
PyBOX        pyridine-bisoxazoline 
PVS         phenyl vinyl sulfide 
py          pyridine 
quat         quaternary carbon 
R          generic alkyl group 
R&D         research and development 
Rf          retention factor 
RL         comparatively large R group 
RM         generic organometallic species 
RS         comparatively small R group 
rt          room temperature (approximately 22 °C) 
s          singlet or second(s) 
SFC         supercritical fluid chromatography 
SOMO        singularly-occupied molecular orbital 
t          triplet 
t1/2         half-life 
t-BDA        tert-butyl diazoacetate 
TBME        tert-butyl methyl ether 
t, tert        tertiary 
THF         tetrahydrofuran 
TLC         thin layer chromatography 
ToF         time-of-flight 
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b) Stereochemical Notation 
Throughout this thesis, representations of stereochemistry are consistent with the 
convention proposed by Maehr,1 in which solid and broken bold lines are used to 
denote relative configuration, and solid and broken wedges represent absolute 
configuration (Figure 2). Where relative configuration is depicted the compound has 
been prepared as a racemate, whereas when absolute configuration is shown a 
compound is enantioenriched or has been prepared as a single enantiomer. 
 
 
 
 
 
When representing absolute stereochemistry, broken wedges are used with the 
convention of the narrow end of the wedge originating from the stereogenic centre, 
with the wedge widening with increasing distance from the stereogenic centre 
(Figure 3). 
 
 
Figure 3: The use of wedges to illustrate absolute stereochemistry 
 
 
 
 
 
 
 
 
 
 
 
CO2Et
SO2Ph
=
H
EtO2C
H
SO2Ph
relative
configuration
absolute
configuration
Figure 2: Depiction of relative and absolute configuration used within this thesis 
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1. Introduction 
1.1. Overview of the Drug Discovery Process 
The drug discovery process is the route by which potential new medicines are 
discovered and developed. The process begins with identification of the biological 
target, followed by hit identification and optimisation, preclinical (in vitro) trials, clinical 
(in vivo) trials and finally drug launch. Producing a marketable drug from an initial hit 
often takes 10–15 years at a cost estimated around US$2.6 billion per successful 
compound.2 Figure 4 shows the 10 stages of drug discovery and development, from 
identification of the biological target through to a successful drug reaching the market.  
 
 
 
 
 
 
 
 
Figure 4: The 10 stages of drug discovery and development 
 
Target identification – Identification and validation of the biological target and its 
drugability. 
Hit identification – Identification of compounds that bind to the biological target and 
which act as the starting points for optimisation. 
Lead generation – Focusses the ‘hits’ to one or a small number of lead compounds. 
Lead optimisation – Optimises the ‘lead’ compound(s) to generate a drug-like 
compound which displays desirable properties and physiological behaviours. 
Target 
identification
Hit 
identification
Lead 
identification
Lead 
optimisation
Preclinical 
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Preclinical trials – May vary depending on the compound, but generally compounds 
undergo pharmacodynamic, pharmacokinetic and ADMET testing. Typically, both 
in vitro and in vivo testing will also be undertaken. These tests allow dosage estimation 
and compound formulation optimisation, in addition to predicting drug-related toxicity.  
Phase I – A small-scale trial in human volunteers who are generally healthy. Results 
give information on dosage, pharmacokinetic parameters and toxicology in humans. 
Phase II – A small/medium-scale trial in human volunteers to determine drug efficacy 
and side-effects. 
Phase III – A large-scale trial aimed at confirming drug safety and efficacy in large 
patient populations. 
Submission – Submission to regulatory review prior to the drug reaching the market. 
Marketing – Matters including advertising and product packaging are addressed to 
maximise sales, with the aim of achieving profit to cover the costs of the total drug 
discovery and development process, and to keep the company viable. 
 
1.2. Attrition in Drug Discovery 
The continued existence of the drug discovery industry in its current form is under very 
real threat.3,4 This is a result of key patent expirations, legal entanglements and 
declining patient confidence over concerns in transparency and integrity all resulting 
in ever-diminishing revenues, combined with increasing regulatory requirements and 
low research and development efficiency which are increasing drug development 
costs.3,4  
 
The low R&D efficiency observed stems from the large number of compounds that 
enter drug development for only one to emerge as a drug. Attrition is the term used for 
this decline in the number of compounds during progression through the drug 
discovery process. Attrition is extremely costly to pharmaceutical companies as vast 
amounts of time and resources are expended on compounds that are not going to 
result in a marketable drug at the end of the process.5 Figure 5 shows the attrition 
rates for various drug discovery and development stages, according to data obtained 
from a recent review of pharmaceutical R&D productivity by Paul and co-workers.5 
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The stages with the highest levels of attrition are the preclinical trials and clinical trial 
phases I, II and III with 31%, 46%, 66% and 30% attrition rates respectively. 
 
 
Figure 5: Attrition rates for the stages of drug discovery and development 
 
The same review showed the cost per work in progress for each phase, which is 
illustrated in Figure 6. It is clear to see that phase III clinical trials are by far the most 
expensive per work in progress, followed by phase II clinical trials. From a financial 
perspective, the stages that are the most expensive per work in progress should 
possess the lowest attrition rates. To achieve this, the reasons for late-stage attrition 
need to be identified and rectified at an earlier stage in the drug discovery process. 
 
Figure 6: The cost per work in progress per phase for the stages of drug discovery and drug development 
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Combining the data from Figures 5 and 6 generates Figure 7, which shows the phase 
cost (uncapitalised) per launch for each phase of the drug discovery and development 
process. 
 
 
Figure 7: The phase costs (uncapitalised) per launch for the phases of drug discovery and development 
 
Figure 7 shows that the four most expensive stages of drug discovery per launch are 
phase III clinical trials, phase II clinical trials, lead optimisation and phase I clinical 
trials. The major reasons for the three phases of clinical trials being so expensive are 
the high cost per work in progress and the high attrition rates, whereas the primary 
reason for lead optimisation being an expensive phase overall is the large number of 
compounds required to generate the optimised molecule. This shows that the drug 
discovery process would obtain enormous financial benefits from earlier optimisation 
practices which reduce attrition during late-stage clinical trials. 
 
Kola and Landis identified the most prominent causes of attrition during 1991 and 
2000, and that the impact of these factors has changed over that time period.4 In 1991 
the largest causes of attrition were poor pharmacokinetic behaviour, insufficient 
bioavailability and insufficient efficacy. By 2000, poor pharmacokinetic behaviour and 
insufficient bioavailability accounted for less than 10%, with the major contributors now 
being toxicological and clinical safety issues and a lack of efficacy. More recently, an 
analysis of combined data on the attrition of drug candidates from AstraZeneca, 
Eli Lilly and Company, GlaxoSmithKline and Pfizer determined the major reasons for 
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attrition during both halves of the 2000–2010 decade.3 Between 2000–2005 the most 
significant causes were non-clinical toxicity (40%), clinical safety (13%), rationalisation 
of company portfolio (13%) and efficacy (11%). Rationalisation of company portfolio 
could occur if the disease area no longer appears commercially viable or a mechanism 
being shown to have efficacy or safety issues. Between 2006–2010 the primary 
causes were very similar, being non-clinical toxicity (40%), rationalisation of company 
portfolio (32%), and clinical safety (8%). This further indicates that the current lead 
causes of attrition in the drug discovery industry are non-clinical toxicology, clinical 
safety and efficacy. By separating the data into the corresponding drug discovery 
phases it was found that non-clinical toxicology was most prominent in preclinical trial 
attrition, clinical safety issues were most prominent in phase I attrition and a lack of 
efficacy was most prominent in phase II attrition. There were not enough data points 
in this publication to obtain statistically relevant information on attrition in phase III. 
 
In an effort to reduce attrition within drug discovery the causes of non-clinical toxicity 
were investigated. To do this, correlations between toxicological success and 
compound physicochemical properties were studied. To illustrate and understand the 
effects of various physicochemical properties, the concept of chemical space can be 
employed. 
 
1.3. Introduction to Chemical Space as a Tool for Medicinal Chemists 
Chemical space is a multi-dimensional concept that serves medicinal chemists as a 
kind of map to illustrate the distribution of molecules and their properties.6,7 Each 
different molecule possesses a variety of molecular properties (e.g. molecular weight, 
lipophilicity, number of hydrogen bond donors, number of hydrogen bond acceptors, 
Fsp3) which are termed molecular descriptors. To visualise a compound’s location in 
chemical space, it’s molecular descriptors are quantified, assigned a dimension and 
plotted on the resulting multi-dimensional graph, generating a data point unique to that 
molecule, called its property space. Due to the difficulty in expressing a graph with 
> 2 dimensions, chemical space representations are often simplified to 2 dimensional 
plots illustrating lipophilicity vs. molecular weight, with other molecular descriptors 
sometimes being displayed alongside.  The multi-dimensional chemical space can 
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also be mapped into two-dimensional plot space through dimensionality reduction 
techniques such as principal component analysis (PCA)8 and self-organising maps 
(SOM)9. 
 
Not all chemical space is useful to medicinal chemists.6 Out of the vast possibilities, 
only a small proportion of chemical space can provide medicinally-relevant 
molecules.6 By plotting the property space data points for known successful 
biologically active molecules, the regions of medicinally-relevant chemical space can 
be uncovered, and in doing so desirable molecular properties can be determined.6 
Likewise, the property space data points for compounds that have failed to pass 
successfully through drug development can be plotted, aiming to correlate the value 
of a particular molecular property with the observed drug developmental failure.6 This 
could identify medicinally-undesirable regions of chemical space and therefore 
medicinally-undesirable molecular properties, which should be avoided to improve 
compound success rates within the pharmaceutical industry. Through such 
investigations, a wide number of physicochemical properties have been implicated in 
toxicology-induced attrition. 
 
1.4. Molecular Properties for Drug-Like Compounds 
Small molecule drugs exert their biological action by binding to specific functionality of 
the target in such a manner as to modulate biochemical processes to elicit the desired 
physiological response. The magnitude and specificity of binding depends on the 
complementarity between the drug molecule and its target in terms of shape, chemical 
functionality and polarity. Shape complementarity maximises the interactions that can 
be achieved between the drug and the desired biological target.  The incorporation of 
complementary chemical functionality offers directional and specific modes of binding, 
achievable through the formation of hydrogen bonds and p-p stacking interactions 
between the drug and the biological target. Binding potency can also be enhanced 
through non-directional interactions such as polarity-based hydrophobic attraction and 
Van der Waals interactions, though over-reliance on these can be detrimental to 
binding selectivity. 
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Whilst developing a drug to possess key interactions that produce both potency and 
selectivity, the overall properties of the molecule must not be overlooked. The 
physicochemical properties of a molecule can have a drastic effect on the probability 
of successful passage through drug development, with the following physicochemical 
properties being implicated in toxicology-induced attrition. 
 
1.4.1. Molecular Weight (MW) 
Excessive MW is widely regarded as one of the most significant causes of off-target 
toxicity within drug discovery. An excessive MW has also been associated with high 
plasma protein binding, which reduces the amount of compound available to elicit the 
desired pharmacological response.10 Similarly, on average as MW increases, so does 
the amount of compound binding to brain tissue.10 The effect of MW on hERG inhibition 
has also been investigated, through the analysis of 35200 molecules screened in a 
hERG inhibition assay.10 Inhibition of the hERG potassium ion channel has the 
possibility of QT prolongation which can result in fatal cardiac arrhythmia. It was found 
that hERG inhibition steadily increased as MW increased.10  
 
In addition, on average as the MW of a compound increases, it’s biological solubility 
decreases.10,11,12,13,14 For an orally administered drug, a lower solubility reduces the 
amount of drug available to permeate the gastrointestinal membrane and enter 
systemic circulation. Excessive MW also has a detrimental effect on cell membrane 
permeation.10 CNS penetration is also significantly reduced by increasing MW, with an 
analysis of 3059 diverse molecules clearly demonstrating that molecules with 
MW < 300 Da on average having a 220´ higher  brain/blood ratio than compounds with 
MW > 700 Da.10  
 
With such significant problems associated with compounds that possess excessive 
MW there must be an explanation as to why so many compounds fall into this known 
region of chemical space. Such an over-representation of high MW compounds in both 
drug discovery screening collections and the drug development process is largely due 
to a drive towards increased potency.15 One of the easiest ways potency can be 
gained is by increasing the number of non-specific interactions made between the 
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compound and the biological target. This is frequently achieved through the addition 
of lipophilic groups, and was termed molecular obesity by Hann in a review on the 
matter.15 This produces the desired potency increase whilst concomitantly increasing 
MW and lipophilicity. 
 
1.4.2. Lipophilicity 
Lipophilicity refers to the ability of a compound to dissolve in non-polar media, and is 
often measured by logP, which is the logarithm of the partition coefficient of the 
compound between water and n-octanol. Several computational methods exist for 
estimating lipophilicity values for organic compounds.16 Among these, the clogP and 
AlogP methods are the most widely used.16 These refer to compound logP (calculated 
using experimental values for smaller compounds and modelling using regression 
techniques) and atomic logP (addition of individual atomic logP contributions),16 
respectively. The use of logP should only be used for compounds that are neutral at 
physiological pH. For compounds that contain ionisable functionalities that are likely 
to be charged at physiological pH, the term logD should be used where the aqueous 
phase is adjusted to a specific pH through the addition of a buffer. 
 
Excessive lipophilicity has a major impact on the behaviour of compounds in the body, 
being linked to decreased biological solubility, increased plasma protein binding, 
increased brain protein binding and increased cytochrome P450 enzyme inhibition.10 
Many of these issues are a result of non-specific interactions with undesired biological 
species. This is because logP (or logD) essentially represents the key events of 
molecular desolvation from aqueous phases to cell membranes and protein binding 
sites, which are generally hydrophobic in nature.17 A compound that possesses a high 
logP (or logD) may readily pass through cell membranes due to a low energy penalty 
to remove waters of hydration from the compound, hydrophobic interactions between 
the compound and the aqueous environment, and lipophilic interactions between the 
compound and the lipophilic cell membrane, but it may also bind to a variety of protein 
binding sites through the same non-specific driving forces. Analysis of 2133 drugs and 
reference compounds from the Cerep Bioprint database has shown that biological 
promiscuity increased dramatically as compound clogP exceeded 3.17 Further 
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evidence came from a study of 245 preclinical Pfizer compounds which also showed 
that compounds with increased lipophilicity had a greater chance of toxicity due to 
off-target binding.18,19 Another set of proteins that are routinely screened are the 
cytochrome P450 isozymes, as they play a critical role in drug metabolism. Inhibition 
of these enzymes can lead to potentially dangerous drug-drug interactions. A screen 
of 7098 compounds against a subset of P450 isozymes showed on average, 
compounds possessing a clogP > 5 exhibited an almost 8-fold greater promiscuity 
than compounds possessing a clogP » 0.19 
 
1.4.3. Polar Surface Area (PSA) 
The polar surface area of a compound is the surface area in Å2 that is occupied by 
atoms of polar functionality. The importance of PSA in drug discovery has been 
highlighted by the analysis of in vivo studies involving 245 Pfizer preclinical 
compounds.18 It showed the effect lipophilicity and PSA can have on the probability of 
a toxicological outcome, which gave rise to the Pfizer 3/75 rule.18 On average, 
compounds with a higher PSA were found to be less likely to result in a toxicological 
event. Desirable PSA ranges do however vary with the biological target. A PSA of 
generally less than 60–70 Å2 is appropriate for CNS-active compounds due to higher 
PSA-possessing compounds struggling to permeate the blood-brain barrier.20 
 
1.4.4. Fsp3 
The term Fsp3 is the number of sp3 hybridised carbon atoms/total number of carbon 
atoms in a molecule. It is frequently used as a measure of molecular complexity and 
indicative of a molecule’s 3-dimensionality.21 Low Fsp3 has been linked to 
promiscuity.19 Increasing Fsp3 was also found to result in a significant increase in 
solubility.21 On average, as compounds progress from the discovery phases to final 
drugs, their average Fsp3 increases by 31%.21 This illustrates that compounds with a 
higher Fsp3 are more successful in drug development, and that ‘hits’ emerging from 
drug discovery possess an Fsp3 that is, on average, significantly below optimal for 
further progression.21 
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1.4.5. Aromatic Ring Count 
The number of aromatic rings that a compound possesses has been linked to the 
success of that compound in the drug development process.22 A review of the impact 
of aromatic ring count on a variety of parameters including serum albumin binding and 
hERG inhibition showed that the fewer aromatic rings a drug candidate possessed, 
the more likely it was to successfully progress through future stages of development.22 
 
1.4.6. Undesirable Functional Groups 
Over time a growing number of functional groups have been recognised as being of 
concern within medicinal chemistry, unless such functionality is required by the 
compound’s mode of action. One such class are functionalities that are highly 
electrophilic, due to the potential for reactivity with biological nucleophiles such as 
DNA or proteins, or undergo hydrolysis by water to yield undesired products. Other 
medicinally-undesirable classes are functionalities that are known toxicophores, are 
redox-active, strongly coordinate metal ions, are aggregators or frequently generate 
false positives in screening.23,24 
 
These physicochemical properties have a significant effect on how likely a compound 
is to proceed through future drug development stages. The next section details how 
these studies have resulted in the development of physicochemical guidelines for use 
within drug discovery and development. 
 
1.5. Physicochemical Guidelines for Drug-Like Compounds 
Despite numerous physicochemical property values/ranges for small molecule drugs 
being linked to an increased probability of toxicological failure, data suggests that 
these warnings may not have been heeded yet. Various recent analyses (published 
between 2013 and 2015) of small molecules in drug discovery libraries revealed that 
they contained large proportions of compounds that deviated from such advice.3,25,26 
For example, the issue of excessive compound size and lipophilicity is currently a 
widespread topic within the drug discovery industry.15,17,27 This is because whilst 
excessive size and lipophilicity are linked to several negative effects, adding lipophilic 
groups onto a compound is generally linked to increased potency and cell 
  24 
permeability.15,28 This results in the drive towards increased potency yielding 
excessively large and lipophilic compounds. This appears to be a growing issue, with 
the size of oral drug compounds having increased dramatically over the last 
40 years.17,27 
 
This implies that a greater awareness is required towards the effect of 
physicochemical properties on the probability of drug development success. To this 
end, it would be beneficial to drug discovery efforts for knowledge on the subject to be 
compiled and made easily accessible, to be used to reduce toxicology-based attrition. 
 
In 1997 Lipinski and co-workers published a “Rule of 5” for drug discovery that offered 
guidelines for physicochemical properties that could improve the probability of oral 
bioavailability.11 The guidelines were based on a study that compared the 
physicochemical properties of two libraries of compounds; one contained the > 50,000 
drugs and pharmacologically-active compounds present in the World Drug Index 
(WDI), and the other was a subset the WDI that had progressed to Phase II clinical 
trials. The differences in the data sets resulted in the following guidelines being 
developed to direct compounds towards oral bioavailability, by stating that poor 
absorption or permeation are more likely when: 
MW > 500 Da 
clogP > 5 
HBD > 5 
HBA > 10  
The “Rule of 5” guide has been widely used to analyse existing compounds as well as 
guide ongoing drug discovery projects towards compounds that are statistically more 
likely to be successful. Whilst hugely successful, the “Rule of 5” has a number of 
limitations and exceptions. The “Rule of 5” was designed for orally administered drugs, 
and so is not applicable for compounds administered through alternative means (e.g. 
intravenously, inhalation). Also, many successful drugs possess physicochemical 
properties that lie outside the “Rule of 5” area.29 
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The “Rule of 5” guidelines were aimed at compounds that were of small molecule 
drug-like size: approximately 400–500 Da. As a result, the idea was particularly 
applicable towards the screening of compound libraries that produced ‘hits’ of small 
molecule drug-like size. However, there are prominent compound library construction 
approaches that acknowledge the benefits of screening smaller compounds, namely 
Lead-Oriented Synthesis (LOS) and Fragment-Based Drug Discovery (FBDD). These 
approaches generate compounds that are smaller than typical drug-like compounds, 
and so the “Rule of 5” is not applicable for the hits produced by these techniques. 
 
1.6. Compound Library Construction Approaches  
Once a biological target has been identified and validated as being druggable, the next 
step is to identify compounds that bind to the biological target and elicit the desired 
biological response. These initial compounds are termed ‘hits’ and are frequently 
identified using high throughput screening (HTS). HTS is a drug discovery technique 
that obtains ‘hits’ through the automated assaying of a large compound library in an 
in vitro assay, and is commonly defined as achieving a screening rate of greater than 
10,000 compounds per week.30,31,32,33 Such high screening rates are commonly 
facilitated by the use of 96-, 384- and 1536-well plates.30,31,32,33 The following sections 
detail some key approaches used to generate libraries of compounds for use in 
biological screening. 
 
1.6.1. Combinatorial Chemistry 
Combinatorial chemistry can be defined as the systematic and repetitive connection 
of various building blocks through covalent bonds to generate a large library of diverse 
molecules.34 Initially, this approach generated huge ‘random’ libraries which primarily 
comprised of large and complex compounds, akin to small molecule drugs or natural 
products (Figure 8).31 The physicochemical properties of such resulting compounds 
were frequently undesirable due to overloaded molecular complexity.31 As a result, 
there has been a clear trend towards the generation of smaller libraries containing 
more focussed “drug-like” subsets.31 
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Whilst not exclusive to libraries resulting from combinatorial chemistry, the sampling 
of compounds comparable in size to small molecule drugs generates an issue in drug 
discovery. Utilising compounds of drug-like size and complexity results in an 
enormous amount of potential chemical space, with estimations ranging 1033–1063 
potential drug-like compounds.35,36 This means that large libraries (often around 106) 
are required, but even then only a tiny percentage of drug-like chemical space is being 
sampled.  
 
An advantage of using such compounds is that ‘hits’ can be identified with relatively 
insensitive equipment.37 Due to their size and complexity, there are usually many ways 
in which the compounds can interact with the biological target, resulting in ‘hits’ 
frequently possessing µM potency which are easily detectible. These hits, whilst 
moderately potent, often bind inefficiently to the biological target. To measure and 
compare binding efficiency, the metric ligand efficiency was developed.38,39 Ligand 
efficiency was defined as the average binding energy per non-hydrogen atom.37,38,39 
 
 
Figure 8: Screening of small molecule drug-like compounds against a biological target 
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1.6.2. Lead-Oriented Synthesis (LOS) 
The amount of potential chemical space available to a library of compounds increases 
dramatically as the size and complexity of the compounds within that library increases, 
and it has been estimated40 that for every heavy atom added the number of 
biologically-relevant potential structures increases by a factor of 10. Such a 
relationship means that an assay that utilises smaller, less complex compounds 
requires a smaller compound library to sample a given fraction of chemical space. An 
alternative way to view it is that for a set library size, the smaller the compounds are 
in the library, the larger the fraction of chemical space the library samples. With this 
principle in mind, lead-oriented synthesis utilises compounds that are smaller and less 
complex than drug-like compounds, with a MW generally 200–350 Da (14–26 heavy 
atoms).40 These molecules are termed lead-like compounds.40 Using the previously 
mentioned heavy atom estimation,40 there are approximately 107 fewer potential 
biologically-relevant molecules with a mass ~300 Da (lead-like) than ~400 Da 
(drug-like). Lead-like compounds therefore sample chemical space more efficiently 
than drug-like compounds. 
 
Lead-oriented synthesis (LOS) generates libraries of lead-like compounds which are 
then screened against a biological target to obtain ‘hits’ which elicit the desired 
physiological response (Figure 9). Typical optimisation within drug development 
observes a relationship whereby an increase in MW generally produces a concomitant 
increase in lipophilicity, as illustrated by the diagonal arrow in Figure 10. Therefore, a 
region of lead-like chemical space was defined by Churcher and co-workers, which 
was located such that compounds within it were predisposed to generate molecules 
within desirable drug-like chemical space through typical optimisation (Figure 10).40 In 
addition to this, Churcher and co-workers developed guidelines which stated that 
lead-like compounds should ideally possess:40 
•   14 ≤ heavy atoms ≤ 26 (MW = 200–350 Da) 
•   –1 ≤ clogP ≤ 3 
•   Chemically reactive, electrophilic or redox active groups removed 
•   Favour molecules with lower degree of aromatic character 
•   Favour molecules with more 3-dimensional shape 
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These guidelines help ensure that the lead-like compounds entering biological 
screening possess desirable molecular properties to maximise the probability of 
successful drug development. 
 
 
Figure 9: Drug discovery through screening of lead-like compounds against a biological target 
 
 
Figure 10: The regions of desirable lead-like and drug-like chemical space as defined by Churcher and 
co-workers40 
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Hits found through screening lead-like compounds are likely to be less potent but 
possess greater ligand efficiency than hits obtained from screening drug-like 
compounds. The lower potency of leads from LOS means that more sensitive 
detecting equipment may be required. A current challenge for LOS is the limited 
methodology to synthesise small, polar compounds, particularly ones which possess 
a variety of functionalities for use as either potential pharmacophores or for further 
derivatisation.40 
 
1.6.3. Fragment-Based Drug Discovery (FBDD) 
Fragment-based drug discovery uses low MW compounds (MW = 150–300 Da, 
< 20 heavy atoms) called fragments to probe for binding interactions with a biological 
target (Figure 11). Due to their low molecular weight, fragments sample chemical 
space even more efficiently than lead-like compounds. Calculations into the size of 
fragment chemical space have been conducted by the Reymond group.41,42 Through 
systematically and computationally enumerating all possible molecules containing up 
to 17 heavy atoms, just over 16.6 ´ 1010 possibilities were calculated. Whilst this 
number may appear very large, it is a miniscule fraction of the 1033–1063 estimated 
possible drug-like compounds.35,36 Fragments possess a size that benefits from being 
small enough  that a library can sample chemical space efficiently, whilst being large 
enough to contain enough molecular complexity to form complementary, specific 
interactions with a biological target. Given that an increase in MW generally produces 
a concomitant increase in lipophilicity during drug development, fragment-like 
chemical space is located so that compounds within it are predisposed to generate 
molecules that lie within desirable lead-like and drug-like chemical space through 
typical optimisation (Figure 12). 
 
The smaller size of fragments (relative to lead-like and drug-like compounds) means 
that they are generally able to form fewer interactions with the biological target, leading 
to lower binding affinities. Millimolar or high micromolar affinity is common and 
therefore higher assay sensitivity is required for FBDD.23 Fragment binding is usually 
detected through X-ray crystallography, surface plasmon resonance and NMR 
spectroscopy techniques. Despite their relatively weak binding potencies, ligand 
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efficiencies of fragment hits are generally higher than those of lead-like or drug-like 
compound hits.  
 
 
Figure 11: Screening fragments against a biological target and optimisation of the ‘hits’ 
 
 
Figure 12: Typical regions of chemical space for fragment, lead-like and drug-like compounds as defined by 
Churcher and co-workers40 
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activity or further elaboration. The limited methodology available which grants access 
to these compounds restricts FBDD.23,43 
 
Fragment ‘hits’ can be optimised by growing one hit in a logical manner, or fragment 
linking can be utilised if two or more hits have been found to bind in proximal sites of 
the biological target. 
 
To help ensure that fragment ‘hits’ possessed suitable physicochemical properties to 
be optimised into a desirable drug-like compound, in 2003 Astex developed 
physicochemical property guidelines for fragments.44 These guidelines stated that 
fragments should ideally possess: 
•   MW ≤ 300 Da 
•   clogP ≤ 3 
•   HBD ≤ 3 
•   HBA ≤ 3 
•   Number of rotatable bonds ≤ 3 
•   Polar surface area (PSA) ≤ 60 Å2 
 
This was elaborated 13 years later when Astex published an updated guide to  
fragment properties, based on the physicochemical properties of the Astex 
collection:23 
•   140 ≤ MW ≤ 230 Da 
•   0 ≤ clogP ≤ 2 
•   0 ≤ freely rotatable bonds ≤ 3 
•   0 ≤ number of chiral centres ≤ 2 
•   Synthetic tractability. 50–100 mg and ≤ 4 synthetic steps from commercially 
available reagents 
•   3-Dimensional shape 
•   Multiple synthetically accessible vectors for 3-dimensional fragment growth 
 
This latter publication highlighted some current challenges in the design and synthesis 
of fragments.23 The first was that it is often difficult to synthesise and isolate fragments 
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that possess high aqueous solubility and polar functionality, which are desirable 
characteristics for fragments. There are also insufficient synthetic methods compatible 
with multiple heteroatoms and polar hydrogen-bonding functionality. Finally, it was 
noted that there is also a lack of methods that allow the incorporation of 3-dimensional 
architecture.23 These conclusions indicate that there needs to be significant 
methodology development aimed at synthesising small, polar,  
3-dimensional compounds suitable for FBDD. The conclusions drawn by Astex 
employees echoed those from Goldberg and co-workers at AstraZeneca, highlighting 
that the challenges for FBDD are widely recognised and the solutions widely sought.25 
 
Over the past 20 years FBDD has grown from a niche area of research to a main drug 
discovery approach and an important alternative to combinatorial techniques.45 Still 
being a relatively young approach, it is extremely encouraging that 2011 and 2016 
have seen the first FDA approvals for drugs discovered through FBDD. The first was 
PLX4720, named Zemurafenib (Zelboraf®), a selective inhibitor of oncogenic B-Raf 
kinase which displays potent antimelanoma activity (Figure 13).46 PLX4720 inhibits 
B-RafV600E with an IC50 of 13 nM, with B-RafV600E being the most frequent oncogenic 
protein kinase mutation known. In phase I clinical trials, a remarkable 81% response 
rate in metastatic melanoma was observed.47 This example exemplifies how rapidly 
FBDD can enable a program, with the drug taking just six years to reach approval. 
The second drug was ABT-199, named Venetoclax (Venclexta™), a first-in-class  
BCL-2-selective inhibitor (Figure 13).48 The BCL-2 protein was the first identified major 
apoptotic regulator and plays a key role in tumorigenesis and chemoresistance.49 The 
apoptotic process is controlled by the dynamic binding interactions of proapoptotic and 
prosurvival proteins, and shifting the balance towards the latter is a known mechanism 
by which cancer cells undermine the normal apoptosis mechanism and gain a survival 
advantage.48,49 Proteins in the B cell CLL/lymphoma 2 family are key regulators of the 
apoptotic process, with the BCL-2, BCL-XL and BCL-W proteins being examples of 
prosurvival proteins.48,49 A previous compound which ABT-199 was based upon, 
Navitoclax, selectively inhibited both BCL-2 and BCL-XL, however despite showing 
clinical efficacy in some BCL-2-dependent haematological cancers, the on-target 
BCL-XL inhibition induced thrombocytopenia (low blood platelet count) which 
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drastically limited its use.48 ABT-199 on the other hand is highly selective, with a 
Ki < 0.010 nM for BCL-2, a Ki = 48 nM for BCL-XL and a Ki = 245 nM for BCL-W. 
ABT-199 inhibits the growth of BCL-2-dependent tumours in vivo whilst having a 
negligible effect on BCL-XL proteins, sparing human platelets.48 Venclexta™ was 
granted breakthrough therapy designation, priority review, accelerated approval and 
orphan drug designation.50 
 
 
Figure 13: Structures for the 1st (Zelborafâ)46 and 2nd (Venclextaä)  approved fragment-based drugs  
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In order to achieve these objectives we aimed to utilise a cyclic scaffold which could 
be directly functionalised to create a diverse library of structurally-related compounds. 
The scaffold should possess multiple bond vectors that predisposes derivatives 
towards 3-dimensionality upon functionalisation. The cyclopropane ring has the 
potential to satisfy these criteria due to it being a low MW, conformationally rigid 
framework which may be built upon in multiple directions to give 3-dimensional 
derivatives. Furthermore, the cyclopropane ring is prevalent in medicinally-relevant, 
biologically active molecules, which will be the topic of the next section. 
 
1.7. Cyclopropanes within Drug Discovery 
The cyclopropane ring is frequently found within natural products and pharmaceutical 
compounds,51 and is the 10th most commonly observed ring in small molecule drugs.52 
These medicinally-relevant cyclopropane-containing compounds possess a wide 
range of biological activities, and are important in the treatment of a variety of diseases 
including asthma (Singulair),53,54 HIV (Efavirenz),55 diabetes (Saxagliptin),56 
depression (Tranylcypromine)57 and cancer (Trametinib)58 to name a few (Figure 14).  
 
 
Figure 14: Structures of some medicinally-important cyclopropane containing compounds. References: 
Milnacipran59, Tasimelteon60 and Ticagrelor.61 
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The cyclopropane ring provides a rigid framework for the 3-dimensional arrangement 
of substituents, allowing access to architecturally complex molecules. In addition to 
this, cyclopropane rings have found widespread use within medicinal chemistry as 
bioisosteres for a variety of functionalities. 
 
Cyclopropane rings have been incorporated as replacements for alkyl chains such as 
methyl,62 ethyl,63 gem-dimethyl64 and iso-propyl65 groups to protect metabolically labile 
positions. An example of this was produced by Meanwell and co-workers, where 
incorporation of a cyclopropane ring increased the metabolic stability of the compound 
in human liver microsomes (HLM) by over a factor of 5 whilst retaining potency 
(Figure 15A).65  
 
The cyclopropane ring can also act as an alkene bioisostere,66 to remove 
alkene-derived metabolic susceptibility whilst retaining conformational rigidity and 
similar bond vectors. Further bioisosteric potential has been demonstrated by using a 
cyclopropane ring to replace a phenyl ring, notably used to great effect in the 
development of Trametinib to reduce lipophilicity and aromatic ring count whilst 
simultaneously increasing potency (Figure 15B).67a Another relevant example is the 
use of a 1,1-disubstituted cyclopropane ring as a bioisostere for an ortho-substituted 
phenyl ring, giving a significant increase in potency (Figure 15C).67b  
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Figure 15: Use of the cyclopropane motif as a bioisostere in medicinally-relevant compounds. A) Comparison of 
bioisosteric alkyl groups in an effort to increase metabolic half-life.65 B) A section of the optimisation of 
Trametinib.67a Numbers in parentheses represent numbers of determinations. C) Use of a 1,1-disubstituted 
cyclopropane as an ortho-substituted phenyl mimic.67b 
 
For the application of cyclopropanes as structural frameworks it is important to have 
reliable methodology that allows access to a wide variety of diversely functionalised 
cyclopropanes. Similarly, for use as bioisosteres there need to be reliable methods 
that allow the ready incorporation of a cyclopropane motif as a late-stage modification. 
For both of these purposes, novel methodology that allows the synthesis and direct 
functionalisation of cyclopropanes is of considerable interest to medicinal chemists.68 
Next, some common approaches to the synthesis of functionalised cyclopropanes 
shall be discussed. 
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1.8. Common Methods to Synthesise Functionalised Cyclopropanes 
There are a number of commonly employed methods to generate functionalised 
cyclopropanes including Michael-initiated ring closure, Simmons-Smith 
cyclopropanation, carbene insertion into an alkene and cross-coupling of a 
cyclopropyl-organometallic species. 
 
1.8.1. Michael-Initiated Ring Closure (MIRC) 
MIRC is a major method of cyclopropane synthesis which proceeds by a nucleophile 
undergoing Michael addition to form an enolate which then undergoes ring closure to 
release a leaving group. Possibly the most utilised of these MIRC reactions is the 
Corey-Chaykovsky cyclopropanation which utilises sulfur-based ylides. 
 
The Corey-Chaykovsky cyclopropanation was developed in 1962 and involves a  
sulfur-based ylide that initially acts as a carbon-centred nucleophile, attacking an 
electron-deficient alkene (Scheme 2A).69 This is followed by ring closure with the 
ylide-carbon now acting as an electrophile. Due to the two-step nature of this 
approach, it is often observed that the stereochemistry of the reactant alkene is lost 
due to free C-C bond rotation in the enolate intermediate. The sulfur ylide is generally 
either dimethylsulfoxonium methylide (1) or dimethylsulfonium methylide (2). 
Dimethylsulfoxonium methylide (1) has much greater thermal stability and was found 
to preferentially undergo cyclopropanation when exposed to a,b-unsaturated carbonyl 
compounds in contrast to dimethylsulfonium methylide (2) which must be handled at 
around –10 °C and preferentially forms epoxides (Scheme 2B).69 More functionalised 
sulfur-based ylides can be utilised, producing cyclopropane products that possess 
increased functionality (Scheme 2C).70 This example also shows that non-Michael 
acceptor electrophiles can be used, providing the alkene is sufficiently 
electron-deficient.  
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Scheme 2: Utilisation of sulfur-based ylides in cyclopropanation reactions 
 
Enantioselective variations of the Corey-Chaykovsky cyclopropanation are rare, but a 
number of methods have been developed, generally utilising either a chiral sulfur ylide, 
an organocatalyst or a metal complex (Scheme 3). Tang showed that 
camphor-derived sulfur ylides can be used to obtain both high enantioselectivity and 
diastereoselectivity, yielding a variety of vinyl cyclopropanes (Scheme 3A).71,72 The 
observed selectivity was attributed to hydrogen bonding between the camphor alcohol 
and the alkene substrate.72 MacMillan developed an asymmetric organocatalytic 
cyclopropanation which utilised an iminium intermediate, activating the ylide by 
making it more electron-deficient and activating the enal substrate through a proposed 
electrostatic activation and stereodirected protocol (Scheme 3B).73 Shibasaki reported 
the use of a catalytic asymmetric La–Li3–(biphenyldiolate)3 + NaI system, that with 
20 mol% of catalyst produced bifunctional cyclopropanes in excellent yields and 
enantioselectivities (Scheme 3C).74 
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Scheme 3: Enantioselective examples of Corey-Chaykovsky cyclopropanation reactions 
 
Various other heteroatom-based ylides have also been shown to be effective 
cyclopropanating agents. Phosphorus-based ylides can be utilised towards 
cyclopropane synthesis (Scheme 4A) however they generally only give moderate 
yields, and like sulfur-based ylides their reactions generally proceed with low 
stereoselectivity.75 Arsenic-based ylides are another alternative, with Shen showing 
that excellent yields and stereoselectivities can be obtained (Scheme 4B).76 It was 
observed that the stereoselectivity of the cyclopropanation reduced when more 
electron-rich olefins were used. Tellurium-based ylides can be effective for the 
diastereoselective and enantioselective synthesis of vinyl cyclopropanes, as shown 
by Tang.77 The diastereoselectivity could be tuned by the reaction conditions such that 
two highly enantioenriched diastereoisomers, 5 and 6, could be obtained using the 
same tellurium ylide (Scheme 4C).  
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Scheme 4: MIRC reactions using phosphorous, arsenic and tellurium-based ylides 
 
Ammonium ylides have been shown to be valuable reagents for cyclopropanation 
reactions, with Gaunt developing both a stoichiometric and a catalytic “one-pot” 
ammonium ylide-based cyclopropanation utilising the tertiary amine DABCO 
(Scheme 5A).78 This included a preliminary study into a stoichiometric 
enantioselective variant, which was later developed to utilise sub-stoichiometric 
amounts of the chiral amine (Scheme 5B).79  
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Scheme 5: Ammonium ylides in cyclopropane synthesis 
 
1.8.2. Simmons-Smith Cyclopropanation 
A significant route to access cyclopropanes is through exposure of an alkene to a zinc 
carbenoid which provides a stereospecific route to the 3-membered carbocycle. This 
approach was first reported by Simmons and Smith in 1958 and it has received much 
attention since then.80 The Simmons-Smith cyclopropanation is proposed to proceed 
through a “butterfly” transition state which involves multiple bonds breaking and 
forming simultaneously (Scheme 6).81 This proposed transition state is consistent with 
the observed retention of configuration for these cyclopropanations. 
 
 
Scheme 6: Simmons-Smith cyclopropanation via proposed “butterfly” transition state 
 
The presence of a proximal hydroxyl group has been shown to greatly improve the 
yield of the cyclopropanation reaction whilst also increasing stereoselectivity by the 
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alcohol directing the zinc carbenoid to one face of the alkene preferentially 
(Scheme 7).81,82,83,84 
 
 
Scheme 7: Stereoselective cyclopropanation directed by a proximal alcohol84 
 
A modified procedure was developed by Furukawa and co-workers which involved the 
use of Et2Zn instead of zinc metal (Figure 16).85,86 This modification produced a 
homogeneous zinc carbene formation and allowed the reaction to be carried out in 
previously incompatible solvents (e.g. non-coordinating solvents).85,86 Denmark and 
co-workers have explored the reactivity of bis(halomethyl)zinc carbenoids,87 with the 
chemistry being developed further to generate enantioenriched cyclopropanes.88,89,90 
Shi and co-workers have published the synthesis and utilisation of a class of tuneable 
zinc carbenoids primarily based on zinc carboxylates.91 The zinc carbenoid derived 
from trifluoroacetic acid was particularly effective in the cyclopropanation of a broad 
range of olefins.91 Charette and co-workers developed a synthesis for a readily 
prepared iodomethylzinc phosphate carbenoid as a powerful cyclopropanation tool.92 
This approach lent itself to the incorporation of a chiral phosphate moiety, enabling 
enantioselective cyclopropanation.92 
 
 
Figure 16: A variety of zinc carbenoid cyclopropanation reagents 
 
A variety of asymmetric approaches utilising zinc carbenoids have been developed, 
making use of either chiral auxiliaries or chiral ligands. Exploiting the former, in 1991 
Charette and co-workers developed an asymmetric cyclopropanation that utilised a 
chiral non-racemic sugar auxiliary to induce asymmetry (Scheme 8).93 The desired 
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enantioenriched cyclopropane could be obtained by the removal of the auxiliary 
through a two-step procedure.  
 
 
Scheme 8: Asymmetric cyclopropanation using a zinc carbenoid and a sugar chiral auxiliary93 
 
Charette’s group also developed an enantioselective cyclopropanation procedure 
utilising an enantioenriched dioxaborolane auxiliary (Scheme 9).94 A transition state 
was proposed where the boron coordinated to the allylic alcohol, with an amide 
carbonyl directing the carbenoid to the olefin resulting in facial selectivity. However, 
the stoichiometric amount of chiral species required for a chiral auxiliary approach is 
undesirable and the development of catalytic systems utilising enantioenriched ligands 
have generally been considered more attractive. 
 
 
Scheme 9: Enantioselective Simmons-Smith cyclopropanation using an enantioenriched dioxaborolane ligand94 
 
The first catalytic enantioselective Simmons-Smith cyclopropanation of an allylic 
alcohol was achieved by the Kobayashi group, who used a chiral, non-racemic 
disulfonamide-based Lewis-acid catalyst (Scheme 10).95 The initial publication 
showed that while the approach was successful in generating enantioenriched 
cyclopropanes, the yields and ee’s varied significantly with the structure of the olefin. 
Denmark optimised the system further, showing that reaction set-up was critical, 
resulting in conditions that were less sensitive to the reactant olefin structure.88,89,90 
O
OBn
BnO
BnO
OH
O
Ph
Et2Zn, CH2I2
toluene
O
OBn
BnO
BnO
OH
O
Ph
HO
Ph
H
H
1. Tf2O, pyridine
2. pyridine, DMF, H2O
>97% yield
dr = 130:1
87% yield
(over 2 steps)
98% ee
Ph
CH3
OH Ph
CH3
OH
O
B
O
O
NMe2
O
Me2N
Bu
Zn(CH2I)2 (2.0 equiv)
CH2Cl2, 0 ºC − rt
(1.0 equiv)
96% yield
85% ee
  44 
 
 
Scheme 10: The first reported catalytic enantioselective Simmons-Smith cyclopropanation95 
 
Charette and co-workers developed an asymmetric titanium-based Lewis-acid catalyst 
(Scheme 11).96 This titanium-based catalyst provided very high enantioselectivities for 
aryl substituted allylic alcohols however was less effective for alkyl substituted 
variants.96,97 
 
 
Scheme 11: Titanium-based Lewis acid catalysis towards cyclopropanes by Charette and Brochu96 
 
1.8.3. Diazo Compound-Derived Carbene Insertion into an Alkene 
The condensation of diazo compounds with alkenes as a cyclopropanation approach 
has been known for over 100 years.98 These early cyclopropanation reactions were 
thermally promoted, often requiring temperatures of ~150 °C.99,100 The high reaction 
temperatures combined with the exothermic nature and the concomitant gas evolution 
made these reactions unpredictable and often violent. Silberrad and Roy 
demonstrated that diazo compound decomposition could be catalysed by a transition 
metal in 1906.101 Early reports of transition metal catalysts being utilised for 
cyclopropanation reactions include that by Stork and Ficini in 1961, where insoluble 
copper bronze was used as a catalyst.102 Heterogeneous transition metal catalysts 
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dominated cyclopropanation methodology until the development of soluble copper 
chelates, with notable examples being developed by Nozaki103 and by Moser.104 
These homogeneous catalysts were perceived to be superior to their heterogeneous 
counterparts due to greater reliability and smoother reactions.103,104 Transition metal 
catalysed diazo decomposition is also a far safer method for diazo decomposition than 
the thermal alternative due to the much lower risk of explosion resulting from rapid 
stoichiometric nitrogen gas evolution. 
 
Since the discovery of transition metal catalysis for diazo compound-derived carbene 
insertion into an alkene, a wide range of transition metals including Cu,105 Rh,106 
Ru,107,108 Pd,109 and Co110,111 have been shown to be successful at this reaction. A 
variety of mechanisms for transition metal-catalysed cyclopropanations have been 
proposed, with the main factor dictating which mechanism is in operation being the 
transition metal.  
 
The most prevalent mechanism involves the formation of an electrophilic carbenoid 
species from the transition metal catalyst and the diazo compound, which then reacts 
with an electron-rich alkene to form the cyclopropane product (Scheme 12). This 
mechanism was first proposed by Yates in 1952 and was based upon observations 
made on the copper-catalysed decomposition of diazoketones.112 Cyclopropanations 
that proceed through an electrophilic carbene mechanism are generally stereospecific, 
occurring with retention of configuration. Transition metals that have been associated 
with this mechanism include copper,113 rhodium,113,114 ruthenium113 and chromium.115 
Commonly, significant amounts of the corresponding maleate and fumarate 
side-products are produced, resulting from reaction of the electrophilic carbenoid with 
a molecule of diazo compound (Scheme 12). 
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Scheme 12: Transition metal-catalysed cyclopropanation via an electrophilic carbene 
 
This mechanism is supported by the widespread observation that electron-rich 
alkenes such as styrene derivatives are far more successful in these cyclopropanation 
reactions than electron-neutral or electron-deficient examples. Further support is 
provided by the detection and characterisation of carbene intermediates. Hofmann 
developed an iminophosphanamide ligand which stabilises otherwise elusive or labile 
copper coordination modes through a combination of enhanced metal-to-ligand back 
donation and steric shielding of the copper centre (Scheme 13).116 This copper 
complex reacted with methyl 2-phenyl-2-diazoacetate in toluene-d8, C6D6 or pentane 
at ambient temperature generating a single new copper complex 7 which was 
unambiguously identified by 1H, 13C{1H}, 29Si{1H} and 31P{1H} NMR spectroscopy 
(Scheme 13).117 
 
 
Scheme 13: Synthesis of a stabilised copper carbene for spectroscopic identification116,117 
 
The downfield 13C NMR signal observed for the ester carbonyl carbon in copper 
carbene complex 7 indicated the presence of an electrophilic carbon centre. Further 
evidence for copper carbene 7 possessing an electrophilic nature was obtained 
through analysis of the restricted rotation of the phenyl ring. The carbene carbon of 7 
can only withdraw stabilising electron density from the phenyl ring p-system if orbital 
overlap is present, hence the energy needed to overcome restricted rotation is 
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influenced by the electrophilicity of the carbene carbon. Using variable temperature 
1H NMR spectroscopy the coalescence temperature of the diastereotopic ortho-phenyl 
protons was measured to be –70 °C, and the corresponding rotational energy barrier 
was found to be in accordance with the carbene carbon atom possessing electrophilic 
character. The addition of styrene to solutions of the copper carbene complex resulted 
in an almost complete loss of spectroscopic signals from the copper carbene complex, 
and the styrene was cyclopropanated to give a mixture of trans and cis 
diastereoisomers. This provides strong support for copper carbenes being present in 
copper-catalysed cyclopropanation reactions. In this same work, the 
iminophosphanamide chelate ring and the carbene plane were found to be mutually 
orthogonal, with a Cu=C rotational barrier of at least 60 kJ mol-1; information that is 
highly valuable in the pursuit of designing ligands which exhibit stereoselectivity over 
the cyclopropanation reaction. 
 
In a recent publication, Fürstner has shown that by using a bis(4-methoxyphenyl) 
carbene backbone to impart meta-stability onto highly reactive intermediates, a 
rhodium carbene was able to be characterised by 1H and 13C NMR, IR, UV, HRMS 
and X-ray crystallography (Figure 17).118 In a similar observation to that made by 
Hofmann with a copper carbene, Fürstner observed a significantly downfield carbene 
carbon 13C NMR chemical shift, indicating the presence of a highly electrophilic 
carbene.118,119 The rhodium carbene was shown to be highly active in the 
cyclopropanation of 4-methoxystyrene and so appears to be a valid intermediate in 
the rhodium catalysed cyclopropanation of alkenes with diazo compounds. 
 
 
Figure 17: Structure of an isolatable rhodium carbene synthesised by the Fürstner group118 
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A drawback with cyclopropanation reactions that proceed via the electrophilic carbene 
mechanism is that the diazo reagent can undergo dimerisation through a transition 
metal-catalysed side reaction, often producing significant amounts of the 
corresponding maleate and fumarate side-products (Scheme 12).120 This problem is 
often overcome by keeping only a low concentration of diazo compound in the reaction 
mixture through a combination of using the alkene in a significant excess, often as the 
solvent, and by slow addition of the diazo reagent. These modifications detract from 
the approach’s desirability due to the increased practical complexity, and especially if 
the alkene reactant is valuable. 
 
In contrast to the electrophilic carbene mechanism which most transition metals 
employ, palladium is believed to utilise a mechanism that proceeds via a  
4-membered palladacyclobutane intermediate which then undergoes reductive 
elimination to release the cyclopropane product (Scheme 14). This mechanism is 
supported by competition experiments which measured the relative ability of various 
alkenes to undergo cyclopropanation with Pd(OAc)2, Cu(OTf)2 and Rh2(OAc)4.121 In 
contrast to Cu(OTf)2 and Rh2(OAc)4, it was found that Pd(OAc)2 preferentially reacted 
with strained or conjugated olefins, and that terminal alkenes were more reactive than 
internal isomers or homologues. In intramolecular competitions it was observed that 
the less substituted alkene was regioselectively cyclopropanated. These observations 
all suggest the operation of a mechanism that involves initial p-complexation to the 
olefin reactant, as opposed to an electrophilic carbene mechanism. DFT calculations 
of the palladium-catalysed cyclopropanation of alkenes by diazomethane have 
supported explanations of the behaviour and selectivity observed, as well as helped 
elucidate the most probable mechanism of the catalytic cycle (Scheme 14).122 
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The PdII precatalyst (8) is reduced to Pd0 by the diazo reagent which is a 
transformation that has been frequently observed.123,124,125 Complexation of 
diazomethane forms a Pd(h2-C2H4)n(kC-CH2N2) complex (10) which then undergoes 
elimination of N2 to generate a (h2-C2H4)Pd=CH2 species (11). This species is critical 
to the nature of the catalytic cycle, as the transition metal complex contains both the 
carbene and the alkene to be cyclopropanated. Oxidative addition of the carbene with 
the coordinated alkene generates the corresponding palladacyclobutane (12), which 
then undergoes an extremely facile reductive elimination to generate the cyclopropane 
product. A potential alternative pathway which involves the attack of a non-coordinated 
alkene to the Pd carbene was calculated to possess a Gibbs free activation energy of 
51.3 kJ mol-1, almost double the 28.1 kJ mol-1 calculated for oxidative addition 
involving the coordinated alkene. The catalytic cycle is completed with the 
coordination of another alkene, regenerating the starting Pd0 species (9). 
 
The role of pallada(II)cyclobutane derivatives in Pd(OAc)2-catalysed cyclopropanation 
reactions is supported by the isolation and observed reactivity of this class of 
complexes. Possessing a bidentate nitrogen ligand, a pallada(II)cyclobutane 
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Scheme 14: Pd-catalysed cyclopropanation mechanism 
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derivative has been structurally characterised.126 Such palladacycles exhibit facile 
reductive elimination to yield cyclopropane derivatives.126 The proposed  
palladium-based catalytic cycle is in accordance with the known propensity of 
coordinatively unsaturated palladium to complex alkenes.127 
 
The third transition metal-catalysed cyclopropanation mechanism is a radical-based 
mechanism, and is known to be employed by CoII.128,129,130 CoII possesses a d7  
d-configuration and when in a square-planar geometry is in the low-spin electronic 
configuration.129  One of the most notable observations with CoII-catalysed 
cyclopropanations is that it allows the cyclopropanation of electron-deficient alkenes. 
Another significant observation of cobalt-catalysed cyclopropanation reactions is the 
absence of diazo dimerisation products which means that an excess of alkene and a  
slow-addition protocol are not required. Both of these observations are in stark 
contrast to a mechanism that proceeds via an electrophilic carbene. 
 
The observation that CoII-based cyclopropanations are very successful with  
electron-deficient alkenes suggests some nucleophilic character of the carbene 
transfer intermediate in these reactions. In a joint experimental and computational 
effort to identify the mechanism, the Zhang group used EPR spectroscopy to probe 
the radical in cobalt(porphyrin) complexes both before and after addition of 
4 equivalents of EDA.128 Upon the addition of EDA there was complete conversion to 
three different paramagnetic species. One was assigned as a cobalt(porphyrin) 
complex coordinating a weak-field ligand (e.g. H2O), the second was assigned as the 
cobalt(porphyrin)(carbene) complex with the carbene bridging between the cobalt and 
a nitrogen of the porphyrin ligand, and the third was assigned as terminal carbene 14 
(Figure 18) due to it being an organic radical which possessed hyperfine coupling to a 
hydrogen and cobalt. Using DFT methods the singly occupied molecular orbitals 
(SOMO) and spin density plots for the ‘bridging carbene’ and the ‘terminal carbene’ 
were calculated. According to these calculations the ‘bridging carbene’ radical resides 
primarily in the Co 3𝑑)* orbital whereas for the ‘terminal carbene’ the radical lies 
mainly on the ‘carbene’ carbon and is delocalised slightly over the neighbouring cobalt 
and oxygen atoms. This strongly indicates that the carbene ligand is redox 
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non-innocent and accepts an electron via intramolecular electron transfer from the CoII 
centre. 
 
Interaction between the singly occupied Co 3𝑑)* orbital and the doubly occupied  
C 2𝑠𝑝)% orbital raises the energy of the Co 3𝑑)* orbital above the p* orbital formed 
from overlap of the doubly occupied Co 3𝑑.) orbital and the empty C 2𝑝. orbital 
(Figure 18). The half filling of the Co–C p* orbital substantially reduces the  
metal–carbon bond order, as has been observed experimentally.131 This also accounts 
for why the carbene species loses typical Fischer-type character, gains radical-type 
behaviour and becomes more nucleophilic. 
 
 
 
Figure 18: Simplified molecular orbital diagram for redox non-innocent behaviour of CoII(porphyrin)(carbene)128 
 
With this information in combination with mechanistic DFT studies, a catalytic cycle 
was proposed (Scheme 15).128 
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Scheme 15: CoII radical-based catalytic cycle for cyclopropanation 
 
This catalytic cycle accounts for the differences observed between cyclopropanation 
reactions that are catalysed by cobalt and those catalysed by closed-shell transition 
metals. To support this mechanism, Zhang aimed to isolate a cobalt-carbene complex, 
however due to their high reactivity only decomposition products were isolated.129  
It was hypothesised that a cobaltIII-carbene radical complex from  
ethyl styryldiazoacetate would be stabilised by resonance, and so may be more stable 
during isolation attempts. Upon incorporation of ethyl styryldiazoacetate with a 
cobalt(porphyrin) complex, a dimeric CoIII complex was obtained in a 90% yield, 
formed from the radical combination of two separate cobaltIII(porphyrin)(carbene) 
complexes.129  
 
Significant advances have been made in the field of asymmetric cyclopropanation of 
electron-deficient alkenes through the utilisation of cobaltII(porphyrin) 
complexes.130,132,133,134 Whilst there are a limited number of examples of radical 
behaviour being observed with paramagnetic forms of the other group 9 metals 
rhodium and iridium, neither of these metals have yet produced cyclopropanation 
reactions that indicate a radical-based mechanism.135,136,137,138 It is relevant to note 
that the Co-catalysed cyclopropanation has occasionally been illustrated as 
proceeding via a four-membered cobaltocycle.139 
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In summary, utilising a wide variety of transition metals catalysts, diazo-derived 
carbene insertion cyclopropanation protocols have proved to be incredibly powerful in 
asymmetric cyclopropanation, a topic which will be covered in Section 2.1.4.  
 
1.8.4. Cross-Coupling of a Pre-Functionalised Cyclopropyl-Species 
The cross-coupling of cyclopropanes bearing appropriate functionality offers a 
powerful route to functionalised cyclopropanes. As a method that can utilise a core 
cyclopropyl species and react it with a variety of partners, this approach offers a 
divergent route to a broad scope of functionalised cyclopropanes.  
 
A wide range of cross coupling reactions are possible on a cyclopropane ring. 
Cyclopropyl Grignard species have been utilised in Kumada-Corriu cross-coupling 
reactions to produce aryl-substituted cyclopropanes (Scheme 16A).140 In addition, 
cyclopropyl zinc species have be used in Negishi cross-couplings141 and cyclopropyl 
stannanes can undergo Stille cross-coupling142 (Scheme 16B and 16C respectively). 
 
 
Scheme 16: Cross-coupling reactions of a variety of cyclopropyl organometallic species 
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Suzuki-Miyaura cross coupling has been demonstrated on cyclopropyl boronic 
acids,143 boronic esters144 and trifluoroborate salts145 to generate a variety of  
aryl-substituted cyclopropanes. Cyclopropyl boronic acids have also been utilised in 
Chan-Lam cross couplings with anilines and amines to produce a broad range of 
cyclopropyl amines in excellent yields (Scheme 17A).146 Silicon-substituted 
cyclopropanes have been utilised in Hiyama-Denmark cross-coupling reactions as 
another route to aryl-substituted cyclopropanes in excellent yields (Scheme 17B).147 
 
 
Scheme 17: A) Chan-Lam and B) Hiyama-Denmark cross-coupling of cyclopropyl species 
 
Cyclopropyl iodides can be used as cross-coupling partners, with an example being 
of a Sonogashira cross-coupling reaction, giving excellent yields of alkyne-substituted 
cyclopropanes (Scheme 18A).148 Cyclopropyl iodides have also been shown to be 
successful coupling partners in Suzuki-Miyaura cross-couplings, with Charette and 
Giroux demonstrating the synthesis of aryl- and vinyl-substituted cyclopropanes in 
excellent yields through this method (Scheme 18B and 18C respectively).149 
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Scheme 18: A) Sonogashira and B), C) Suzuki-Miyaura cross-couplings using cyclopropyl iodides 
 
Despite the various ways to synthesise cyclopropanes, there is a lack of methodology 
that allows the synthesis of a bifunctional cyclopropyl scaffold that can undergo 
divergent functionalisation to generate a wide range of cyclopropane-containing 
compounds. 
 
1.9. Project Aims 
The research detailed in this PhD thesis aimed to develop methodology that allowed 
access to a diverse range of cyclopropane-containing compounds for use within 
medicinal chemistry through the divergent functionalisation of a readily accessible 
bifunctional cyclopropyl scaffold (Scheme 19). This methodology could then be used 
to generate libraries of cyclopropane-containing compounds in minimal synthetic 
steps. 
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Scheme 19: General plan for the divergent synthesis of bifunctional cyclopropanes 
 
Functionalised cyclopropanes possess a rigid 3-dimensional structure which makes 
them attractive design elements in drug discovery. The cyclopropane ring can be 
utilised to great effect within medicinal chemistry as a core scaffold or as a bioisostere 
for a variety of functional groups. These attributes allow novel functionalised 
cyclopropanes to access new and pharmaceutically-significant areas of both chemical 
and intellectual property (IP) space. To achieve this the cyclopropyl scaffold requires 
functional handles that utilise the 3-dimensional bond vectors granted by the 
cyclopropane ring. The functional handles must also undergo orthogonal, divergent 
derivatisation. 
 
A cyclopropyl scaffold possessing an ester and a sulfide was targeted (Scheme 20). 
This could potentially be synthesised by a transition metal-catalysed cyclopropanation 
of ethyl diazoacetate and phenyl vinyl sulfide. Synthesis of both trans and cis scaffold 
diastereoisomers would increase the shape diversity of the derivatised products 
(Figure 19).  Once synthesised, the cyclopropyl scaffold could then undergo 
orthogonal derivatisation of the ester and sulfide functionalities, generating a wide 
variety of medicinally-relevant compounds. Functionalisation would proceed as to 
yield compounds with desirable physicochemical properties for use within drug 
discovery. 
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Scheme 20: Synthetic plan for the divergent synthesis of bifunctional cyclopropanes 
 
 
Figure 19: 3-Dimensional schemes of trans- and cis-substituted cyclopropanes 15 and 16, respectively 
 
With these derivatisation reactions in mind, Figure 20 shows a range of bifunctional 
cyclopropanes that could potentially be synthesised through this approach, along with 
some of their calculated physicochemical properties. 
 
 
Figure 20: Bifunctional cyclopropane-containing compounds potentially accessible through the planned approach 
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2. Results and Discussion 
2.1 Transition Metal-Catalysed Cyclopropanation of Phenyl Vinyl 
Sulfide with Ethyl Diazoacetate 
Compounds (trans)- and (cis)-ethyl 2-(phenylsulfanyl)-cyclopropane-1-carboxylate 
(15 and 16) were targeted as bifunctional scaffolds that could undergo orthogonal 
derivatisation to yield a wide variety of cyclopropane-containing compounds for use 
within drug discovery. The planned route to these cyclopropanes was through a 
transition metal-catalysed cyclopropanation of PVS with EDA (Scheme 21). The 
thermally-promoted cyclopropanation of PVS and EDA had been reported once by 
Kaiser and co-workers in 1962.99 The reaction required extreme heating (100–170 °C) 
in a sealed vessel and gave a 76% yield of 15 and 16. There are considerable safety 
concerns with such extreme heating of diazo compounds, particularly in sealed 
vessels, due to the stoichiometric N2(g) evolution. In order to develop a safer reaction, 
transition metal catalysis was explored. 
 
 
Scheme 21: Synthetic scheme for proposed cyclopropanation to yield trans- and cis-cyclopropyl scaffolds 
 
An analysis of prominent cyclopropanation literature showed that a large number of 
transition metals can be successfully utilised in cyclopropanation reactions between 
diazo compounds and alkenes. Exploration of some of the most prominent catalyst 
systems revealed that they were often based on CuI, CuII, RhII or PdII,150,151,152,109 
which led to the investigation of these transition metals for the cyclopropanation of 
PVS with EDA. 
 
The complexes CuOTf, Cu(OTf)2, Cu(acac)2, Rh2(OAc)4, Pd(OAc)2 and PdCl2 were 
tested for activity in the cyclopropanation of PVS with EDA. All complexes were stored 
in a desiccator except for CuOTf which was stored and handled in a glovebox. All 
reaction vessels were flame dried and purged with Ar(g) before use to eliminate any 
issues from O2 or moisture-based sensitivity any of the complexes may have, which if 
N2 S S
solvent
15 16EDA PVS
catalyst
EtO
O
S
Ph
Ph Ph
OEtO OEtO
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not controlled thoroughly could cause erroneous results. PVS was vacuum distilled 
before use, and the diazo reagent was added as  a  CH2Cl2  solution via syringe pump 
over 8 hours. Initial investigations began using 0.5 mol% catalyst loading and with 
anhydrous CH2Cl2 as the solvent at 30 °C, as similar conditions have been frequently 
utilised.150,151 At 30 °C only Cu(acac)2, CuOTf and Cu(OTf)2 generated cyclopropane 
products (Table 1, entries 4–6). Using CuOTf gave the highest yield out of the catalysts 
screened, and the observation that the catalysed cyclopropanation proceeded at a 
temperature as low as 30 °C was encouraging. The resulting cyclopropanes 15 and 
16 were readily separated through silica chromatography and the diastereoisomers 
distinguished by their J-coupling constants in their 1H NMR spectrums. Typical 
cyclopropyl 1H NMR coupling constants are in the ranges of 3Jtrans = 4.5-7.5 Hz, 
3Jcis = 7.5-11.0 Hz and 2Jgem = 4.5-7.0 Hz. As expected for a cyclopropanation that 
proceeded via an electrophilic carbene, dimerisation of EDA was observed generating 
diethyl maleate and diethyl fumarate side-products. 
 
Table 1: Catalyst optimisation for the transition metal-catalysed cyclopropanation of PVS with EDA 
 
 
  
 
 
 
 
 
 
 
 
 
a Cat. (0.5 mol%) added to flame-dried vial, sealed and flushed with Ar(g). A solution of phenyl vinyl sulfide  
(131 µL, 1.0 mmol) in CH2Cl2 (7.0 mL, 0.14 M) was added and warmed with stirring to 30 °C. A solution of  
ethyl diazoacetate (118 µL, 1.0 mmol) in CH2Cl2 (118 µL, 8.5 M) was added over 8 h and then stirred for a further 
16 h. b Same method as for a but stirred for a total of 48 h. 
 
2.1.1 Bomb Calorimetry of PVS, EDA and the Product Cyclopropanes 
To better understand the hazards associated with this cyclopropanation and to 
develop cyclopropanation conditions that operated at an acceptable temperature, 
bomb calorimetry of PVS, EDA and a sample of 15 and 16 was carried out. Bomb 
calorimetry of PVS showed a slight and gradual increase in temperature beginning at 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
Catalyst (0.5 mol%)
15 161.0 equiv
CH2Cl2, 30 °C
 24–48 h
Entry Catalyst Solvent Yield 
trans + cis (%) 
1a Rh2(OAc)4 CH2Cl2 0 
2b PdCl2 CH2Cl2 0 
3b Pd(OAc)2 CH2Cl2 0 
4b Cu(acac)2 CH2Cl2 5 
5b Cu(OTf)2 CH2Cl2 4 
6b Cu(OTf)·toluene CH2Cl2 33 
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289 °C and with a maximum at 340 °C which corresponded to exothermic 
decomposition of the substance (Figure 21). 
 
 
Figure 21: Bomb calorimetry data for phenyl vinyl sulfide 
 
Bomb calorimetry of EDA (Figure 22) showed a sharp increase in temperature 
beginning at 99 °C and reaching a maximum at 120 °C which corresponded to rapid 
exothermic decomposition. 
 
Figure 22: Bomb calorimetry data for ethyl diazoacetate 
Bomb calorimetry of a 1:1 mixture of 15 and 16 showed a very gradual decrease in 
temperature beginning at 223 °C which corresponded to evaporation of the 
compounds (Figure 23). 
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Figure 23: Bomb calorimetry data for a 1:1 mixture of 15 and 16 
 
The bomb calorimetry data obtained illustrated how the various species in the 
cyclopropanation reaction behave at high temperatures, confirmed that EDA is the 
species in the reaction mixture that is most sensitive to high temperatures, and also 
provided insight into the onset temperature for thermally activated EDA 
decomposition. In light of this, the transition metal-catalysed cyclopropanation of PVS 
and EDA should be conducted at a reaction temperature that is significantly below 
99 °C. 
 
2.1.2. CuI-Catalysed Cyclopropanation of PVS with EDA 
Copper has been used as a catalyst in cyclopropanation reactions for over 50 years, 
with an early report coming from Stork and Ficini in 1961 using copper bronze as a 
heterogeneous catalyst.102 Homogeneous copper catalysts emerged in the mid 
1960’s, with notable independent examples from Nozaki103 and Moser.104 The first 
asymmetric, metal-catalysed cyclopropanation of diazo compounds was developed by 
Nozaki and utilised a copper catalytic centre with two chiral salicylaldimine ligands.153 
Whilst the enantiomeric excesses observed were low, this seminal publication 
demonstrated that a homogeneous metal-catalysed reaction can be rendered 
enantioselective through the attachment of a chiral ligand to the metal centre. The 
addition of either a CuI or CuII source had been known to catalyse cyclopropanation 
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reactions of diazo compounds, however in 1985 Aratani provided significant evidence 
that the active catalyst in at least some CuII-based systems was actually a CuI species 
that had been generated through in situ reduction of the CuII source.154 This process 
often occurs through the heating of the CuII precatalyst and diazo reagent to 70–80 °C, 
evolving nitrogen as the reduction proceeds.154 Alternatively, the reduction can be 
effected through pre-treatment with a reducing agent such as phenylhydrazine at room 
temperature.105,154 To avoid the need for a CuII reduction step prior to 
cyclopropanation, the catalytically-active CuI salt or complex can be added directly. 
CuI species are, however, frequently more moisture sensitive than their CuII 
counterparts and are prone to disproportionation to form Cu0 and CuII.155 The amount 
of disproportionation observed is dependent upon the relative stabilities of the copper 
species in the reaction mixture, including the effects of any species in the mixture 
capable of coordinating to the copper species.155 Of the copper-based salts, CuOTf 
has been found to be a privileged cyclopropanation catalyst.156 This is believed to be 
due to the weakly coordinating nature of the triflate anion, which allows the copper 
carbene to coordinate to the alkene during the reaction.156 
 
Following on from CuOTf being the most successful screened catalyst for the 
cyclopropanation of PVS with EDA, it was apparent that the slow addition of the diazo 
compound over 8 hours reduced the utility of the reaction. Evans and co-workers 
reported a procedure where a more dilute solution of diazo reagent was added over 
only 1.5 hours, which gave them good to excellent yields of cyclopropanes through 
the CuI-catalysed cyclopropanation of styrene.105 This more rapid diazo addition 
protocol was tested on the PVS cyclopropanation, with almost identical results being 
obtained for the 1.5-hour and 8-hour addition protocols (Table 2). The 1.5-hour diazo 
addition protocol was therefore carried forward due to the significant improvement in 
practicality. It was evident from the reaction mixture after work-up that the quantity of 
cyclopropane product and the remaining PVS did not account for all of the PVS that 
was added to the reaction mixture. This was due to polymerisation of PVS, which 
readily occurred at ambient temperature, resulting in insoluble polymeric material 
being formed during the reaction. In addition to the risk of heating diazo compounds, 
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keeping PVS polymerisation at a minimum was a second reason why a low reaction 
temperature was desirable. 
 
Table 2: The effect of diazo compound addition time on the CuOTf-catalysed cyclopropanation 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
The next variable to be optimised was the reaction solvent. A diverse range of solvents 
were tested, investigating the effects of solvent polarity and whether chlorinated or 
aromatic solvents were particularly effective (Table 3). Chlorinated solvents gave the 
highest yields (entries 1–3), with chloroform being optimal (entry 2). Non-chlorinated 
solvents gave significantly lower yields in all cases. Aromatic solvents (entries 4 and 
5) favoured the formation of the trans-diastereoisomer, producing the highest 
diastereoselectivities observed during the solvent screen. It was, however, desired 
that the cyclopropanation of PVS with EDA would be non-stereoselective, so that a 
single cyclopropanation reaction would generate both diastereoisomers 15 and 16 in 
substantial quantities. This would give two stereoisomeric cyclopropyl scaffolds with 
significantly different synthetic vectors. Both cyclopropyl scaffolds could then be taken 
forward for divergent functionalisation to generate a wide range of products with a 
broad spectrum of functionalities and 3-dimensional structures. Therefore, due to it 
giving the highest yield and possessing the advantage of reasonably low 
diastereoselectivity, chloroform was taken forward as the reaction solvent for further 
optimisation.  
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(0.5 mol%)
15 161.0 equiv
CH2Cl2, 30 °C, 24 h
Entry Addition time 
(h) 
Remaining PVS 
(equiv) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 8 0.32 51:49 33 
2 1.5 0.37 50:50 33 
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Table 3: Solvent effects on the CuOTf-catalysed cyclopropanation of PVS with EDA 
 
 
 
1,2-DCE = 1,2-Dichloroethane. Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
 
At this point in the optimisation a series of control reactions were performed, to 
investigate how the polymerisation of PVS was affected by the presence of EDA and 
CuOTf (Table 4). 
 
Table 4: Control reactions study on the CuOTf-catalysed cyclopropanation of PVS and EDA 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
 
Without the addition of CuOTf, no cyclopropanation was observed as expected 
(Table 4, entry 1). A 12% loss of PVS through polymerisation was also observed. In 
the absence of EDA, no cyclopropanation was observed as would be expected, and a 
similar amount of PVS polymerisation was observed (entry 2). With the exclusion of 
both CuOTf and EDA, there was a slight decrease in the amount of recovered PVS 
N2
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EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(0.5 mol%)
15 161.0 equiv
solvent, 30 °C, 24 h
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(0.5 mol%)
15 161.0 equiv
CHCl3, 30 °C
Entry Solvent Remaining PVS 
(equiv) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 CH2Cl2 0.37 50:50 33 
2 CHCl3 0.27 58:42 41 
3 1,2-DCE 0.17 52:48 35 
4 Toluene 0.32 65:35 12 
5 Benzene 0.30 63:37 21 
6 Hexane 0.54 52:48 10 
7 THF 0.14 55:45 26 
8 Ethyl acetate 0.19 55:45 10 
Entry Variable Reaction time 
(h) 
Remaining PVS 
(equiv) 
Remaining PVS 
(equiv) 
Yield 
trans + cis (%) 
1 No CuOTf 24 0.88 0.87 0 
2 No EDA 24 0.83 - 0 
3 No CuOTf or EDA 24 0.70 - 0 
4 No CuOTf or EDA 48 0.56 - 0 
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after 24 hours, which further decreased after 48 hours (entries 3 and 4). These results 
indicated that PVS polymerisation was not greatly accelerated by the presence of EDA 
or CuOTf and that the longer the reaction time, the more PVS was consumed through 
polymerisation. 
 
The degree of air and moisture exclusion was next investigated by running the reaction 
with either a batch of CuOTf that had been stored and handled in a glovebox as per 
the usual experimental procedure, or by using a batch of CuOTf that had been stored 
in a desiccator (Table 5). 
 
Table 5: The effect of CuOTf storage on the cyclopropanation of PVS and EDA 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
 
Both batches of CuOTf gave the same yield of cyclopropanes, however the reaction 
that utilised catalyst from a desiccator gave 14% less recovered PVS (Table 5, 
entries 1 and 2). Having more PVS in the reaction mixture was beneficial to the 
reaction, and may have proved to be significant after further reaction optimisation, so 
the CuOTf used continued to be stored and handled under glovebox conditions. 
 
During reaction optimisation it was apparent that the cyclopropanation was slightly 
capricious, with repeat reactions giving small variations in yield. To ensure accurate 
and reliable results, all reactions that investigated a particular parameter of the 
reaction optimisation were run simultaneously, using the same equipment and 
reagents. To ensure valid conclusions could be drawn from sets of data that were 
probing different parameters of the reaction optimisation, and so had been set up at 
different times, a control reaction was run alongside each batch of optimisation 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(0.5 mol%)
15 161.0 equiv
CHCl3, 30 °C, 24 h
Entry Catalyst storage Remaining PVS 
(equiv) 
Yield 
trans + cis (%) 
1 Glovebox 0.27 41 
2 Desiccator 0.41 41 
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reactions. The results of these control reactions were compared to each other to 
ensure that any differences in yields during optimisation were the result of intentional 
and reproducible changes to the reaction conditions as part of the optimisation 
process. 
 
To check that the capricious nature of the reaction was not a result of product instability 
to either work-up or chromatography conditions, a stationary phase stability study was 
conducted, similar to that described by the Bull group.157 This study involved stirring a 
known amount of a 1:1 mixture of 15 and 16 in a medium of interest for 1 hour at room 
temperature and measuring the difference in the amount of the cyclopropanes present 
after this time through 1H NMR analysis with comparison to an internal standard. This 
study showed that the cyclopropane products were stable to the typical 
chromatography eluent used (n-hexane:ether mixture), silica, silica + 1% Et3N, basic 
Al2O3 and Florisil®. A moderate reduction in the amount of recovered cyclopropanes 
had occurred over the hour with neutral Al2O3 (Grade I). This showed that the 
cyclopropane products were stable for prolonged periods of time under the standard 
work-up and chromatography conditions. Therefore, the variability in the 
cyclopropanation results would be monitored throughout the remaining optimisation 
process through control reactions. 
 
The effect of reducing the reaction scale was investigated next. Due to the purification 
of PVS by vacuum distillation prior to use requiring heating to approximately 70 °C, 
combined with the thermally induced polymerisation of PVS observed at ambient 
temperatures and above, significant amounts of PVS were being consumed as a result 
of polymerisation-attributed losses during vacuum distillation. Reducing the reaction 
scale from 1.0 mmol to 0.5 mmol was investigated (Table 6, entries 1 and 4). Whilst a 
decrease in cyclopropanation yield and diazo dimerisation was observed, this could 
be attributed to the heterogeneous nature of the catalyst. 
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Table 6: The effect of scale and temperature on the CuOTf-catalysed cyclopropanation reaction 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
To investigate the temperature-dependence of the reaction, experiments were run at 
temperatures ranging 20–35 °C (Table 6, entries 2–5). The yield of cyclopropanes 
increased from 20 °C until 30 °C, after which there was no improvement. To gain the 
maximum benefits from both reaction output and safety, a temperature of 30 °C was 
deemed optimum. The “EDA dimerisation %” is the percentage of reactant EDA that 
underwent dimerisation to form either diethyl fumarate or diethyl maleate 
side-products as measured by analysis of the 1H NMR spectrum for the reaction 
mixture. The amount of dimerisation didn’t vary significantly between 20 °C and 35 °C 
(entries 2–5). 
 
The next variable to be optimised was the catalyst loading (Table 7). Increasing the 
catalyst loading to 1 mol% gave a significant increase in the yield of cyclopropanes, 
however further increasing it to 2 mol% gave no benefit. This appeared to be due to 
the CuOTf reaching a solubility limit in the reaction mixture, and at 2 mol% catalyst 
loading small particles of undissolved catalyst could be seen. From this investigation 
it was concluded that 1 mol% catalyst loading was optimum. Due to the acidic nature 
of chloroform,158 and the potential sensitivity of PVS polymerisation159 and CuOTf 
deactivation to acidic conditions,155 20 mol% of the sterically hindered base 
2,6-lutidine was added as an additive (entry 4). This, however, decreased the yield of 
cyclopropanes obtained and did not reduce PVS polymerisation. 
 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(0.5 mol%)
15 161.0 equiv
CHCl3, temperature
24 h
Entry mmol of PVS Temperature 
(°C) 
EDA dimerisation 
(%) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 1.0 30 30 56:44 41 
2 0.5 20 13 53:47 15 
3 0.5 25 6 50:50 22 
4 0.5 30 5 56:44 27 
5 0.5 35 6 56:44 27 
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Table 7: Effect of catalyst loading on the CuOTf-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. a + 20 mol% 2,6-lutidine. 
 
To investigate how the reaction progressed with time, the cyclopropanation was 
stopped after 3, 18 and 24 hours and the three results compared (Table 8). The 
reaction proceeded rapidly at first but slowed down significantly after the first 3 hours 
(entry 1). The difference between the yields at 18 hours and 24 hours was only 4%, 
however it showed that the reaction was still proceeding (entries 2 and 3). The reaction 
time was therefore kept at 24 hours.  
 
Table 8: The effect of reaction time on the CuOTf-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
 
  
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
The next parameters to be investigated were the number of equivalents of diazo 
reagent used and the diazo reagent itself (Table 9). Due to copper-catalysed diazo 
dimerisation reducing the amount of diazo reagent in the reaction mixture, it seemed 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(mol%)
15 161.0 equiv
CHCl3, 30 ºC
24 h
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
CuOTf⋅toluene
(1 mol%)
15 161.0 equiv
CHCl3, 30 ºC
Time
Entry Catalyst loading 
(mol%) 
EDA dimerisation 
(%) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 0.5 5 56:44 27 
2 1.0 20 56:44 45 
3 2.0 13 57:43 40 
4   1.0a 20 57:43 28 
Entry Time 
(h) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 3 53:47 30 
2 18 53:47 40 
3 24 57:43 44 
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plausible that increasing the equivalents of the diazo compound could be a way to 
increase the yield of the cyclopropanation reaction. This however was not the case 
and the reaction appeared to be insensitive to the number of equivalents of diazo 
compound for the range observed (entries 1–3). For the remaining optimisation with 
EDA, 2.0 equivalents of EDA were used due to the possibility that an increased 
amount of EDA may improve the reaction with further-optimised conditions. 
 
Table 9: The effect of diazo equivalents on the CuOTf-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
To probe the steric effects of the diazo compound in the cyclopropanation, tert-butyl 
diazoacetate was tested, with a significant decrease in yield observed (entry 4). There 
was very little change in the diastereoselectivity of the reaction, and the 
trans-diastereoisomer was still favoured. At this point in the optimisation almost all 
reaction parameters had been assessed and the yield of cyclopropanes had plateaued 
at around 45%.  
 
The incorporation of a ligand can enable the reactivity of the catalytic metal centre to 
be tuned. The addition of a ligand can also improve solubility in organic solvents as 
well as provide a scaffold from which asymmetric induction can be explored. In 
particular, bisoxazoline-derived (BOX) ligands have shown significant success in 
copper-catalysed cyclopropanation reactions. Due to its frequent appearance in the 
literature and its availability, ligand 17 was utilised for further optimisation. Once the 
reaction conditions had been further optimised for the inclusion of 17, alternative 
N2
O
RO Ph
S
S
ORO
Ph
S
ORO
Ph
CuOTf⋅toluene
(1 mol%)
CHCl3, 30 ºC, 24 h
Entry R Diazo compound 
equivalents 
Diazo dimerisation 
(%) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 Et 1.0 18 56:44 45 
2 Et 1.5 12 56:44 45 
3 Et 2.0 11 54:46 46 
4 t-Bu 1.0 11 60:40 25 
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ligands would also be analysed. Due to the BOX ligand being highly enantioenriched, 
chiral induction to produce enantioenriched cyclopropane products was feasible. Any 
enantioenrichment observed in the product cyclopropanes will not be extensively 
analysed in this section. Such observations will be discussed in Section 2.1.4.1 as a 
part of the development of an asymmetric transition metal-catalysed cyclopropanation 
of PVS with EDA. 
 
Before ligand 17 was tested in the cyclopropanation of PVS with EDA, it was important 
to conduct a test to ensure that the CuI(BOX) complex was being formed and utilised 
successfully. The cyclopropanation of styrene with EDA was therefore performed, and 
the results compared to the same reaction reported by Evans and co-workers 
(Scheme 22).105 The hypothesis was that if the results were similar then it would 
suggest that the CuI(BOX) complex was indeed being formed successfully. The 
method to form the complex involved the CuOTf and ligand being stirred in chloroform 
for 1 hour at room temperature. The reaction mixture was then warmed to 30 °C, 
styrene added, followed by the slow addition of a solution of EDA in CHCl3 via syringe 
pump over 1.5 hours. After the slow addition was complete the reaction mixture was 
stirred for a further 14 hours. 
 
 
Scheme 22: CuI(BOX)-catalysed cyclopropanation of styrene with EDA. Yield determined by 1H NMR spectroscopy 
with comparison to internal standard (1,3,5-trimethoxybenzene). Diastereoselectivity was determined by 1H NMR 
spectroscopy. 
 
N2
O
EtO Ph
Ph
OEtO
Ph
OEtOCuOTf⋅toluene
(1 mol%)
18 192.0 equiv 0.5 mmol
O
N N
O
(1.1 mol%)
CHCl3, 30 ºC, 16.5 h
This work
94% yield
trans:cis = 68:32
ee (trans) = 66%
Evans and co-workers
No yield declared
trans:cis = 68:32
ee (trans) = 49%
17
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An excellent yield of 94% was achieved, with the same diastereoselectivity as that 
observed by Evans and co-workers.105 In addition, the enantioenrichment of the  
trans-diastereoisomer was found to be greater than that previously recorded.105 
 
The results from this test showed that the method used to generate and use the 
CuI(BOX) complex was successful, and so this protocol was applied to the 
cyclopropanation of PVS with EDA (Table 10). When enantioenriched BOX ligand 17 
was incorporated into the CuOTf-catalysed system, the yield of cyclopropane products 
improved to 54% (Table 10, entry 1), which was a significant improvement on the 46% 
obtained without the addition of BOX 17 (Table 9, entry 3). The asterisk of products 
15* and 16* denotes enantioenriched material, in this instance from the asymmetric 
cyclopropanation. After this the CuI source was evaluated. Whilst CuOTf had proved 
hugely successful in copper-catalysed cyclopropanation reactions, a variety of other 
CuI sources were tested for an improvement on the current system. Copper(I) halides 
were unsuccessful at the cyclopropanation (Table 10, entries 2–4), either giving very 
low yields on no cyclopropane products at all. Whilst Cu(MeCN)4BF4 gave a 
significantly lower yield than CuOTf, it did catalyse the cyclopropanation reaction 
reasonably well. From these results it appeared that CuI sources with weakly 
coordinating anions performed best in this cyclopropanation, which matched 
observations by Salomon and Kochi on a variety of CuI-catalysed cyclopropanation 
reactions.156 This was explained to be a result of CuI sources with weakly coordinating 
counterions being able to coordinate the reactant alkene during the reaction.156 
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Table 10: The effect of CuI source on the catalysed cyclopropanation of PVS with EDA 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
With this counterion effect in mind, additives were tested which could act as a source 
of an alternative weakly coordinating anion (Table 11). 
 
Table 11: The effect of additives on the CuI-catalysed cyclopropanation of PVS with EDA 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15* 16*2.0 equiv
CuI source (1 mol%)
O
N N
O
(1.1 mol%)
CHCl3, 30 ºC, 24 h
17
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15* 16*2.0 equiv
CuOTf⋅toluene (1.0 mol%)
Additive (2.0 mol%)
O
N N
O
(1.1 mol%)
CHCl3, 30 ºC, 24 h
17
Entry Catalyst Remaining PVS 
(equiv) 
Diazo dimerisation 
(%) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 CuOTf·toluene 0.00 25 50:50 54 
2 CuCl 0.00 3 50:50 4 
3 CuBr 0.29 48 - 0 
4 CuI 0.08 18 38:62 8 
5 Cu(MeCN)4BF4 0.02 10 50:50 36 
Entry Additive Remaining PVS 
(equiv) 
Diazo dimerisation 
(%) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 None 0.00 25 50:50 54 
2 AgSbF6 0.07 30 52:48 56 
3 AgPF6 0.01 14 53:47 47 
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The addition of silver(I) salts with hexafluoroantimonate and hexafluorophosphate 
anions did not provide significant improvements to the cyclopropanation reaction, so 
were not investigated further (Table 11). 
 
The next parameter to be optimised was the method of solvent purification. Chloroform 
had been identified as the optimal solvent early in the optimisation (Table 3, entry 2). 
Up until this point the chloroform had been distilled immediately prior to use by stirring 
the chloroform with Na2CO3 for 10 minutes (pre-dry) before being distilled over 
Na2SO4. However, slight variations in yields were being observed and as a result, 
control reactions had been run alongside each set of reactions to ensure valid and 
comparable results were obtained. It was a possibility that small differences in the 
chloroform purity were generating the observed slight variations in the 
cyclopropanation results, and that a more robust purification may resolve this. To this 
end, the pre-dry method, distillation drying agent and a filtration procedure were 
analysed, to investigate whether a particular set-up removed impurities more 
effectively than the others. Firstly, the commercial chloroform was tested without 
purification, which gave a 35% yield (Table 12, entry 1). This was a significant 
decrease from the 54% obtained previously (Table 11, entry 1), showing that the water 
content of the solvent was an important factor for the reaction. Next, filtration of the 
solvent through a pad of a drying agent and basic acid scavenger was investigated 
(entries 2–4). No benefit was observed from K2CO3 or neutral alumina (Grade I), and 
a significant yield decrease was observed with basic alumina (Grade I). Next the 
pre-dry and distillation procedures were assessed (entries 5–7). The optimum 
procedure from those tested was our initial procedure; pre-dry with Na2CO3 followed 
by distillation over Na2SO4 (entry 7). The 47% yield obtained illustrated the 
characteristic variability of this reaction (compare to 54%, Table 11, entry 1), hence 
investigation into solvent purification continued. The next stage was to combine the 
optimal pre-dry and distillation procedure with a filtration step (entries 8–10), however 
these efforts made no constructive difference to the reaction. Using chloroform that 
had been distilled and then stored in a round bottomed flask under an inert atmosphere 
for 24 hours resulted in a significant decrease in yield (entry 11), which demonstrated 
the necessity for freshly dried solvent. 
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Table 12: Solvent, reagent and work-up effects on the cyclopropanation of PVS with EDA 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard  
(1,3,5-trimethoxybenzene or dibenzyl ether). a CHCl3 aged for 1 day. b PVS not vacuum distilled prior to use.  
c 2 mol% of catalyst, 2.2 mol% of ligand. d 5 mol% of catalyst, 5.5 mol% of ligand. 
 
With no improvement in yield obtained from the investigation into solvent purification, 
the optimisation proceeded to testing various reaction work-up conditions and other 
variables. The work-up for the reaction up until this point had been filtration through a 
pad of silica. A variation using a pad of Celite® (entry 12) gave comparable results to 
a silica work-up (entry 10). A work-up that consisted of adding EDTA to sequester the 
copper followed by an aqueous work-up also gave comparable yields (entry 13). Using 
PVS that had not been purified by vacuum distillation prior to use did not reduce the 
yield of cyclopropanes (entry 14). Increasing the catalyst loading to 2 mol% and the 
ligand loading to 2.2 mol% (entries 15–17) increased the yield of cyclopropanes 
significantly, with the larger effect observed with the optimised pre-dry and distillation, 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15* 16*2.0 equiv
CuOTf⋅toluene (1.0 mol%)
O
N N
O
(1.1 mol%)
CHCl3, 30 ºC, 24 h
17
Entry Pre-dry Distillation Filtration Work-up Remaining 
PVS 
(equiv) 
Diazo 
dimerisation 
(%) 
Yield 
trans + cis 
(%) 
1 - - - Silica 0.01 13 35 
2 - - K2CO3 Silica 0.18 12 35 
3 - - Neutral Al2O3 Silica 0.15 20 31 
4 - - Basic Al2O3 Silica 0.25 14 27 
5 K2CO3 Na2SO4 - Silica 0.07 15 41 
6 CaCl2 CaCl2 - Silica 0.08 17 36 
7 Na2CO3 Na2SO4 - Silica 0.06 12 47 
8 Na2CO3 Na2SO4 K2CO3 Silica 0.09 16 41 
9 Na2CO3 Na2SO4 Neutral Al2O3 Silica 0.12 18 48 
10 Na2CO3 Na2SO4 Basic Al2O3 Silica 0.37 17 32 
11a Na2CO3 Na2SO4 Basic Al2O3 Silica 0.11 23 23 
12 Na2CO3 Na2SO4 Basic Al2O3 Celite® 0.17 19 34 
13 Na2CO3 Na2SO4 Basic Al2O3 EDTA 0.08 15 35 
14b Na2CO3 Na2SO4 Basic Al2O3 Celite® 0.20 23 35 
15c Na2CO3 Na2SO4 - Silica 0.02 4 44 
16c Na2CO3 Na2SO4 Neutral Al2O3 Silica 0.11 20 47 
17c Na2CO3 Na2SO4 Basic Al2O3 Celite® 0.00 4 43 
18d Na2CO3 Na2SO4 - Celite® 0.00 27 50 
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followed by either no filtration step (entry 15) or filtration with neutral alumina 
(entry 16). Increasing the catalyst loading to 5 mol% and the ligand loading to 
5.5 mol% increased the yield slightly, reaching 50% (entry 18). At a catalyst loading of 
5 mol% the copper complex was not fully dissolved in the reaction, with solid material 
being visible in the reaction mixture, which explained why such a small increase in 
yield was observed upon proceeding from a catalyst loading of 2 mol% up to 5 mol%. 
 
A lot of work had been carried out towards the optimisation of a CuI-catalysed 
cyclopropanation of PVS with EDA, with moderate yields being achieved. To improve 
the yield, a different system was considered. Given the wealth of reports of 
CuI-catalysed cyclopropanations of styrenes, the application of the developed 
conditions to a phenylsulfide-substituted styrene was investigated. This offered the 
possibility of increased yields compared to the cyclopropanation using PVS due to the 
more electron-rich alkene, whilst still retaining the desired phenyl sulfide functional 
handle for use during later scaffold derivatisation.  The synthesis of cis-substituted 
styrene 20 proceeded from thiophenol and phenylacetylene, producing only the 
cis-diastereoisomer (Scheme 23) using a procedure from Deng and co-workers.160 
Using the developed CuI-catalysed cyclopropanation conditions on vinyl sulfide 20, no 
cyclopropane-containing products were obtained (Scheme 24). 
 
 
Scheme 23: Synthesis of a phenylsulfide-substituted styrene 
 
 
Scheme 24: Attempted CuI-catalysed cyclopropanation of a cis-substituted vinyl sulfide 
SH
K3PO4 (1.5 equiv)
N-Methyl-2-pyrrolidone
80 °C, 24 h(1.5 equiv)
S
20
71%
N2
O
EtO
Ph
S
S
OEtO
Ph
S
OEtO
Ph
21* 22*2.0 equiv
CuOTf⋅toluene (1.0 mol%)
O
N N
O
(1.1 mol%)
CHCl3, 30 ºC, 24 h
Ph
Ph Ph
17
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With a large number of parameters explored, the optimisation of the  
CuI-catalysed cyclopropanation of PVS with EDA had been thoroughly investigated. 
However, the reaction gave only moderate yields of the desired cyclopropanes, 
utilised a catalyst that necessitated storage and handling in a glovebox, and required 
a slow-addition protocol for addition of the diazo reagent. 
 
Attention therefore returned to other potential transition metal catalysts that may be 
suitable for the cyclopropanation of PVS with EDA. Of particular interest was CoII, 
which had received significant recent attention for the cyclopropanation of 
non-styrene-based alkenes.139 
 
2.1.3. CoII-Catalysed Cyclopropanation of PVS with EDA 
Cobalt complexes have been shown to be very effective at catalysing the 
cyclopropanation of non-electron-rich alkenes.130,161,162 The use of novel CoII 
complexes has greatly facilitated the cyclopropanation of non-styrene-based 
derivatives, with styrenes occupying a huge proportion of the transition 
metal-catalysed cyclopropanation literature owing to their electron-rich nature.163,164 
 
In particular, White and Shaw reported utilising a CoII(salen)-type complex (23, 
Scheme 25) to perform asymmetric cyclopropanation on a variety of 1,1-substituted 
alkenes producing a range of tri-substituted cyclopropanes.139 Within the scope there 
was a single example using a 1,1-substituted vinyl sulfide (Scheme 25). The synthesis 
produced the tri-substituted cyclopropanes in excellent yields and with high diastereo- 
and enantioselectivities, however for the vinyl sulfide example there was a significant 
reduction in all three outputs compared to the rest of the scope. An issue with this 
methodology is the extensive catalyst synthetic route (11 steps) which resulted in only 
a 12% overall yield.165 With such a lengthy catalyst synthesis it would require a 
considerable amount of time and resources before even beginning the synthesis of 
the desired cyclopropane-containing compounds. This publication does however 
demonstrate how CoII(salen)-type complexes can be used to great effect to induce 
considerable enantioenrichment in a vinyl sulfide substrate, which due to its 
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conformational flexibility is a much more challenging substrate than more rigid 
examples such as styrene derivatives. 
 
 
Scheme 25: Asymmetric CoII-catalysed cyclopropanation of a 1,1-substituted vinyl sulfide139 
 
With CoII having been shown to be capable of catalysing cyclopropanation reactions 
effectively,130,139,161-164 the development of a CoII-catalysed cyclopropanation of PVS 
with EDA was therefore explored. 
 
A concise account of this work can be found in the European Journal of Organic 
Chemistry (see Appendix 1).166 
 
2.1.3.1. CoII-Catalysed Cyclopropanation Optimisation 
Initially, the conditions by White and Shaw served as a starting point for a 
CoII-catalysed cyclopropanation of PVS with EDA.139 In contrast to the catalyst 
designed by White and Shaw (Scheme 25),165 this methodology would ideally utilise a 
readily accessible catalyst. A CoII(salen)-type complex was chosen that was based on 
the Jacobsen ligand,167 a ligand that has been very successful in a variety of transition 
metal-catalysed reactions including cyclopropanations and epoxidations 
(Scheme 26).110,168 This CoII complex was commercially available169 and could be 
synthesised in two steps on multi-gram scale (Scheme 26). The synthesis comprised 
of diimine formation followed by CoII complexation to give the desired CoII(salen)-type 
N2
O
EtO Ph
S
n-Pr
OEtO
S
OEtO
24 25(1.5 equiv)
KSAc (5.0 mol%)
(5.0 mol%)
CH2Cl2, rt, 48 hn-Pr
S n-PrPh
Ph
N
N
O
O t-Bu
t-Bu
t-Bu
t-Bu
Co
24:25 = 16:1
87% yield (24 + 25)
88% ee
23
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complex. Due to the commercial availability of highly enantioenriched 
trans-1,2-diaminocyclohexane the enantioenriched CoII complex could also easily be 
synthesised. 
 
 
Scheme 26: Synthesis of racemic complex 28 via Schiff base 27 for use in this work 
 
White and Shaw observed that the CoII-catalysed cyclopropanation of  
1,1-disubstituted alkenes was promoted by electron-donor additives.139 Of these 
additives, potassium thioacetate was found to be particularly efficient. The rationale 
for this behaviour was that the additive bound to one axial site of the cobalt 
(salen)-type complex, activating the complex towards reaction with the diazo 
reagent.139  
 
Beginning the optimisation process towards an effective CoII-catalysed 
cyclopropanation of PVS with EDA, catalyst 28 (5 mol%) with potassium acetate 
(5 mol%) were used in CH2Cl2 (0.2 M) at room temperature (22 °C) (Table 13, entry 1). 
No reaction was observed at room temperature so warmer temperatures were tested 
(entries 2 and 3). At 30 °C only a reduction in PVS recovery was observed as a result 
of thermal polymerisation, with the polymeric material visible in the flask (entry 2). At 
40 °C however, a 22% yield of cyclopropanes 15 and 16 was observed in an 
approximately 1:1 ratio of diastereoisomers as determined through analysis of the 
1H NMR spectrum of the reaction mixture following aqueous work-up (entry 3). Notably 
no dimerisation of the diazo reagent was observed, with no diethyl maleate or diethyl 
fumarate side-products present in the 1H NMR spectrum of the reaction mixture prior 
to purification.  This behaviour is typical for cobalt-catalysed cyclopropanation 
reactions utilising diazo reagents.170 This meant that there was no requirement to use 
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
H2N NH2
O
OH
t-Bu
t-Bu
EtOH, reflux, 2 h
81%
(2.0 equiv)
Co(OAc)2
(1.0 equiv)
EtOH, reflux, 4 h
91%
1)
2)
26 28
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a slow addition protocol for the diazo compound. This also allowed the diazo reagent 
to be used as the limiting reagent instead of in excess; a desirable situation due to the 
potentially explosive nature of diazo compounds. Additionally, CoII catalyst 28 was air 
and moisture stable so it did not need to be stored and handled in a glovebox, further 
increasing the practicality of this reaction. Running the reaction without the potassium 
thioacetate additive significantly increased the yield of cyclopropanes, suggesting that 
the additive was inhibiting the cyclopropanation (entry 4).  
 
Table 13: Effect of temperature and KSAc additive on the CoII-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
With the knowledge that CoII(salen)-type complex 28 successfully catalysed the 
desired reaction, a solvent screen was undertaken. A broad range of solvents were 
investigated (Table 14). Chlorinated solvents such as 1,2-dichloroethane, 
1,2-dichlorobenzene and chlorobenzene gave similar yields to dichloromethane, 
however chloroform was notably inferior and carbon tetrachloride gave no 
cyclopropanation (entries 1–6). Aromatic solvents performed well (entries 6–9), with 
benzene giving a 73% yield (entry 8). Hydrocarbon solvents resulted in reasonable 
yields, with the reaction in cyclohexane producing a 55% yield of cyclopropanes 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15 160.3 mmol
(5.0 mol%)
CH2Cl2 (0.2 M), Temperature, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
Additive (5.0 mol%)
28
Entry Additive Temperature 
(°C) 
Remaining PVS 
(equiv) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 KSAc 22 1.00 - - 
2 KSAc 30 0.85 - - 
3 KSAc 40 0.07 47:53 22 
4 - 40 0.09 52:48 40 
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(entries 10–12). More polar organic solvents gave a range of successes (entries  
13–16), with tert-butyl methyl ether giving a good yield of 69% (entry 15). Finally, H2O 
was tested which gave a quantitative yield of cyclopropanes (entry 17). The reagents 
were not soluble in H2O, and the reaction mixture appeared as regions of 
organic-soluble species being agitated by the stirring H2O. Following on from this 
observation the reaction was run as a stirring mixture of neat reagents which produced 
a 93% yield of cyclopropanes (entry 18). It therefore appeared that a high 
concentration of reagents was advantageous to the reaction. Interestingly, all solvents 
explored gave a dr of approximately 50:50. 
 
Table 14: Effect of solvent on the CoII-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15 160.3 mmol
(5.0 mol%)
Solvent (0.2 M), 40 °C, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
28
Entry Solvent Remaining PVS 
(equiv) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 CH2Cl2 0.09 52:48 40 
2 CHCl3 0.58 48:52 13 
3 1,2-DCE 0.17 47:53 41 
4 1,2-DCB 0.62 50:50 38 
5 CCl4 0.74 - 0 
6 PhCl 0.50 50:50 50 
7 Toluene 0.20 45:55 53 
8 Benzene 0.23 48:52 73 
9 Xylenes 0.33 49:51 41 
10 Pentane 0.08 50:50 34 
11 Cyclohexane 0.80 45:55 55 
12 Heptane 1.02 48:52 29 
13 THF 0.04 45:55 14 
14 Ethyl acetate 0.72 51:49 36 
15 TBME 0.54 48:52 69 
16 i-PrOH 0.53 51:49 44 
17 H2O 0.41 47:53 100 
18 No solvent 0.00 46:54 93 
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The solvent screen had shown that conducting the cyclopropanation on H2O 
(Table 14, entry 17) or neat (Table 14, entry 18) produced excellent yields of the 
desired bifunctional cyclopropyl-scaffolds on a 0.3 mmol scale. The aim of the overall 
approach was to be able to use these bifunctional scaffolds in a plethora of reactions, 
and so large quantities of the scaffolds would be required, ideally from a single 
reaction. Therefore, the next step was to investigate the scalability of the 
cyclopropanation reaction in both systems.  
 
To do this, the scale of the reaction was gradually increased from 0.3 mmol. Initially, 
the number of equivalents of PVS was decreased as the reaction scale increased, 
reducing the excess from 0.5 to 0.1 equivalents (Table 15, entries 1–6). This was due 
to the possibility that the thermal polymerisation of PVS may remain reasonably 
consistent throughout cyclopropanations of varying scales. This however was 
observed not to be the case, and a decrease in yield was observed both neat 
(entries 1, 3, 5) and on H2O (entries 2, 4, 6). Despite this, the cyclopropanation gave 
good results both neat and on H2O up to a scale of 10 mmol. When the reaction was 
run neat on a 20 mmol scale a significant exotherm was generated with concomitant 
gas evolution observed, also producing a significantly lower yield of cyclopropanes 
(entry 9). This exotherm and rapid gas evolution was not observed when the 20 mmol 
reaction was carried out on H2O, and an excellent yield was achieved (entry 10). This 
is unsurprising as H2O is an excellent heat sink because of its large heat capacity, 
facilitating exotherm dissipation.171 Due to the significantly increased safety and yield 
of the 20 mmol scale cyclopropanation reaction when run on H2O compared to when 
run neat, further scale increases for the neat protocol was not investigated further. 
Increasing the reaction scale further on H2O using 40 mmol of diazo compound 
produced an excellent yield with no vigorous gas evolution (entry 11). This 40 mmol 
reaction produced 7.9 g of isolated cyclopropanes. 
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Table 15: The effect of reaction scale on the cyclopropanation of PVS with EDA either neat or on H2O 
 
 
 
 
 
 
 
 
 
 
a Yield determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. b Reaction was run at 30 °C. c H2O (0.5 M). 
 
The optimised conditions (Table 15, entry 11) fulfilled the aims for the 
cyclopropanation reaction by allowing access to the desired bifunctional 
cyclopropanes through a high yielding, scalable and practical CoII-catalysed 
cyclopropanation of PVS with EDA. 
 
2.1.3.2. Purification of Large-Scale Cyclopropanation Reactions 
When the 28-catalysed cyclopropanation between PVS and EDA was carried out on 
a 10 mmol scale or larger, a small amount of an impurity was present that discoloured 
the cyclopropane products from pale yellow to dark brown. The impurity could not be 
removed from the cyclopropane products effectively through standard silica 
chromatography, nor could it be obtained cleanly to aid its identification. However, a 
small sample of the impurity mixed with the CoII(salen)-type catalyst 28 was obtained 
through careful chromatography of a cyclopropanation reaction mixture, giving a 
red/brown solid. The 1H NMR spectrum of the sample possessed very broad peaks, 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15 16
(5.0 mol%)
H2O (0.2 M) or neat, 40 ºC, 24 h
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
0.3 mmol
28
Entry mmol of EDA Solvent Reactant PVS 
(equiv) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1a 0.3 Neat 1.5 46:54 93 
2a 0.3 H2O 1.5 47:53 100 
3b 2.7 Neat 1.2 45:55 86 
4 2.7 H2O 1.2 47:53 100 
5 5.0 Neat 1.1 47:53 60 
6c 5.0 H2O 1.1 47:53 81 
7 10 Neat 1.5 53:47 70 
8c 10 H2O 1.5 47:53 85 
9 20 Neat 1.5 52:48 46 
10c 20 H2O 1.5 45:55 85 
11c 40 H2O 1.5 46:54 89 
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indicating that the sample contained paramagnetic species, however this could be due 
to either the impurity being paramagnetic and/or the paramagnetic CoII(salen)-type 
catalyst 28 present in the mixture (Figure 24). IR spectroscopy did not reveal the 
presence or absence of significant peaks compared to that of a sample of pure 
CoII(salen)-type catalyst 28, indicating that the unknown species possessed a similar 
structure to 28. The addition of certain solvents (e.g. i-hexane) to a sample of 
CoII(salen)-type catalyst 28 resulted in very rapid formation of a brown solid material 
that strongly resembled the impurity obtained from the CoII-catalysed 
cyclopropanation. 
 
 
Figure 24: The 1H NMR spectrum for a mixture of the unknown impurity and CoII(salen)-type complex 28  
 
Analysis of CoII(salen)-catalysed processes showed that a possible side-reaction was 
the oxygenation of the CoII(salen)-type complex to form oxidised cobalt species 
(Figure 25).172,173,174,175 With notable separate examples from Mingos176 and from 
Jackson and co-workers,177 the oxygenation of CoII amine and Schiff base complexes 
most commonly form characteristically brown µ-peroxo-dimeric species (Figure 25A).  
These dinuclear species are diamagnetic, with both cobalt ions in their +3 oxidation 
state. The structure of these species has been confirmed by characterisation including 
X-ray crystallography.178,179 
 
Less frequently, paramagnetic mononuclear ‘superoxo-like’ species are formed, 
usually when the cobalt complex is particularly sterically bulky, hindering the formation 
of a µ-peroxo-dimeric species (Figure 25B). Characterisation including EPR 
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spectroscopy and X-ray crystallography have confirmed both the electronic and 
geometric structure of these species, possessing an O2 with an end-on (h1) binding 
mode, a terminal oxygen radical and the cobalt in the +3 oxidation state.180,181,182,183   
 
A mononuclear ‘sideways bonded’ h2-superoxo complex is also possible with certain 
ligands, producing a diamagnetic complex, though their existence is rare  
(Figure 25C).177 The structure of such a species possessing a tetraamine ligand has 
been confirmed by X-ray crystallography.177 
 
 
Figure 25: The various types of cobalt-based molecular oxygen adducts 
 
Through the observations made and the existing literature on the matter, the impurity 
was assigned as an oxygenated Co(salen)-type species, however to determine which 
mode of O2 binding was present would require the isolation of the species. Both the 
diamagnetic µ-peroxo-bridged dimer and the paramagnetic ‘superoxo-like’ species 
formed from catalyst 28 have been reported and characterised by UV–vis and electron 
paramagnetic resonance (EPR) NMR spectroscopy by the Doorslaer group.178  The 
impurity posed a problem, as it couldn’t be readily removed from the desired 
cyclopropane products.  
 
In order to use the CoII-catalysed cyclopropanation on large scales in an effective 
manner, a protocol was required that would allow the easy removal of this impurity, 
granting access to the pure cyclopropane products. In developing a successful 
purification method, it was hoped to also gain knowledge on why purification of the 
cyclopropanation reaction mixture became an issue with larger reaction scales. 
 
The first purification method to be investigated was the separation of the 
cyclopropanes and the Co salen-derived impurity between non-polar and polar 
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phases. The cyclopropanes possess a non-polar nature and would therefore reside 
within a non-polar phase, and it was hoped that the presence of the metal in the 
impurity would allow for polar interactions which could draw it into the polar phase 
(Table 16).  
 
Table 16: Solvent combinations tested towards cyclopropane purification 
 
 
 
 
 
 
 
A variety of separations between i-hexane and polar solvents were attempted however 
none of them separated the Co(O2)(salen)-type species from the product 
cyclopropanes. Polar solvents were chosen that may coordinate to the metal of the 
impurity species and promote it entering the more polar phase. These solvents 
included H2O, MeOH and ionic liquid 29 (1-butyl-3-methylimidazolium 
tetrafluoroborate). Similarly, separation between xylenes and either DMF or DMSO 
did not produce the desired separation. An extension of this approach was the addition 
of a ligand which possessed the ability to form hydrogen bonds with suitable solvents. 
The hypothesis was that ligands 30–33 may coordinate to the metal of Co(salen)-type 
species and facilitate dissolution of the complex in aqueous media by hydrogen 
bonding with H2O, allowing separation from the cyclopropane products through 
organic extractions (Figure 26). Ligands 30–33 (5.0 equiv, with respect to 28) were 
added to samples of catalyst 28 in H2O (20 mL) and i-hexane (10 mL) and the resulting 
mixture was stirred at room temperature for 1 hour. The phases were then separated 
and analysed by LCMS for the presence of Co complex. For all of ligands 30–33 the 
Co complex remained almost exclusively present in the organic phase, so the process 
was repeated using Et2O (10 mL) as the organic phase. Again, the Co complex was 
almost entirely located in the organic phase after the addition of ligands 30–33. 
 
Non-polar phase Polar phase 
i-Hexane H2O 
i-Hexane H2O + MeOH 
i-Hexane 29 
i-Hexane DMSO 
i-Hexane DMSO + H2O 
i-Hexane DMF 
i-Hexane NH3(aq) (38%) 
Xylenes DMF 
Xylenes DMSO 
N
N
BF4
29
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Figure 26: Ligands tested to achieve separation between the Co-containing impurity and product cyclopropanes 
 
The next purification approach was to investigate whether the Co(O2)(salen)-type 
species was insoluble enough in a non-polar solvent to precipitate out of solution, 
allowing its removal through filtration. i-Hexane and toluene were tested however 
neither proved successful. These solvents were tested again however this time with 
prior incubation with one of ligands 30–33 (5.0 equiv) for one hour before filtration. No 
precipitation was visually observed and there was no separation of materials after 
filtration of the solution. 
 
The next approach was filtration through a stationary phase that would retain basic 
species. SCX columns are cartridges filled with a silica-based stationary phase with a 
benzene sulfonic acid sorbent which can be used to remove basic materials from a 
mixture. The aim was to investigate whether the imine nitrogen atoms in the  
Co(O2)(salen)-type impurity may result in its retention, allowing the cyclopropane 
products to pass through unhindered. The retained species may then be obtained by 
eluting with NH3/MeOH. This however was not the case, and all species eluted from 
the SCX column in the initial methanol extraction. 
 
Acid-catalysed hydrolysis of the Co(O2)(salen)-type species was explored as a route 
to decompose the impurity and allow the components to be separated from the product 
cyclopropanes. Immediately after a cyclopropanation reaction, 100 equivalents (with 
respect to 28) of HCl(aq) and methanol (10 mL) were added. The methanol was added 
to aid the solubilisation of the complex. The mixture was stirred in an ice bath for 
1 hour, however, after extraction with i-hexane the intact impurity was still present with 
the cyclopropanes. 
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Due to the significant size difference between the product cyclopropanes and a 
Co(O2)(salen)-type complex, filtration through a size exclusion medium (i.e. 
nanofiltration) was an option. Nanofiltration is the filtration of a solution or mixture 
through a membrane that possesses pores of a nanometre size. A variety of 
membranes possessing different pore sizes can be purchased, designed for the 
separation of different sized species for a variety of applications such as water 
treatment and food production.184 Assuming an approximately spherical molecular 
shape, each filter can be given an approximate molecular weight cut-off, where 
compounds whose MW exceeds this will be unable to pass through the filter. The MW 
of the Co(O2)(salen)-type impurity was estimated to be > 600 Da, given that the CoII 
catalyst possessed a MW of 604 Da. The MW of the diastereoisomeric cyclopropanes 
were 222 Da, meaning a variety of filters possessed cut-off ranges between the two 
MW’s. The Dow N270 (MW cut-off 200–400 Da), GE Osmonics HL (MW cut-off  
150–300 Da), TriSep TS40 (MW cut-off 200–300 Da) and Synder NFW (MW cut-off 
300–500 Da) membranes were tested. The membranes spanned a range of brands to 
examine their individual technologies, however they all suffered from a common 
weakness frequently encountered in nanofiltration filter membranes which was that 
they were only usable in highly polar solvents; non-polar solvents resulted in their 
decomposition. Water was the preferred nanofiltration solvent for filter stability, 
however the cyclopropanation reaction mixture was insoluble in it. Therefore 
methanol, which was also a recommended solvent, was used for the nanofiltration 
procedures. Initially the nanofiltration appeared to give purified cyclopropane products, 
indicated by the very pale yellow filtrate. However, before the filtration was complete 
there was decomposition of the filter membrane in all cases, allowing all materials to 
pass through. This likely resulted from the build-up of lipophilic Co(O2)(salen)-type 
material on the filter during the filtration process, causing the filter membrane to 
decompose in the non-polar environment. Nanofiltration options that displayed 
significantly higher tolerances to non-polar solvents were available from Evonik in the 
form of DuraMem and PuraMem, however both were prohibitively expensive. 
 
The next approach investigated the effect of basic additives in silica chromatography. 
Whilst many eluent systems had been tested early on in the purification attempts, the 
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effect of basic additives had not been explored. In order to do this, the reaction mixture 
of a 28-catalysed cyclopropanation reaction between PVS and EDA was purified by 
silica chromatography using an eluent of heptane + 1% Et3N. This obtained, in order 
of elution and after concentration under reduced pressure, the  
trans-cyclopropane (Rf = 0.46) as a pale yellow oil, the cis-cyclopropane (Rf = 0.30) as 
a pale yellow oil, the starting CoII-catalyst (Rf = 0.28) as a red solid, and when the 
eluent polarity was increased by eluting with 50–100% Et2O in heptane + 1% Et3N, 
the Co(O2)(salen)-type species (Rf = 0.00) as a brown solid (Rf values were calculated 
using the same eluent of 9:2 n-hexane:Et2O + 1% Et3N). 
 
With the isolation of the Co(O2)(salen)-type species, studies into its identity were 
continued. The isolated sample displayed a complex 1H NMR spectrum consisting of 
a multitude of sharp peaks that were located at similar chemical shifts to the 
CoII(salen)-type complex and the salen-type ligand. The signals were not broad, 
implying that the sample was a diamagnetic species. The sample also produced a 
similar IR spectrum to the CoII(salen)-type complex and the salen-type ligand. MALDI 
ToF mass spectrometry analysis of the sample showed a peak corresponding to a 
mass of 1241.9 Da, comparable to the calculated MW of the µ-peroxo-bridged dimer, 
1239.5 Da. In addition, the substance possessed the characteristic appearance 
common to µ-peroxo-bridged dimeric species derived from structurally similar CoII 
complexes.172,173,175,177,178,179 The Co(O2)(salen)-type species was therefore assigned 
as the diamagnetic µ-peroxo-bridged dimer 34 (Figure 27), originating from CoII 
complex 28. This allowed speculation on the reason for why the impurity was generally 
observed on larger-scale reactions (greater than around 2.7 mmol) and not on 
small-scale ones (up to around 2.7 mmol). As the scale of the reaction was increased, 
so was both the size of the reaction vessel and the number of empty, Ar(g) flushed 
balloons to accommodate the increased N2(g) evolution. Whilst the reaction vessel was 
flushed with Ar(g) before use, any O2(g) still present in the vessel headspace or in the 
balloons would be capable of generating the µ-peroxo-bridged dimer of CoII 
complex 28. In addition, one molecule of O2 oxygenated two complexes of 28, 
meaning only trace quantities of O2 were required to cause perceptible levels of 
catalyst oxygenation. 
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Figure 27: The structure for µ-peroxo-bridged dimer 34 
 
The addition of Et3N to the chromatography eluent had allowed separation of the 
Co(salen)-type species from the cyclopropanation reaction mixture. This enabled 
assignment of the Co(salen)-type impurity to be made, however the purification 
required careful chromatography to obtain the cyclopropyl scaffolds pure due to the 
similar Rf’s of the cis-cyclopropyl scaffold and 28. This made the basic 
chromatography method impractical. During chromatography with Et3N as an additive, 
the Co(peroxo)(salen)-type species 34 had a much lower Rf than the cyclopropanes 
and 28, whereas previously co-elution issues had been encountered. During 
chromatography, the Co(peroxo)(salen)-type species 34 appeared as a brown band, 
28 as a red band and the cyclopropanes as pale yellow bands on the silica. Visually 
analysing the chromatographic progression of the Co-catalysed cyclopropanation 
reaction mixture both with and without 1% Et3N additive to the eluent revealed that in 
the absence of Et3N, the Co(peroxo)(salen)-type species 34 was being dragged down 
the column by 28 which, in turn was co-eluting with the cyclopropane products. Thus, 
it appeared that converting any remaining 28 in the cyclopropanation reaction mixture 
to 34 would resolve the purification issues. Doing so would both remove the species 
with a similar Rf to the cyclopropanes and prevent the accelerated elution of the 
Co(peroxo)(salen)-type species. It may then be possible to remove the 
Co(O2)(salen)-type species simply by filtration through a pad of silica, obtaining the 
reaction mixture free of catalyst-derived species from the filtrate. 
 
The first step of this approach was to develop a system that oxygenated any remaining 
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CoII(salen)-type catalyst in the cyclopropanation reaction mixture to the corresponding 
µ-peroxo-bridged dimer.  
 
The O2-binding activity of a CoII complex is highly dependent on its crystal structure 
and physical state, with forms of the same species frequently being observed as 
‘active’ or ‘inactive’ towards oxygenation.174 This has been demonstrated for the 
oxygenation of CoII(salen) by Appleton who showed that the complex existed in two 
visually distinct solid forms, a brown form which was active to oxygenation and a dark 
red form which was inactive to oxygenation.185 The inactive form existed as dimeric 
units where one cobalt atom interacted with an oxygen atom (Figure 28A). The active 
form also existed as dimeric units, however one cobalt atom was directly above the 
other (Figure 28B). The larger channels in the active form allowed oxygen to enter 
easily, facilitating oxygenation. When Co(salen) was dissolved in a donor solvent (e.g. 
DMF, DMSO or pyridine) in the presence of molecular oxygen, [(solvent)Co(salen)]2O2 
rapidly formed and precipitated as a dark brown solid.185 
 
Figure 28: Reproduction of a scheme showing the ‘inactive’ and ‘active’ forms of solid CoII(salen) by Appleton185 
 
It is well documented that the oxygenation of cobalt complexes is highly dependent on 
the solvent used, and that the oxygenation process is often reversible.174,175 Air is 
usually a competent enough oxidant to oxygenate CoII complexes, however when this 
is not the case, pure O2 or H2O2 can be used.177 The most notable solvent properties 
that affect oxygenation are oxygen solubility,186 its ability to dissolve the cobalt 
species,172,187,188 and whether the solvent can facilitate oxygenation through 
coordination to the cobalt species.172,178,187,188,189 To begin this investigation, 10 mL of 
a variety of solvents were added to 10 mg samples of complex 28 and O2(g) was 
bubbled through (Table 17). Some solvent-catalyst systems showed almost immediate 
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oxygenation, such as i-hexane (entry 1), THF (entry 10), 2-MeTHF (entry 11) and DMF 
(entry 12). Notably, the properties of these solvents are in agreement with the 
necessary solvent properties mentioned previously, with THF, 2-MeTHF and DMF all 
being able to coordinate to cobalt, and i-hexane possessing an extremely high oxygen 
solubility.186 Interestingly, oxygenation in n-hexane (entry 2) proceeded much slower 
than in i-hexane (entry 1), suggesting a significant difference in solvation ability and/or 
oxygen solubility between these isomeric solvents. Given the widespread observation 
that amines can facilitate oxygenation of cobalt complexes owing to their propensity 
towards coordination, the effect of amines on the oxygenation of the cyclopropanation 
reaction mixture was investigated.172 Using pyridine as the solvent proved to give 
successful oxygenation (entry 13), however the addition of 10% Et3N to either Et2O 
(entry 14) or i-hexane (entry 15) proved to retard the oxygenation. 
 
Table 17: The effect of solvent on the oxygenation of 28 to 34  
 
 
 
Entry   Solvent   Oxygenation  observed?   Time  
1   i-­Hexane   Yes   <10  s  
2   n-­Hexane   Yes   1  min  
3   Et2O   Yes   2  min  
4   EtOAc   No   -­  
5   TBME   No   -­  
6   CH2Cl2   Yes   2  h  
7   Toluene   No   -­  
8   i-­Propanol   No   -­  
9   Acetone   No   -­  
10   THF   Yes   <10s  
11   2-­MeTHF   Yes   <10s  
12   DMF   Yes   <10s  
13   Pyridine   Yes   <10s  
14   Et2O  (+10%  Et3N)   No   -­  
15   i-­Hexane  (+10%  Et3N)   Yes   5  min  
Solvent, time
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Ideally, in addition to facilitating the oxygenation of 28, the solvent would also allow 
direct filtration of the mixture to obtain the desired cyclopropane products whilst 
completely retaining the µ-peroxo-bridged dimer. This would require the use of a 
low-polarity solvent, as a high-polarity solvent would result in co-elution of all materials. 
It could be possible to perform the oxygenation in a high-polarity solvent, concentrate 
the mixture, re-dissolve in a lower-polarity solvent and filter the mixture, however 
concentration of the oxygenated mixture under reduced pressure presented the risk 
of driving off the O2 from at least some of the µ-peroxo-bridged dimer, resulting in the 
recovery of a mixture of Co species and making the oxygenation procedure pointless. 
Therefore, the criteria for an oxygenation solvent returned to one that both facilitated 
the oxygenation and was sufficiently non-polar to retain the µ-peroxo-bridged dimer 
during filtration. The solvent that performed optimally in both of these requirements 
was i-hexane (Table 17, entry 1). 
 
Using i-hexane as the oxygenation solvent allowed successful oxygenation not only 
with pure O2 but also air. Using air is much more desirable than using pure O2 due to 
its significantly lower flammability. 
 
Having developed a practical technique to remove the Co(salen)-type species from 
the reaction mixture and allow the cyclopropane products to be obtained cleanly, the 
possibility of recycling µ-peroxo-bridged dimer 34 to obtain CoII(salen)-type complex 
28 was investigated. It has been observed that cobalt µ-peroxo-bridged dimers can 
release their bound O2 through either heating under reduced pressure or treatment 
with certain solvents such as benzene or chloroform.172,190 Based on these 
observations, a sample of CoII(salen)-type complex 28 was oxygenated with i-hexane 
to obtain the dark brown µ-peroxo-bridged dimer 34 after concentration. Dissolving 
this sample in chloroform and stirring at room temperature regenerated the vivid red 
CoII(salen)-type complex 28 along with concomitant gas evolution. Following on from 
this, a reaction mixture of the 28-catalysed cyclopropanation of PVS with EDA was 
oxygenated in i-hexane and then purified by silica chromatography to obtain samples 
of both the cyclopropane products and the µ-peroxo-bridged dimer. However, 
dissolving this sample of the µ-peroxo-bridged dimer in chloroform did not regenerate 
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CoII-catalyst 28. One possible reason for the lack of deoxygenation could be that 
residual material from the cyclopropanation reaction was hindering the loss of O2 from 
the µ-peroxo-bridged dimer. In 1977, Niswander and Taylor proposed a mechanism 
whereby the O2 was ‘locked in’ by the coordination of an external ligand.191 This 
hypothesis was based on thermogravimetric analysis of a µ-peroxo-bridged dimer that 
possessed an external ligand on each cobalt atom which showed that the O2 and the 
external ligand (e.g. solvent) were lost from the cobalt complex at approximately the 
same temperature.191 In the case of the sample from the cyclopropanation of PVS and 
EDA, the external ligand could reasonably be either H2O or excess PVS. The 
opposition towards µ-peroxo-bridged dimer deoxygenation was observed for samples 
of the µ-peroxo-bridged dimer from cyclopropanations run on H2O and neat, however 
this does not rule out H2O as a potential external ligand. This is because there were 
routes through which the µ-peroxo-bridged dimer could become exposed to H2O even 
with the neat reaction, including from the atmosphere or the solvent during work-up 
and chromatography. Alternatively, PVS may be acting as an external ligand, 
stabilising the µ-peroxo-bridged dimer. An excess of 0.5 equivalents of PVS (with 
respect to EDA) was used in the cyclopropanation reaction to compensate for loss 
through thermal polymerisation. With a catalyst loading of 5 mol%, there was likely an 
abundance (with respect to the catalyst) of PVS remaining which may be implicated 
in the stabilisation of the µ-peroxo-bridged dimer during deoxygenation conditions.  
 
In conclusion, a practical technique has been developed to remove the Co(salen)-type 
species from the cyclopropanation reaction mixture and in doing so allows the 
cyclopropane products to be obtained cleanly. 
 
2.1.3.3. Open-Flask CoII-Catalysed Cyclopropanation 
With optimised cyclopropanation and oxygenative work-up conditions in hand, effort 
was directed to try to make the cyclopropanation reaction protocol safer and simpler 
by performing the reaction under an air atmosphere. Whilst the CoII-catalysed 
cyclopropanation displayed no sudden N2(g) evolution when conducted on H2O even 
at the largest scale reactions conducted (utilising 40 mmol of EDA), by conducting the 
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reaction in an open flask N2(g) evolution would not be a safety issue, making the 
approach even more desirable, particularly for large-scale industrial applications. 
 
One potential problem with having the CoII-catalysed cyclopropanation run under an 
air atmosphere was that CoII catalyst 28 may potentially undergo oxygenation when 
under an oxygen-containing atmosphere, reducing the amount of active catalyst in the 
reaction. Conducting a 5.0 mmol scale cyclopropanation reaction using the optimised 
conditions from Section 2.1.3.1, except this time in a flask open to air, gave a greatly 
reduced yield of 25% (Table 18, entry 1). Conducting the reaction in the absence of 
solvent gave a much higher yield of 48% (entry 2), however this was notably lower 
than the 60% yield obtained under an argon atmosphere (Table 15, entry 5). Due to 
the observation that chloroform facilitates the deoxygenation of Co µ-peroxo-dimers, 
chloroform was tested as a reaction solvent under an air atmosphere, with reflux 
condensers being fitted to prevent solvent loss through evaporation. Whilst a 1.0 M 
concentration of chloroform gave a poor yield (Table 18, entry 3), a significant increase 
was observed upon increasing the concentration to 10.0 M (Table 18, entry 4).  
 
Table 18: Solvent effects on the open-flask CoII-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
a Concentration = 1.0 M. b Concentration = 10.0 M. 
 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15 165.0 mmol
(5.0 mol%)
Solvent, 40 °C, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
28
Entry Solvent PVS recovery 
(%) 
Yield 
trans + cis (%) 
1a H2O 1.16 25 
2 Neat 0.39 48 
3a CHCl3 0.15 26 
4b CHCl3 0.38 54 
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An alternative approach was explored whereby the reactants were dissolved in a 
dense organic phase which was then shielded from the atmosphere by a layer of less 
dense H2O (Figure 29). The hypothesis was that, provided the stirring was not so 
vigorous as to create a vortex within the mixture, the H2O phase would shield the 
cyclopropanation reaction mixture from the O2-containing atmosphere but the N2 
evolved from the reaction would be free to escape. Solvents that have a higher density 
than H2O primarily include chlorinated solvents, which have been shown to be capable 
of facilitating the deoxygenation of Co µ-peroxo-dimers; a desirable attribute for this 
objective. 
 
 
Figure 29: Reaction set-up for the biphasic air-atmosphere CoII-catalysed cyclopropanation of PVS with EDA 
 
To see which chlorinated solvent would be optimum for the cyclopropanation reaction, 
a sample of the solvent screen from Table 14 is shown (Table 19). The highest yielding 
chlorinated solvent was chlorobenzene (Table 19, entry 6). 
 
 
 
 
H2O phase
Higher density organic phase
Stirrer bar
H2O phase
Higher density organic phase
Stirrer bar
H2O phase
Higher density organic phase
Stirrer bar
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Table 19: The effectiveness of chlorinated solvents in the CoII-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
Diastereoselectivity was determined by 1H NMR spectroscopy. 
 
The cyclopropanation reaction was set up according to Figure 29 using a biphasic 
solvent system of chlorobenzene and H2O (Table 20, entry 1). For comparison, the 
reaction was also set up without the H2O phase (entry 2), and the open-flask reactions 
on H2O (entry 3) and neat (entry 4) are also shown. The use of chlorobenzene and 
H2O gave a poor yield (entry 1), however it was much higher than that of just 
chlorobenzene (entry 2). The use of a neat system however proved superior, giving a 
yield of 48% (entry 4). 
 
 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15 160.3 mmol
(5.0 mol%)
Solvent (0.2 M), 40 °C, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
28
Entry Solvent PVS recovery 
(equiv) 
dr 
trans:cis 
Yield 
trans + cis (%) 
1 CH2Cl2 0.09 52:48 40 
2 CHCl3 0.58 48:52 13 
3 CCl4 0.74 - 0 
4 1,2-Dichloroethane 0.17 47:53 41 
5 1,2-Dichlorobenzene 0.62 50:50 38 
6 PhCl 0.50 50:50 50 
  97 
Table 20: The CoII-catalysed cyclopropanation of PVS with EDA under an air atmosphere 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
 
Success had been obtained in achieving a reasonable yield of the desired 
cyclopropanes through a CoII-catalysed cyclopropanation under an air atmosphere. 
The optimum yield obtained of 48% was, however, significantly lower than when the 
reaction was conducted under an Ar(g) atmosphere. For this reason, the open-flask 
cyclopropanation was not investigated further. The cyclopropanation conditions 
developed in Section 2.1.3.1 continued to be used as the optimised cyclopropanation 
methodology for upcoming cyclopropanation reactions. 
 
2.1.3.4. Cyclopropanation of Alternative Reagents 
The developed cyclopropanation methodology gave access to large quantities of the 
cyclopropyl sulfide scaffolds 15 and 16. These scaffolds were hugely important to the 
project because both the ester and sulfide functionalities offered a variety of 
derivatisation possibilities. The phenyl sulfide functionality presented a group which is 
well tolerated in biology and could give facile access to oxidised functionalities 
including sulfoxides and sulfones, both of which also have a significant presence in 
medicinal chemistry. The sulfoxide functionality also presents the opportunity for 
derivatisation of the intact cyclopropane ring through a sulfoxide-metal exchange 
protocol. For projects that would definitely utilise a sulfoxide-metal exchange protocol, 
N2
O
EtO Ph
S
S
OEtO
Ph
S
OEtO
Ph
15 165.0 mmol
(5.0 mol%)
Solvent, 40 °C, 24 h
Open-air atmosphere
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
28
Entry Solvent PVS recovery 
(equiv) 
Yield 
trans + cis (%) 
1 PhCl (1.0 M) with H2O (20 mL, 0.25 M) 0.85 38 
2 PhCl (1.0 M) 0.78 14 
3 H2O (1.0 M) 1.16 25 
4 No solvent 0.39 48 
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it could be advantageous if cyclopropyl sulfoxides 35 and 36 could be formed directly 
through the cyclopropanation of phenyl vinyl sulfoxide (Scheme 27). However, when 
using the optimised conditions developed for the 28-catalysed cyclopropanation of 
phenyl vinyl sulfide with EDA, the reaction with phenyl vinyl sulfoxide was 
unsuccessful, producing no cyclopropane-containing products. This was attributed to 
the alkene of phenyl vinyl sulfoxide being too electron-deficient for reaction with the 
carbon-centred radical of the cobalt complex resulting from EDA binding to 28, 
preventing the cyclopropanation reaction.  
 
 
Scheme 27: Attempted CoII-catalysed cyclopropanation of phenyl vinyl sulfoxide with EDA 
 
In order to gain more information on the alkene requirements of the cyclopropanation 
reaction, vinyl sulfides with significantly different steric and electronic properties were 
examined. With this aim in mind, vinyl sulfides with substitution on the aryl ring were 
targeted, namely o-Me, o-CF3, p-Cl, p-CF3 and p-OMe. Oxidation of the substituted 
aryl thiols using a procedure published by Alam and co-workers192 gave the 
corresponding disulfides in almost quantitative yields (Table 21, entries 1–4). The 
p-OMe substituted aryl disulfide was not synthesised from the corresponding thiol as 
it was commercially available. Treating the disulfides with vinyl magnesium bromide 
generated the vinyl sulfides (entries 5–9). Vinyl sulfides are known to be susceptible 
to polymerisation on silica and thermally induced polymerisation, causing difficulties 
with their isolation. Electron-rich vinyl sulfides appeared to be more stable during silica 
chromatography than high pH reverse-phase chromatography (entries 5 and 9) in 
contrast to electron-deficient vinyl sulfides which responded better to high pH reverse 
phase chromatography (entries 6 and 8). The p-Cl substituted vinyl sulfide was 
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sufficiently pure to be taken on without further purification (entry 7), though based on 
the observed trends it would be expected that high pH reverse-phase chromatography 
would be a reasonable purification method if required. 
 
Table 21: Oxidative formation of symmetrical disulfides followed by vinyl sulfide synthesis 
 
 
 
a Isolated by silica chromatography. b Isolated by high pH reverse phase chromatography. c Product was sufficiently 
pure after work-up to be used without further purification. 
 
The o-CF3, p-Cl and the p-CF3 substituted phenyl vinyl sulfides were subjected to the 
neat reaction conditions. Cyclopropanation of these electron-poor vinyl sulfides 
occurred in very low yields (Table 22). The cyclopropanation appeared to favour the 
trans-diastereoisomer upon addition of an electron withdrawing group at the para 
position of the aromatic ring, however this could be an artefact resulting from 
calculating diastereoselectivity from such low yields of products and remains 
unconfirmed. 
 
 
S
R
S
S
R
RSH
R
N
N OBr
O Br
(0.25 equiv)
CHCl3 (0.1 M), rt, 2-21 h
BrMg
(1.5-2.0 equiv)
THF (0.12 M), 0 ºC, 3-4 h
R = o-Me
R = o-CF3
R = p-Cl
R = p-CF3
37
38
39
40
R = o-Me
R = o-CF3
R = p-Cl
R = p-CF3
R = p-OMe
41
42
43
44
45
Entry R Yield 
Disulfide (%) 
 Entry R Yield 
Vinyl sulfide (%) 
1 o-Me 99  5 o-Me 35a (8b) 
2 o-CF3 99  6 o-CF3 73b 
3 p-Cl 98  7 p-Cl 83c 
4 p-CF3 96  8 p-CF3 38b 
    9 p-OMe 13a 
  100 
Table 22: CoII-catalysed cyclopropanation of phenyl vinyl sulfide derivatives with substitution on the aryl ring 
 
 
 
 
 
 
  
Yields were determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene 
or dibenzyl ether). 
 
To investigate the effect of steric bulk on the diazo reagent in the cyclopropanation 
reaction, tert-butyl diazoacetate (t-BDA) was tested using the optimised conditions. 
With the potential for the difference in lipophilicity between EDA and t-BDA to result in 
different behaviour during the reaction, the reaction was explored using neat 
conditions, H2O and cyclohexane (Table 23). The reaction proceeded best in H2O 
(entry 2), giving a 76% yield of the t-butyl ester-substituted cyclopropanes 52 and 53. 
The use of t-BDA gave a slight preference towards formation of the trans-cyclopropane 
diastereoisomer 52. In all solvents tested, the cyclopropanation of t-BDA gave lower 
yields than that of EDA (Table 23, entries 1–3 and Table 14, entries 11, 17 and 18). In 
addition, t-BDA is a much more expensive reagent than EDA. For these reasons, 
cyclopropanation of t-BDA was not pursued further. 
 
 
R = o-CF3
R = p-Cl
R = p-CF3
42
43
44
46
48
50
N2
O
EtO
S
OEtO
S
OEtO
(5.0 mol%)
Neat, 40 °C, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
S
R
R R
47
49
51
28
Entry R Vinyl sulfide recovery 
(equiv) 
dr 
(trans:cis) 
Yield 
trans + cis (%) 
1 o-­CF3 1.26 51:49 8 
2 p-­Cl 0.43 67:33 3 
3 p-­CF3 0.71 65:35 1 
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Table 23: CoII-catalysed cyclopropanation of PVS with t-BDA 
 
 
 
 
 
 
 
All yields were determined by 1H NMR spectroscopy with comparison to internal standard 
(1,3,5-trimethoxybenzene or dibenzyl ether). 
 
2.1.3.5. Conclusions 
The first transition metal-catalysed cyclopropanations of PVS with EDA have been 
developed, initially using CuI and later, more successfully, utilising CoII. This enabled 
the practical synthesis of the desired trans- and cis-bifunctional cyclopropyl scaffolds 
15 and 16. The CoII-catalysed cyclopropanation has been demonstrated on a 40 mmol 
scale, generating almost 8 g of cyclopropanes in an 89% yield. The CoII(salen)-type 
catalyst 28 is air and moisture stable and it does not cause dimerisation of the diazo 
reagent, meaning that a glovebox and syringe pump are not required. A facile 
oxygenative work-up procedure was developed to facilitate the purification of the 
cyclopropane-containing products. An open-flask CoII-catalysed cyclopropanation 
procedure was developed, however with a maximum yield of 48% achieved, it was not 
utilised. The optimised CoII-catalysed cyclopropanation conditions gave low yields 
when applied to alkenes that were more electron-deficient than PVS. The sterically 
bulky diazo compound t-BDA gave very good yields under the optimised conditions. 
The cyclopropanation conditions developed in Section 2.1.3.1 continued to be used 
as the optimised cyclopropanation methodology for upcoming cyclopropanation 
reactions. 
N2
O
t-BuO
S
Ot-BuO
S
Ot-BuO
52 53
(5.0 mol%)
Solvent (0.2 M), 40 °C, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
S
(0.3 mmol)
28
Entry Solvent PVS recovery 
(equiv) 
trans:cis (dr) trans + cis (%) 
1 Neat 0.88 58:42 19 
2 H2O 0.56 57:43 76 
3 Cyclohexane 0.86 54:46 38 
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2.1.4. Asymmetric Transition Metal-Catalysed Cyclopropanation 
Asymmetric cyclopropanation reactions have been of huge interest ever since the first 
example in 1966 by the Nozaki group using chiral salicylaldimine ligands.153 The 
enantioenrichment in the cyclopropane products was very low, however it 
demonstrated that metal-catalysed cyclopropanation reactions could effect 
enantioselective control through the incorporation of chiral ligands. 
 
Since then a wide variety of transition metals have demonstrated the capability to 
catalyse enantioselective cyclopropanation reactions through the incorporation of 
enantioenriched ligands (Schemes 28–30). 
 
One notable example was produced by the Evans group, performing an asymmetric 
CuI-catalysed cyclopropanation using a chiral BOX ligand to obtain the product 
cyclopropanes in excellent yields and enantioselectivity, and with moderate 
diastereoselectivity (Scheme 28A).105 Examples of asymmetric ruthenium-catalysed 
cyclopropanations have been developed by the Nishiyama group107 utilising a PyBOX 
ligand (Scheme 28B) and by the Miller group108 using a salen-type complex 
(Scheme 28C). 
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Scheme 28: Asymmetric transition metal-catalysed cyclopropanation reactions 
 
An example of asymmetric rhodium-catalysed cyclopropanation has been 
demonstrated by the Davies group using a ‘paddle wheel’ complex to obtain 
trifunctionalised cyclopropanes in excellent yields and with extremely high 
enantioselectivity (Scheme 29A).106 Asymmetric palladium-catalysed 
cyclopropanation was attempted by the Denmark group, however despite the reaction 
proceeding in excellent yields with a variety of chiral complexes, the cyclopropane 
O
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Ph
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CO2Et
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CO2Et
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99% ee
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97% ee
CHCl3, 25 ºC(5 equiv)
CuOTf (1 mol%)
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(5 equiv) CH2Cl2, 30−35 ºC, 20 h
CO2Me
Ph
82% yield (54 + 55)
trans:cis = 89:11
CO2Me
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NO
N N
O
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(7 mol%)
[RuCl2(p-cymene)]2 
(2.5 mol%)
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(5 equiv)
(1 mol%)
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CO2Et
OEt
80% yield (56 + 57)
trans:cis = 80:20
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A)
C)
B)
54
92% ee
55
97% ee
56
69% ee
57
78% ee
N N
O O
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t-Bu t-Bu
t-But-Bu
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products were racemic (Scheme 29B).193 After product decomposition and 
racemisation were ruled out experimentally, the lack of enantio-induction was 
attributed to either partial or complete decomplexation of the chiral ligand during the 
course of the reaction. 
 
 
Scheme 29: Examples of asymmetric rhodium- and palladium-catalysed cyclopropanation reactions 
 
Katsuki developed a salen-type/BINOL-derived ligand which when used in a  
CoII-catalysed cyclopropanation gave excellent yields and enantioselectivities and 
was highly cis-selective (Scheme 30A).110 Asymmetric CoII-catalysed 
cyclopropanation has also been demonstrated by Zhang with a chiral porphyrin CoII 
complex to synthesise a wide variety of trisubstituted cyclopropanes in excellent 
yields, enantioselectivities and cis-diastereoselectivity (Scheme 30B).111 
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Scheme 30: Examples of asymmetric cobalt-catalysed cyclopropanation reactions 
 
It is notable that the vast majority of successful asymmetric cyclopropanations have 
been carried out on substrates with limited conformational flexibility in the vicinity of 
the alkene, predominantly using styrene-derivatives but also including acrylates, 
acrylamides, vinyl ethers and vinyl amines. These substrates delocalise electron 
density between the alkene and the adjacent oxygen/nitrogen heteroatom or aromatic 
ring due to the efficient orbital overlap between the C 2𝑝 and C/N/O 2𝑝 orbitals, with 
the stabilisation resulting in restricted rotation about the C-C/N/O s-bond. These 
compounds are more successful in asymmetric cyclopropanations as a result of the 
increased rigidity of the alkene. This increased rigidity allows the chiral information of 
the chirality source to be transferred to the cyclopropanation transition state more 
N N
O O
Co
Ph Ph
N2
t-BuO2C
(5 equiv)
OMe
(5 mol%)
NMI (10 mol%)
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94% yield
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O
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(1.2 equiv)
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O
n-hexane, -20 ºC, 24 h
(1 mol%)
99% yield
cis:trans >99:1
87% ee
A)
B)
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efficiently, enabling greater enantioenrichment in the product cyclopropanes. In 
contrast, there is free rotation around the two C-S s-bonds of PVS at 25 °C, giving 
significant conformational flexibility around the alkene (Figure 30).194,195 
 
 
Figure 30: Relevant modes of bond rotation present in PVS 
 
A rare and important example of a transition metal-catalysed cyclopropanation of a 
vinyl sulfide by diazo-derived carbene insertion into an alkene was reported by White 
and Shaw in 2014, who developed an enantioenriched chiral CoII catalyst to 
cyclopropanate a variety of 1,1-substituted alkenes.139 The cyclopropanation gave an 
excellent yield, high diastereoselectivity and high enantioselectivity with the 
1,1-substituted vinyl sulfide example (Scheme 25), though all three values were 
significantly lower than those obtained for the rest of the alkene scope. With respect 
to the stereoselectivity, it is significant that the presence of the n-propyl chain on the 
vinyl sulfide would sterically hinder the rotation of the thiophenyl group. 
 
2.1.4.1. Asymmetric CuI-Catalysed Cyclopropanation of PVS with EDA 
A considerable amount of success has been achieved in the field of CuI-catalysed 
asymmetric cyclopropanation. A notable example was produced by the Evans group 
which used a CuI(BOX) catalyst (Scheme 31A).105 In fact, CuI salts and 
bisoxazoline-derived ligands have proved to be a particularly effective combination for 
asymmetric cyclopropanation (Scheme 31).196,197  
 
S
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Scheme 31: CuI-catalysed cyclopropanation reactions utilising CuI(BOX) catalytic systems. A).105 B).197  
 
The proposed mechanism of stereo- and enantio-induction was detailed by Haufe and  
co-workers, using a fluorostyrene substrate as an example (Schemes 31B and 32).197 
The substituents on the carbene carbon are perpendicular to the plane of the BOX 
ligand. When the alkene approaches the CuI(carbene)(BOX) complex, a number of 
steric interactions take place, contributing to the transition state energy for the 
formation of each cyclopropane isomer. The interactions between the substituents on 
the alkene and the substituents on the carbene (Scheme 32) are significant in 
determining which diastereoisomer is favoured. The asymmetric induction was 
explained by an interaction between the carbene substituents and the BOX ligand. In 
the case of attack of the olefin on the si face of the carbene (Scheme 32A), a steric 
interaction with the bulky R group of the BOX ligand would hinder the rotation of the 
ester group into the plane necessary for cyclopropane formation. Since such an 
interaction is absent for the alkene attacking the re face of the carbene (Scheme 32B), 
the latter is favoured. Selectivity was observed to increase as R increased in size. The 
gem-dimethyl group on the BOX ligand acts to fine-tune the bite angle between the 
nitrogen donor atoms and the copper metal. 
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Scheme 32: Proposed mechanism for asymmetric CuI(BOX)-catalysed cyclopropanation197 
 
A structurally similar type of complex is derived from the PyBOX ligand. Such 
Cu(PyBOX) complexes have also been utilised in asymmetric cyclopropanations of 
various alkenes (Scheme 33).198 
 
 
 
Scheme 33: CuIIPyBOX-catalysed asymmetric cyclopropanation of styrene198 
 
With a considerable number of CuI(BOX)-catalysed cyclopropanation examples 
present in the literature, a range of BOX ligands were tested with the optimised 
CuI-catalysed cyclopropanation conditions for PVS and EDA (Table 24, entries 1–5). 
The ligands were chosen so that they possessed a variety of side-arms and 
investigated whether the gem-dimethyl motif was beneficial to the cyclopropanation. 
 
Ligand 17 had been used in the optimisation of the CuI-catalysed reaction and was 
found to generate no observable enantioselectivity for the trans-diastereoisomer 
O
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35% ee
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(Table 24, entry 1). Insufficient material was obtained for the cis-diastereoisomer to 
obtain an enantioselectivity value, denoted by a dash in Table 24. The slight variation 
in yield between entry 1 and previous entries in the optimisation of the 
cyclopropanation reaction (Table 12, entry 18) was due to the capricious nature of the 
CuI-catalysed reaction. Changing the i-Pr ligand arms to the more sterically bulky t-Bu 
produced a very small amount of enantioselectivity (entry 2). Removal of the 
gem-dimethyl groups on the ligand had very little effect on the yield or selectivity of 
the reaction (entry 3). Introducing phenyl ring substituents onto the ligand increased 
the selectivity, though it still remained < 10% ee (entry 4). Benzyl ligand arms resulted 
in a decrease in enantioselectivity (entry 5) compared to t-Bu (entry 2) and phenyl 
(entry 4). There was very little variation in the yield and diastereoselectivity of the 
cyclopropanation reaction with these BOX ligands, despite the significantly different 
steric bulk of the various ligand arms. A PyBOX ligand was tested due to the 
observation that enantioenriched chiral Cu(PyBOX) catalytic systems are capable of 
transferring chiral information during cyclopropanation reactions,198 however this 
resulted in very low enantioselectivity, extremely low diastereoselectivity and a yield 
of only 20% (entry 6). 
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Table 24: CuI-catalysed enantioselective cyclopropanation of PVS with EDA 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (1,3,5-trimethoxybenzene). 
 
Due to the lack of success in developing a valuable asymmetric CuI-catalysed 
cyclopropanation reaction, the use of enantioenriched CoII(salen)-type catalysts was 
investigated. 
 
2.1.4.2. Asymmetric CoII-Catalysed Cyclopropanation of PVS with EDA 
Enantioenriched chiral CoII(salen)-type complexes have been widely utilised in 
asymmetric syntheses, including asymmetric cyclopropanation.110,139,199 Chiral 
salen-type complexes contain one or more element of chirality on the ligand, with the 
carbon numbering for the salen-type skeleton shown in Figure 31. Insight into the 
mechanisms of chiral induction by enantioenriched chiral salen-type complexes has 
been developed through notable contributions by the Jacobsen group and the Katsuki 
group. The presence of a chiral diamine backbone causes the complex to possess a 
‘stepped’ conformation, with one aromatic ring of the salen-type complex protruding 
EtO
O
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Ligand (1.1 mol%)
S
EtO O
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EtO O
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N N
O
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O
N N
O
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O
N N
O
t-Bu t-Bu
O
N N
O
Ph Ph
O
N N
O
Ph Ph
N
N
OO
N
i-Pr i-Pr
17 60 61
62 63 64
CHCl3 (0.14 M), 30 °C, 24 h
Ph
S
(2.0 equiv) 15* 16*
Entry Ligand Diazo 
dimerisation (%) 
ee 
(trans) 
ee 
(cis) 
dr 
trans:cis 
Yield 
trans + cis (%) 
1 1 13 0 - 53:47 40 
2 2 18 3 2 53:47 37 
3 3 7 3 2 51:49 35 
4 4   23 7 6 51:49 34 
5 5   3 2 - 54:46 37 
6 6   7 3 - 53:47 20 
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below the plane of the coordinated transition metal and one aromatic ring protruding 
above (Scheme 34).200,201,202 When the diazo species reacts with the transition metal 
with concomitant release of N2, the most sterically bulky substituent on the carbene 
carbon is directed towards the downwards-facing side of the complex to reduce 
unfavourable interactions.200  
 
 
Figure 31: Carbon numbering for the salen-type complex skeleton 
 
The successful approach trajectory of the alkene is subject to debate, with three likely 
possibilities having been identified. It is widely recognised that the alkene takes a  
side-on perpendicular approach towards the transition metal complex.203,204,205,206 For 
all three alkene approach trajectories a common requirement for enantioselectivity is 
the inclusion of bulky substituents on the ligand to prevent the alkene approaching 
from the opposite side to the diamine (Scheme 34, approach c and Scheme 35, 
approach g).203,207  
 
The first two approaches were described by Jacobsen and were dependent upon the 
ligand employed.203 When a bulky diamine backbone such as a chiral 
1,2-diphenylethylenediamine is used, approach d is blocked off. The presence of a 
chiral diamine results in the complex adopting a ‘stepped’ conformation, and the 
alkene attacks from the ‘downward’ facing aromatic ring as it is more accessible 
(approach a).203  
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Scheme 34: Explanation of enantioselectivity of chiral 1,2-diphenylethylenediamine-derived salen-type complexes 
 
The second approach described by Jacobsen is applicable when a less sterically bulky 
diamine such as a 1,2-diaminocyclohexane is used, and bulky groups on the 
salicylaldehyde-derived section of the complex prevent approaches g, e and f 
(Scheme 35).203 In this circumstance attack from the side of the chiral diamine is 
possible (approach h).203  
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Scheme 35: Explanation of enantioselectivity of chiral 1,2-diaminocyclohexane-derived salen-type complexes 
 
An alternative alkene approach has been described by Katsuki that incorporated 
electronic effects.207 The observation that conjugated alkenes generally gave higher 
enantioselectivities than alkyl-substituted alkenes led to the proposal that repulsive  
p-p interactions also played a part in determining the enantioselectivity of the 
cyclopropanation by affecting alkene orientation during its approach.207 As an alkene 
approaches the transition metal complex along trajectory l (Scheme 36), it is exposed 
to a different electronic environment operating on either side of the N---M axis. The 
salicylaldehyde-derived component of the ligand is rich in p-electrons whereas the 
aliphatic diamine component has no p-electrons. Therefore, alkenes that possess 
substituents that are rich in p-electrons such as styrenes suffer p-p electronic repulsion 
which directs the p-electron-rich substituent towards the cyclohexyl part of the 
complex. This mechanistic approach predicts that alkenes bearing a substituent that 
is both p-electron rich and sterically bulky will generally elicit high enantioselectivity as 
a result of the synergistic alkene-orienting effects of p-p repulsive interactions and 
steric repulsion between the alkene substituents and the complex. This explains why 
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styrene-derivatives are frequently shown to give extremely high enantioselectivities in 
asymmetric salen-type complex-catalysed cyclopropanation reactions.164 
 
 
Scheme 36: Katsuki’s explanation for the enantioselectivity of chiral salen-type complexes207 
 
It was observed that the enantioselectivity of cis-alkenes was controlled principally by 
the chiral diamine backbone whereas the enantioselectivity of trans-alkenes was 
largely dictated by chirality attached at the C9 and C9’ positions.208 This was proposed 
to be due to cis-alkenes approaching the complex parallel to the plane of the complex, 
whereas trans-alkenes approach diagonally from above the complex to minimise steric 
clash of the alkene substituents with the complex (Figure 32A).208 These different 
trajectories result in cis- and trans-alkenes being influenced differently by chirality at 
different positions on the complex (Figure 32B).208 
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Figure 32: A) The different proposed alkene trajectories for cis- and trans-alkenes towards salen-type 
complexes.208 B) Approximate regions of influence for chirality at the C8 (and C8’) and the C9 (and C9’) carbons.  
C’ functionalities have been removed for visual clarity.208  
 
In all cases the asymmetric induction is dependent on a combination of factors being 
fulfilled; the induction of a conformational preference for the diazo-derived component 
through a ‘stepped’ complex, the selection of an alkene approach trajectory through 
appropriate ligand structure, and obtaining facial selectivity of the incoming alkene 
through appropriate ligand structure. 
 
With the success of the racemic cyclopropanation of PVS with EDA catalysed by CoII 
complex 28, an enantiopure variant of 28 was obtained commercially, and a variety of 
structurally-related enantiopure CoII(salen)-type complexes were synthesised that 
would investigate the effects of catalyst steric bulk and electronic properties on the 
asymmetric cyclopropanation of PVS with EDA (Scheme 37). These enantiopure 
complexes were used in neat asymmetric CoII-catalysed cyclopropanation reactions 
of PVS with EDA (Table 25). The major enantiomeric products were (1S,2R)-15 and 
(1S,2S)-16, determined through comparison of chiral HPLC data with that of 
enantiopure material whose configuration had been confirmed by X-ray 
crystallography (Section 2.1.4.3). Enantiopure complex 28* gave a reasonable 
enantioenrichment of 40% for the trans-diastereoisomer and a good 
enantioenrichment of 64% for the cis-diastereoisomer (Table 25, entry 1). 
Replacement of the 1,2-diaminocyclohexane backbone with a 
1,2-diphenylethylenediamine backbone drastically reduced the yield to 6% and 
significantly reduced the enantioselectivity for both diastereoisomers (entry 2). The 
reduction in yield was likely attributed to all alkene approaches being blocked by either 
the t-Bu groups on the salicylaldehyde component or the phenyl groups of the diamine 
component. 
N
N
O
O
M
R
Me
Ar
H
Et
N N
O OM
RS RL
RS
RLH
H
H H
A) B)
  116 
 
74
NN
EtO
OO
OEt
Co
H2N NH2
O
OH
OEt
EtOH (0.03 M)
reflux, 3.5 h
97%
(2.0 equiv)
Co(OAc)2
(1.0 equiv)
EtOH, H2O, toluene
reflux, 1 h
54%
2)
3)
Cl
Cl
Cl
Cl
1) NCS (2.12 equiv)
AcOH (0.26 M)
reflux, 17 h
71%
(0.5 equiv)
N
O
N
O
Co
t-Bu
NN
t-Bu
O O
N
O
N
O
Co
HOOH
N
OH
N
HO t-Bu
NN
t-Bu
O O
N
OH
N
HO
HOOH
68
69
Co(OAc)2 (1.0 equiv)
EtOH (0.08 M)
reflux, 17 h
14%
Co(OAc)2 (1.0 equiv)
EtOH (0.05 M)
reflux, 17 h
14%
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
H2N NH2
O
OH
t-Bu
t-Bu
EtOH (0.06 M)
reflux, 20 h
61%
(2.0 equiv)
Co(OAc)2
(1.0 equiv)
EtOH, H2O, toluene
 reflux, 3 h
75%
1)
2)
NN
EtO
OO
OEt
Co
H2N NH2
O
OH
OEt
EtOH (0.07 M)
reflux, 3 h
98%
(2.0 equiv)
Co(OAc)2
(1.0 equiv)
EtOH, H2O, toluene
 reflux, 3 h
88%
1)
2)
71
66
  117 
 
Scheme 37: Synthesis of enantiopure chiral CoII(salen)-type complexes. The synthesis of 66 proceeded via Schiff 
base 65, 71 proceeded via Schiff base 70, 74 proceeded via aldehyde 72 and Schiff base 73, and 76 proceeded 
via Schiff base 75. 
 
CoIIsalen (67) possessed far less steric bulk than complexes 28* and 66 and due to 
an absence of chirality would not result in enantioenriched cyclopropanes, however it 
was of interest to observe how a lack of steric bulk around the catalyst affected 
catalytic performance in the cyclopropanation reaction. A significant decrease in yield 
was observed compared to 28*, however it did show that even such a rudimentary 
ligand was able to give a reasonable yield of the desired cyclopropanes. Next, complex 
68 was examined (entry 4), possessing the 1,2-diaminocyclohexane backbone and an 
intermediate steric bulk between complexes 28* and 67. Complex 68 gave extremely 
low yields and there was not enough cyclopropane-containing material generated to 
obtain enantioselectivity data. Complex 69 possessed alcohol functionality and very 
little steric bulk around the complex, and gave an extremely low yield of cyclopropanes 
(entry 5). The ethyl diether variant, complex 71, gave a slightly higher yield and 
reasonable enantioselectivity for both diastereoisomers (entry 6). Carreira has 
demonstrated that chlorinated salen-type complexes similar to complex 74 can give 
higher yields in transition metal-catalysed cyclopropanation reactions than their 
non-chlorinated counterparts.209 Using the methodology described by Carreira and 
co-workers,209 the tetrachlorinated analogue of complex 71 was synthesised and 
tested, with the increased steric bulk and reduced electron-richness resulting in a 
significantly reduced yield (entry 7). Synthesis of the electron-poor tetraiodo 
CoII(salen)-type complex 76 gave a low yield of cyclopropanes with low 
enantioselectivities for both trans and cis diastereoisomers. 
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Table 25: The effect of enantiopure chiral catalyst structure on the enantioselective cyclopropanation of PVS with 
EDA 
 
 
 
 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
Diastereoselectivity was determined by 1H NMR spectroscopy. As illustrated, the major enantiomeric products were 
(1S,2R)-15 and (1S,2S)-16. 
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Entry Complex ee 
(trans) 
ee 
(cis) 
dr 
trans:cis 
Yield 
trans + cis (%) 
1 28* 40 64 47:53 100 
2 66 32 42 44:56 6 
3 67 - - 48:52 40 
4 68 - - 49:51 5 
5 69 - - 43:57 6 
6 71 51 57 49:51 17 
7 74 - - 57:43 4 
8 76 29 23 50:50 9 
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After generating and testing a diverse range of highly enantioenriched CoII-containing 
salen-type complexes in the cyclopropanation of PVS with EDA (Table 25) it was 
apparent that complex 28* gave the most promising overall asymmetric 
cyclopropanation, determined as a combination of giving the highest yield of products 
and inducing some of the highest enantioselectivities. The effect of reaction solvent 
and temperature using complex 28* was therefore investigated to try to optimise this 
asymmetric cyclopropanation further (Table 26). A solvent screen was conducted on 
a range of solvents with very different properties (Table 26). From this it was clear that 
conducting the reaction in cyclohexane produced the highest enantioselectivities in a 
reasonable yield (entry 4), and conducting the reaction on H2O gave the highest yield 
with reasonably good enantioselectivity observed (entry 5). 
 
Table 26: Solvent effects on the asymmetric 28*-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
Diastereoselectivity was determined by 1H NMR spectroscopy. As illustrated, the major enantiomeric products were 
(1S,2R)-15 and (1S,2S)-16. 
 
Given the observation by White and Shaw that electron-donating additives could 
increase the enantioselectivity of CoII-catalysed cyclopropanation reactions, the effect 
of additives was investigated.139 The most successful additives from the work by White 
and Shaw were chosen,139 however none gave significant improvements (Table 27). 
N2
O
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S
OEtO
Ph
S
OEtO
Ph
15* 16*
(5.0 mol%)
Solvent (0.2 M), 40 ºC, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
S
Ph
28*
Entry Solvent ee 
(trans) 
ee 
(cis) 
dr 
trans:cis 
Yield 
trans + cis (%) 
1 Benzene 44 60 48:52 73 
2 Toluene   47 63 44:55 53 
3 TBME 49 66 48:52 69 
4 Cyclohexane   53 73 45:55 55 
5 H2O   40 64 47:53 100 
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Table 27: Effect of additives in the asymmetric cyclopropanation optimisation using CoII(salen)-type complex 28* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
Diastereoselectivity was determined by 1H NMR spectroscopy. As illustrated, the major enantiomeric products were 
(1S,2R)-15 and (1S,2S)-16. 
 
The effect of reducing the reaction temperature was investigated for the 
cyclopropanation on H2O and in cyclohexane (Table 28). Testing a variety of 
temperatures on H2O showed only very small gains in enantioselectivity over the 
temperature range investigated but a sharp decrease in yield was observed at 20 °C 
(entry 4). A sample of these temperatures were investigated using cyclohexane as the 
reaction solvent and again there was very little difference in the enantioselectivity of 
the reaction (entries 5 and 6). 
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(5.0 mol%)
Additive (5 mol%)
H2O, 40 ºC, 24 h
(1.5 equiv)
NN
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Co
S
Ph
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Entry Additive ee 
(trans) 
ee 
(cis) 
dr 
trans:cis 
Yield 
trans + cis (%) 
1 None 40 64 47:53 100 
2 KSAc 48 63 48:52 100 
3 DMSO 46 66 48:52 100 
4 Br2 - - - 0 
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Table 28: Temperature effects on the asymmetric 28*-catalysed cyclopropanation of PVS with EDA 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
Diastereoselectivity was determined by 1H NMR spectroscopy. As illustrated, the major enantiomeric products were 
(1S,2R)-15 and (1S,2S)-16. 
 
Investigation into the enantioselective cyclopropanation of PVS and EDA with 
CoII(salen)-type complexes generated two sets of optimised conditions, both utilising 
enantiopure CoII(salen)-type complex 28*. These sets of conditions enabled 
enantioenrichments of 56% (trans) and 77% (cis) to be achieved. 
 
2.1.4.3. Isolation and Characterisation of Single Enantiomers  
With the difficulties observed in achieving an asymmetric cyclopropanation, separation 
of the enantiomers was explored. Chiral SFC is a powerful method for the separation 
of chiral species into their single enantiomers and is commonly utilised for industrial 
applications.210 SFC is similar to HPLC, except that SFC utilises a supercritical fluid 
such as CO2 as an eluent and is notable for its increased speed and efficiency as well 
as its reduced environmental impact.210  
 
Using chiral SFC, a sample of approximately 500 mg of trans-diastereoisomer 15 was 
separated into its individual enantiomers with high efficiency (1S,2R = 100% ee, 
N2
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S
OEtO
Ph
S
OEtO
Ph
15* 16*
(5.0 mol%)
Solvent (0.2 M), Temperature, 24 h
(1.5 equiv)
NN
t-Bu
t-Bu
OO
t-Bu
t-Bu
Co
S
Ph
28*
Entry Solvent Temperature (°C) ee 
(trans) 
ee 
(cis) 
dr 
trans:cis 
Yield 
trans + cis (%) 
1 H2O 40 40 64 47:53 100 
2 H2O 30 48 65 47:53 92 
3 H2O 25 51 66 47:53 92 
4 H2O 20 52 77 45:55 57 
5 Cyclohexane 40 53 73 45:55 55 
6 Cyclohexane 25 56 74 40:60 68 
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1R,2S = 97.1% ee, see experimental section, Figure 54 for details). The same process 
was undertaken to achieve enantiopure samples of both enantiomers of 
cis-diastereoisomer 16 (1S,2S = 100% ee, 1R,2R = 99.4% ee, see experimental 
section, Figure 55 for details). The enantiopure sulfides were oils, however oxidation 
using an excess of mCPBA produced the corresponding enantiopure sulfones as 
crystalline solids (sulfide oxidation is covered in more detail in Section 2.3.1).  
 
These enantiopure sulfones were analysed by single crystal X-ray diffraction to 
determine their absolute configurations, aided by the presence of the heavy sulfur 
atom (Figure 33). The crystallographic data can be found in the Cambridge 
Crystallographic Data Centre (CCDC), with the corresponding CCDC references given 
in Figure 33. The assignment of absolute configuration for each of the enantiopure 
sulfones was then used to assign the absolute configuration of the corresponding 
ancestral enantiopure sulfide.  
 
 
Figure 33: X-ray crystal structures for enantiopure cyclopropyl sulfones with their corresponding absolute 
configuration and CCDC references 
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Optical rotation data in the form of [𝛼]$%&  measurements of each of the enantiopure 
compounds are shown in Figure 34, which allows future absolute configurational 
assignment of enantiopure samples of this scaffold to be made through simple optical 
rotation measurement. 
 
 
Figure 34: Specific rotation data and absolute configuration for enantiopure synthesised compounds. Optical 
rotations were measured in CHCl3. Concentration (c) is in units of g mL-1 
 
Through the use of chiral SFC, significant quantities of enantiopure bifunctional 
cyclopropyl scaffolds have been obtained. This could be of tremendous use in 
situations where the absolute configuration of the target cyclopropane-containing 
products is important to the biological activity or function of the compounds.  
 
It is of importance to note that for the derivatisation of the bifunctional cyclopropyl 
scaffolds (Sections 2.2, 2.3 and 2.4), racemic material was used. 
 
2.1.4.4. Conclusions 
In pursuit of an effective synthesis of enantiomerically-enriched scaffolds 15 and 16, 
an asymmetric cyclopropanation of PVS with EDA was examined, investigating a 
variety of CuI(BOX), CuI(PyBOX) and CoII(salen)-type complexes. Two sets of 
prominent conditions were developed for enantiopure CoII(salen)-type complex 28*, 
inducing enantioenrichments of 56% (trans) and 77% (cis). Chiral supercritical fluid 
chromatography enabled access to enantiopure samples of 15 and 16. X-ray 
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crystallography of the corresponding sulfones allowed the absolute configuration of 
each isomer, and hence the absolute configuration of the precursor sulfides, to be 
determined. It is important to make clear that the upcoming derivatisation of the 
bifunctional cyclopropyl scaffolds (Sections 2.2–2.4) employed racemic material. 
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2.2. Scaffold Functionalisation: Ester Derivatisation 
Having developed a high yielding and scalable synthesis of racemic bifunctional 
cyclopropyl scaffolds 15 and 16, a variety of methods were developed that allowed the 
functionalisation of these scaffolds by manipulation of the synthetic handles. 
 
2.2.1. Hydrolysis 
Hydrolysis of the ethyl ester of cyclopropanes 15 and 16 would generate the 
corresponding cyclopropyl carboxylic acid compounds. Cyclopropyl carboxylic acid 
compounds are widely found in biologically active natural products and 
pharmaceutical compounds (Figure 35).211, 212 ,213 ,214  
 
 
Figure 35: Structures for selected biologically active cyclopropyl carboxylic acids. References: 
(+)-trans-chrysanthemic acid,211 cis-L-a-(carboxycyclopropyl)glycine,212 MK-0952,213 UPF-648.214 
 
A variety of literature methods enable the hydrolysis of an ethyl ester-substituted 
cyclopropane to the corresponding carboxylic acid-substituted cyclopropane, with a 
notable example being produced by the Padwa group (Scheme 38).215 The readily 
available reagents and facile reaction set-up made this an attractive approach. 
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Scheme 38: Base-mediated hydrolysis of an ethyl ester-substituted cyclopropane by Padwa215 
 
A similar set of conditions were established for the hydrolysis of 15 and 16 with very 
successful results. Following acidic work-up, quantitative yields of the carboxylic acids 
were obtained with both the trans- and the cis-diastereoisomers with no epimerisation 
observed in either case (Scheme 39).  
 
 
Scheme 39: Base-mediated hydrolysis of 15 and 16 to generate carboxylic acids 79 and 80, respectively 
 
The corresponding sodium carboxylate salt was isolated in a quantitative yield by 
concentrating the reaction mixture after reaching completion instead of conducting an 
acidic work-up (Scheme 40). 
 
 
Scheme 40: Synthesis of sodium carboxylate-substituted cyclopropanes 81 and 82 from 15 and 16, respectively 
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These sodium carboxylate-substituted cyclopropanes presented significant potential 
as cyclopropyl-building blocks. Possible transformations of the sodium carboxylate 
salts included amidation,216 esterification,217 and reduction.218 
 
2.2.2. Amidation 
Amide bond formation utilising the ethyl ester functionality of cyclopropanes 15 and 
16 would allow the divergent synthesis of a variety of amide-substituted 
cyclopropanes, which are important motifs in medicinal chemistry (Figure 36).219,220  
 
 
Figure 36: Structures for selected biologically active amide-substituted cyclopropanes. References: GPR88 
agonist.219 VU0359595.220 
 
To test amidation conditions, the cis-cyclopropyl scaffold 16 was used due to the 
increased steric bulk around the ester. Benzylamine was used as the amine reactant 
due to its high reactivity in amidation reactions. 
 
Initially catalytic systems were tested. Porco Jr. developed an amidation system that 
used 10 mol% of Zr(Ot-Bu) and was capable of utilising a broad scope of esters and 
amines.221 Similar conditions were tested to those optimised by Porco Jr., changing 
the catalyst to Zr(Oi-Pr)·HOi-Pr due to the significantly lower air and moisture 
sensitivity of this species (Scheme 41). The reaction failed to give any amide product 
and the reactant ester was recovered. This lack of reactivity may be attributed to the 
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cyclopropane donating electron density into the ester p-system making it less reactive, 
use of a less reactive catalyst or coordination of the sulfur to the catalyst. 
 
 
Scheme 41: Attempted Zr(Oi-Pr)·HOi-Pr-catalysed amide bond formation 
 
Morimoto and Ohshima reported a protocol that used La(OTf)3 as a catalyst for amide 
bond formation using a variety of ethyl esters, including examples that were 
conjugated to aromatic systems.222 When an enantioenriched chiral centre was 
present a to the ester carbonyl carbon, enantioenrichment was retained. Following on 
from this promising research, the optimised conditions were replicated using the 
cyclopropyl ester 16, however no reaction was observed (Scheme 42). 
 
 
Scheme 42: Attempted La(OTf)3-catalysed amide bond formation 
 
Jamieson has shown that 20 mol% of trifluoroethanol can catalyse the amidation of a 
variety of methyl esters, however when an enantioenriched chiral centre was present 
a to the ester carbonyl carbon, almost complete racemisation was observed.223 The 
optimised conditions were tested with cyclopropyl ester 16 however no reaction was 
observed (Scheme 43). 
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Scheme 43: Attempted trifluoroethanol-catalysed amide bond formation 
 
Ishar has shown that Montmorillonite can act as a catalyst in microwave-assisted 
amidation reactions.224 Whilst only a small substrate scope was achieved by Ishar, the 
optimised conditions were tested on 16 for 20 minutes however no amidation product 
was observed (Scheme 44). The reaction was run again but with 10 equivalents of 
benzylamine and at 190 °C, however again no reaction was observed. 
 
 
Scheme 44: Attempted Montmorillonite-catalysed amide bond formation 
 
Next, the cyclopropyl carboxylate was investigated with stoichiometric reagents. It has 
already been shown that the cyclopropyl sodium carboxylates 81 and 82 can be easily 
generated in a quantitative manner from esters 15 and 16, respectively (Section 2.2.1). 
Batey has shown that sodium carboxylates can be used directly in HBTU-mediated 
amide bond formation reactions.216 Due to the carboxylate of 81 and 82 having an 
a chiral centre there was concern over the potential for epimerisation. Low levels of 
epimerisation have been noted to occur by Batey for a variety of substrates.216 It has 
been observed that amidation using the structurally similar coupling reagent HATU 
results in significantly less epimerisation than the same couplings using HBTU.225 
Using conditions inspired by the work by Batey,216 sodium carboxylates 81 and 82 
were successfully reacted with benzylamine, morpholine, 1-methylpiperazine and 
1,2,3,4-tetrahydroquinoline to produce a variety of amide substituted cyclopropanes 
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(Scheme 45). Primary, secondary and anilinic amines were successful with this 
protocol, producing the amide-substituted cyclopropanes 83–90 in excellent yields and 
with no epimerisation in any examples. 
 
 
Scheme 45: HATU-mediated amide bond formation of cyclopropyl carboxylates 81 and 82 
 
2.2.3. Reduction to an Alcohol 
The cyclopropylmethanol motif can be found in medicinally relevant compounds, 
notably in molecules belonging to the constanolactone and solandelactone families, 
and other structurally-similar compounds such as halicholactone (Figure 37).226,227,228  
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Figure 37: Structures of some cyclopropylmethanol-containing natural products.  
References: Constanolactone  A.226 Solandelactone G.227 Halicholactone.228 
 
The cyclopropylmethanol motif could be generated from scaffolds 15 and 16 by 
reduction of the ethyl ester. Reductions of cyclopropyl esters typically involve the use 
of a strong hydride reducing agent such as LiAlH4.229,230 This is due to the 
cyclopropane ring donating electron density into the ester p-system, making it less 
electrophilic and thus reducing its reactivity to nucleophiles. Hydride reducing agents 
that were less reactive than LiAlH4 were tested first however, to explore the 
possibilities of greater functional group tolerance. 
 
To optimise the reduction reaction, cyclopropane 15 was tested. Initially, reduction 
attempts began with DIBAL in THF at –78 °C however this gave no reaction. The 
reactivity of DIBAL is significantly affected by the Lewis acidity of the reaction 
solvent.231 Therefore, the reduction was also attempted using DIBAL in cyclohexane 
at –78 °C however no reaction was again observed. Performing the reaction at 0 °C 
in THF also gave no reduction. A NaBH4/LiCl system that formed LiBH4 in situ was 
tested,232 however this reducing system also gave no reaction. 
 
The failure of both DIBAL and LiBH4 systems in reducing the cyclopropyl ester of 15 
was unsurprising given the widespread observation of the resistance of cyclopropyl 
esters to reduction.229,230 The more commonly used reducing agent LiAlH4 was then 
explored. These conditions gave the primary alcohol products 91 and 92 in excellent 
yields and with no epimerisation (Scheme 46).  
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Scheme 46: LiAlH4 reduction of cyclopropyl scaffolds 15 and 16 to form 91 and 92, respectively 
 
2.2.4. Transesterification 
Cyclopropyl esters are frequently found within medicinal chemistry and biologically 
active compounds (Figure 38).233,234 An interesting medicinally-relevant behaviour of 
cyclopropyl esters is that they are more resilient to hydrolysis than simple alkyl esters 
due to orbital overlap between the cyclopropane ring and the ester and the 
electron-donating effect of the cyclopropane ring. 
 
 
Figure 38: Examples of biologically active ester-substituted cyclopropanes. References: P388 leukemia 
antitumour active compound.233 NO production inhibitor.234 
 
Given the unreactive nature of the cyclopropyl ester towards various amidation 
techniques, the overall transesterification process was approached instead via the 
cyclopropyl carboxylic acid species. Using conditions that had been developed by 
Bartoli and co-workers,235 cyclopropyl carboxylic acid 80 was converted to phenyl 
ester-substituted cyclopropane 93 in an excellent yield and with no epimerisation 
(Scheme 47). The success of this reaction with phenol, a relatively unreactive alcohol, 
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suggested that this method would be suitable for esterification with a wide range of 
alcohol substrates. 
 
 
Scheme 47: Esterification of cyclopropyl carboxylic acid 80 to generate cyclopropyl ester 93 
 
2.2.5. Conclusions 
The cyclopropyl ester functionality on scaffolds 15 and 16 have been derivatised 
selectively to form a variety of pharmaceutically-relevant motifs. The ester has been 
converted into carboxylic acid, sodium carboxylate salt, amide, hydroxymethyl and 
phenyl ester derivatives using facile and high yielding methodologies. 
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2.3. Scaffold Functionalisation: Sulfide Derivatisation 
Derivatisation of the ethyl ester functionality of the readily available cyclopropanes 15 
and 16 has been demonstrated with a range of transformations, producing a diverse 
variety of cyclopropane-containing compounds (Section 2.2). Next, derivatisation of 
the sulfide functionality of cyclopropyl scaffolds 15 and 16 was investigated. This 
would proceed through oxidation of the sulfide functionality, followed by exploration of 
a sulfoxide–metal exchange protocol as a divergent route to a wide variety of 
cyclopropane-containing compounds. 
 
A concise account of this work can be found in the European Journal of Organic 
Chemistry (see Appendix 1).166 
 
2.3.1. Oxidation 
Cyclopropyl sulfides, sulfoxides and sulfones are all important motifs within drug 
discovery (Figure 39).236,237,238 With the sulfide functionality on scaffolds 15 and 16 
there was the possibility of accessing the corresponding sulfoxides and sulfones 
through oxidation reactions. 
 
 
Figure 39: Structures of a biologically active cyclopropyl sulfide, sulfoxide and sulfone. 
References: Sulfide.236 Sulfoxide LY404040.237 Sulfone.238 
 
The oxidation of sulfides to their corresponding sulfoxides or sulfones has been 
achieved with a variety of oxidants including H2O2,239,240 meta-chloroperbenzoic acid 
(mCPBA),241 oxone,242 sodium hypochlorite243 and O2.244 Each of these oxidants has 
their own advantages and disadvantages for their use, though of these options, 
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mCPBA stood out as an attractive choice due to its crystalline solid form making it 
easy to handle and its low associated hazards. It is generally obtained commercially 
containing approximately 25% meta-chlorobenzoic acid (mCBA), however it can be 
easily purified through a basic potassium phosphate wash to yield pure mCPBA which 
can be stored for many months at 4 °C without observable levels of decomposition to 
mCBA occurring. 
 
Analysis of sulfide oxidation literature led to initial conditions consisting of  
2.5 equivalents of mCPBA and a reaction temperature of 25 °C being used 
(Scheme 48).241 These conditions were found to generate the desired cyclopropyl 
sulfones in quantitative yields and with complete retention of configuration. 
 
 
Scheme 48: Oxidation of 15 and 16 to produce the corresponding sulfones 94 and 95 
 
Next, selective oxidation to generate the corresponding sulfoxides was tackled 
(Table 29). Using the conditions shown in Scheme 48 but with only 1.05 equivalents 
of oxidant produced a near-statistical mixture of sulfur-containing species (Table 29, 
entries 1 and 2). A key factor in the selectivity of this reaction was temperature, and 
conducting the reaction at 0 °C generated the cyclopropyl sulfoxides in excellent yields 
with complete retention of configuration on the cyclopropane ring. Due to the 
generation of a new chiral centre at sulfur, diastereoisomers were generated, with 
sulfoxides 96 obtained in a dr of 58:42 and sulfoxides 97 obtained in a dr of 75:25 
(entries 3 and 4, respectively). It is noteworthy that these oxidations were conducted 
on multi-gram scales, allowing large quantities of cyclopropyl sulfoxides to be 
generated easily. 
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Table 29: Selective oxidation optimisation of cyclopropyl sulfides 15 and 16 to sulfoxides 96 and 97, respectively 
 
 
 
 
a Oxidation was conducted on 13.3 mmol of sulfide, producing 2.9 g of cyclopropyl sulfoxide product. b Oxidation 
was conducted on 6.7 mmol of sulfide, producing 1.6 g of cyclopropyl sulfoxide product. 
 
2.3.2. Sulfoxide–Magnesium Exchange, Electrophilic Trap Protocol 
The development of a facile and high yielding CoII-catalysed cyclopropanation 
(Section 2.1.3.1) and the development of a high yielding and selective oxidation 
(Section 2.3.1) allow ready access to the topologically-different cyclopropyl sulfoxides 
96 and 97. Development of a successful sulfoxide–metal exchange, electrophilic trap 
protocol for these cyclopropyl sulfoxides would enable a method to divergently 
functionalise the intact cyclopropane ring directly with a variety of electrophilic species 
to generate a diverse collection of cyclopropane-containing compounds. 
 
Functional group–metal exchange reactions (also frequently called ligand-exchange 
reactions) are an important class of reactions that allow the interchange of a 
heteroatom or heteroatom-centred functional group with a metal, usually lithium or 
magnesium, from an organometallic species. This generates a new organometallic 
species that can be trapped with an electrophile. Various heteroatoms have been 
shown to be capable of this class of reaction including the Group 15 element 
phosphorus (as phosphine oxides245,246,247), Group 16 elements sulfur (as 
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sulfoxides248,249,250,251 and sulfones252) and selenium (as selenoxides247), and the 
halides chloride,252 bromide252,253 and iodide252,253,254. The most common are  
iodine–metal exchange and sulfoxide–metal exchange because of the ease of 
incorporating the necessary heteroatom into the molecule of interest and the high 
reaction rates for their exchange.252  
 
The halogen–metal exchange reaction is an equilibrium, favouring the more stable 
organometallic species (Scheme 49).255,256 This has been demonstrated through the 
analysis of the relationship between the anion orbital electronegativity of various 
organolithium species and the observed equilibrium constants for their exchange 
reactions with phenyl iodide. 255 It was found that the equilibrium is governed principally 
by the relative stabilities of the organolithium species on either side of the equilibrium, 
as highlighted by the equilibrium favouring the formation of organolithium species with 
greater carbanion orbital s-character and less substitution on the carbanion carbon.255  
 
 
Scheme 49: Equilibria for the halogen–metal exchange reaction 
 
Qualitative rates for sulfoxide/halogen–metal exchange are in the order SO ≈ I > Br > 
Cl,248,257 with relative rates for iodine, bromine and chlorine–metal exchange being 
approximately 1011:106:1, respectively.252 Sulfoxide–metal exchange, using a 
p-tolylsulfinyl group, has been approximated at being slightly faster than iodine–metal 
exchange, however accurate rate measurement became problematic for the case of 
the sulfoxide–metal exchange as a result of the very rapid reaction.252 Interestingly, 
sulfonyl–metal exchange with a p-tolylsulfonyl group undergoes exchange at least 104 
times slower than a bromide.252 Fluorine is unreactive towards halogen–metal 
exchange.252,258  
 
There are three prominent possible mechanisms for halogen–metal exchange; an 
electron exchange (radical) mechanism, a four-centre transition state mechanism and 
an “ate-complex” mechanism.259 The electron transfer (radical) mechanism 
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(Scheme 50) is supported by the observation of skeletal rearrangement products when 
alkyl bromide substrates that acted as radical probes were treated with 
tert-butyllithium.260,261 These observations suggested a radical mechanism being at 
least a minor pathway for the exchange reaction.259,260 Radicals have also been 
detected in exchange reaction mixtures by EPR NMR spectroscopy, though this only 
demonstrated that radicals may have been generated in the reaction mixture and not 
that they were involved in the exchange mechanism.262 
 
 
Scheme 50: Possible mechanisms for halogen–metal exchange 
 
Rogers and Houk examined the initial rates of reaction between bromobenzene and 
n-butyllithium and found the reaction to be first order in both reactants.263 In the same 
work, a Hammett relationship for the reaction of substituted bromobenzenes with 
n-butyllithium suggested a build-up of negative charge on the aromatic ring in the 
transition state (r»2). Such a large r value for the reaction suggested that it did not 
proceed via a radical mechanism but instead either a 4-centre transition state or an  
“ate-complex” (Scheme 50), the latter having been initially proposed by Wittig and 
Schöllkopf in 1958.264 Such an “ate-complex” was isolated and characterised by 
Farnham and Calabrese in 1986.265 The complex was obtained by reacting 
pentafluorophenyllithium with pentafluorophenyl iodide at –78 °C (Scheme 51). Due 
to its decomposition at higher temperatures the complex was treated with 
tetramethylethylenediamine (TMEDA) which stabilised the hypervalent iodine salt 
through complexation and allowed its isolation whilst under an inert atmosphere. The 
sample was crystallised and X-ray crystallography performed, which showed that the 
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hypervalent iodine salt possessed a near-linear geometry along the C–I–C bonds 
(ÐC–I–C = 175°). The isolated “ate-complex” was a competent nucleophile, delivering 
a C6F5 group to perfluoro-2-methyl-2-pentene in a 92% yield. This proved both that 
“ate-complexes” could be formed through the reaction of an organolithium and an 
organoiodide and that they were indeed competent nucleophiles. 
 
 
Scheme 51: Isolation and reaction of a 10-I-2 hypervalent “ate-complex” by Farnham and Calabrese265 
 
Another important finding of this research was that the hypervalent iodine salt favoured 
a near-linear geometry along the C–I–C bonds,265 which was supported by the findings 
of Beak and Allen in their use of a combination of isotopic labelling and an endocyclic 
restriction system.266 A system was designed where an organolithium and an 
arylbromide functionality existed in the same molecule, separated by a spacer of 
variable length. Isotopic labelling of the bromide enabled differentiation between 
intramolecular and intermolecular reaction to be made. It was observed that no 
intramolecular bromine–lithium exchange occurred with a spacer length that 
generated a 6- or 8-membered endocyclic ring, suggesting that the bond angles 
required for successful intramolecular reaction could not be attained in these systems. 
Such intramolecular bromine–lithium exchange was however observed with a spacer 
length that generated an 18-membered endocyclic ring. The authors’ interpretation of 
the findings was that if a four-centre transition state mechanism was applicable then 
the intramolecular reactions via a 6- or 8-membered endocyclic ring should have been 
successful. However, due to a successful intramolecular reaction requiring a much 
larger endocyclic ring, it was concluded that there is a geometric requirement in the 
mechanism of halogen–metal exchange that the entering and leaving groups in the 
exchange should be close to linearity, which is what was observed in the isolated 
“ate-complex” by Farnham and Calabrese.265  
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In conclusion, the mechanism(s) involved appear to be intricately related to the 
organohalide involved. Literature analysis suggests that aryl iodides,267 alkyl 
iodides268,269 and aryl bromides256,263,270 proceed via an “ate-complex” mechanism 
whereas alkyl bromides260,261,269 proceed via both “ate-complex” and radical 
mechanisms. 
 
Sulfoxide–metal exchange was first discovered by Fuchs in 1929.271 Since then, 
sulfoxide–metal exchange has become a valuable method for both the generation of 
substituted sulfoxides272 and functionalised organometallic species.248  
Sulfoxide–metal exchange occurs through nucleophilic attack of the reagent Grignard 
species at the electron-deficient sulfur, followed by expulsion of a sulfur-substituent 
with concomitant recovery of a tetrahedral-sulfur species (Scheme 52).273,274,275 The 
substituent expulsion is selective, favouring the loss of the substituent that results in 
the lowest energy organometallic species.275 
 
 
Scheme 52: Equilibria for a sulfoxide–metal exchange reaction 
 
Investigations into the mechanistic details of sulfoxide–metal exchange have 
supported the reaction proceeding via either a 5-coordinate oxasulfurane intermediate 
or a transition state involving simultaneous bond formation and bond breakage 
(Scheme 53).274,275,276 
 
 
Scheme 53: Sulfoxide–metal exchange mechanism via a transition state or an oxasulfurane intermediate 
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Durst examined the sulfoxide–lithium exchange of various sulfoxides and claimed that 
the results supported an SN2 mechanism for the exchange reaction proceeding via a 
transition state, as opposed to via an oxasulfurane intermediate.275 This was based 
on the observation that sulfoxide–lithium exchange on a sulfoxide possessing two 
feasible leaving groups only produced one sulfoxide-containing product. However, the 
mechanistic explanation presumed that the energy barriers for forming the two 
oxasulfurane intermediates were very similar, and did not account for reversibility of 
the exchange reaction. Anderson and co-workers observed that treatment of 
p,p’-ditolylsulfoxide with p-tolyllithium produced a significant amount of p,p’-ditolyl from 
a coupling mechanism.274 From this it was concluded that the reaction proceeded via 
a 5-coordinate oxasulfurane intermediate resulting from nucleophilic attack of the 
organolithium into the sulfoxide sulfur. Similarly, Oae and co-workers demonstrated 
that both sulfoxide–metal exchange and coupling products could be generated from 
the same reaction of an organometallic species with a sulfoxide, indicating that in 
addition to the coupling mechanism, the sulfoxide–metal exchange mechanism also 
proceeded via an oxasulfurane intermediate.276 Furthermore, a variety of sulfuranes 
and oxasulfuranes have been synthesised and isolated (Figure 40).277,278 
 
 
Figure 40: Structures of a synthesised sulfurane277 and oxasulfurane278 
 
Performing sulfoxide–metal exchange on an enantiopure sulfoxide generated the 
product sulfoxide with clean inversion of stereochemistry at sulfur as demonstrated by 
Lockard (Scheme 54).272 Mislow observed partial racemisation with sulfoxides 
possessing an a-proton, and explained this with an elimination–addition mechanism 
via the reversible formation of a methylene sulfine species (Scheme 55).273 
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Scheme 54: Sulfoxide–lithium exchange giving clean inversion of stereochemistry at sulfur.272  
 
 
 
Scheme 55: A possible racemisation pathway if the sulfoxide possesses an a-proton and the Grignard reagent is 
very sterically bulky.273  
 
In the absence of factors that would dictate otherwise (e.g. conjugative orbital overlap 
of the intermediate organometallic species), sulfoxide–metal exchange proceeds with 
retention of configuration at the generated carbanion carbon. O’Brien and co-workers 
have demonstrated this by performing sulfoxide–magnesium exchange on a substrate 
possessing a stereogenic carbon a to the sulfoxide sulfur (Scheme 56).279 The 
substrate was diastereomerically pure and highly enantioenriched (99:1 er at sulfur). 
The sulfoxide–magnesium exchange generated the chiral Grignard intermediate 
which was then trapped with an electrophile to generate the desired product in an 
excellent yield and with complete enantio-retention at carbon. 
 
 
Scheme 56: Complete retention of configuration at carbon during sulfoxide–magnesium exchange.279 
 
Sulfoxide–metal exchange followed by electrophilic trapping has been demonstrated 
as a powerful method to generate and utilise complex organometallic species derived 
from a variety of sulfoxide substrates (Scheme 57, A and B). In addition, the 
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organometallic species can be trapped through transition metal-catalysed 
cross-coupling (Scheme 57, C and D). 
 
 
Scheme 57: Examples of sulfoxide–metal exchange followed by either trapping with an electrophile or transition 
metal-catalysed cross-coupling. References: A280, B281, C248, D282 
 
Sulfoxide–metal exchange and halogen–metal exchange have been performed on 
cyclopropanes, demonstrating both trapping of the cyclopropyl organometallic species 
with electrophiles and transition metal-catalysed cross-coupling (Scheme 58). 
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Scheme 58: Examples of cyclopropyl sulfoxide/halogen–metal exchange reactions. References: A250, B283, C284 
 
Knochel and co-workers demonstrated sulfoxide–magnesium exchange followed by 
transmetalation to copper before trapping the cyclopropyl organometallic species with 
methallyl bromide, generating the tetrasubstituted cyclopropane in an excellent yield 
(Scheme 58A).250 Two consecutive sulfoxide–lithium exchange, electrophilic trap 
protocols have been demonstrated on a single cyclopropane ring by Marek and 
co-workers, with the resulting cyclopropyl lithium intermediates being trapped with 
benzyl bromide and a proton from H2O (Scheme 58B).283 Iodine–magnesium 
exchange on a cyclopropane ring has been demonstrated by Knochel with a 
cis-substituted cyclopropane ring also bearing an ethyl ester functionality 
(Scheme 58C).284 The cis-oriented ester reportedly stabilised the cyclopropyl Grignard 
intermediate by both chelation and inductive effects. There were no comments on 
observations of Grignard attack into the ester carbonyl, suggesting chemoselectivity 
for the iodide, which was an important factor during the design of the target bifunctional 
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cyclopropyl scaffold for the work presented in this thesis. The observation that a 
cyclopropyl ester was unaffected by halogen–magnesium exchange conditions meant 
that sulfoxide/halogen–magnesium exchange and ester functionalisation offered the 
possibility of orthogonal and divergent functionalisation pathways for a bifunctional 
cyclopropyl scaffold. Whilst examples of cyclopropanes possessing an exchangeable 
functionality and additional compatible functionality exist (Scheme 58), they often 
require a relatively lengthy synthesis for use as an initial scaffold. In contrast, 
cyclopropanes 96 and 97 bearing ester and sulfoxide functionality have been shown 
to be readily accessed in 2 synthetic steps (Sections 2.1.3.1 and 2.3.1). 
 
With a facile route to bifunctional cyclopropyl sulfoxides 96 and 97, the development 
of a robust and reliable sulfoxide–metal exchange, electrophilic trap protocol which 
would enable divergent functionalisation of the intact cyclopropane ring commenced. 
In the sulfoxide–magnesium exchange of cyclopropyl sulfoxide 96 with an alkyl 
organometallic reagent the exchange reaction has two potential exchange pathways 
by which it can proceed (Scheme 59). The prevalence of each pathway is dictated by 
the stability of the organometallic species it produces, indicated by its pKaH, with the 
generation of the organometallic species possessing the lowest pKaH value being 
favoured. i-PrMgCl is a representative alkyl organometallic reagent commonly used 
for sulfoxide/halogen–magnesium exchange reactions and possesses a pKaH of 51.285 
 
 
Scheme 59: Potential reaction pathways for the sulfoxide–magnesium exchange of 96 
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Provided that at least one of the sulfoxide substituents generates a product 
organometallic species with a pKaH below 51 it is reasonable to assume that the 
sulfoxide–magnesium exchange may proceed on thermodynamic grounds. If this was 
not the case then no exchange reaction would be expected. In a scenario where the 
two sulfoxide substituents generated organometallic products with similar pKaH values 
then both pathways may be utilised to a significant extent, producing a mixture of 
products. For the sulfoxide–magnesium exchange of cyclopropyl sulfoxide 96, the 
phenyl anion produced from Pathway 1 possesses a pKaH of 43,286 however the pKaH 
of the ester-substituted cyclopropyl anion 99 produced by Pathway 2 is unknown. The 
pKaH of cyclopropane however is 46,285,287,288 and the presence of the 
electron-withdrawing ester would act to reduce that significantly. From the observation 
made by Knochel and co-workers (Scheme 58A) that a sulfoxide possessing a phenyl 
ring and a nitrile-substituted cyclopropane underwent clean sulfoxide–magnesium 
exchange with i-PrMgCl to generate the cyclopropyl Grignard species, it appeared 
likely that sulfoxide–magnesium exchange on 96 would also result in the selective 
generation of a cyclopropyl Grignard species.250 
 
2.3.2.1. Reaction Optimisation 
Initial optimisation of the sulfoxide–metal exchange reaction began on the 
trans-cyclopropyl sulfoxide 96. Knochel has previously described how the cyclopropyl 
organometallic species that would originate from cis-cyclopropyl sulfoxide 97 could 
benefit from stabilisation as a result of metal chelation by the ester,284 therefore 
trans-cyclopropyl sulfoxide 96 was used for the optimisation, where such chelating 
stabilisation was not possible. After analysis of the literature on sulfoxide/iodine–metal 
exchange, an initial set of conditions were selected (Scheme 60). 
 
 
Scheme 60: Initial sulfoxide–magnesium exchange conditions for cyclopropyl sulfoxide 96 
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The success of the reaction would be analysed by the yields of the products obtained; 
the yield of iso-propyl phenyl sulfoxide 100 indicated the success of the  
sulfoxide–magnesium exchange and the yield of the trapped cyclopropane indicated 
the success of the electrophilic trapping of the cyclopropyl Grignard intermediate. As 
such, during early optimisation a variety of electrophiles were tested whilst varying 
reaction conditions to try to find a competent electrophile whilst investigating reaction 
parameters. 
 
The concentrations of the organometallic reagents used in the sulfoxide–metal 
exchange optimisation were regularly and frequently determined throughout the period 
of their use. This ensured the correct amount of reagent was being added. The 
organometallic reagent concentration was determined by titration with salicylaldehyde 
phenylhydrazone as developed by Love and Jones,289 with two colour changes 
observed; colourless to yellow and yellow to red (Scheme 61). The concentration was 
calculated using the volume of organometallic reagent added for the solution to just 
turn a persistent orange colour.  
 
 
Scheme 61: Organometallic reagent titration using salicylaldehyde phenylhydrazone, as initially developed by 
Love and Jones289 
 
The initial conditions involved the addition of a solution of i-PrMgCl (0.32 mL, 1.87 M 
in THF, 1.5 equiv) to a –78 °C solution of the cyclopropyl sulfoxide (95 mg, 1.0 equiv) 
in THF (4.0 mL, 0.1 M), followed by the addition of 4,4’-dimethylbenzophenone as the 
electrophilic trap (Table 30). The reaction was successful, giving a 41% yield of the 
trapped cyclopropane 101 and a quantitative yield of iso-propyl phenyl sulfoxide 
(Table 30, entry 1). The reaction also proceeded with complete retention of 
configuration at the cyclopropyl carbon. The same conditions were used with EtMgCl 
as the Grignard reagent, however this produced inferior results, as indicated by the 
lower yield of alkyl phenyl sulfoxide by-product (entries 1 and 2). Interestingly, a higher 
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yield of trapped cyclopropane 101 was observed with EtMgCl. Knochel has shown that 
the presence of inorganic salts, particularly LiCl, can improve certain reactions 
involving organometallic species,290 however using i-PrMgCl·LiCl in the reaction 
showed a significant decrease in the yield of the trapped cyclopropane 101 (entry 3). 
No remaining reactant sulfoxide 96 and no side-products resulting from electrophilic 
attack of a Grignard species into the cyclopropyl ester were observed for any of these 
reactions (Table 30, entries 1–3). 
 
Table 30: Effect of Grignard reagent on the sulfoxide–magnesium exchange of 96 
 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
 
Next, the order of addition for the sulfoxide–magnesium exchange was investigated 
(Table 31). The electrophile was changed to benzophenone, as the CH3 groups on  
4,4’-dimethylbenzophenone and the related by-products generated a complex 
1H NMR spectrum for the unpurified material, which made accurate yields difficult to 
determine. Additionally, removing the +I inductive effects of the methyl substituents 
would make the electrophile slightly more electrophilic, improving the trapping of the 
cyclopropyl Grignard intermediate. The equivalents of the electrophile were also 
increased from 1.5 to 2.0 and the exchange temperature was kept at –78 °C for the 
1 h electrophilic trapping time.  
 
The addition of i-PrMgCl to a solution of the sulfoxide gave slightly higher yields of the 
trapped cyclopropane 104 and of the sulfoxide by-product 100 than addition of a 
solution of the sulfoxide to i-PrMgCl (Table 31). 
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Table 31: Effect of addition order on the sulfoxide–magnesium exchange of 96 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
 
The yield of trapped cyclopropane-containing product was still low despite achieving 
a high yield of iso-propyl phenyl sulfoxide by-product. This indicated that the 
electrophile was still not very reactive with the cyclopropyl Grignard intermediate being 
formed. Benzaldehyde was therefore tested, due to its highly electrophilic nature, 
however it too gave a low yield of the trapped cyclopropane-containing product 
(Table 32, entry 1). In order to potentially increase the reactivity of the reaction it would 
be possible to perform a sulfoxide–lithium exchange and form a cyclopropyl 
organolithium intermediate. However, the presence of organolithium species in the 
reaction mixture could have significant detrimental effects due to undesirable side 
reactions such as electrophilic attack into the cyclopropyl ester. The reaction was 
repeated using n-BuLi however this generated an extremely complex reaction mixture 
with no signs of cyclopropane-containing material by 1H NMR spectroscopy (Table 32, 
entry 2). 
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Table 32: Effect of performing sulfoxide–magnesium exchange and sulfoxide–lithium exchange on 96 
 
 
 
 
 
 
Yields determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
 
With a low yield of trapped cyclopropane still being obtained, I2 was tested as an 
electrophile given its weak I–I s-bond. This produced an excellent 82% yield of trapped 
iodocyclopropane 106 with complete retention of configuration at the cyclopropyl 
carbon, along with an almost quantitative yield of the sulfoxide by-product 100 
(Scheme 62). The sulfoxide–magnesium exchange, I2 trap was also carried out using 
cis-cyclopropyl sulfoxide 97, generating the corresponding cis-cyclopropyl iodide 107 
in a good yield of 58% with complete retention of configuration at the cyclopropyl 
carbon. Analysis of the 1H NMR spectrum from the unpurified reaction mixture of 107 
indicated that significantly more product was synthesised, however some was lost 
upon purification due to its volatility. 
 
 
Scheme 62: Sulfoxide–magnesium exchange of 96 followed by electrophilic trapping with I2 
 
The consistently high yield of iso-propyl phenyl sulfoxide 100 obtained from the 
sulfoxide–magnesium exchange conditions and the finding that I2 acted as an effective 
electrophile to give good yields of the trapped cyclopropane 106 enabled investigation 
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iodocyclopropane 106 as a starting point to investigate the stability of the cyclopropyl 
Grignard intermediate, there was sufficient yield margin to confidently observe both 
trends of decreasing yields caused by a reaction variable promoting degradation of 
the cyclopropyl Grignard intermediate and trends of increasing yields due to a reaction 
variable promoting the electrophilic trapping. 
 
2.3.2.2. Stability Investigations into Cyclopropyl-MgCl Intermediate 
As mentioned briefly previously, Knochel demonstrated that organometallic species 
can have their stability and reactivity increased by the presence of inorganic salts, 
particularly LiCl, for certain reactions.290 This was tested previously (Table 30, entry 3), 
where using i-PrMgCl·LiCl resulted in an excellent yield of the by-product sulfoxide but 
a significantly decreased yield of the trapped cyclopropane product. In the context of 
Knochel’s work, this could potentially be explained by the cyclopropyl Grignard that 
was formed by i-PrMgCl·LiCl being more stable and therefore less reactive under the 
reaction conditions. If this were the situation, it may be the case that the presence of 
LiCl in the reaction mixture results in a slower rate of electrophilic trapping but a higher 
overall yield due to the increased stability of the intermediate if given enough time to 
react. To examine the effects, if any, of the presence of LiCl on the stability of the 
cyclopropyl Grignard intermediate over time, the sulfoxide–magnesium exchange was 
conducted with either i-PrMgCl or i-PrMgCl·LiCl and the I2 electrophilic trap added 
after various time periods after Grignard reagent addition, ranging from immediately 
afterwards to two hours later. Each of the reaction mixtures were worked-up and the 
yield of iodocyclopropane 106 calculated through analysis of the 1H NMR spectrum by 
comparison with a known amount of added dibenzyl ether as an internal standard. The 
results are plotted in Graph 1, with each data point representing an individual reaction. 
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Graph 1: The effect of LiCl and sulfoxide–magnesium exchange time on the yield of 106. Yields determined by 
1H NMR spectroscopy with comparison to internal standard (dibenzyl ether). 
 
It can be seen from Graph 1 that the addition of LiCl makes essentially no observable 
difference to the reaction, with the yields at each time period being almost identical for 
i-PrMgCl and i-PrMgCl·LiCl. Given that i-PrMgCl is much less expensive than 
i-PrMgCl·LiCl, the sulfoxide–magnesium exchange protocol continued to use i-PrMgCl 
for the remaining reaction optimisation and scope. It can also be seen from Graph 1 
that the sulfoxide–magnesium exchange was complete after 10 minutes at –78 °C, 
meaning that any greater amount of time was not of benefit. Finally, Graph 1 illustrates 
that the cyclopropyl Grignard intermediate was stable at –78 °C for at least 2 hours 
with no degradation, as can be seen from the constant yield of 106 between exchange 
times of 10 minutes and 2 hours. Presented with its impressive stability at –78 °C, the 
thermal stability of the cyclopropyl Grignard intermediate 99 was investigated over a 
range of temperatures (Graph 2). 
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Graph 2: Investigation into the thermal stability of the cyclopropyl Grignard species derived from 96. Yields 
determined by 1H NMR spectroscopy with comparison to internal standard (dibenzyl ether).  
 
The sulfoxide–magnesium exchange was conducted at –78 °C for 10 minutes, then 
the reaction mixture was warmed to either –30 °C, 0 °C or 25 °C and kept at this 
incubation temperature for between 10 minutes and 2 hours. After this time, I2 was 
added to trap the remaining cyclopropyl Grignard intermediate, with the reaction being 
left for 1 hour at the incubation temperature to allow this to occur. The results from this 
investigation which are displayed in Graph 2 show that there was complete stability of 
cyclopropyl Grignard intermediate 99 at –30 °C and 0 °C for up to 2 hours, however 
there was significant degradation at 25 °C. At 25 °C there was an approximate 50% 
decrease in yield between the data points corresponding to incubation for 10 minutes 
and 1 hour, and around a 67% decrease between incubation for 10 minutes and 
2 hours. There were no clearly identified products formed from the decomposition of 
the cyclopropyl Grignard intermediate. This demonstrated that to achieve the 
maximum reactivity of the cyclopropyl Grignard intermediate whilst ensuring its 
complete stability, 0 °C was the optimum temperature to conduct the electrophilic 
trapping. 
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With the stability of the cyclopropyl Grignard intermediate now well understood, the 
resulting optimised conditions were to be tested with a wide variety of electrophiles to 
generate a diverse collection of cyclopropane-containing compounds. 
 
2.3.2.3. Electrophile Scope for trans-Cyclopropyl Scaffold 
With the optimised sulfoxide–magnesium exchange, electrophilic trap conditions 
proven to be successful with both trans- and cis-cyclopropyl sulfoxide 
diastereoisomers 96 and 97, the electrophile scope was explored (Schemes 63 and 
64 respectively). First, the electrophile scope for trans-cyclopropyl sulfoxide 96 is 
described, with the ethyl ester abbreviated to CO2Et for conciseness (Scheme 63). 
The synthesised cyclopropane-containing compounds are shown along with a variety 
of their physicochemical properties, namely, molecular weight, lipophilicity (AlogP, 
calculated by LLAMA software),291 number of hydrogen bond donors and acceptors, 
fraction of sp3 centres and the polar surface area of the compound. 
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Scheme 63: Electrophile scope for the sulfoxide–magnesium exchange, electrophilic trapping of 96. a Trapping 
time = 1 h. b Trapping time = 3 h. c Trapping time = 6 h. d Electrophilic trapping conducted at –78 °C. 
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The trans-Grignard intermediate derived from trans-cyclopropyl sulfoxide 96 was 
trapped effectively with aliphatic-, aryl- and heteroaryl-substituted aldehydes, giving 
excellent yields of the resulting trans-cyclopropane products 108–110 (Scheme 63, 
entries 1–3). The physicochemical properties of these compounds fit well within 
fragment guidelines and possess functionality that can act as potential 
pharmacophores or synthetic vectors for further manipulations. Dialkyl, diaryl and 
diheteroaryl ketones were also competent electrophiles, giving good to excellent yields 
of the product cyclopropanes 111–113 (entries 4–6). Due to the large rate difference 
between sulfoxide–magnesium exchange and chlorine–magnesium exchange the aryl 
chloride functionality in entry 5 remained untouched, with no products observed from 
chlorine–magnesium exchange. This left the aryl chloride functionalities as possible 
synthetic vectors for further derivatisation. These ketone-derived 
cyclopropane-containing products fitted well into fragment or lead-like chemical space. 
Acyl chlorides could be used to trap the cyclopropyl Grignard intermediate, giving a 
reasonable yield of the cyclopropyl ketone 114 (entry 7). This occurred without the 
need to transmetalate the cyclopropyl Grignard to copper, which is often required to 
efficiently react a Grignard species with an acyl chloride.284,292 Such transmetalations 
generally use CuCN, which is potentially extremely dangerous due to the risk of 
hydrogen cyanide evolution. Phenyl isocyanate was an effective electrophile, 
generating cyclopropyl amide 115 in an excellent yield (entry 8), and trapping with a 
disulfide produced the cyclopropyl sulfide 116 in a good yield (entry 9). Having 
generated a range of cyclopropane-containing fragments and lead-like compounds 
through the sulfoxide–magnesium exchange, electrophilic trap protocol, the utilisation 
of this methodology towards synthesising cyclopropyl building blocks was explored. 
As shown in the reaction optimisation, I2 was an effective trap which generated 
cyclopropyl iodide 106 in an excellent yield (entry 10). Trapping with an iso-propoxy 
dioxaborolane generated the corresponding cyclopropyl boronic ester 117 in a good 
yield (entry 11), and trapping with a silyl chloride generated the corresponding 
cyclopropyl silane 118 (entry 12). Cyclopropane-containing products 106, 107 and 108 
could be taken forward for further derivatisation through cross-coupling of the installed 
functionality, with methods for these transformations having been developed for 
similar cyclopropanes.293,294,295 Finally, trapping with N,N-dimethylformamide 
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generated cyclopropyl aldehyde 119 in an excellent yield (entry 13), which could be 
used as a building block in derivatisation reactions such as reductive amination.296 
 
2.3.2.4. Electrophile Scope for cis-Cyclopropyl Scaffold 
A similar electrophile scope was achieved with the cis-Grignard intermediate derived 
from cis-cyclopropyl sulfoxide 97 (Scheme 64). Aliphatic-, aryl- and 
heteroaryl-substituted aldehydes were successful electrophiles, giving good to 
excellent yields of the resulting cis-cyclopropane products 120–122 which fit within 
fragment guidelines (Scheme 64, entries 1–3). The more electron-rich aldehydes 
(entries 1 and 2) resulted in lactonisation after the initial electrophilic trapping, 
producing the corresponding bicyclic product. The observed electronic-dependence of 
the lactonisation was due to the more electron-rich oxyanions being more reactive 
towards the proximal ester carbonyl. Dialkyl, diaryl and diheteroaryl ketones were also 
successful, generating 123–126 (entries 4–6). Similar to when trapping with 
aldehydes, lactonisation was observed with certain ketone substrates. Phenyl acyl 
chloride was compatible, giving a good yield of the cis-cyclopropyl ketone 127 
(entry 7). Finally, cis-cyclopropyl iodide 107 and cis-cyclopropyl boronic ester 128 
building blocks were synthesised in good to excellent yields (entries 8 and 9). 
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Scheme 64: Electrophile scope for the sulfoxide–magnesium exchange, electrophilic trapping of 97. a Trapping 
time = 1 h. b Trapping time = 3 h. c Trapping time = 6 h. d Electrophilic trapping conducted at 0 °C. 
 
Having demonstrated a wide electrophile scope for the sulfoxide–magnesium 
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trans- and cis-cyclopropyl Grignard intermediates for cross-coupling methodology 
began. 
 
2.3.3. Sulfoxide–Magnesium Exchange, Negishi Cross-Coupling 
Protocol 
(Hetero)aryl-substituted cyclopropanes are of huge importance to medicinal 
chemistry297 and are found within a large number of pharmaceutical drugs (Figure 41). 
 
 
Figure 41: Examples of medicinally important (hetero)aryl-substituted cyclopropanes. References: MK-0952.213 
Ticagrelor.298 Oral melatonin receptor agonist.299 BMS-505130.300 Cipralisant.301 GPR88 agonist.219 
 
With a powerful sulfoxide–magnesium exchange protocol in hand, it was a possibility 
to build upon that with cross-coupling methodology to allow aromatic and 
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cyclopropane rings however only a very limited scope of aromatic halides was 
achieved.284,292  
 
In 2013 the Bull group developed methodology for a sulfoxide–magnesium exchange, 
Negishi cross-coupling protocol on aziridines which allowed the installation of a variety 
of substituted phenyl rings from the corresponding bromobenzenes (Scheme 65).282 
 
 
Scheme 65: Sulfoxide–magnesium exchange, Negishi cross-coupling on an aziridine282 
 
It was envisaged that combining the optimised set of sulfoxide–magnesium exchange 
conditions developed for the ester-substituted cyclopropyl sulfoxides 96 and 97 with a 
suitable set of Negishi cross-coupling conditions would enable direct functionalisation 
of the intact cyclopropane with (hetero)aromatic rings. With this in mind, it seemed 
reasonable that the Negishi cross-coupling conditions developed within the Bull 
group282 for aziridinyl Grignards could be applied to cyclopropyl Grignards, functioning 
as a starting point from which optimisation could be conducted if necessary. 
 
Given the known instability of the ester-substituted cyclopropyl Grignard species 99 at 
25 °C, the Negishi cross-coupling protocol was adapted to allow transmetalation to 
zinc to occur at 0 °C over 1 hour before warming the reaction mixture to 25 °C for the 
Negishi cross-coupling to take place. These conditions proved to be very successful 
in the cross-coupling of bromobenzene with either trans- or cis-cyclopropyl sulfoxides 
96 and 97, giving the corresponding aryl-substituted cyclopropane 129 or 130 in an 
excellent yield with complete retention of configuration at the cyclopropyl carbon 
(Scheme 66). With the success of the sulfoxide–magnesium exchange, Negishi 
cross-coupling protocol determined, a variety or aromatic and heteroaromatic 
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bromides were tested. The electron-poor 4-chlorobromobenzene gave an excellent 
yield of 131, with no reaction observed at the aryl chloride, leaving the functional 
handle intact for further elaboration. Also, the electron-rich 4-bromoanisole gave an 
excellent yield of 132. b-Bromostyrene gave an excellent yield of the vinyl 
cyclopropane 133. Next, the cross-coupling of heteroaromatics onto the intact 
cyclopropane ring was investigated. 2-Bromopyridine and 2-bromopyrimidine gave 
good yields of the pyridine- and pyrimidine-substituted cyclopropanes 134 and 135 as 
fragments possessing low lipophilicities. Finally, a 3-bromoindole was successful, 
producing the indole-substituted cyclopropane 136 in a 94% yield as a potential 
lead-like compound. 
 
 
Scheme 66: Scope of (hetero)aryl bromides for the sulfoxide–magnesium exchange, Negishi cross-coupling 
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The high yields and broad (hetero)aryl bromide scope achieved show that the 
sulfoxide–magnesium exchange, Negishi cross-coupling protocol developed for 
cyclopropanes 96 and 97 is a powerful way to generate (hetero)aryl-substituted 
cyclopropanes in a divergent manner. 
 
2.3.4. Conclusions 
A sulfoxide–magnesium exchange, electrophilic trap protocol has been developed for 
cyclopropyl sulfoxides 96 and 97 that allows chemoselective generation and reaction 
of the cyclopropyl Grignard whilst leaving the cyclopropyl ester functionality intact. The 
stability of the trans-cyclopropyl Grignard intermediate 99 originating from 
trans-cyclopropyl sulfoxide 96 was investigated. The trans-cyclopropyl Grignard 
intermediate 99 was stable at –30 °C and 0 °C but underwent gradual decomposition 
at 25 °C. To maximise the reactivity of 99 whilst ensuring its complete stability during 
its trapping, the electrophilic trap reaction was conducted at 0 °C. These optimised 
conditions led to both the trans- and the cis-cyclopropyl sulfoxides undergoing 
successful sulfoxide–magnesium exchange and being trapped with a wide range of 
electrophiles. This formed a diverse collection of cyclopropane-containing compounds 
possessing a variety of functionalities and physicochemical properties. A  
sulfoxide–magnesium exchange, Negishi cross-coupling protocol was developed 
which allowed the trans- and the cis-cyclopropyl scaffolds to be directly functionalised 
with a variety of (hetero)aromatic rings. The sulfoxide–magnesium exchange protocols 
allowed a diverse range of cyclopropane-containing compounds to be divergently 
synthesised from the cyclopropyl sulfoxides 96 and 97. The synthesised 
cyclopropane-containing compounds possessed suitable physicochemical properties 
for use as fragments, lead-like compounds or building blocks within medicinal 
chemistry. The collection of synthesised cyclopropane-containing compounds 
possessed a diverse variety of functionalities that could be potential pharmacophores 
or be utilised as synthetic vectors for further derivatisation. No epimerisation was 
observed for any of the reactions. Additionally, no reaction was observed at the 
cyclopropyl ester functionality, leaving this synthetic vector intact. 
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2.4. Sequential Scaffold Functionalisation using Both Synthetic 
Vectors 
A variety of methods have been developed in this work to divergently functionalise the 
designed bifunctional scaffolds 15 and 16 orthogonally through the ester functionality 
(Section 2.2) and through the sulfide functionality (Section 2.3). Having established 
these methods, they could then be used for the consecutive functionalisation of a 
single cyclopropyl scaffold to allow the generation of a huge scope of 
cyclopropane-containing compounds. 
 
2.4.1. Sequential Scaffold Functionalisation: Amidation and 
Oxidation 
The first demonstration of using these methodologies for difunctionalisation of a 
cyclopropyl scaffold utilised a selection of the cyclopropyl amides generated in 
Section 2.2.2. The remaining sulfide functional handle on these cyclopropyl amides 
was oxidised to the corresponding sulfone, creating a small set of cyclopropyl amide 
sulfones 137–140 in extremely high yields (Scheme 67). For compounds 137 and 139, 
aqueous work-up proved problematic due to their high water solubility. This difficulty 
was overcome by an aqueous-free work-up. Excess mCPBA was quenched by the 
addition of solid Na2S2O5 to the reaction. This was followed by removal of the reaction 
solvent, redissolution in acetone containing 5% Et3N and filtration of the suspension. 
Under this procedure, after collection of the filtrate, all mCPBA derived materials had 
been removed, providing the sulfones in excellent purity and yield.  These 
cyclopropane-containing compounds possessed interesting lead-like properties, with 
137 and 139 having notably low lipophilicity for their MW; desirable for populating new 
regions of chemical space. 
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Scheme 67: Oxidation of amide-substituted cyclopropyl sulfides to the corresponding sulfones 
 
2.4.2. Sequential Scaffold Functionalisation: Sulfoxide–Magnesium 
Exchange, Negishi Cross-Coupling and Amidation 
To further illustrate the synthetic potential that could be obtained by the combination 
of the designed bifunctional scaffolds and the orthogonal derivatisation 
methodologies, a second complex bifunctional cyclopropane was proposed. Synthesis 
was achieved by utilising the developed sulfoxide–magnesium exchange, Negishi 
cross-coupling, hydrolysis and amidation reactions. 
 
Sulfoxide–magnesium exchange, Negishi cross-coupling of 96 to give 
pyridine-substituted cyclopropane 134 has already been demonstrated in this work, 
giving a 60% yield (Scheme 68). Hydrolysis of 134 to form the corresponding sodium 
carboxylate salt 141 in a quantitative yield followed by amidation with pyrrolidine in an 
82% yield gave the desired cyclopropane product 142, functionalised with both a 
pyridine ring and a pyrrolidine amide (Scheme 68). This compound fits well within 
fragment chemical space. 
 
 
S
ON
R
R'
Ph S
ON
R
R'
Ph
O O
mCPBA
(3.0 equiv)
S
ON
Ph
N
S
ON
Ph
O O O O
S
ON
Ph
N
O O
S
ON
Ph
O O
quant.
137
quant.
139
98%
138
86%
140
CH2Cl2 (0.02 M)
25 °C, 6 h
MW = 308
AlogP = 0.16
HBD/HBA = 0/5
Fsp3 = 0.53
PSA = 57.69 Å2
MW = 341
AlogP = 2.00
HBD/HBA = 0/4
Fsp3 = 0.32
PSA = 54.45 Å2
MW = 308
AlogP = 0.16
HBD/HBA = 0/5
Fsp3 = 0.53
PSA = 57.69 Å2
MW = 341
AlogP = 2.00
HBD/HBA = 0/4
Fsp3 = 0.32
PSA = 54.45 Å2
S
ON
R
R'
Ph S
ON
R
R'
Ph
O O
mCPBA
(3.0 equiv)
CH2Cl2 (0.02 M)
25 °C, 6 h
  165 
 
Scheme 68: Hydrolysis and amidation of 134 to generate the complex bifunctional cyclopropane fragment 142 
via cyclopropyl sodium carboxylate 141 
 
2.4.3. Sequential Scaffold Functionalisation: Sulfoxide–Magnesium 
Exchange, Negishi Cross-Coupling and Reduction 
Finally, a bifunctional lead-like cyclopropane-containing compound was targeted that 
would possess suitable physicochemical properties for incorporation into drug 
discovery libraries and would also demonstrate the utility of this work. Inspiration for 
this was obtained from the selective serotonin reuptake inhibitor BMS-505130 
(Figure 42).300 Cyclopropanes possessing similar functionality could be obtained 
quickly and easily through the developed sulfoxide–magnesium exchange, Negishi 
cross-coupling protocol and ester reduction reaction.  
 
 
Figure 42: The structure of BMS-505130300 and a similar bifunctional cyclopropane 
 
A sulfoxide–magnesium exchange, Negishi cross-coupling reaction produced the 
sulfonyl-protected cyclopropyl indole 143 in an excellent yield (Scheme 69). This 
reaction was performed on a 1.5 mmol scale and produced over 400 mg of 143, 
demonstrating that the sulfoxide–magnesium exchange, Negishi cross-coupling 
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Scheme 69: Sulfoxide–magnesium exchange, Negishi cross-coupling of 97 followed by ester reduction 
 
The three examples (Schemes 68–70) demonstrate how the bifunctional scaffolds 15 
and 16 can utilise the various developed methodologies to produce a wide variety of 
cyclopropane-containing compounds.  
 
2.4.4. Conclusions 
Using methodologies developed and described in previous sections of this thesis, both 
synthetic handles on the designed cyclopropyl scaffolds have been utilised in 
orthogonal derivatisation reactions to generate a variety of cyclopropane-containing 
compounds. The synthesised compounds sample distinct regions of chemical space 
and possess a very diverse range of chemical and structural features. These 
compounds illustrate the enormous scope of cyclopropane-containing compounds that 
are possible through the orthogonal derivatisation of the bifunctional cyclopropyl 
scaffolds 15 and 16. 
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2.5. Physicochemical Property Analysis 
The physicochemical properties of a compound have a dramatic effect on the way that 
that compound behaves in the body and as such, compound physicochemical 
properties are carefully analysed within medicinal chemistry (Sections 1.2–1.5). Two 
of the most important physicochemical properties for medicinal chemistry are 
lipophilicity and MW. These parameters are often plotted against each other on a graph 
as a useful way to analyse these important molecular properties for both individual 
compounds and entire libraries. 
 
It has been found that compound libraries within medicinal chemistry contain an 
over-representation of linear and flat compounds.302 The 3-dimensionality of a 
compound can be represented with a Principal Moments of Inertia (PMI) plot.303 A 
recent analysis by Morley and co-workers analysed a library of around 1000 fragments 
that were reportedly representative of commercial fragment space and found that the 
majority occupied the region of chemical space close to the rod-like–disk-like axis 
(Figure 43).302  
 
 
Figure 43: A PMI plot of approximately 1000 fragments representative of commercial chemical space by Morley 
and co-workers302 
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As such, a variety of physicochemical properties as well as 3D shape features for the 
synthesised cyclopropane-containing compounds were calculated to ensure that they 
were desirable for use within medicinal chemistry. 
 
2.5.1. Synthesised Cyclopropane-Containing Compounds 
The physicochemical properties for the synthesised cyclopropane-containing 
compounds are shown in Figure 44.291 The properties were calculated using the Lead 
Likeness and Molecular Analysis (LLAMA) computational tool, developed by Nelson, 
Marsden and co-workers.291 The LLAMA tool estimates lipophilicity using  AlogP 
calculations instead of the more commonly-used term of clogP. This is due to LLAMA 
calculating the atomic logP (addition of individual atomic logP contributions)291 
opposed to the compound logP (calculated using experimental values for smaller 
compounds and modelling using regression techniques). 
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Figure 44: Physicochemical properties of the synthesised compounds calculated by the LLAMA software291 
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The physicochemical properties for compounds 106, 107, 117, 118, 119 and 128 were 
not included due to their possession of functionality that would be undesirable for 
compound screening. The small library of compounds produced by the divergent 
functionalisation of cyclopropyl scaffold 15 and 16 possess varied physicochemical 
properties and fit within either fragment or lead-like chemical space (Figure 44).  
 
To analyse the MW and AlogP diversity of the library, the AlogP value for each 
compound was plotted against its MW (Graph 3). The plot showed that the small library 
of compounds sampled a large range of lipophilicities and MW’s, with a weak positive 
correlation between the two parameters. The weak positive correlation between the 
AlogP and the MW in the library produced by this methodology showed that regions of 
chemical space that are typically difficult to sample, e.g. high MW compounds with a 
polar nature, could be readily accessed through this approach.  
 
 
Graph 3: AlogP vs. MW plot for the synthesised cyclopropane-containing compounds 
 
Using the LLAMA software, a PMI plot for these compounds was generated 
(Figure 45). The small library of synthesised cyclopropane-containing compounds 
sampled a large range of chemical space, with the compounds being located away 
from the frequently-overpopulated rod-like–disk-like axis. This confirmed that the 
synthesised cyclopropanes possessed significant 3-dimensionality. 
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Figure 45: A plot produced from the LLAMA-generated PMI data for the synthesised cyclopropane-containing 
compounds 
 
Three pairs of diastereoisomers have been illustrated in Figure 45, showing both the 
trans- and cis-diastereoisomers, highlighting the difference that the cyclopropane 
configuration can make on the 3-dimensional structure of the compound. 
 
2.5.2. Virtual Cyclopropane-Containing Compounds 
A feature of the LLAMA software was that it allowed the virtual derivatisation of 
molecular scaffolds using a limited set of common transformations and a library of 
reactants.291 This feature was utilised in the virtual derivatisation of the 
cyclopropane-containing compounds synthesised in this work, this time including the 
cyclopropyl building blocks 106, 107, 117, 118, 119 and 128. The 
cyclopropane-containing compounds were virtually functionalised using the default 
LLAMA set of reactants (Figure 46). 
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Figure 46: The default LLAMA reactant set 
 
The default set of transformations that could be used by the software did not include 
an ester hydrolysis reaction, which meant that the ester functionality on the bifunctional 
cyclopropanes could not undergo theoretical functionalisation. Therefore, the 
hydrolysis of an ester to form the corresponding carboxylic acid was enabled by adding 
a piece of SMARTS code (Figure 47) via ‘Advanced settings > Add a new reaction to 
the library’. 
 
[*;;$([CX3](=O)):1][OX2H0][#6]>>[*:1][OX2H1]  
 
Figure 47: SMARTS code to enable the ester hydrolysis reaction to produce the corresponding carboxylic acid  
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This meant that the set of reactions that could be employed by the software consisted 
of BOC deprotection, reductive amination, Suzuki-Miyaura cross-coupling, 
Buchwald-Hartwig amination, sulfonamide formation, urea formation, alcohol 
alkylation, carbamate formation, secondary amide alkylation, secondary amide 
arylation, amide formation, alcohol arylation, urea alkylation, urea arylation, 
esterification and ester hydrolysis.  
 
Submitting the 56 synthesised cyclopropane-containing compounds for virtual 
functionalisation with the set of 44 default reactants and allowing a maximum of two 
functionalisations from the enabled reaction set generated 1187 compounds 
(Figure 48). 
 
 
Figure 48: Theoretical derivatisation of the synthesised bifunctional cyclopropanes 
 
The number and variety of synthetic vectors on the synthesised 
cyclopropane-containing compounds allowed a substantial virtual library of 
cyclopropane-containing compounds to be generated. An AlogP vs. MW plot was 
constructed for these virtually generated compounds which showed that the 
compound library sampled fragment, lead-like and drug-like chemical space to a 
sizeable degree (Graph 4). 
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Graph 4: AlogP vs. MW plot for the theoretically-functionalised cyclopropanes 
 
Constructing a PMI plot with the data for the 1187 compounds demonstrated that these 
derivatised cyclopropane-containing compounds sampled a huge amount of chemical 
space, possessing varied 3-dimensional structures (Figure 49). The compounds 
occupied regions of chemical space that were distant from the  
rod-like–disk-like axis, with many compounds possessing PMI data points around the 
centre of the plot. 
 
 
Figure 49: PMI plot for the 1187 theoretically-functionalised cyclopropane-containing compounds 
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Through the use of AlogP vs. MW (Graph 4) and PMI (Figure 49) plots it was clear that 
the library of virtually functionalised cyclopropane-containing compounds both 
contained compounds that possessed appropriate physicochemical properties for use 
within drug discovery and contained a vast amount of shape diversity that explored 
less-populated regions of chemical space. 
 
2.5.3. Conclusions 
The physicochemical properties of the individual synthesised cyclopropane-containing 
compounds have been calculated and the compound collection has been analysed 
with MW vs. AlogP and PMI plots. The compounds fit well within fragment or lead-like 
chemical space, and would be useful when incorporated into an existing drug 
discovery compound library. The collection of cyclopropane-containing compounds 
samples a large amount of chemical space, with a considerable variety of 
3-dimensional structures present. The PMI data points for the synthesised compounds 
were located significantly away from the frequently-overpopulated rod-like–disk-like 
axis, in a region of chemical space that is of substantial interest within medicinal 
chemistry. The synthesised cyclopropane-containing compounds were virtually 
derivatised with the LLAMA software.291 This virtual derivatisation of 56 synthesised 
cyclopropanes with the default LLAMA library of 44 reactants, in ≤ 2 reactions  
using common medicinal chemistry transformations generated 1187 
cyclopropane-containing products. These theoretical compounds occupied fragment, 
lead-like and drug-like chemical space, and possessed an enormous amount of shape 
diversity. 
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3. Conclusions and Future Work 
3.1. Conclusions 
A CoII-catalysed cyclopropanation of PVS with EDA has been developed for the 
synthesis of the desired trans- and cis-bifunctional cyclopropyl scaffolds (Scheme 70). 
Notable characteristics of the developed cyclopropanation include that it is scalable, 
being capable of generating multi-gram quantities of the products from a single 
reaction. In addition, the CoII(salen)-type catalyst is air and moisture stable, meaning 
a glovebox is not required for its storage and handling. Furthermore, the CoII catalyst 
does not cause dimerisation of the diazo reagent, meaning that a slow addition 
protocol using a syringe pump is not required and that the diazo reagent can be used 
as the limiting reagent, reducing the quantity used in the reaction and hence increasing 
the safety of the method. These factors make the cyclopropanation extremely 
practical. 
 
 
Scheme 70: Overview of the developed CoII-catalysed cyclopropanation of PVS with EDA.304 
 
The asymmetric cyclopropanation of PVS with EDA was examined with a variety of 
CuI(BOX), CuI(PyBOX) and CoII(salen)-type complexes. The investigation led to two 
sets of prominent conditions being developed for enantiopure CoII(salen)-type 
complex 28*, inducing enantioenrichments of 56% (trans) and 77% (cis) (Scheme 71). 
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Scheme 71: Optimised enantioselective CoII-catalysed cyclopropanation of PVS with EDA 
 
Using chiral supercritical fluid chromatography, enantiopure samples of 15 and 16 
were obtained. X-ray crystallography of the corresponding sulfones allowed the 
absolute configurations of each isomer, and hence the absolute configuration of the 
precursor sulfides, to be determined. 
 
Having developed practical access to the trans- and cis-bifunctional cyclopropyl 
scaffolds 15 and 16, the ethyl ester functionality was divergently derivatised through 
hydrolysis, amidation, reduction and esterification reactions (Scheme 72). 
 
Oxidation of the sulfide on scaffolds 15 and 16 was achieved, enabling the 
corresponding sulfoxides or sulfones to be obtained selectively and in excellent yields. 
Conditions for sulfoxide–magnesium exchange have been developed for cyclopropyl 
sulfoxides 96 and 97, with the stability of the trans-cyclopropyl Grignard 96 being 
investigated. These stability investigations showed that the Grignard intermediate was 
stable for multiple hours up to 0 °C, but became unstable at 25 °C. This allowed the 
reactivity of the cyclopropyl Grignard to be maximised whilst retaining its stability under 
the reaction conditions. This resulted in a wide variety of electrophiles being 
successfully utilised in the electrophilic trapping of the cyclopropyl Grignard 
intermediates derived from 96 and 97 and in doing so, generated a variety of 
cyclopropane-containing compounds (Scheme 72). The cyclopropyl Grignard 
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intermediates were also utilised in Negishi cross-coupling reactions, allowing the intact 
cyclopropane ring to be directly functionalised with a range of aromatic and 
heteroaromatic rings (Scheme 72). 
 
 
 
Scheme 72: Divergent derivatisation of the bifunctional cyclopropyl scaffolds 15 and 16 
 
The physicochemical properties of the synthesised cyclopropane-containing 
compounds were calculated and plotted in AlogP vs. MW and PMI plots to illustrate the 
chemical space that the compound collection sampled. The compounds were found 
to sample a large amount of chemical space and possessed a wide range of 
3-dimensional structures that were located significantly away from the  
rod-like–disk-like axis. The synthesised fragments, lead-like compounds and building 
blocks were submitted to virtual derivatisation with the LLAMA computational tool. This 
generated a collection of 1187 cyclopropane-containing compounds which also 
displayed a broad distribution of medicinally-relevant physicochemical properties and 
3-dimensional structures. 
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In summary, a fast and efficient route has been developed to generate trans- and 
cis-bifunctional cyclopropyl scaffolds, which can be orthogonally derivatised through a 
variety of reactions in a divergent manner to synthesise medicinally-relevant 
compounds. 
 
Future project-oriented work should be directed towards a variety of targets, each 
extending on from the methodology that has already been developed. 
 
3.2. Future Work: Biological Screening 
The cyclopropane-containing fragments and lead-like compounds that have been 
synthesised in this work should be submitted for biological screening against a variety 
of biological targets. 
 
3.3. Future Work: Asymmetric Cyclopropanation 
Another area of future work is to improve on the asymmetric induction achieved 
already through the design and synthesis of suitable enantiopure CoII-catalysts. 
Towards this aim, complexes were designed that possessed the advantages of two 
related commonly used ligand structures; salen-type and porphyrin. Enantioenriched 
salen-type complexes generally require fewer synthetic steps to synthesise than 
enantioenriched porphyrin complexes. Additionally, the chirality of a salen-type 
complex is located closer to the reactive metal centre than for a porphyrin complex, 
suggesting higher transfer of chiral information may be possible. However, salen-type 
complexes are known to twist conformation depending on a variety of factors including 
the transition metal used and the presence of any external ligands.305 This makes 
predicting or explaining the stereochemical induction of a salen-type complex less 
than trivial. In contrast, porphyrin complexes retain their rigidity and are therefore much 
less conformationally varied.306 Consequently, the resulting complex designs should 
benefit from the increased synthetic ease and closer chirality location associated with 
a salen-type complex and the rigidity associated with a porphyrin complex. Additional 
benefits that were desired were stability of the complex towards silica chromatography 
to allow facile separation and reuse, and a relatively inexpensive source of chirality.  
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Towards this aim, two salenophen-related ligands have been designed. The first 
proposed catalyst design, complex 145, makes use of the salen-type scaffold 
architecture, possessing chirality attached to the imine functionality as opposed to a 
conventional chiral diamine backbone used in typical salen-type complexes 
(Figure 50). In 2001, Katsuki proposed that during transition metal(salen)-type 
complex-catalysed cyclopropanation the alkene approached by crossing the imine 
functionality (illustrated previously in Scheme 36).199 Having the chirality located at 
this mechanistically-important region of the complex may allow better chiral induction 
between the complex and the cyclopropanation transition state. Additionally, adding 
substitution to the imine would make it less electrophilic and therefore more resistant 
to decomposition, potentially allowing its isolation and reuse through silica 
chromatography of the cyclopropanation reaction mixture. 
 
 
Figure 50: Structure of designed C2-symmetric CoII-complex 145 
 
In addition to the bond linking it to the imine carbon, the chiral carbon would possess 
three groups of distinctly different sizes, allowing steric differentiation. This steric 
differentiation of the groups would generate a C2-symmetric CoII-complex. The first 
step in the synthesis of 145 would be the fluorination of 2-phenylpropionic acid 146 or 
2-phenylpropionyl chloride 148 to generate 149 (Scheme 73). Fluorine would be 
required as a replacement for a proton due to the acidity of the position a to the 
carbonyl. Not substituting this proton would leave the enantioenriched ligand 
vulnerable to base-mediated epimerisation. The incorporation of fluorine should still 
allow steric differentiation between itself, a methyl and a phenyl group. The 
transformation could be achieved through a racemic fluorination as demonstrated by 
Zhang and co-workers to give 147,307 followed by a chiral resolution with  
(S)-(–)a-methyl benzylamine as demonstrated by Hamman (Scheme 73, route a),308 
or an asymmetric fluorination of acyl chloride 148 utilising an Evans chiral auxiliary 
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(Scheme 73, route b).309 The reaction with 2,4-di-tert-butylphenol to generate 150 
could be carried out using a protocol by Nicolaou and co-workers,310 which would be 
followed by diamine formation to give Schiff base 151 and cobalt complexation to yield 
the desired C2-symmetric CoII-complex 145. 
 
 
 
Scheme 73: Proposed synthetic routes to CoII-complex 145 
 
An alternative asymmetric ligand, 152, and the corresponding CoII-complex, 153, were 
also designed as part of this work but have not yet been synthesised (Figure 51A). 
This design would possess similar benefits to those outlined for complex 145, however 
in addition, it was anticipated that the chiral arms of the C2-symmetric ligand 
(highlighted in blue, Scheme 51B) would also interact with the carbonyl of the cobalt 
carbene intermediate (red, Figure 51B) via a hydrogen bond. This interaction would 
generate a strong conformational preference for the carbene during the 
cyclopropanation reaction. Such hydrogen bonding interactions have been used to 
great effect by Zhang and co-workers in enantioselective CoII(porphyrin)-catalysed 
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cyclopropanations.130 As discussed in Section 2.1.4.2, successful asymmetric 
induction in a cyclopropanation reaction proceeding via carbene insertion relies on 
three requirements being fulfilled; control over the carbene orientation, control over 
the alkene approach trajectory and control over the alkene orientation. The hydrogen 
bonding interaction is expected to fulfil the first of these requirements. The chiral arm 
is anticipated to act as an effective obstruction towards reaction from one side of the 
complex, fulfilling the second requirement. Finally, the alkene approach trajectory 
would result in the incoming alkene passing within close proximity to one of the 
fluoro-substituted aromatic rings on complex 153 (pink, Figure 51B). This would be 
expected to generate alkene facial selectivity, favouring the alkene orientation that 
minimises steric repulsion between its substituents and the fluoro-substituted ring. 
This interaction could fulfil the third requirement for successful asymmetric induction; 
control of the alkene orientation. If successful, these factors would result in the CoII 
complex generating highly enantioenriched cyclopropanes, with the potential for the 
ligand to be used in other asymmetric transition metal-catalysed reactions. 
 
 
Figure 51: A) Designed structure for complex 153. B) Potential asymmetric induction mechanism for the 
153-catalysed cyclopropanation of EDA with PVS 
 
The proposed synthesis of CoII complex 153 begins with a formylation of 154 to give 
155, followed by a one-pot borylation, Suzuki-Miyaura cross-coupling sequence to 
generate 157 (Scheme 74). Such one-pot cross-coupling reactions have been 
reported, with a notable example being produced by Molander, Trice and Kennedy.311 
The presence of two fluoro substituents on aryl bromide 156 in the Suzuki-Miyaura 
cross-coupling reaction allow regiocontrol in the upcoming I2-promoted ring closure 
FF
R'
R'
O N
NOF
R'
R'
F Co
153
OH
OHR' =
A) B)
O
N
N
O
Co
H O
O
O
H
F
F
S
  185 
step and result in slightly greater conformational rigidity to the chiral side-arms. A Heck 
reaction would install a substantial portion of the chiral side-arm which would be 
followed by the I2-promoted ring closure reaction at the only available position to give 
aldehyde 160.  
 
 
 
Scheme 74: Designed structures and proposed synthesis of ligand 152 and CoII-complex 153. References for 
conditions: Formylation.312,313 Borylation, Suzuki-Miyaura cross-coupling.311 I2-mediated cyclisation.314,315 Potential 
conditions for di-imine formation and CoII complexation can be found in the experimental section of this thesis. 
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Borylation and Suzuki-Miyaura cross-coupling of 160 with 
3,5-dihydroxybromobenzene 161 would generate the racemic salicylaldehyde-related 
component of the ligand, 162. Chiral separation of the two enantiomers would produce 
the enantiomerically pure 163, along with its enantiomer. Condensation of 163 with 
1,2-diaminobenzene 164 would produce the desired enantiopure ligand 152. Cobalt 
insertion with a CoII salt such as Co(OAc)2 would result in the designed 
CoII(salen)-type complex 153. 
 
3.4. Recovery of CoII Catalyst 
Future work could also focus on developing a method for the regeneration of the CoII 
catalyst after oxygenation with air. One approach towards this may be through the use 
of hydroquinone as a reducing agent which has been shown to facilitate the removal 
of bound O2 from transition metal complexes.316 
 
3.5. Expansion of the Cyclopropyl Scaffold Derivatisation 
Methodology 
Future work should be conducted on developing more reactions that can be performed 
on the bifunctional cyclopropane scaffolds to further increase the number and variety 
of cyclopropane-containing compounds that can be created from them. 
 
One such reaction that should be investigated is the decarbonylative organoboron 
cross-coupling of the cyclopropyl ester functionality. Muto and co-corkers have 
described a nickel-catalysed cross-coupling of aryl esters with boronic acids.317 An 
aryl ester was required for the reaction to proceed and ethyl esters were found to be 
virtually unreactive under the otherwise identical conditions, however it has been 
demonstrated in this thesis that a phenyl ester-substituted cyclopropane can be 
synthesised in an excellent yield (Section 2.2.4). This reaction is proposed to proceed 
via a transmetalation–decarbonylation pathway, which offers the possibility of 
retention of stereochemical information adjacent to the ester carbonyl.317 The reaction 
was largely demonstrated on aromatic esters, however there were limited examples 
using benzylic esters, giving moderate yields.317 If successful, this methodology would 
allow the installation of (hetero)aromatics onto the intact cyclopropane ring, utilising 
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the ester functionality. This would be complementary to the sulfoxide–magnesium 
exchange, Negishi cross-coupling protocol utilised on scaffolds 15 and 16 in this work. 
 
Another alternative method of functionalisation that should be investigated is the 
transformation of the cyclopropyl ethyl ester of scaffolds 15 and 16 into an amine. 
Amine-substituted and more generally nitrogen-substituted cyclopropanes are widely 
found within pharmaceutical drugs and are a very important motif within medicinal 
chemistry (Figure 52). 
 
 
Figure 52: Examples of pharmaceutically-relevant nitrogen-substituted cyclopropanes. 
References: (±)Tranylcypromine×HCl.318 Ticagrelor.298 Trametinib.319 
 
Routes to form an amine-substituted cyclopropane from an ethyl ester-substituted 
cyclopropane exist (Scheme 75),320 and the transformation should be tested on 
cyclopropyl scaffolds 15 and 16 to demonstrate that the scaffolds are compatible with 
the reaction conditions, allowing access to the cyclopropyl amine motif. 
 
 
Scheme 75: A route to form an amine-substituted cyclopropane from an ester-substituted cyclopropane by 
Hyland and co-workers320 
 
In addition, methodology could be explored for the formation of a cyclopropyl amine 
through the developed sulfoxide–magnesium exchange followed by trapping with an 
NH
F
F
NN
N
N N
OH
HO
O OH
S
Ticagrelor
AstraZeneca
Platelet aggregation inhibitor
NH3Cl
(±)-Tranylcypromine⋅HCl
Monoamine oxidase inhibitor
Depression
MAO A (Ki = 19 µM)
MAO B (Ki = 16 µM)
N
N
O O
N
H
O
N
O
N
HF
I
Trametinib (Mekinist)
GlaxoSmithKline
MEK inhibitor
Anti-cancer activity
P-MEK (Ki = 12 nM)
OMe
O O NH2
OMe
1) 1 M NaOH, EtOH
2) (i) DPPA, Et3N, t-BuOH
(ii) Boc2O
3) (i) TFA, CH2Cl2
(ii) 1 M HCl, Et2O
49%
  188 
electrophilic nitrogen source, such as that developed by Narasaka and co-workers 
using 4,4,5,5-tetramethyl-1,3-dioxolan-2-one O-sulfonyloxime (Scheme 76).321 
 
 
Scheme 76: Proposed route to amine-substituted cyclopropanes via a sulfoxide–magnesium exchange protocol 
 
Another synthetic transformation that could be explored using the methodology that 
has been developed for cyclopropyl scaffolds 15 and 16 is the trapping of the 
cyclopropyl Grignard intermediate with an electrophilic fluorinating agent, generating 
the corresponding fluorine-substituted species. Fluorine-substituted cyclopropanes 
are medicinally-relevant motifs and it would be highly desirable to be able to 
synthesise such a motif (Figure 53). 
 
 
Figure 53: Examples of medicinally-relevant compounds possessing the cyclopropyl fluoride motif. 
References: TYK2 inhibitor.322 PAK1 inhibitor.323 
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4. Experimental 
4.1. General Experimental Considerations 
All non-aqueous reactions were run under an inert atmosphere (argon) with 
flame-dried glassware using standard techniques. Anhydrous solvents were obtained 
by filtration through drying columns (THF, CH2Cl2, toluene, DMF). Where applicable, 
rt denotes a room temperature of approximately 22 °C, and a specifically noted 
temperature e.g. “stirred at 25 °C” indicates the stated temperature was accurately 
maintained. 
 
Flash column chromatography was performed using 230–400 mesh silica with the 
indicated solvent system according to standard techniques. Analytical thin-layer 
chromatography (TLC) was performed on precoated, glass-backed silica gel plates. 
Visualisation of the developed chromatogram was performed by UV absorbance 
(254 nm), aqueous potassium permanganate, vanillin, ninhydrin or p-anisaldehyde 
stains as appropriate. 
 
Infrared spectra (nmax, FTIR ATR) were recorded in reciprocal centimetres (cm-1).  
 
Nuclear magnetic resonance spectra were recorded on 400 or 500 MHz 
spectrometers. Chemical shifts for 1H NMR spectra are recorded in parts per million 
from tetramethylsilane with the solvent resonance as the internal standard 
(chloroform: d = 7.27 ppm, DMSO: d = 2.50 ppm). Data is reported as follows: chemical 
shift [multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet and br = broad), 
coupling constant in Hz, integration, assignment]. 13C NMR spectra were recorded 
with complete proton decoupling. Chemical shifts are reported in parts per million from 
tetramethylsilane with the solvent resonance as the internal standard (13CDCl3: d = 
77.0 ppm, (13CD3)2SO: d = 39.5 ppm). J values are reported in Hz. Assignments of 1H 
and 13C spectra were based upon the analysis of d and J values, as well as COSY, 
HSQC, HMBC and NOESY experiments where appropriate. 
 
Melting points are uncorrected. 
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Optical rotations (a’) were recorded in CHCl3 at the indicated temperature (T °C) and 
were converted to the corresponding specific rotations [𝛼]$/ . 
 
Commercial reagents were used as supplied or purified by standard techniques where 
necessary. 
 
Use of diazo compounds: Although we have not experienced any problems in the 
handling or reaction of diazo reagents, extreme care should be taken when 
manipulating them due to their potentially explosive nature. 
 
CuI-catalysed cyclopropanation: For the CuI-catalysed procedure, all catalysts were 
stored in a desiccator, except for CuIOTf which was stored and handled in a glovebox. 
Reactions were conducted in a sealed microwave vial. Slow addition of the diazo 
compound solution was achieved with a syringe pump. 
 
CoII-catalysed cyclopropanation: For the CoII-catalysed procedure, no special 
precautions were taken to exclude air or moisture from the catalyst during storage or 
handling. After all reagents were added, the reaction vessel was sealed with either a 
crimp seal microwave vial lid with a septum, or a suba seal and the reaction vessel 
flushed with Ar(g). Ar(g) flushed, deflated balloons were attached to the flask, so that 
the total potential volume of the balloons when inflated was greater than the volume 
of N2(g) evolved from the reaction. On scales where ≥ 10 mmol of diazo compound 
were used, a precautionary blast shield was placed between the reaction flask and the 
fume hood sash.  
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4.2. Experimental Details and Characterisation Data 
 
Synthesis of 15 and 16 by CoII-catalysed cyclopropanation 
 
(trans)-Ethyl 2-(phenylsulfanyl)cyclopropane-1-carboxylate (15) and  
(cis)-Ethyl 2-(phenylsulfanyl)cyclopropane-1-carboxylate (16) 
 
 
 
A flask containing (±)N,N′-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamino 
cobalt(II) (28) (1.21 g, 2.0 mmol, 5 mol%) was flushed with Ar(g) for 15 min. Water 
(80 mL, degassed with Ar(g)), phenyl vinyl sulfide (7.84 mL, 60 mmol, 1.5 equiv) and 
ethyl diazoacetate (4.84 mL, containing 13 wt% CH2Cl2, 40 mmol, 1.0 equiv) were 
added and the mixture was warmed to 40 °C. After stirring at 40 °C for 24 h, the mixture 
was cooled to rt. i-Hexane (20 mL) was added and air bubbled through the stirring 
mixture for 15 min. Filtration of the mixture through a pad of silica, washing with 
CH2Cl2, followed by purification by flash column chromatography (15:1 pentane:Et2O) 
gave (trans)-ethyl 2-thiophenylcyclopropane carboxylate 15 (3.66 g, 41%) as a yellow 
oil followed by (cis)-ethyl 2-thiophenylcyclopropane carboxylate 16 (4.25 g, 48%) as a 
yellow oil. 
 
(trans)-Ethyl 2-(phenylsulfanyl)cyclopropane-1-carboxylate (15) 
Rf = 0.54 (4:1 n-hexane:Et2O). IR (film)/cm-1 3078 (CH), 3059 (CH), 2981 (CH), 2941 
(CH), 2906 (CH), 1725 (C=O), 1584, 1480, 1380. 1H NMR (400 MHz, CDCl3) d  
7.35–7.28 (m, 4 H, 4 × Ph-H), 7.21-7.17 (m, 1 H, Ph-H), 4.25–4.13 (m, 2 H, CH2CH3), 
2.77 (ddd, J = 8.5, 5.6, 3.6 Hz, 1 H, Hc), 1.92 (ddd, J = 8.5, 5.4, 3.6 Hz, 1 H, Hd), 1.67 
(ddd, J = 8.5, 5.4, 4.9 Hz, 1 H, Hb), 1.29 (t, J = 7.1 Hz, 3 H, CH3), 1.25 (ddd, J = 8.5, 
5.6, 4.9 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 172.3 (C=O), 136.8 (Ph-C quat), 
128.9 (2 × Ph-C), 127.2 (2 × Ph-C), 125.7 (Ph-C), 61.0 (CH2CH3), 24.2 (C(Hd)), 22.3 
(C(Hc)), 17.2 (C(Ha)(Hb)), 14.2 (CH3). HRMS (ES) m/z Calcd for C12H15O2S+ [M+H]+: 
223.0793; Found: 223.0795. 
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(cis)-Ethyl 2-(phenylsulfanyl)cyclopropane-1-carboxylate (16) 
Rf = 0.35 (4:1 n-hexane:Et2O). IR (film)/cm-1 3074 (CH), 3059 (CH), 2981 (CH), 2937 
(CH), 2906 (CH), 2874, 1728 (C=O), 1585, 1480, 1380. 1H NMR (400 MHz, CDCl3) d 
7.37–7.34 (m, 2 H, 2 × Ph-H), 7.30–7.25 (m, 2 H, 2 × Ph-H), 7.17–7.13 (m, 1 H, Ph-H), 
4.06 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.70 (ddd, J = 7.8, 7.8, 6.7 Hz, 1 H, Hc), 2.25 (ddd, 
J = 7.8, 7.8, 6.7 Hz, 1 H, Hd), 1.49–1.45 (m, 2 H, Ha + Hb), 1.11 (t, J = 7.1 Hz, 3 H, 
CH3). 13C NMR (101 MHz, CDCl3) d 169.6 (C=O), 137.1 (Ph-C quat), 128.7 (2 × Ph-C), 
127.5 (2 × Ph-C), 125.5 (Ph-C), 60.8 (CH2CH3), 22.07 (C(Hd)), 22.05 (C(Hc)), 14.1 
(CH3), 13.2 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C12H15O2S+ [M+H]+: 223.0793; 
Found: 223.0801. The observed data for (cis)-Ethyl 2-(phenylsulfanyl)cyclopropane-
1-carboxylate (IR, 1H, 13C) was consistent with that previously reported.284  
 
These compounds display characteristic J-values which have been considered in all 
assignments:[9] 
 
 
 
 
Synthesis of CoII(salen)-type complex 28 via Schiff base 27 
 
(±)-N,N’-Bis[(E)-3,5-di-tert-butylsalicylidene]-(trans)-1,2-cyclohexanediamine 
(27) 
 
 
 
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (4.0 g, 17.0 mmol), ethanol (40 mL) and 
(±)-1,2-trans-diaminocyclohexane (1.0 mL, 1.1 g, 9.4 mmol) were stirred at reflux for 
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3.5 h. The reaction mixture was cooled to rt and the mixture filtered, washing with 
ethanol, to give Schiff base (±)-27 (3.79 g, 81%) as a vivid yellow crystalline solid. Rf 
= 0.76 (2:1 n-hexane:Et2O). mp = 213–216 °C. IR (pure sample)/cm-1 2949 (CH), 2862 
(CH), 1630 (C=N), 1468, 1437, 1362. 1H NMR (400 MHz, CDCl3) d 13.70 (s, 2 H, 2 ´ 
N=CH), 8.29 (s, 2 H, 2 ´ OH), 7.29 (d, J = 2.5 Hz, 2 H, 2 ´ Ar-H), 6.97 (d, J = 2.5 Hz, 
2 H, 2 ´ Ar-H), 3.37–3.26 (m, 2 H, 2 ´ NCH), 1.93 (d, J = 13.5 Hz, 2 H, CH2), 1.89–
1.86 (m, 2 H, CH2), 1.78–1.69 (m, 2 H, CH2), 1.56–1.43 (m, 2 H, CH2), 1.41 (s, 18 H, 
2 ´ C(CH3)3, 1.23 (s, 18 H, 2 ´ C(CH3)3). 13C NMR (101 MHz, CDCl3) d 165.8 (2 ´ 
N=C), 158.0 (2 ´ Ar-C quat.), 139.9 (2 ´ Ar-C quat.), 136.3 (2 ´ Ar-C quat.), 126.7 (2 ´ 
Ar-C), 126.0 (2 ´ Ar-C), 117.8 (2 ´ Ar-C quat.), 72.4 (2 ´ NCH), 34.9 (4 ´ C(CH3)3), 
33.3 (2 ´ NCH2), 31.4 (2 ´ C(CH3)3), 29.4 (2 ´ C(CH3)3), 24.3 (2 ´ NCH2CH2). HRMS 
(ES) m/z Calcd for C36H55N2O2+ [M+H]+: 547.4264; Found: 547.4247. Observed data 
(1H, 13C) was consistent with that previously reported.324 
 
(±)-N,N’-Bis[(E)-3,5-di-tert-butylsalicylidene]-(trans)-1,2-cyclohexanediamino 
cobalt(II) (28) 
 
 
To a 50 mL round bottomed flask were added Co(OAc)2 (0.647 g, 3.66 mmol), EtOH 
(30 mL) and (±)-27 (2.00 g, 3.66 mmol) and the mixture stirred at reflux for 3.5 h. The 
reaction mixture was allowed to cool to rt, then filtered, washing with ethanol. 
Recrystallisation from i-propanol gave complex (±)-28 (2.01 g, 91%) as a vivid red 
solid. Melting point > 250 °C. IR (pure sample)/cm-1 2947 (CH), 2913 (CH), 2864 (CH), 
1595, 1528, 1462, 1360, 1339. HRMS (ES) m/z Calcd for C36H52N2O2+ [M]+: 603.3361; 
Found: 603.3355.  
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Synthesis of disulfides 37–40 
 
Bis(2-methylphenyl) disulfide (37) 
 
 
 
 
2-Methylbenzenethiol (3.8 mL, 4.0 g, 32.2 mmol, 1.0 equiv), CHCl3 (310 mL) and  
1,3-dibromo-5,5-dimethylhydantoin (2.3 g, 8.05 mmol, 0.25 equiv) were stirred at rt for 
1.5 h. The reaction mixture was filtered and concentrated under reduced pressure. 
The residue was dissolved in EtOAc (100 mL), washed with 1.0 M KOH(aq) (250 mL) 
and the aqueous phase extracted with EtOAc (100 mL). The organic phases were 
combined, washed with brine, dried (MgSO4), filtered and concentrated under reduced 
pressure to give disulfide 37 (3.91 g, 99%) as a yellow crystalline solid. Rf (9:1 
i-hexane:Et2O) = 0.55. 1H NMR (400 MHz, CDCl3) d 7.52–7.49 (m, 2 H, 2 ´ Ar-H), 
7.18–7.10 (m, 6 H, 6 ´ Ar-H), 2.43 (s, 6 H, 2 ´ CH3). 13C NMR (101 MHz, CDCl3) d 
137.4 (2 ´ Ar-C quat), 135.4 (2 ´ Ar-C quat), 130.3 (2 ´ Ar-C), 128.6 (2 ´ Ar-C), 127.3 
(2 ´ Ar-C), 126.7 (2 ´ Ar-C), 20.1 (2 ´ CH3). The observed data (1H, 13C) was 
consistent with that previously reported.325 
 
Bis(2-trifluoromethylphenyl) disulfide (38) 
 
 
 
2-(Trifluoromethyl)benzenethiol (3.7 mL, 5.0 g, 28.1 mmol, 1.0 equiv), CHCl3 (270 mL) 
and 1,3-dibromo-5,5-dimethylhydantoin (2.0 g, 7.02 mmol, 0.25 equiv) were stirred at 
rt  for 3 h. The reaction mixture was filtered and concentrated under reduced pressure. 
The residue was dissolved in EtOAc (100 mL), washed with 1.0 M KOH(aq) (250 mL) 
and the aqueous phase extracted with EtOAc (100 mL). The organic phases were 
combined, washed with brine, dried (MgSO4), filtered and concentrated under reduced 
pressure to give disulfide 38 (4.90 g, 99%) as a beige crystalline solid. Rf (9:1 
S
S
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F FF
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i-hexane:Et2O) = 0.43. 1H NMR (400 MHz, CDCl3) d 7.84 (d, J = 8.0 Hz, 2 H, 2 ´ Ar-H), 
7.64, (d, J = 8.0 Hz, 2 H, 2 ´ Ar-H), 7.49 (t, J = 8.0 Hz, 2 H, 2 ´ Ar-H), 7.33 (t, J = 
8.0 Hz, 2 H, 2 ´ Ar-H). 13C NMR (101 MHz, CDCl3) d 135.4 (2 ´ Ar-C-S), 132.5 (2 ´ 
Ar-C), 129.5 (2 ´ Ar-C), 128.5 (q, J = 31.3 Hz, 2 ´ Ar-C quat), 127.2 (2 ´ Ar-C), 126.7 
(q, J = 5.1 Hz, 2 ´ Ar-C), 123.6 (q, J = 274.7 Hz, 2 ´ CF3). The observed data (1H, 13C) 
was consistent with that previously reported.326 
 
Bis(4-chlorophenyl) disulfide (39) 
 
 
 
4-Chlorobenzenethiol (4.05 g, 28.0 mmol, 1.0 equiv), CHCl3 (270 mL) and  
1,3-dibromo-5,5-dimethylhydantoin (2.0 g, 7.0 mmol, 0.25 equiv) were stirred at rt for 
2 h. The reaction mixture was filtered and concentrated under reduced pressure. The 
residue was dissolved in EtOAc (100 mL), washed with 1.0 M KOH(aq) (250 mL) and 
the aqueous phase extracted with EtOAc (100 mL). The organic phases were 
combined, washed with brine, dried (MgSO4), filtered and concentrated under reduced 
pressure to give disulfide 39 (3.941 g, 98%) as a yellow crystalline solid. Rf (9:1 
i-hexane:Et2O) = 0.60. 1H NMR (400 MHz, CDCl3) d 7.42–7.38 (m, 4 H, 4 ´ Ar-H), 
7.29–7.26 (m, 4 H, 4 ´ Ar-H). 13C NMR (101 MHz, CDCl3) d 135.2 (2 ´ Ph-C quat), 
133.7 (2 ´ Ph-C quat), 129.4 (4 ´ Ph-C), 129.3 (4 ´ Ph-C). The observed data (1H, 
13C) was consistent with that previously reported.327 
 
Bis(4-trifluoromethylphenyl) disulfide (40) 
 
 
 
4-(Trifluoromethyl)benzenethiol (3.85 g, 28.0 mmol, 1.0 equiv), CHCl3 (270 mL) and 
1,3-dibromo-5,5-dimethylhydantoin (2.0 g, 7.0 mmol, 0.25 equiv) were stirred at rt for 
2 h. The reaction mixture was filtered and concentrated under reduced pressure. The 
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residue was dissolved in EtOAc (100 mL), washed with 1.0 M KOH(aq) (250 mL) and 
the aqueous phase extracted with EtOAc (100 mL). The organic phases were 
combined, washed with brine, dried (MgSO4), filtered and concentrated under reduced 
pressure to give disulfide 40 (4.744 g, 96%) as a cream crystalline solid. Rf (9:1 
i-hexane:Et2O) = 0.57. 1H NMR (400 MHz, CDCl3) d 7.82–7.34 (m, 8 H, 8 ´ Ar-H). 
13C NMR (101 MHz, CDCl3) d 140.8 (d, J = 1.5 Hz, 4 ´ Ar-C), 129.6 (q, J = 33.3 Hz, 2 
´ Ar-C quat), 126.6 (2 ´ Ar-C-S), 126.1 (q, J = 4.4 Hz, 4 ´ Ar-C), 123.8 (q, J = 272.7 Hz, 
2 ´ CF3). The observed data (1H, 13C) was consistent with that previously reported.327  
 
 
Synthesis of vinyl sulfides 41–45 
 
2-Methylphenylvinyl sulfide (41) 
 
 
 
Vinyl magnesium bromide (1.0 M in THF, 2.44 mL, 2.44 mmol, 2.0 equiv) was added 
to a 0 °C solution of disulfide 37 (300 mg, 1.22 mmol, 1.0 equiv) in THF (10 mL) and 
the reaction mixture was stirred at 0 °C for 3.5 h, then rt for 1 h. The reaction mixture 
was concentrated under reduced pressure, dissolved in i-hexane, filtered and 
concentrated under reduced pressure. Purification (12 g RediSep silica cartridge,  
3–10% Et2O:i-hexane, 20 column volumes) gave the vinyl sulfide 41 (65 mg, 35%) as 
a colourless oil. 1H NMR (400 MHz, CDCl3) d 7.40–7.37 (m, 1 H, Ar-H), 7.24–7.12 (m, 
3 H, 2 ´ Ar-H), 6.47 (dd, J = 16.5, 9.6 Hz, 1 H, Ha), 5.31 (d, J = 9.6 Hz, 1 H, Hc), 5.15 
(d, J = 16.5 Hz, 1 H, Hb), 2.40 (s, 3 H, CH3). The observed data (1H) was consistent 
with that previously reported.328 
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2-Trimethylphenylvinyl sulfide (42) 
 
 
 
Vinyl magnesium bromide (1.0 M in THF, 2.25 mL, 2.25 mmol, 2.0 equiv) was added 
to a 0 °C solution of disulfide 38 (400 mg, 1.13 mmol, 1.0 equiv) in THF (9.25 mL) and 
the reaction stirred at 0 °C for 3 h, then rt for 1 h. The reaction mixture was 
concentrated under reduced pressure and purified (150 g C18 RediSep cartridge, 
ammonium bicarbonate(aq):acetonitrile). The required fractions were combined and 
extracted with i-hexane (5 × 100 mL). The organic phases were combined, washed 
with brine, dried (MgSO4), filtered and concentrated under reduced pressure (in a 
water bath cooled to 5–10 °C) to obtain vinyl sulfide 42 (168 mg, 73%) as a light pink 
oil. 1H NMR (400 MHz, CDCl3) d 7.68 (d, J = 8.0 Hz, 1 H, Ar-H), 7.49 (m, 2 H, 2 ´ 
Ar-H), 7.34 (m, 1 H, Ar-H), 6.50 (dd, J = 16.6, 9.6 Hz, 1 H, Ha), 5.51–5.48 (d, J = 
9.6 Hz, 1 H, Hc), 5.50–5.46 (d, J = 16.6 Hz, 1 H, Hb). 
 
4-Chlorophenylvinyl sulfide (43) 
 
 
 
Vinyl magnesium bromide (1.0 M in THF, 2.1 mL, 2.1 mmol, 2.0 equiv) was added to 
a 0 °C solution of disulfide 39 (300 mg, 1.04 mmol, 1.0 equiv) in THF (8.5 mL) and the 
reaction mixture stirred at 0 °C for 3 h, then room temperature for 1 h. Sat. NH4Cl(aq) 
(10 mL was added and stirred for 10 min. The mixture was extracted with CH2Cl2 (2 × 
15 mL), the organic phases were combined and washed with 1.0 M KOH(aq), with the 
aqueous phase being washed with CH2Cl2 (15 mL). The organic phases were 
combined and concentrated under reduced pressure to give vinyl sulfide 43 (147 mg, 
83%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) d 7.32–7.28 (m, 4 H, 4 ´ Ar-H), 
6.49 (dd, J = 16.6, 9.6 Hz, 1 H, Ha), 5.39 (d, J = 9.6 Hz, 1 H, Hc), 5.35 (d, J = 16.6 Hz, 
1 H, Hb). The observed data (1H) was consistent with that previously reported.329  
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4-Trifluoromethylphenylvinyl sulfide (44) 
 
 
 
Vinyl magnesium bromide (1.0 M in THF, 1.7 mL, 1.7 mmol, 1.5 equiv) was added to 
a 0 °C solution of disulfide 40 (400 mg, 1.13 mmol, 1.0 equiv) in THF (9.25 mL) and 
the reaction mixture stirred at 0 °C for 2.5 h, then room temperature for 2 h. Sat. 
NH4Cl(aq) (10 mL) was added and stirred for 10 min. The mixture was extracted with 
CH2Cl2 (2 × 20 mL), then the organic phases were combined and washed with 1.0 M 
KOH(aq), with the aqueous phase being extracted with CH2Cl2 (20 mL). The organic 
phases were combined and concentrated under reduced pressure. Purification (24 g 
RediSep silica cartridge, 100% i-hexane, 20 column volumes) gave vinyl sulfide 44 
(89 mg, 38%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) d 7.70–7.32 (m, 5 H, 5 ´ 
Ar-H), 6.55 (dd, J = 12.0, 8.0 Hz, 1 H, Ha), 5.55 (d, J = 12.0 Hz, 1 H, Hb), 5.55 (d, J = 
8.0 Hz, 1 H, Hc). The observed data (1H) was consistent with that previously 
reported.330 
 
4-Methoxyphenylvinyl sulfide (45) 
 
 
 
Vinyl magnesium bromide (1.0 M in THF, 2.2 mL, 2.2 mmol, 1.5 equiv) was added to 
a 0 °C solution of bis(4-methoxyphenyl)disulfide (400 mg, 1.44 mmol, 1.0 equiv) in 
THF (12 mL) and the reaction mixture stirred at 0 °C for 3.5 h, then rt for 1 h. Sat. 
NH4Cl(aq) (10 mL) was added and stirred for 10 min. The mixture was extracted with 
CH2Cl2 (2 × 10 mL), the organic phases combined and washed with 1.0 M KOH(aq), 
with the aqueous phase being extracted with CH2Cl2 (10 mL). The organic phases 
were combined and concentrated under reduced pressure. Purification (24 g RediSep 
silica cartridge, 1–3% Et2O:i-hexane, 20 column volumes) gave vinyl sulfide 45 
(30.0 mg, 13%) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) d 7.37 (d, J = 9.0 Hz, 
2 H, 2 ´ Ar-H), 6.89 (d, J = 9.0 Hz, 2 H, 2 ´ Ar-H), 6.47 (dd, J = 16.6, 9.8 Hz, 1 H, Ha), 
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5.22 (d, J = 9.8 Hz, 1 H, Hc), 5.10 (d, J = 16.6 Hz, 1 H, Hb), 3.81 (s, 3 H, CH3). The 
observed data (1H) was consistent with that previously reported.329  
 
 
Synthesis of Enantiopure C2-Symmetric CoII-(Salen)-Type Complexes 
 
Complexes 28* and 67 were obtained commercially from Sigma Aldrich. 
 
 
Synthesis of complex 66 
 
2,2'-{[(1R,2R)-1,2-diphenylethane-1,2diyl]bis[azanylylidene(E)-methanyl 
ylidene]}bis(4,6-di-tert-butylphenol) (65) 
 
 
 
 
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (600 mg, 2.56 mmol, 2.0 equiv), EtOH 
(20 mL) and (1R,2R)-(+)-1,2-diphenylethylenediamine (272 mg, 1.28 mmol, 1.0 equiv) 
were stirred at reflux for 20 h. The reaction was cooled, then filtered to give Schiff base 
65 (500 mg, 61%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) d 13.60 (s, 2 H, 
2 ´ N=CH), 8.40 (s, 2 H, 2 ´ Ar-H), 7.36–6.93 (m, 12 H, 2 ´ Ar-H + 10 ´ Ph-H), 4.71 
(s, 2 H, 2 ´ CH(N)), 1.42 (s, 18 H, C(CH3)3), 1.21 (s, 18 H, C(CH3)3). 13C NMR 
(101 MHz, CDCl3) d 167.2 (2 ´ C=N), 158.0 (2 ´ Ar-C quat), 140.0 (2 ´ Ar-C quat), 
139.8 (2 ´ Ar-C quat), 136.4 (2 ´ Ar-C quat), 128.3 (4 ´ Ph-C), 128.0 (4 ´ Ph-C), 127.4 
(2 ´ Ar-C), 127.1 (2 ´ Ar-C), 126.3 (2 ´ Ar-C), 117.9 (2 ´ Ar-C quat), 35.0 (2 ´ CH(N)), 
34.0 (4´ C(CH3)3 quat), 31.4 (C(CH3)3), 29.4 (C(CH3)3). The observed data (1H) was 
consistent with that previously reported.331  
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N,N'-Bis[(E)-(3,5-di-tert-butyl)-2-hydroxyphenylmethylene]-[(1R,2R)-1,2-
diphenylethylenediamino]cobalt(II) (66) 
 
  
  
A mixture of Co(OAc)2 (123 mg, 0.70 mmol, 1.0 equiv), H2O (2.0 mL) and ethanol 
(4.0 mL) was added to a solution of 65 (450 mg, 0.70 mmol, 1.0 equiv) in toluene 
(4.0 mL, 0.18 M). The reaction mixture was stirred at reflux for 3 h, cooled to rt, 
concentrated under reduced pressure, then recrystallised from ethanol to obtain 66 
(327 mg, 67%) as a vivid red solid. mp > 250 °C. IR (film)/cm-1 2951 (CH), 2904 (CH), 
2867 (CH), 1589 (C=N), 1525, 1454, 1319, 1250, 1179, 787, 698. FTMS (+ p NSI) m/z 
Calcd for C44H54CoN2O2+ [M]+: 701.3512; Found: 701.3505. The observed data (IR) 
was consistent with that previously reported.201 
 
 
Synthesis of complex 68 
 
N,N′-Bis[(E)-5-tert-butyl-3-[(morpholin-4-yl)methyl]-2-hydroxybenzylidene]-
[(1S,2S)-1,2-cyclohexanediamino]cobalt(II) (68) 
 
  
  
4-tert-Butyl-2-[({(1S,2S)-2-[(E)-({5-tert-butyl-2-hydroxy-3-[(morpholin-4yl)methyl] 
phenyl}methylidene)amino]cyclohexyl}imino)methyl]-6-[(morpholin-4yl)methyl]phenol 
(100 mg, 0.16 mmol, 1.0 equiv), EtOH (2.0 mL) and Co(OAc)2 (28 mg, 1.0 equiv) were 
stirred at reflux for 17 h. The reaction mixture was cooled slowly to -78 °C and filtered 
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to give complex 68 (15 mg, 14%) as a vivid orange solid. High pH LCMS; 1.286 min, 
mass found: 689.4. 
  
  
Synthesis of complex 69 
 
N,N′-Bis[(E)-2,3-dihydroxybenzylidene]-[(1R,2R)-1,2-cyclohexanediamino] 
cobalt(II) (69) 
 
  
  
3-({[(1R,2R)-2-{(E)-[(2,3dihydroxyphenyl)methylidene]amino}cyclohexyl]imino} 
methyl)benzene-1,2-diol (155 mg, 0.44 mmol, 1.0 equiv), EtOH (8 mL) and Co(OAc)2 
(77 mg, 0.44 mmol, 1.0 equiv) were stirred at reflux for 17 h. The reaction mixture was 
cooled to rt and filtered. The filtrate was recrystallised from a solution of EtOH (30 mL), 
MeOH (30 mL) and CHCl3 (5 mL) to give complex 69 (25 mg, 14%) as a brown solid. 
FTMS (+p NSI) m/z Calcd for C20H20N2O4Co+ [M]+: 411.0750; Found: 411.0750. 
 
 
Synthesis of complex 71 
 
2-Ethoxy-6-({[(1R,2R)-2-{(E)-[(3-ethoxy-2-hydroxyphenyl)methylidene] 
amino}cyclohexyl]imino}methyl)phenol (70) 
 
 
 
A solution of 3-ethoxy-2-hydroxybenzaldehyde (283 mg, 1.7 mmol, 2.0 equiv) in EtOH 
(10 mL) was added to a solution of (1R,2R)-(–)-1,2-diaminocyclohexane (97 mg, 
0.85 mmol, 1.0 equiv) in EtOH (3 mL) and the mixture was stirred at reflux for 3 h. The 
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mixture was concentrated under reduced pressure to give Schiff base 70 (342 mg, 
98%) as a vivid yellow oil. Rf (2:1 n-hexane:Et2O) = 0.10. IR (film)/cm-1 2980 (CH), 
2930 (CH), 2859 (CH), 1625 (C=N), 1462, 1244, 1077. 1H NMR (400 MHz, CDCl3) d 
13.93 (s, 2 H, 2 ´ OH), 8.24 (s, 2 H, 2 ´ HC=N), 6.86 (dd, J = 7.8, 1.6 Hz, 2 H, 2 ´ 
Ar-H), 6.78 (dd, J = 7.8, 1.6 Hz, 2 H, 2 ´ Ar-H), 6.71 (t, J = 7.8 Hz, 2 H, 2 ´ Ar-H), 4.07 
(q, J = 7.0 Hz, 4 H, 2 ´ CH2CH3), 3.34–3.26 (m, 2 H, 2 ´ NCH), 2.01–1.69 (m, 8 H, 4 
´ CH2), 1.48 (t, J = 7.0 Hz, 6 H, 2 ´ CH3). 13C NMR (101 MHz, CDCl3) d 164.7 (2 ´ 
C=N), 151.7 (2 ´ Ar-quat), 147.5 (2 ´ Ar-quat), 123.1 (2 ´ Ar-H), 118.4 (2 ´ Ar-quat), 
117.8 (2 ´ Ar-H), 115.0 (2 ´ Ar-H), 72.4 (2 ´ NCH), 64.3 (2 ´ OCH2), 33.0 (2 ´ CH2), 
24.0 (2 ´ CH2), 14.9 (2 ´ CH3). ES+ m/z Calcd for C24H31N2O4+ [M-H]+: 411.2284; 
Found: 411.2291. The observed data (1H, 13C) was consistent with that previously 
reported.332 
 
N,N′-Bis[(E)-3-ethoxy-2-hydroxybenzylidene]-[(1R,2R)-1,2-cyclohexane 
diamino]cobalt(II) (71) 
 
 
 
A mixture of Co(OAc)2 (33 mg, 0.18 mmol), H2O (1.0 mL) and ethanol (2.5 mL) was 
added to a solution of 70 (74 mg, 0.18 mmol) in toluene (1.5 mL, 0.12 M). The reaction 
mixture was refluxed for 3 h, cooled to rt, concentrated under reduced pressure, then 
recrystallised from CHCl3 to give 71 (74 mg, quant) as a brown solid. mp > 250 °C. 
IR (film)/cm-1 3250 (CH), 2980 (CH), 2935 (CH), 2864 (CH), 1635 (C=N), 1603, 1561, 
1469, 1447, 1390, 1247, 1222. FTMS (+ p NSI) m/z Calcd for C20H20CoN2O4+ [M]+: 
411.0750; Found: 411.0750. 
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Synthesis of complex 74 
 
2,3-Dichloro-5-ethoxy-6-hydroxybenzaldehyde (72) 
 
 
 
3-Ethoxysalicylaldehyde (283 mg, 1.7 mmol), AcOH (6.5 mL), then 
N-chlorosuccinimide (481 mg, 3.6 mmol, 2.1 equiv) were added to a flask and stirred 
at 80 °C for 17 h. The reaction was cooled to rt, H2O (50 mL) added, and the mixture 
extracted with CH2Cl2 (3 ´ 40 mL). The organic phases were combined, washed with 
brine, dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by flash chromatography (10:1 n-hexane:Et2O) gave aldehyde 72 (285 mg, 71%) as a 
yellow crystalline solid. Rf (8:1 n-hexane:Et2O) = 0.28. IR (film)/cm-1 3088 (CH), 2941 
(CH), 2899 (CH), 1639 (C=O), 1572, 1451, 1241. 1H NMR (400 MHz, CDCl3) d 12.33 
(s, 1 H, OH), 10.41 (s, 1 H, C=O(H)), 7.11 (s, 1 H, Ar-H), 4.11 (q, J = 7.0 Hz, 2 H, CH2), 
1.51 (t, J = 7.0 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 195.9 (C=O), 153.5 (Ar-C 
quat), 147.2 (Ar-C quat), 125.4 (Ar-C quat), 123.0 (Ar-C quat), 119.7 (Ar-C), 117.0 
(Ar-C quat), 65.3 (CH2), 14.5 (CH3). 
 
3,4-Dichloro-2-({[(1R,2R)-2-{(E)-[(2,3-dichloro-5-ethoxy-6-hydroxyphenyl) 
methylidene]amino}cyclohexyl]imino}methyl)-6-ethoxyphenol (73) 
 
 
 
Aldehyde 72 (200 mg, 0.85 mmol, 2.0 equiv), EtOH (15 mL) and (1R,2R)-(–)-1,2-
diaminocyclohexane (49 mg, 0.43 mmol, 1.0 equiv) were stirred at 90 °C for 3.5 h. The 
reaction mixture was concentrated under reduced pressure to give Schiff base 73 
(225 mg, 97%) as a yellow crystalline solid. Rf (EtOAc) = 0.68. 1H NMR (400 MHz, 
CDCl3) d 15.09 (s, 2 H, 2 ´ OH), 8.64 (s, 2 H, (H)C=N), 6.84 (s, 2 H, 2 ´ Ar-H), 4.05 
(q, J = 6.8 Hz, 4 H, 2 ´ CH2), 3.48–3.31 (m, 2 H, 2 ´ CH), 2.06 (m, 2 H, CH2), 1.91 (m, 
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2 H, CH2), 1.78–1.64 (m, 2 H, CH2), 1.60–1.44 (m, 2 H, CH2), 1.48 (t, J = 6.8 Hz, 6 H, 
2 ´ CH3). 13C NMR (101 MHz, CDCl3) d 163.2 (C=N), 156.4 (Ar-C quat), 147.9 (Ar-C 
quat), 123.4 (Ar-C quat), 120.1 (Ar-C quat), 115.9 (Ar-C), 114.3 (Ar-C), 70.8 (2 ´ NCH), 
64.7 (2 ´ OCH2), 32.6 (2 ´ CH2), 23.8 (2 ´ CH2), 14.6 (2 ´ CH3). 
 
N,N'-Bis[(E)-(2,3-di-chloro)-5-ethoxy-6-hydroxyphenylmethylene]-[(1R,2R)-1,2-
cyclohexanediamino]cobalt(II) (74) 
 
 
 
Co(OAc)2 (48 mg, 0.27 mmol, 1.0 equiv), H2O (150 µL), EtOH (1.5 mL), toluene 
(1.5 mL) and 73 (150 mg, 0.27 mmol, 1.0 equiv) were stirred at 100 °C for 1 h. EtOH 
(1.5 mL) was added and the mixture stirred at 100 °C for 2 h. Concentration under 
reduced pressure followed by recrystallisation from CHCl3 gave complex 74 (89 mg, 
54%) as a brown solid. mp > 250 °C. FTMS (+ p NSI) m/z Calcd for C24H24CoN2O4Cl4+ 
[M]+: 602.9817; Found: 602.9813. 
 
 
Synthesis of complex 76 
 
2-({[(1R,2R)-2-{(E)-[(2-hydroxy-3,5-diiodophenyl)methylidene]amino}cyclo 
hexyl]imino}methyl)-4,6-diiodophenol (75) 
 
 
 
A solution of (1R,2R)-(–)-1,2-diaminocyclohexane (97 mg, 0.85 mmol, 1.0 equiv) in 
EtOH (4 mL) was added to a mixture of 3,5-diiodosalicylaldehyde (636 mg, 1.7 mmol, 
2.0 equiv) in EtOH (10 mL) and the mixture was stirred at reflux for 3.5 h. The mixture 
was cooled to rt and concentrated under reduced pressure. Recrystallisation from 
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EtOH (10 mL) gave Schiff base 75 (571 mg, 81%) as an orange crystalline solid. Rf 
(2:1 n-hexane:Et2O) = 0.21. mp = 130–133 °C. IR (film)/cm-1 3059 (OH), 2931 (CH), 
2854 (CH), 1623 (C=N), 1436, 1275, 1155, 865. 1H NMR (400 MHz, CDCl3) d 14.55 
(s, 2 H, 2 ´ OH), 8.05 (s, 2 H, 2 ´ HC=N), 8.01 (d, J = 2.0 Hz, 2 H, 2 ´ Ar-H), 7.43 (d, 
J = 2.0 Hz, 2 H, 2 ´ Ar-H), 3.35 (dd, J = 8.1, 4.2 Hz, 2 H, 2 ´ NCH), 2.03–1.40 (m, 8 H, 
4 ´ CH2). 13C NMR (101 MHz, CDCl3) d 163.0 (2 ´ C=N), 160.9 (2 ´ Ar-C quat), 148.8 
(2 ´ Ar-C), 140.0 (2 ´ Ar-C), 119.5 (2 ´ Ar-C quat), 87.7 (2 ´ Ar-C quat), 79.3 (2 ´ Ar-C 
quat), 71.8 (2 ´ CH2), 32.8 (2 ´ CH2), 23.9 (2 ´ CH2). FTMS (+ p NSI) m/z Calcd for 
C20H19N2O2I4+ [M-H]+: 826.7626; Found: 826.7631. The observed data (IR, 1H) was 
consistent with that previously reported.333 
 
N,N'-Bis[(E)-(3,5-di-iodo)-2-hydroxyphenylmethylene]-[(1R,2R)-1,2-cyclo 
hexanediamino]cobalt(II) (76) 
 
 
 
A mixture of Co(OAc)2 (33 mg, 0.18 mmol, 1.0 equiv), H2O (1.0 mL) and ethanol 
(2.5 mL) was added to a solution of 75 (148 mg, 0.18 mmol, 1.0 equiv) in toluene 
(1.5 mL). The reaction mixture was stirred at reflux for 3 h, cooled to rt, concentrated 
under reduced pressure, then recrystallised in 3:2 ethanol:CHCl3 (v/v) to give 76 
(151 mg, 95%) as a vivid orange solid. mp > 250 °C. IR (film)/cm-1 3003 (CH), 2938 
(CH), 2858 (CH), 1738, 1599, 1568, 1490, 1422, 1398, 1160, 1031. FTMS (+ p NSI) 
m/z Calcd for C20H16CoN2O2I4+ [M]+: 882.6717; Found: 882.6714.  
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Synthesis of 79–82 through ester hydrolysis 
 
(trans)-2-(Phenylsulfanyl)cyclopropane-1-carboxylic acid (79) 
 
 
 
Aqueous NaOH (1.0 M, 0.55 mL, 0.55 mmol, 1.1 equiv) was added to a solution of  
(trans)-ethyl 2-thiophenylcyclopropane carboxylate 15 (111 mg, 0.50 mmol, 1.0 equiv) 
in ethanol (2.5 mL) and the solution stirred at 30 °C for 24 h. HCl(aq) (1.0 M, 10 mL) 
was added and the mixture was extracted with EtOAc (5 ´ 10 mL). The combined 
organic phases were dried (MgSO4), filtered and concentrated under reduced 
pressure to give carboxylic acid 79 (97 mg, quant) as a white crystalline solid. Rf = 
0.18 (1:1 pentane:Et2O). mp = 106-110 °C. IR (film)/cm-1 3008 (CH), 2863 (CH), 2530, 
1679 (C=O), 1585, 1440, 1272, 1223, 928. 1H NMR (400 MHz, CDCl3) d 7.37–7.29 
(m, 4 H, 4 × Ph-H), 7.25–7.18 (m, 1 H, Ph-H), 2.85 (ddd, J = 8.4, 5.8, 3.5 Hz, 1 H, Hc), 
1.95 (ddd, J = 8.7, 5.3, 3.5 Hz, 1 H, Hd), 1.73 (ddd, J = 8.4, 5.3, 5.0 Hz, 1 H, Hb), 1.35 
(ddd, J = 8.7, 5.8, 5.0 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 178.3 (C=O), 136.3 
(Ph-C quat), 129.0 (2 ´ Ph-C), 127.6 (2 ´ Ph-C), 126.0 (Ph-C), 24.1 (C(Hd)), 23.5 
(C(Hc)), 17.9 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C10H9O2S+ [M-H]+: 193.0323; 
Found: 193.0332. 
 
(cis)-2-(Phenylsulfanyl)cyclopropane-1-carboxylic acid (80) 
 
 
 
 
Aqueous NaOH (1.0 M, 0.55 mL, 0.55 mmol, 1.1 equiv) was added to a solution of  
(cis)-ethyl 2-thiophenylcyclopropane carboxylate 16 (111 mg, 0.50 mmol, 1.0 equiv) 
in ethanol (2.5 mL) and the solution stirred at 30 °C for 24 h. HCl(aq) (1.0 M, 10 mL) 
was added and the mixture was extracted with EtOAc (5 ´ 10 mL). The combined 
organic phases were dried (MgSO4), filtered and concentrated under reduced 
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pressure to give carboxylic acid 80 (97 mg, quant) as a cream crystalline solid. Rf = 
0.22 (1:1 pentane:Et2O). mp = 76-79 °C. IR (film)/cm-1 3044 (CH), 2685 (CH), 2533, 
1688 (C=O), 1478, 1436, 1202, 902. 1H NMR (400 MHz, DMSO-d6) d 12.25 (br s,  
1 H, CO2H), 7.36–7.29 (m, 4 H, 4 × Ph-H), 7.18–7.13 (m, 1 H, Ph-H), 2.77 (ddd, J = 
8.1, 8.0, 6.4 Hz, 1 H, Hc), 2.23 (ddd, J = 8.0, 7.9, 6.3 Hz, 1 H, Hd), 1.45 (ddd, J = 8.1, 
7.9, 5.0 Hz, 1 H, Ha), 1.13 (ddd, J = 6.4, 6.3, 5.0 Hz, 1 H, Hb). 13C NMR (101 MHz, 
DMSO-d6) d 170.6 (C=O), 137.3 (Ph-C quat), 129.0 (2 ´ Ph-C), 126.4 (2 ´ Ph-C), 
125.2 (Ph-C), 21.3 (C(Hd)), 20.9 (C(Hc)), 12.6 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for 
C10H9O2S+ [M-H]+: 193.0323; Found: 193.0311. 
 
(trans)-Sodium 2-(phenylsulfanyl)cyclopropane-1-carboxylate (81) 
 
 
 
Aqueous NaOH (1.0 M, 2.9 mL, 2.9 mmol, 1.0 equiv) was added to a solution of 
(trans)-ethyl 2-thiophenylcyclopropane carboxylate 15 (646 mg, 2.9 mmol, 1.0 equiv) 
in ethanol (14.5 mL) and the solution stirred at 30 °C for 24 h. The reaction mixture 
was concentrated under reduced pressure to give sodium carboxylate salt 81 (622 mg, 
quant) as a cream solid. mp = 207-212 °C. IR (film)/cm-1 3521 (CH), 3232 (CH), 1567 
(C=O), 1417, 1318, 1251, 955. 1H NMR (400 MHz, DMSO-d6) d 7.34–7.27 (m, 4 H, 
4 × Ph-H), 7.15–7.10 (m, 1 H, Ph-H), 2.39 (ddd, J = 7.9, 4.9, 3.7 Hz, 1 H, Hc), 1.43 
(ddd, J = 8.8, 5.5, 3.7 Hz, 1 H, Hd), 1.30 (ddd, J = 7.9, 5.5, 3.8 Hz, 1 H, Hb), 0.76 (ddd, 
J = 8.8, 4.9, 3.8 Hz, 1 H, Ha). 13C NMR (101 MHz, DMSO-d6) d 174.9 (C=O), 138.4 
(Ph-C quat), 128.9 (2 ´ Ph-C), 125.8 (2 ´ Ph-C), 124.8 (Ph-C), 27.2 (C(Hd)), 18.3 
(C(Hc)), 15.0 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C10H9O2S+ [M-Na]+: 193.0323; 
Found: 193.0317. 
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(cis)-Sodium 2-(phenylsulfanyl)cyclopropane-1-carboxylate (82) 
 
 
 
Aqueous NaOH (1.0 M, 4.5 mL, 4.5 mmol, 1.0 equiv) was added to a solution of 
(cis)-ethyl 2-thiophenylcyclopropane carboxylate 16 (1.00 g, 4.50 mmol, 1.0 equiv) in 
ethanol (22.5 mL) and the solution stirred at 30 °C for 24 h. The reaction mixture was 
concentrated under reduced pressure to give sodium carboxylate salt 82 (0.98 g, 
quant) as a cream solid. mp = 236-240 °C. IR (film)/cm-1 3078 (CH), 3055 (CH), 3016 
(CH), 1586 (C=O), 1424, 1315, 1282, 956. 1H NMR (400 MHz, DMSO-d6) d 7.36–7.33 
(m, 2 H, 2 × Ph-H), 7.27–7.22 (m, 2 H, 2 × Ph-H), 7.09–7.05 (m, 1 H, Ph-H), 2.24 (ddd, 
J = 8.2, 8.0, 5.9 Hz, 1 H, Hc), 1.77 (ddd, J = 8.2, 8.0, 6.5 Hz, 1 H, Hd), 1.10 (ddd, J = 
8.0, 8.0, 4.0 Hz, 1 H, Ha), 0.90 (ddd, J = 6.5, 5.9, 4.0 Hz, 1 H, Hb). 13C NMR (101 MHz, 
DMSO-d6) d 173.2 (C=O), 139.8 (Ph-C quat), 128.6 (2 ´ Ph-C), 126.3 (2 ´ Ph-C), 
124.3 (Ph-C), 24.2 (C(Hd)), 19.4 (C(Hc)), 13.3 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for 
C10H9O2S+ [M-Na]+: 193.0323; Found: 193.0319. 
 
 
Synthesis of 83–90 through amide bond formation 
 
(cis)-N-Benzyl-2-(phenylsulfanyl)cyclopropane-1-carboxamide (83) 
 
 
 
HATU (228 mg, 0.60 mmol, 1.2 equiv) was added to a solution of (cis)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 82 (108 mg, 0.50 mmol, 1.0 equiv) in  
N,N-dimethylformamide (2.5 mL) and stirred at 40 °C for 10 min. Benzylamine  
(66 µL, 0.60 mmol, 1.2 equiv) was added and the solution stirred for 20 min. 
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Diisopropylethylamine (0.27 mL, 1.50 mmol, 3.0 equiv) was added and the solution 
stirred for 24 h. Water (100 mL) was added and the mixture was extracted with EtOAc  
(5 ´ 20 mL). The combined organic phases were washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (Et2O) gave amide 83 (123 mg, 87%) as a white solid. Rf = 
0.32 (Et2O). mp = 137-140 °C. IR (film)/cm-1 3303 (NH), 3060 (CH), 1645 (C=O), 1552, 
1244, 687. 1H NMR (400 MHz, CDCl3) d 7.36–7.09 (m, 10 H, 10 × Ph-H), 6.11 (br s, 
1 H, NH), 4.37 (d, J = 5.7 Hz, 2 H, PhCH2), 2.64 (ddd, J = 8.2, 7.7, 6.4 Hz, 1 H, Hc), 
2.10 (ddd, J = 8.2, 7.7, 6.6 Hz, 1 H, Hd), 1.49–1.41 (m, 2 H, Ha + Hb). 13C NMR 
(101 MHz, CDCl3) d 168.5 (C=O), 138.0 (Ph-C quat), 137.1 (Ph-C quat), 128.9 (2 ´ 
Ph-C), 128.5 (2 ´ Ph-C), 127.7 (2 ´ Ph-C), 127.34 (2 ´ Ph-C), 127.28 (Ph-C), 125.6 
(Ph-C), 43.9 (PhCH2), 23.4 (C(Hd)), 21.1 (C(Hc)), 12.9 (C(Ha)(Hb)). HRMS (ES) m/z 
Calcd for C17H18NOS+ [M+H]+: 284.1109; Found: 284.1117. 
 
 (trans)-N-Benzyl-2-(phenylsulfanyl)cyclopropane-1-carboxamide (84) 
 
 
 
HATU (183 mg, 0.48 mmol, 1.2 equiv) was added to a solution of (trans)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 81 (87 mg, 0.40 mmol, 1.0 equiv) in 
N,N-dimethylformamide (2.0 mL) and stirred at 40 °C for 10 min. Benzylamine  
(53 µL, 0.48 mmol, 1.2 equiv) was added and the solution stirred for 20 min. 
Diisopropylethylamine (0.21 mL, 1.20 mmol, 3.0 equiv) was added and the solution 
stirred for 24 h. Water (100 mL) was added and the mixture was extracted with CH2Cl2 
(5 ´ 20 mL). The combined organic phases were washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (2:1 pentane:Et2O) gave amide 84 (112 mg, 99%) as a white 
solid. Rf = 0.17 (2:1 pentane:Et2O). mp = 129-130 °C. IR (film)/cm-1 3287 (NH), 3092 
(CH), 2916 (CH), 1636 (C=O), 1559, 1391, 1222, 736, 695. 1H NMR (400 MHz, CDCl3) 
d 7.39–7.24 (m, 9 H, 9 × Ph-H), 7.18–7.13 (m, 1 H, Ph-H), 6.04 (br s, 1 H, NH), 4.57 
(dd, J = 14.7, 6.1 Hz, 1 H, NC(H)H), 4.41 (dd, J = 14.7, 5.4 Hz, 1 H, NC(H)H), 2.80 
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(ddd, J = 8.5, 5.5, 3.5 Hz, 1 H, Hc), 1.74 (ddd, J = 8.3, 5.5, 4.7 Hz, 1 H, Ha), 1.61 (ddd, 
1 H, J = 8.3, 5.4, 3.5 Hz, Hd), 1.19 (ddd, J = 8.5, 5.4, 4.7 Hz, 1 H, Hb). 13C NMR 
(101 MHz, CDCl3) d 170.6 (C=O), 138.1 (Ph-C quat), 137.4 (Ph-C quat), 128.9 (2 ´ 
Ph-C), 128.8 (2 ´ Ph-C), 127.8 (2 ´ Ph-C), 127.6 (Ph-C), 126.7 (2 ´ Ph-C), 125.4 
(Ph-C), 43.9 (PhCH2), 26.3 (C(Hd)), 21.1 (C(Hc)), 16.5 (C(Ha)(Hb)). HRMS (ES) m/z 
Calcd for C17H18NOS+ [M+H]+: 284.1109; Found: 284.1103. 
 
(trans)-(Morpholin-4-yl)-2-[(phenylsulfanyl)cyclopropyl]methanone (85) 
 
 
 
HATU (183 mg, 0.48 mmol, 1.2 equiv) was added to a solution of (trans)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 81 (87 mg, 0.40 mmol, 1.0 equiv) in  
N,N-dimethylformamide (2.0 mL) and stirred at 40 °C for 10 min. Morpholine (42 µL, 
0.48 mmol, 1.2 equiv) was added and the solution stirred for 20 min. 
Diisopropylethylamine (0.21 mL, 1.20 mmol, 3.0 equiv) was added and the solution 
stirred for 24 h. H2O (100 mL) was added and the mixture was extracted with EtOAc 
(6 ´ 20 mL). The combined organic phases were washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (Et2O) gave amide 85 (101 mg, 96%) as a white solid. Rf = 
0.36 (Et2O). mp = 77-78 °C. IR (film)/cm-1 2962 (CH), 2893 (CH), 2856 (CH), 1629 
(C=O), 1441, 1233, 1117, 880. 1H NMR (400 MHz, CDCl3) d 7.33–7.28 (m, 4 H, 4 × 
Ph-H), 7.21–7.16 (m, 1 H, Ph-H), 3.70–3.52 (m, 8 H, 2 ´ OCH2 + 2 ´ NCH2), 2.80 (ddd, 
J = 8.2, 5.4, 3.6 Hz, 1 H, Hc), 1.94 (ddd, J = 8.7, 5.3, 3.6 Hz, 1 H, Hd), 1.74 (ddd, J = 
8.2, 5.3, 4.6 Hz, 1 H, Hb), 1.22 (ddd, J = 8.7, 5.4, 4.6 Hz, 1 H, Ha). 13C NMR (101 MHz, 
CDCl3) d 169.4 (C=O), 137.2 (Ph-C quat), 128.9 (2 ´ Ph-H), 127.3 (2 ´ Ph-H), 125.7 
(Ph-H), 66.8 (OCH2), 66.7 (OCH2), 46.0 (NCH2), 42.6 (NCH2), 22.6 (C(Hd)), 22.0 
(C(Hc)), 16.9 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C14H18NO2S+ [M+H]+: 264.1058; 
Found: 264.1056. 
 
 
Hb
Hd
Hc
Ha
S
O
NO
  211 
(trans)-(4-Methylpiperazin-1-yl)[2-(phenylsulfanyl)cyclopropyl]methanone (86) 
 
 
 
HATU (183 mg, 0.48 mmol, 1.2 equiv) was added to a solution of (trans)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 81 (87 mg, 0.40 mmol, 1.0 equiv) in 
N,N-dimethylformamide (2.0 mL) and stirred at 40 °C for 10 min. 1-Methylpiperazine 
(54 µL, 0.48 mmol, 1.2 equiv) was added and the solution stirred for 20 min. 
Diisopropylethylamine (0.21 mL, 1.20 mmol, 3.0 equiv) was added and the solution 
stirred for 24 h. Water (100 mL) was added and the mixture was extracted with EtOAc 
(6 ´ 20 mL). The combined organic phases were washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (1:19 MeOH:CH2Cl2) gave amide 86 (106 mg, 96%) as a 
brown gum. Rf = 0.17 (1:19 MeOH:CH2Cl2). IR (film)/cm-1 3078 (CH), 3005 (CH), 2938 
(CH), 2846 (CH), 2791, 1632 (C=O), 1439, 737. 1H NMR (400 MHz, CDCl3) d 7.33–
7.27 (m, 4 H, 4 × Ph-H), 7.21–7.15 (m, 1 H, Ph-H), 3.76–3.70 (m, 1 H, NCH(H)), 3.63–
3.55 (m, 3 H, 3 ´ NCH(H)), 2.78 (ddd, J = 8.2, 5.4, 3.7 Hz, 1 H, Hc), 2.42–2.37 (m, 3 H, 
3 ´ NCH(H)), 2.34–2.29 (m, 4 H, 1 ´ NCH(H) + NCH3), 1.98 (ddd, J = 8.8, 5.4, 3.7 Hz, 
1 H, Hd), 1.72 (ddd, J = 8.2, 5.4, 4.6 Hz, 1 H, Hb), 1.20 (ddd, J = 8.8, 5.4, 4.6 Hz, 1 H, 
Ha). 13C NMR (101 MHz, CDCl3) d 169.2 (C=O), 137.3 (Ph-C quat), 128.9 (2 ´ Ph-C), 
127.1 (2 ´ Ph-C), 125.6 (Ph-C), 55.2 (NCH2), 54.7 (NCH2), 46.0 (CH3), 45.5 (NCH2), 
42.2 (NCH2), 22.7 (C(Hd)), 21.8 (C(Hc)), 16.8 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for 
C15H21N2OS+ [M+H]+: 277.1375; Found: 277.1374. 
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(trans)-(3,4-Dihydroquinolin-1(2H)-yl)[2-(phenylsulfanyl)cyclopropyl] 
methanone (87) 
 
 
 
HATU (183 mg, 0.48 mmol, 1.2 equiv) was added to a solution of (trans)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 81 (87 mg, 0.40 mmol, 1.0 equiv) in  
N,N-dimethylformamide (2.0 mL) and stirred at 40 °C for 10 min. 
1,2,3,4-Tetrahydroquinoline (60 µL, 0.48 mmol, 1.2 equiv) was added and the solution 
stirred for 20 min. Diisopropylethylamine (0.21 mL, 1.20 mmol, 3.0 equiv) was added 
and the solution stirred for 24 h. Water (100 mL) was added and the mixture was 
extracted with EtOAc (6 ´ 20 mL). The combined organic phases were washed with 
brine (30 mL), dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (2:1 pentane:Et2O) gave amide 87 
(116 mg, 94%) as a yellow gum. Rf = 0.23 (2:1 pentane:Et2O). IR (film)/cm-1 3058 
(CH), 2945 (CH), 2887 (CH), 1641 (C=O), 1491, 1397, 737. 1H NMR (400 MHz, CDCl3) 
d 7.35–7.27 (m, 4 H, 4 × Ar-H), 7.20–7.09 (m, 5 H, 5 × Ph-H), 3.82 (t, J = 6.6 Hz, 2 H, 
CH2), 2.96 (ddd, J = 8.1, 5.5, 3.7 Hz, 1 H, Hc), 2.73 (t, J = 6.6 Hz, 2 H, CH2), 2.26 (ddd, 
J = 8.8, 5.3, 3.7 Hz, 1 H, Hd), 1.96 (m, 2 H, CH2), 1.82 (ddd, J = 8.1, 5.3, 4.5 Hz, 1 H, 
Hb), 1.17 (ddd, J = 8.8, 5.5, 4.5 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 170.6 
(C=O), 138.6 (Ar-C quat), 137.1 (2 ´ Ar-C quat), 128.9 (2 ´ Ar-C), 128.5 (Ar-C), 127.6 
(2 ´ Ar-C), 126.2 (Ar-C), 125.7 (Ar-C), 125.3 (Ar-C), 124.7 (Ar-C), 43.1 (NCH2), 26.8 
(CH2), 24.5 (CH2), 24.1 (C(Hd)), 23.3 (C(Hc)), 18.1 (C(Ha)(Hb)). HRMS (ES) m/z Calcd 
for C19H20NOS+ [M+H]+: 310.1266; Found: 310.1259. 
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(cis)-(Morpholin-4-yl)-2-[(phenylsulfanyl)cyclopropyl]methanone (88) 
 
 
 
HATU (228 mg, 0.60 mmol, 1.2 equiv) was added to a solution of (cis)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 82 (108 mg, 0.5 mmol, 1.0 equiv) in  
N,N-dimethylformamide (2.5 mL) and stirred at 40 °C for 10 min. Morpholine (52 µL,  
0.60 mmol, 1.2 equiv) was added and the solution stirred for 20 min. 
Diisopropylethylamine (0.27 mL, 1.50 mmol, 3.0 equiv) was added and the solution 
stirred for 24 h. Water (100 mL) was added and the mixture was extracted with EtOAc 
(5 ´ 20 mL). The combined organic phases were washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (EtOAc) gave amide 88 (98 mg, 74%) as a yellow gum. Rf = 
0.26 (EtOAc). IR (film)/cm-1 3055 (CH), 2963 (CH), 2855 (CH), 1635 (C=O), 1437, 
1228, 1112, 1035, 840, 739. 1H NMR (400 MHz, CDCl3) d 7.39–7.36 (m, 2 H, 2 × 
Ph-H), 7.31–7.29 (m, 2 H, 2 × Ph-H), 7.21–7.17 (m, 1 H, Ph-H), 3.74–3.58 (m, 3 H, 
3 ´ C(H)H), 3.55–3.45 (m, 3 H, 3 ´ C(H)H), 3.38–3.28 (m, 2 H, 2 ´ C(H)H), 2.76 (ddd, 
J = 8.1, 8.0, 5.9 Hz, 1 H, Hc), 2.18 (ddd, J = 8.0, 8.0, 6.2 Hz, 1 H, Hd), 1.61 (ddd, J = 
6.2, 5.9, 5.5 Hz, 1 H, Hb), 1.43 (ddd, J = 8.1, 8.0, 5.5 Hz, 1 H, Ha). 13C NMR (101 MHz, 
CDCl3) d 166.5 (C=O), 137.0 (Ph-C quat), 128.8 (2 ´ Ph-C), 128.4 (2 ´ Ph-C), 126.0 
(Ph-C), 66.8 (OCH2), 66.4 (OCH2), 45.7 (NCH2), 42.3 (NCH2), 21.5 (C(Hd)), 20.9 
(C(Hc)), 12.8 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C14H18NO2S+ [M+H]+: 264.1058; 
Found: 264.1058. 
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(cis)-(4-Methylpiperazin-1-yl)[2-(phenylsulfanyl)cyclopropyl]methanone (89) 
 
 
 
HATU (228 mg, 0.60 mmol, 1.2 equiv) was added to a solution of (cis)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 82 (108 mg, 0.50 mmol, 1.0 equiv) in  
N,N-dimethylformamide (2.5 mL) and stirred at 40 °C for 10 min. 1-Methylpiperazine  
(67 µL, 0.60 mmol, 1.2 equiv) was added and the solution stirred for 20 min. 
Diisopropylethylamine (0.27 mL, 1.50 mmol, 3.0 equiv) was added and the solution 
stirred for 24 h. Water (100 mL) was added and the mixture was extracted with EtOAc 
(5 ´ 20 mL). The combined organic phases were washed with brine (30 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (1:19 MeOH:CH2Cl2) gave amide 89 (125 mg, 90%) as a 
brown gum. Rf = 0.08 (1:19 MeOH:CH2Cl2). IR (film)/cm-1 3004 (CH), 2937 (CH), 2793 
(CH), 1635 (C=O), 1438, 1291, 1225, 1001, 739. 1H NMR (400 MHz, CDCl3) d 7.38–
7.36 (m, 2 H, 2 × Ph-H), 7.30–7.26 (m, 2 H, 2 × Ph-H), 7.19–7.15 (m, 1 H, Ph-H), 
3.72–3.66 (m, 1 H, NC(H)H), 3.59–3.52 (m, 2 H, 2 ´ NC(H)H), 3.41–3.36 (m, 1 H, 
NCH(H)), 2.74 (ddd, J = 8.0, 8.2, 5.9 Hz, 1 H, Hc), 2.44–2.31 (m, 2 H, 2 ´ NCH(H)), 
2.31–2.24 (m, 1 H, NCH(H)), 2.26 (s, 3 H, CH3), 2.20 (ddd, J = 8.1, 8.0,  
6.1 Hz, 1 H, Hd), 2.12 (m, 1 H, NCH(H)), 1.59 (ddd, J = 6.1, 5.9, 5.5 Hz, 1 H, Hb), 1.41 
(ddd, J = 8.2, 8.1, 5.5 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 166.2 (C=O), 137.1 
(Ph-C quat), 128.8 (2 ´ Ph-C), 128.4 (2 ´ Ph-C), 125.9 (Ph-C), 54.9 (NCH2), 54.6 
(NCH2), 46.0 (CH3), 45.3 (NCH2), 41.9 (NCH2), 21.6 (C(Hd)), 20.9 (C(Hc)), 12.9 
(C(Ha)(Hb)). HRMS (ES) m/z Calcd for C15H21N2OS+ [M+H]+: 277.1375; Found: 
277.1371. 
 
 
 
Hc
Hb
HdHa
S
N
O
N
  215 
(cis)-(3,4-Dihydroquinolin-1(2H)-yl)[2-(phenylsulfanyl)cyclopropyl]methanone 
(90) 
 
 
 
HATU (228 mg, 0.60 mmol, 1.2 equiv) was added to a solution of (cis)-sodium 
2-(phenylsulfanyl)cyclopropane-1-carboxylate 82 (108 mg, 0.50 mmol, 1.0 equiv) in  
N,N-dimethylformamide (2.5 mL) and stirred at 40 °C for 10 min. 
1,2,3,4-Tetrahydroquinoline (75 µL, 0.60 mmol, 1.2 equiv) was added and the solution 
stirred for 20 min. Diisopropylethylamine (0.27 mL, 1.50 mmol, 3.0 equiv) was added 
and the solution stirred for 24 h. Water (100 mL) was added and the mixture was 
extracted with EtOAc (5 ´ 20 mL). The combined organic phases were washed with 
brine (30 mL), dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (2:1 pentane:Et2O) gave amide 90 
(122 mg, 79%) as a yellow gum. Rf = 0.15 (2:1 pentane:Et2O). IR (film)/cm-1 3004 
(CH), 2937 (CH), 2793 (CH), 1635 (C=O), 1438, 1291, 1225, 1001, 739. 1H NMR 
(400 MHz, CDCl3) d 7.42–7.40 (m, 2 H, 2 ´ Ph-H), 7.29–7.26 (m, 2 H, 2 ´ Ph-H), 7.19–
7.07 (m, 5 H, 5 ´ Ar-H), 4.14–4.12 (m 1 H, 1 ´ CH(H)), 3.57–3.54 (m, 1 H, CH(H)), 
2.68–2.64 (m, 3 H, 2 ´ CH(H) + Hc), 2.42 (ddd, J = 8.0, 8.0, 6.3 Hz, 1 H, Hd), 2.05–
1.98 (m, 1 H, CH(H)), 1.85–1.75 (m, 1 H, CH(H)), 1.70 (ddd, J = 6.3, 6.2, 5.1 Hz, 1 H, 
Hb), 1.44 (ddd, J = 8.0, 8.0, 5.1 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 167.8 
(C=O), 138.9 (Ar-C quat), 137.1 (2 ´ Ar-C quat), 128.82 (2 ´ Ph-C), 128.78 (2 ´ Ph-C), 
128.5 (Ar-C), 126.0 (Ar-C), 125.9 (Ar-C), 125.1 (2 ´ Ar-C), 124.5 (Ar-C), 43.4 (NCH2), 
26.9 (CH2), 24.0 (CH2), 23.8 (C(Hc)), 22.6 (C(Hd)), 15.0 (C(Ha)(Hb)). HRMS (ES) m/z 
Calcd for C19H20NOS+ [M+H]+: 310.1266; Found: 310.1267. 
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Synthesis of 91–92 through reduction 
 
(trans)-[2-(Phenylsulfanyl)cyclopropyl]methanol (91) 
 
 
 
Lithium aluminium tetrahydride (1.0 M in THF, 1.0 mL, 1.0 mmol, 2.5 equiv) was added 
dropwise over 5 min to a 0 °C solution of (trans)-ethyl 2-thiophenylcyclopropane 
carboxylate 15 (89 mg, 0.40 mmol, 1.0 equiv) in THF (0.5 mL) and the solution stirred 
at 0 °C for 10 min. The solution was warmed to 25 °C and stirred for 3 h. The reaction 
mixture was cooled to 0 °C, EtOAc (5 ml) was added and the mixture stirred for 15 min. 
The mixture was warmed to 25 °C, sat. aq. potassium sodium tartrate (5.0 mL) was 
added and the mixture stirred for 1 h. The organic phase was separated, and the 
aqueous phase extracted with Et2O (6 ´ 10 mL). The combined organic phases were 
washed with brine (20 mL), dried (MgSO4), filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (2:1 pentane:Et2O) gave 
alcohol 91 (63 mg, 87%) as a yellow oil. Rf = 0.13 (2:1 pentane:Et2O). IR (film)/cm-1 
3340 (OH), 3059 (CH), 3004 (CH), 2923 (CH), 2873 (CH), 1584, 1480, 1271, 1025, 
738, 690. 1H NMR (400 MHz, CDCl3) d 7.41–7.39 (m, 2 H, 2 × Ph-H), 7.32–7.28 (m, 
2 H, 2 × Ph-H), 7.18–7.14 (m, 1 H, Ph-H), 3.73 (dd, J = 11.4, 6.1 Hz, 1 H, OCH(H)), 
3.56 (dd, J = 11.4, 7.1 Hz, 1 H, OCH(H)), 2.17 (ddd, J = 8.0, 4.3, 4.5 Hz, 1 H, Hc), 
1.48–1.40 (m, 1 H, Hd), 1.05 (ddd, J = 8.0, 5.5, 4.8 Hz, 1 H, Hb), 0.95 (ddd, J = 8.9, 
4.8, 4.5 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 138.2 (Ph-C quat), 128.8 (2 ´ 
Ph-C), 126.8 (2 ´ Ph-C), 125.3 (Ph-C), 65.2 (OCH2), 24.9 (C(Hc)), 17.4 (C(Hd)), 13.2 
(C(Ha)(Hb)). HRMS (EI) m/z Calcd for C10H12OS+ [M]+: 180.0609; Found: 180.0599. 
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(cis)-[2-(Phenylsulfanyl)cyclopropyl]methanol (92) 
 
 
 
Lithium aluminium tetrahydride (1.0 M in THF, 1.0 mL, 1.0 mmol, 2.5 equiv) was added 
dropwise over 5 min to a solution of (cis)-ethyl 2-thiophenylcyclopropane carboxylate 
16 (89 mg, 0.40 mmol, 1.0 equiv) in THF (0.5 mL) at 0 °C. The solution was stirred at 
0 °C for 10 min then 25 °C for 3 h. The reaction mixture was cooled to 0 °C, EtOAc 
(5 ml) was added and the mixture stirred for 15 min. The mixture was warmed to 25 °C, 
sat. aq. potassium sodium tartrate (5.0 mL) was added and the mixture stirred for 1 h. 
The organic phase was separated, and the aqueous phase extracted with Et2O (6 ´ 
10 mL). The combined organic phases were washed with brine (20 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure to give cyclopropane 92 
(63 mg, 87%) as a colourless oil. Rf = 0.40 (1:1 pentane:Et2O). IR (film)/cm-1 3245 
(OH), 3069 (CH), 3008 (CH), 2928 (CH), 2869 (CH), 1582, 1478, 1438, 1056, 1022, 
733. 1H NMR (400 MHz, CDCl3) d 7.41–7.38 (m, 2 H, 2 × Ph-H), 7.33–7.29 (m, 2 H, 
2 × Ph-H), 7.19–7.14 (m, 1 H, Ph-H), 3.87 (dd, J = 11.7, 4.4 Hz, 1 H, OCH(H)), 3.69 
(dd, J = 11.7, 8.6 Hz, 1 H, OCH(H)), 2.48 (ddd, J = 8.0, 7.1, 5.1 Hz, 1 H, Hc), 1.71–
1.62 (m, 1 H, Hd), 1.28 (ddd, J = 8.4, 8.0, 5.5 Hz, 1 H, Ha), 0.61 (ddd, J = 5.5, 5.3, 
5.1 Hz, 1 H, Hb). 13C NMR (101 MHz, CDCl3) d 138.2 (Ph-C quat), 129.0 (2 ´ Ph-C), 
126.4 (2 ´ Ph-C), 125.4 (Ph-C), 62.5 (OCH2), 21.2 (C(Hd)), 18.1 (C(Hc)), 10.9 
(C(Ha)(Hb)). HRMS (EI) m/z Calcd for C10H10S+ [M-H2O]+: 162.0503; Found: 
162.0507. 
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Synthesis of 93 through esterification 
 
(cis)-Phenyl-2-(phenylsulfanyl)cyclopropane-1-carboxylate (93) 
 
 
 
Phenol (485 mg, 5.15 mmol, 2.0 equiv), di-tert-butyl dicarbonate (590 µL, 2.57 mmol, 
1.0 equiv), MgCl2 (20 mg, 0.26 mmol, 0.1 equiv), MeCN (0.5 mL) and 
(cis)-2-(phenylsulfanyl)cyclopropane-1-carboxylic acid 80 (500 mg, 2.57 mmol, 
1.0 equiv) were stirred at 25 °C for 15 h. H2O (30 mL) was added and the mixture was 
extracted with EtOAc (3 ´ 20 mL). The organic phases were combined, dried (MgSO4), 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (19:1 pentane:EtOAc) gave ester 93 (515 mg, 74%) as a white 
crystalline solid. Rf = 0.24 (19:1 pentane:EtOAc). 1H NMR (400 MHz, CDCl3) d  
7.50–7.41 (m, 2 H, 2 × PhH), 7.39–7.25 (m, 4 H, 4 × Ph-H), 7.24–7.14 (m, 2 H, 2 × 
Ph-H), 6.85–6.75 (m, 2 H, 2 × Ph-H), 2.90 (q, J = 7.3 Hz, 1 H, Hc), 2.54 (q, J = 7.3 Hz, 
1 H, Hd), 1.62 (m, 2 H, Ha + Hb). 13C NMR (101 MHz, CDCl3) d 168.2 (C=O), 150.6 
(Ph-C quat.), 137.0 (Ph-C quat.), 129.2 (2 × Ph-C), 128.9 (2 × Ph-C), 127.4 (2 × Ph-C), 
125.68 (Ph-C), 125.67 (Ph-C), 121.5 (2 × Ph-C), 22.8 (C(Hc)), 22.3 (C(Hd)), 13.6 
(C(Ha)(Hb)). HRMS (EI) m/z Calcd for C16H14O2S+ [M]+: 270.0715; Found: 270.0710. 
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Synthesis of 94–97 through sulfide oxidation 
 
(trans)-Ethyl-2-(benzenesulfonyl)cyclopropane-1-carboxylate (94) 
 
 
 
mCPBA (62 mg, 0.36 mmol, 2.5 equiv) was added to a solution of (trans)-ethyl 
2-thiophenylcyclopropane carboxylate 15 (32 mg, 0.14 mmol, 1.0 equiv) in CH2Cl2 
(5.0 mL) and the mixture stirred at 25 °C for 24 h. Water (15 mL) and sat. aq. NaHCO3 
(15 mL) were added and the mixture was extracted with CH2Cl2 (3 × 15 mL). The 
combined organic phases were washed with brine (15 mL), dried (MgSO4), filtered 
and concentrated under reduced pressure to give sulfone 94 (39 mg, quant.) as a pale 
yellow crystalline solid. Rf = 0.45 (1:2 n-hexane:Et2O). mp = 53-56 °C. IR (film)/cm-1 
3074 (CH), 3041 (CH), 2991 (CH), 2964 (CH), 2906 (CH), 1721 (C=O), 1449, 1306 
(S=O), 1147 (S=O). 1H NMR (400 MHz, CDCl3) d 7.93–7.90 (m, 2 H, 2 × Ph-H), 7.68 
(t, J = 7.5 Hz, 1 H, Ph-H), 7.59 (t, J = 7.5 Hz, 2 H, 2 × Ph-H), 4.13 (q, J = 7.1 Hz, 2 H, 
CH2CH3), 2.98 (ddd, J = 8.8, 5.9, 4.1 Hz, 1 H, Hc), 2.52 (ddd, J = 9.7, 5.6, 4.1 Hz, 1 H, 
Hd), 1.73 (ddd, J = 9.7, 5.9, 5.6 Hz, 1 H, Ha), 1.55 (ddd, J = 8.8, 5.6, 5.6 Hz, 1 H, Hb), 
1.25 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 170.2 (C=O), 139.7 (Ph-C 
quat.), 133.9 (Ph-C), 129.4 (2 × Ph-C), 127.7 (2 × Ph-C), 61.6 (CH2), 40.3 (C(Hc)), 
20.1 (C(Hd)), 14.0 (CH3), 13.3 (C(Ha)(Hb)). HRMS (EI) m/z Calcd for C12H14O4S+ [M]+: 
254.0613; Found: 254.0619. 
 
 (cis)-Ethyl-2-(benzenesulfonyl)cyclopropane-1-carboxylate (95) 
 
 
 
mCPBA (56 mg, 0.33 mmol, 2.5 equiv) was added to a solution of (cis)-ethyl 
2-thiophenylcyclopropane carboxylate 16 (29 mg, 0.13 mmol, 1.0 equiv) in CH2Cl2  
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(5.0 mL) and the mixture stirred at 25 °C for 25 h. H2O (10 mL) and sat. aq. NaHCO3  
(15 mL) were added and the mixture was extracted with CH2Cl2 (3 × 15 mL). The 
combined organic phases were washed with brine (20 mL), dried (MgSO4), filtered 
and concentrated under reduced pressure to give sulfone 95 (33 mg, quant.) as a pale 
yellow crystalline solid. Rf = 0.33 (1:2 n-hexane:Et2O). mp = 100–102 °C. IR (film)/cm-1 
3098 (CH), 3063 (CH), 3042 (CH), 2984 (CH), 2937 (CH), 2910 (CH), 1733, 1447, 
1324 S=O), 1150 (S=O). 1H NMR (400 MHz, CDCl3) d 7.95–7.93 (m, 2 H, 2 × Ph-H), 
7.68–7.64 (m, 1 H, Ph-H), 7.59–7.55 (m, 2 H, 2 × Ph-H), 4.28–4.14 (m, 2 H, CH2CH3), 
2.81 (ddd, J = 8.8, 8.5, 6.5 Hz, 1 H, Hc), 2.25 (ddd, J = 8.5, 8.5, 7.5 Hz, 1 H, Hd), 2.08 
(ddd, J = 7.5, 6.5, 6.1 Hz, 1 H, Hb), 1.45 (ddd, J = 8.8, 8.5, 6.1 Hz, 1 H, Ha), 1.29 (t, 
J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) 166.9 (C=O), 140.4 (Ph-C quat.), 
133.6 (Ph-C), 129.1 (2 × Ph-C), 127.7 (2 × Ph-C), 61.8 (CH2), 39.6 (C(Hc)), 23.5 
(C(Hd)), 13.9 (CH3), 10.4 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C12H15O4S+ [M+H]+: 
255.0691; Found: 255.0694. 
 
(trans)-Ethyl 2-(benzenesulfinyl)cyclopropane-1-carboxylate (96) 
 
 
 
mCPBA (2.40 g, 13.9 mmol, 1.05 equiv) was added portionwise (3 ´ 0.80 g over 
30 min) to a solution of (trans)-ethyl 2-(phenylsulfanyl)cyclopropane-1-carboxylate 15 
(2.95 g, 13.3 mmol, 1.0 equiv) in CH2Cl2 (133 mL) at 0 °C. The reaction was stirred at 
0 °C for 2 h, then aqueous KOH (3.0 M, 50 mL) was added and the phases separated. 
The aqueous phase was extracted with CH2Cl2 (5 ´ 50 mL), then the organic phases 
were combined, washed with brine (50 mL), dried (MgSO4), filtered and concentrated 
under reduced pressure. Purification by flash column chromatography (1:1 to 1:2 
n-hexane:Et2O) afforded a yellow oil which was dissolved in CH2Cl2, dried (MgSO4), 
filtered and concentrated under reduced pressure to give sulfoxides 96 (2.91 g, 92%, 
dr = 53:47) as a pale yellow oil. Rf = 0.24 (1:2 n-hexane:Et2O). IR (film)/cm-1 3094 
(CH), 3055 (CH), 2982 (CH), 2941 (CH), 2910 (CH), 1726 (C=O), 1444, 1381, 1258, 
1182, 1048 (S-O).  
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Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 7.67–7.61 (m, 2 H, 2 × Ph-H), 
7.57–7.52 (m, 3 H, 3 × Ph-H), 4.16 (dq, J = 7.1, 1.3 Hz, 2 H, CH2CH3), 2.75–2.68 (m, 
1 H, Hc), 2.21 (ddd, J = 9.4, 5.6, 4.2 Hz, 1 H, Hd), 1.69 (ddd, J = 9.4, 6.0, 5.2 Hz, 1 H, 
Ha), 1.34 (ddd, J = 8.5, 5.6, 5.2 Hz, 1 H, Hb), 1.27 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR 
(101 MHz, CDCl3) d 171.5 (C=O), 143.8 (Ph-C quat), 131.4 (Ph-C), 129.3 (2 × Ph-C), 
123.9 (2 × Ph-C), 61.3 (CH2CH3), 40.6 (C(Hc)), 18.2 (C(Hd)), 14.1 (CH3), 8.1 
(C(Ha)(Hb)). 
Minor diastereoisomer 1H NMR (400 MHz, CDCl3) d 7.69–7.61 (m, 2 H, 2 × Ph-H), 
7.57–7.52 (m, 3 H, 3 × Ph-H), 4.07 (t, J = 7.1 Hz, 2 H, CH2CH3), 2.75–2.68 (m, 1 H, 
Hc), 2.40 (ddd, J = 9.1, 5.7, 4.1 Hz, 1 H, Hd), 1.57 (ddd, J = 8.9, 5.7, 5.2 Hz, 1 H, Hb), 
1.51 (ddd, J = 9.1, 6.2, 5.2 Hz, 1 H, Ha), 1.20 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR 
(101 MHz, CDCl3) d 171.4 (C=O), 143.9 (Ph-C quat), 131.3 (Ph-C), 129.3 (2 × Ph-C), 
123.9 (2 × Ph-C), 61.2 (CH2CH3), 41.4 (C(Hc)), 15.8 (C(Hd)), 14.1 (CH3), 11.7 
(C(Ha)(Hb)). 
HRMS (ES) m/z Calcd for C12H15O3S+ [M+H]+: 239.0742; Found: 239.0731. 
 
(cis)-Ethyl-2-(benzenesulfinyl)cyclopropane-1-carboxylate (97) 
 
 
 
mCPBA (1.21 g, 7.03 mmol, 1.05 equiv) was added portionwise (3 ´ 0.40 g over  
30 min) to a solution of (cis)-ethyl 2-thiophenylcyclopropane carboxylate 16  
(1.49 g, 6.69 mmol, 1.0 equiv) in CH2Cl2 (67 mL) at 0 °C. The reaction was stirred at 
0 °C for 3 h then warmed to 25 °C for 16 h 30 min. Aqueous KOH (3.0 M, 50 mL) was 
added and the phases separated. The aqueous phase was extracted with CH2Cl2 
(5 ´ 30 mL), then the organic phases were combined, washed with brine (50 mL), 
dried (MgSO4), filtered and concentrated under reduced pressure to give sulfoxides 
97 (1.56 g, 98%, dr = 75:25) as a pale yellow oil. IR (film)/cm-1 3059 (CH), 2983 (CH), 
2941 (CH), 1725 (C=O), 1444, 1382, 1188, 1040 (S-O). 
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Major diastereoisomer: Rf = 0.23 (Et2O). 1H NMR (400 MHz, CDCl3) d 7.68–7.64 (m, 
2 H, 2 × Ph-H), 7.57–7.50 (m, 3 H, 3 × Ph-H), 4.23 (dt, J = 7.1, 0.7 Hz, 2 H, CH2CH3), 
2.61 (ddd, J = 8.4, 8.2, 6.7 Hz, 1 H, Hc), 2.13 (ddd, J = 8.4, 8.2, 6.5 Hz, 1 H, Hd), 2.07 
(ddd, J = 6.7, 6.5, 5.6 Hz, 1 H, Hb), 1.63 (ddd, J = 8.2, 8.2, 5.6 Hz, 1 H, Ha), 1.30 (t, 
J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 170.0 (C=O), 145.1 (Ph-C quat.), 
131.2 (Ph-C), 129.3 (2 × Ph-C), 124.0 (2 × Ph-C), 61.5 (CH2CH3), 43.3 (C(Hc)), 21.2 
(C(Hd)), 14.2 (CH3), 14.1 (C(Ha)(Hb)). 
Minor diastereoisomer: Rf = 0.31 (Et2O). 1H NMR (400 MHz, CDCl3) d 7.76–7.73 (m, 
2 H, 2 × Ph-H), 7.57–7.50 (m, 3 H, 3 × Ph-H), 4.31 (dt, J = 7.1, 4.5 Hz, 2 H, CH2CH3), 
2.68 (ddd, J = 8.8, 8.0, 6.5 Hz, 1 H, Hc), 2.31 (ddd, J = 8.0, 8.0, 6.4 Hz, 1 H, Hd), 1.75 
(ddd, J = 6.5, 6.4, 5.7 Hz, 1 H, Hb), 1.38 (ddd, J = 8.8, 8.0, 5.7 Hz, 1 H, Ha), 1.35 (t, 
J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 170.1 (C=O), 145.2 (Ph-C quat), 
131.0 (Ph-C), 129.3 (2 × Ph-C), 124.0 (2 × Ph-C), 61.7 (CH2CH3), 44.3 (C(Hc)), 20.9 
(C(Hd)), 13.6 (CH3), 11.8 (C(Ha)(Hb)). 
HRMS (ES) m/z Calcd for C12H15O3S+ [M+H]+: 239.0742; Found: 239.0754. 
 
 
Synthesis of 106–119 through sulfoxide–magnesium exchange, 
electrophilic trapping 
 
(trans)-Ethyl-2-iodocyclopropanecarboxylate (106) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a −78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
solution of I2 (203 mg, 0.80 mmol, 2.0 equiv) in THF (0.5 mL) was added and the 
reaction stirred at −78 °C for 1 h. The reaction mixture was warmed to rt, sat. aq NH4Cl 
(5 mL) added and the mixture was stirred for 5 min. Water (10 mL) was added and the 
mixture was extracted with CH2Cl2 (3 × 30 mL). The combined organic phases were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (100% n-hexane to 10:1 n-hexane:Et2O) 
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gave cyclopropane 106 (79 mg, 82%) as a yellow oil. IR (film)/cm-1 2981 (CH), 1721 
(C=O), 1396, 1376, 1174, 1033. 1H NMR (400 MHz, CDCl3) d 4.15 (q, J = 7.1 Hz, 2 H, 
CH2CH3), 2.77 (ddd, J = 8.2, 5.6, 3.7 Hz, 1 H, Hd), 1.97 (ddd, J = 9.0, 5.6, 3.7 Hz,  
1 H, Hc), 1.63 (ddd, J = 8.2, 5.6, 5.6 Hz, 1 H, Ha), 1.32-1.24 (m, 1 H, Hb), 1.27 (t, J = 
7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 171.9 (C=O), 61.1 (CH2CH3), 24.6 
(C(Hc)), 19.6 (C(Ha)(Hb)), 14.2 (CH3), -17.1 (C(Hd)). HRMS (EI) m/z Calcd for C6H9O2I+ 
[M]+: 239.9647; Found: 239.9651. 
 
(trans)-Ethyl 2-[cyclopentyl(hydroxyl)methyl]cyclopropane-1-carboxylate (108) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Cyclopentanecarboxaldehyde (85 µL, 0.80 mmol, 2.0 equiv) was added and the 
reaction stirred at 0 °C for 1 h. The reaction was warmed to rt, sat. aq NH4Cl (5 mL) 
added and the mixture was stirred for 5 min. Water (10 mL) was added and the mixture 
was extracted with CH2Cl2 (5 × 30 mL). The combined organic phases were washed 
with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (2:1 pentane:Et2O) gave cyclopropane 
108 as a mixture of two diastereoisomers (dr = 56:44, 60 mg, 71%) as a colourless oil. 
Rf = 0.16 (2:1 pentane:Et2O). IR (film)/cm-1 3450 (OH), 2952 (CH), 2911 (CH), 2869 
(CH), 1724 (C=O), 1703 (C=O), 1176. 
Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 4.14-4.08 (m, 2 H, OCH2CH3), 
2.94 (dd, J = 7.3, 7.3 Hz, 1 H, CH(OH)), 2.06-1.93 (m, 1 H, CH(CH2)2), 1.84-1.73 (m, 
2 H, CHCH2CH2), 1.64-1.54 (m, 4 H, CH(CH2)2), 1.67-1.55 (m, 1 H, Hd), 1.60-1.54 
(m, 1 H, Hc), 1.41-1.30 (m, 2 H, CHCH2CH2), 1.24 (t, J = 7.2 Hz, 3 H, CH3), 1.25-1.17 
(m, 1 H, Hb), 0.92-0.87 (m, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 174.2 (C=O), 77.2 
(CH(OH)), 60.5 (CH2CH3), 46.7 (CH(CH2)2), 28.9 (CH2), 28.6 (CH2), 28.0 (C(Hc)), 25.5 
(CH2), 25.2 (CH2), 17.4 (C(Hd)), 14.2 (CH3), 13.2 (C(Ha)(Hb)). 
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Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) d 4.14-4.08 (m, 2 H, OCH2CH3), 
3.07 (dd, J = 7.1, 7.1 Hz, 1 H, CH(OH)), 2.06-1.93 (m, 1 H, CH(CH2)2), 1.84-1.73 (m, 
2 H, CHCH2CH2), 1.64-1.54 (m, 4 H, CH(CH2)2), 1.67-1.55 (m, 1 H, Hd), 1.60-1.54 
(m, 1 H, Hc), 1.41-1.30 (m, 2 H, CHCH2CH2), 1.24 (t, J = 7.2 Hz, 3 H, CH3), 1.14-1.08 
(m, 1 H, Hb), 0.96-0.92 (m, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 174.0 (C=O), 76.4 
(CH(OH)), 60.5 (CH2CH3), 46.9 (CH(CH2)2), 28.9 (CH2), 28.8 (CH2), 27.2 (C(Hc)), 25.5 
(CH2), 25.2 (CH2), 18.3 (C(Hd)), 14.2 (CH3), 11.4 (C(Ha)(Hb)). 
HRMS (ES) m/z Calcd for C12H19O2+ [M-OH]+: 195.1385; Found: 195.1386. 
 
(trans)-Ethyl 2-(hydroxy(phenyl)methyl)cyclopropane-1-carboxylate (109) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a −78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Benzaldehyde (81 µL, 0.80 mmol, 2.0 equiv) was added and the reaction stirred at 
0 °C for 1 h. The reaction was warmed to rt, sat. aq NH4Cl (5 mL) added and the 
mixture was stirred for 5 min. H2O (10 mL) was added and the mixture was extracted 
with CH2Cl2 (3 × 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (10:1 n-hexane:Et2O) gave cyclopropane 109 as a mixture of 
two diastereoisomers (dr = 61:39, 83 mg, 94%) as a colourless oil. Rf = 0.16 (2:1 
n-hexane:Et2O). IR (film)/cm-1 3458 (OH), 2982 (CH), 1722 (C=O), 1703 (C=O), 1180.  
Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 7.40–7.28 (m, 5 H, 5 ´ Ph-H), 
4.21 (d, J = 7.3 Hz, 1 H, CH(OH)), 4.16–4.02 (m, 2 H, CH2CH3), 2.56 (br s, 1 H, OH), 
1.86–1.78 (m, 1 H, Hd), 1.81 (ddd, J = 8.5, 4.3, 4.3 Hz, 1 H, Hc), 1.25 (t, J = 7.1 Hz, 
3 H, CH3), 1.24–1.18 (m, 1 H, Ha), 0.97 (ddd, J = 8.5, 6.4, 4.5 Hz, 1H, Hb). 13C NMR 
(101 MHz, CDCl3) d 173.7 (C=O), 142.8 (Ph-C quat), 128.5 (2 ´ Ph-C), 127.83 (Ph-C), 
126.00 (2 ´ Ph-C), 75.6 (CH(OH)), 60.6 (CH2CH3), 29.2 (C(Hd)), 18.8 (C(Hc)), 14.1 
(CH3), 12.5 (C(Ha)(Hb)). 
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Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) d 7.40–7.28 (m, 5 H, 5 ´ Ph-H), 
4.47 (d, J = 6.0 Hz, 1 H, CH(OH)), 4.16–4.02 (m, 2 H, CH2CH3), 2.45 (br s, 1 H, OH), 
1.89–1.78 (m, 1 H, Hd), 1.71 (ddd, J = 8.8, 4.6, 4.6 Hz, 1 H, Hc), 1.24–1.18 (m, 1 H, 
Ha), 1.22 (t, J = 7.1 Hz, 3 H, CH3), 1.10 (ddd, J = 8.8, 6.4, 4.2 Hz, 1 H, Hb). 13C NMR 
(101 MHz, CDCl3) d 173.8 (C=O), 142.8 (Ph-C quat), 128.4 (2 ´ Ph-C), 127.78 (Ph-C), 
126.03 (2 ´ Ph-C), 73.9 (CH(OH)), 60.5 (CH2CH3), 28.4 (C(Hd)), 17.6 (C(Hc)), 14.1 
(CH3), 12.2 (C(Ha)(Hb)).  
HRMS (ES) m/z Calcd for C15H20NO3+ [M+H+CH3CN adduct]+: 262.1443; Found: 
262.1447. The observed data (IR, 1H, 13C) was consistent with that previously 
reported.334 
 
(trans)-Ethyl 2-[hydroxy(pyridine-3-yl)methyl]cyclopropane-1-carboxylate (110) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a  
-78 °C solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for  
10 min. 3-Pyridinecarboxaldehyde (75 µL, 0.80 mmol, 2.0 equiv) was added and the 
reaction stirred at 0 °C for 1 h. The reaction was warmed to rt, sat. aq NH4Cl (5 mL) 
added and the mixture stirred for 5 min. H2O (10 mL) was added and the mixture was 
extracted with CH2Cl2 (6 × 20 mL) then EtOAc (6 ´ 20 mL). The combined organic 
phases were concentrated under reduced pressure, dissolved in CH2Cl2, washed with 
brine, dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by flash column chromatography (4:1 EtOAc:toluene) gave cyclopropane 110 as a 
mixture of two diastereoisomers (dr = 52:48, 80 mg, 90%) as a white oil. Rf = 0.26 (4:1 
EtOAc:toluene). IR (film)/cm-1 3169 (OH), 2982 (CH), 1719 (C=O), 1177, 1028, 713. 
Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 8.47 (br s, 1 H, He), 8.40-8.38 
(m, 1 H, Hh), 7.79-7.73 (m, 1 H, Hf), 7.28-7.24 (m, 1 H, Hg), 4.73 (br s, 1 H, OH), 4.26 
(d, J = 7.2 Hz, 1 H, CH(OH)), 4.13–4.00 (m, 2 H, CH2CH3), 1.85-1.76 (m, 1 H, Hc), 
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1.83-1.74 (m, 1 H, Hd), 1.23-1.18 (m, 1 H, Ha), 1.21 (t, J = 7.1 Hz, 3 H, CH3), 0.99 
(ddd, J = 8.4, 6.4, 4.5 Hz, 1 H, Hb). 13C NMR (101 MHz, CDCl3) d 173.5 (C=O), 148.5 
(Ar-C), 147.3 (Ar-C), 139.1 (Ar-C quat), 134.0 (Ar-C), 123.6 (Ar-C), 72.7 (CH(OH)), 
60.6 (CH2CH3), 29.0 (C(Hd)), 18.7 (C(Hc)), 14.1 (CH3), 12.5 (C(Ha)(Hb)). 
Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) d 8.47 (br s, 1 H, He), 8.40-8.38 
(m, 1 H, Hh), 7.79-7.73 (m, 1 H, Hf), 7.28-7.24 (m, 1 H, Hg), 4.73 (br s, 1 H, OH), 4.50 
(d, J = 5.7 Hz, 1 H, CH(OH)), 4.13–4.00 (m, 2 H, CH2CH3), 1.81-1.71 (m, 1 H, Hd), 
1.78-1.71 (m, 1 H, Hc), 1.23-1.18 (m, 1 H, Ha), 1.20 (t, J = 7.1 Hz, 3 H, CH3), 1.14 
(ddd, J = 8.5, 6.5, 4.3 Hz, 1 H, Hb). 13C NMR (101 MHz, CDCl3) d 173.6 (C=O), 148.5 
(Ar-C), 147.4 (Ar-C), 139.2 (Ar-C quat), 134.1 (Ar-C), 123.6 (Ar-C), 71.1 (CH(OH)), 
60.6 (CH2CH3), 28.3 (C(Hd)), 17.7 (C(Hc)), 14.1 (CH3), 12.1 (C(Ha)(Hb)). 
HRMS (ES) m/z Calcd for C12H16NO3+ [M+H]+: 222.1130; Found: 222.1131. 
 
(trans)-Ethyl 2-(3-hydroxyoxetan-3-yl)cyclopropane-1-carboxylate (111) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
3-Oxetanone (52 µL, 0.8 mmol, 2.0 equiv) was added and the reaction stirred at 0 °C 
for 1 h. The reaction was warmed to rt, sat. aq NH4Cl (5 mL) added and the mixture 
stirred for 5 min. Water (10 mL) was added and the mixture was extracted with CH2Cl2 
(3 × 10 mL then 7 × 20 mL) followed by EtOAc (6 ´ 20 mL). The combined organic 
phases were concentrated under reduced pressure, dissolved in CH2Cl2, washed with 
brine, dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by flash column chromatography (1:39 MeOH:CH2Cl2) gave cyclopropane 111 (49 mg, 
66%) as a pale yellow oil. Rf = 0.10 (1:39 MeOH:CH2Cl2). IR (film)/cm-1 3400 (OH), 
2977 (CH), 2956 (CH), 2876 (CH), 1723 (C=O), 1702 (C=O), 1316, 1178. 1H NMR 
(400 MHz, CDCl3) d 4.58 (d, J = 6.8 Hz, 1 H, oxetane C(H)H), 4.54 (d, J =  
6.8 Hz, 1 H, oxetane C(H)H), 4.50 (d, J = 6.8 Hz, 1 H, oxetane C(H)H), 4.44 (d, J = 
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6.8 Hz, 1 H, oxetane C(H)H), 4.19-4.07 (m, 2 H, CH2CH3), 3.29 (br s, 1 H, OH), 1.94 
(ddd, J = 9.2, 6.5, 4.4 Hz, 1 H, Hd), 1.72 (ddd, J = 8.6, 4.9, 4.4 Hz, 1 H, Hc), 1.26 (t, 
J = 7.1 Hz, 3 H, CH3), 1.25–1.18 (m, 1 H, Ha), 1.10 (ddd, J = 8.6, 6.5, 4.6 Hz, 1 H, Hb). 
13C NMR (101 MHz, CDCl3) d 173.8 (C=O), 83.3 (oxetane-CH2), 82.5 (oxetane-CH2), 
72.8 (oxetane-C quat), 60.8 (CH2CH3), 27.2 (C(Hd)), 16.4 (C(Hc)), 14.1 (CH3), 10.8 
(C(Ha)(Hb)). HRMS (CI+) m/z Calcd for C9H18NO4+ [M+NH4]+: 204.1236; Found: 
204.1226. 
 
(trans)-Ethyl-2-[bis(4-chlorophenyl)(hydroxyl)methyl]cyclopropane-1-
carboxylate (112) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
4,4-Dichlorobenzophenone (201 mg, 0.80 mmol, 2.0 equiv) in toluene (1.0 mL) was 
added and the reaction stirred at 0 °C for 3 h. The reaction was warmed to rt, sat. aq. 
NH4Cl (5 mL) added and the mixture stirred for 5 min. Water (20 mL) was added and 
the mixture was extracted with EtOAc (5 ´ 20 mL). The combined organic phases were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (3:1 pentane:toluene) gave cyclopropane 
112 (117 mg, 80%) as a pale yellow oil. Rf = 0.59 (5:1 pentane:Et2O). IR (film)/cm-1 
2969 (CH), 2923 (CH), 2877 (CH), 1652 (C=O), 1587, 1490, 1399, 1089, 1013, 906, 
728. 1H NMR (400 MHz, CDCl3) d 7.39–7.28 (m, 8 H, 8 ´ Ar-H), 4.13 (q, J = 7.2 Hz, 
2 H, CH2CH3), 2.18 (ddd, J = 9.0, 6.7, 4.5 Hz, 1 H, Hc), 1.95 (br s, 1 H, OH), 1.79 (ddd, 
J = 8.7, 4.8, 4.5 Hz, 1 H, Hd), 1.30–1.23 (m, 4 H, Hb + CH3), 1.13 (ddd, J = 8.7, 6.7, 
4.3 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 173.8 (C=O), 144.7 (Ar-C-Cl), 144.4 
(Ar-C-Cl), 133.5 (2 ´ Ar-C quat), 128.5 (2 ´ Ar-C), 128.4 (2 ´ Ar-C), 128.0 (2 ´ Ar-C), 
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127.9 (2 ´ Ar-C), 75.6 (C(OH)), 60.8 (CH2CH3), 31.5 (C(Hc)), 17.5 (C(Hd)), 14.2 (CH3), 
11.9 (C(Ha)(Hb)). FTMS (+p NSI) m/z Calcd for C19H18O3Cl2Na+ [M+Na]+: 387.0525; 
Found: 387.0526. 
 
(trans)-Ethyl 2-[hydroxydi(pyridin-2-yl)methyl]cyclopropane-1-carboxylate 
(113) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
solution of di(2-pyridyl)ketone (147 mg, 0.80 mmol, 2.0 equiv) in toluene (1.0 mL) was 
added and the reaction stirred at 0 °C for 3 h. The reaction was warmed to rt, sat. aq. 
NH4Cl (5 mL) added and the mixture stirred for 5 min. Water (10 mL) was added and 
the mixture was extracted with EtOAc (3 × 30 mL). The combined organic phases were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (1:1 pentane:Et2O) gave cyclopropane 
113 (107 mg, 90%) as a colourless oil. Rf = 0.23 (1:1 pentane:Et2O). IR (film)/cm-1 
3319 (OH), 3057 (CH), 2982 (CH), 1718 (C=O), 1587, 1571, 1433, 1177, 749. 1H NMR 
(400 MHz, CDCl3) d 8.52–8.49 (m, 2 H, 2 ´ Ar-H), 7.85–7.82 (m, 2 H, 2 ´ Ar-H),  
7.69–7.64 (m, 2 H, 2 ´ Ar-H), 7.18–7.14 (m, 2 H, 2 ´ Ar-H), 6.28 (br s, 1 H, OH),  
4.11–4.00 (m, 2 H, CH2CH3), 2.85 (ddd, J = 9.0, 6.5, 4.4 Hz, 1 H, Hc), 1.83–1.79 (m, 
1 H, Hd), 1.22–1.16 (m, 4 H, Ha + CH3), 1.10 (ddd, J = 9.0, 4.8, 3.9 Hz, 1 H, Hb). 
13C NMR (101 MHz, CDCl3) d 174.2 (C=O), 163.0 (Ar-C quat), 162.9 (Ar-C quat), 
147.53 (Ar-C), 147.47 (Ar-C), 136.8 (2 ´ Ar-C), 122.2 (2 ´ Ar-C), 120.9 (2 ´ Ar-C), 74.8 
(C(OH)), 60.2 (CH2CH3), 31.3 (C(Hc)), 16.6 (C(Hd)), 14.2 (CH3), 11.2 (C(Ha)(Hb)). 
HRMS (EI) m/z Calcd for C17H18N2O3+ [M]+: 298.1317; Found: 298.1315. 
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(trans)-Ethyl 2-benzoylcyclopropane-1-carboxylate (114) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Benzoyl chloride (119 µL, 0.80 mmol, 2.0 equiv) was added and the reaction stirred at 
0 °C for 3 h. The reaction was warmed to rt, sat. aq NH4Cl (5 mL) added and the 
mixture stirred for 5 min. Water (10 mL) was added and the mixture was extracted with 
EtOAc (5 × 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
chromatography (9:1–2:1 n-hexane:EtOAc) gave cyclopropane 114 (44 mg, 38%) as 
a colourless oil. Rf = 0.22 (9:1 n-hexane:EtOAc). IR (film)/cm-1 3063 (CH), 2982 (CH), 
1724 (C=O), 1672, 1332, 1207, 1004. 1H NMR (400 MHz, CDCl3) d 8.04–8.02 (m, 2 H, 
2 ´ Ph-H), 7.62–7.58 (m, 1 H, Ph-H), 7.50 (t, J = 7.6 Hz, 2 H, 2 ´ Ph-H), 4.19 (q, J = 
7.1 Hz, 2 H, CH2CH3), 3.20 (ddd, J = 8.7, 5.8, 3.9 Hz, 1 H, Hc), 2.39 (ddd, J = 8.7, 5.9, 
3.9 Hz, 1 H, Hd), 1.66–1.58 (m, 2 H, Ha + Hb), 1.30 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR 
(101 MHz, CDCl3) d 197.0 (C=O ketone), 172.3 (C=O ester), 137.0 (Ph-C quat), 133.3 
(Ph-C), 128.6 (2 ´ Ph-C), 128.2 (2 ´ Ph-C), 61.1 (CH2CH3), 25.9 (C(Hc)), 24.7 (C(Hd)), 
17.9 (C(Ha)(Hb)), 14.2 (CH3). FTMS (+p APCI) m/z Calcd for C13H15O3+ [M+H]+: 
219.1016; Found: 219.1016. The observed data (1H) was consistent with that 
previously reported.335 
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(trans)-Ethyl 2-(phenylcarbamoyl)cyclopropane-1-carboxylate (115) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Phenyl isocyanate (87 µL, 0.80 mmol, 2.0 equiv) was added and the reaction stirred 
at 0 °C for 6 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added and the 
mixture stirred for 5 min. Water (20 mL) was added and the mixture was extracted with 
Et2O (5 × 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (1:1 pentane:Et2O) gave cyclopropane 115 (70 mg, 75%) as 
a white solid. Rf = 0.31 (1:1 pentane:Et2O). mp = 90-91°C. IR (film)/cm-1 3282 (NH), 
2977 (CH), 2934 (CH), 1722 (C=O), 1652, 1440, 1365, 1338, 1257, 1206, 1185, 1172, 
988, 939, 750, 693. 1H NMR (400 MHz, CDCl3) d 7.97 (br s, 1 H, NH), 7.53–7.51 (m, 
2 H, 2 ´ Ph-H), 7.33–7.30 (m, 2 H, 2 ´ Ph-H), 7.13–7.09 (t, J = 7.4 Hz, 1 H, Ph-H), 
4.19 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.28 (ddd, J = 9.1, 5.7, 3.9 Hz, 1 H, Hc), 2.12 (ddd, 
J = 8.9, 5.8, 3.9 Hz, 1 H, Hd), 1.58 (ddd, J = 9.1, 5.8, 3.8 Hz, 1 H, Hb), 1.43 (ddd, J = 
8.9, 5.7, 3.8 Hz, 1 H, Ha), 1.30 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 
173.0 (C=O ester), 168.4 (C=O amide), 137.8 (Ph-C quat), 129.0 (2 ´ Ph-C), 124.3 
(Ph-C), 119.7 (2 ´ Ph-C), 61.3 (CH2CH3), 25.1 (C(Hd)), 22.0 (C(Hc)), 15.3 (C(Ha)(Hb)), 
14.2 (CH3). HRMS (ES) m/z Calcd for C13H16NO3+ [M+H]+: 234.1130; Found: 
234.1137. 
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(trans)-Ethyl 2-[(4-methoxyphenyl)sulfanyl]cyclopropane-1-carboxylate (116) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
solution of bis(4-methoxyphenyl)disulfide (223 mg, 0.80 mmol, 2.0 equiv) in THF 
(0.5 mL) was added and the reaction stirred at 0 °C for 6 h. The reaction was warmed 
to rt, sat. aq. NH4Cl (5 mL) added and the mixture stirred for 5 min. Water (20 mL) was 
added and the mixture was extracted with EtOAc (5 × 30 mL). The combined organic 
phases were washed with brine, dried (MgSO4), filtered and concentrated under 
reduced pressure. Purification by flash column chromatography (15:1 pentane:Et2O) 
gave cyclopropane 116 (55 mg, 55%) as a yellow oil. Rf = 0.24 (9:1 pentane:Et2O). IR 
(film)/cm-1 2981 (CH), 2961 (CH), 2836 (CH), 1721 (C=O), 1494, 1242, 1173, 1030, 
821. 1H NMR (400 MHz, CDCl3) d 7.34–7.31 (m, 2 H, 2 ´ Ar-H), 6.89–6.85 (m, 2 H, 
2 ´ Ar-H), 4.20–4.09 (m, 2 H, CH2CH3), 3.81 (s, 3 H, OCH3), 2.74 (ddd, J = 8.3, 5.7, 
3.6 Hz, 1 H, Hc), 1.90 (ddd, J = 8.8, 5.3, 3.6 Hz, 1 H, Hd), 1.57 (ddd J = 8.3, 5.3, 5.0 Hz, 
1 H, Hb), 1.27 (t, J = 7.2 Hz, 3 H, CH2CH3), 1.21 (ddd, J = 8.8, 5.7, 5.0 Hz, 1 H, Ha). 
13C NMR (101 MHz, CDCl3) d 172.3 (C=O), 158.8 (Ar-C-OCH3), 131.2 (2 ´ Ar-C), 
126.5 (Ar-C quat), 114.7 (2 ´ Ar-C), 60.8 (CH2CH3), 55.3 (OCH3), 24.5 (C(Hd)), 24.2 
(C(Hc)), 17.2 (C(Ha)(Hb)), 14.2 (CH2CH3). FTMS (+p APCI) m/z Calcd for C13H17O3S+ 
[M+H]+: 253.0893; Found: 253.0891. 
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(trans)-Ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate (117) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (163 µL, 0.80 mmol, 2.0 equiv) 
was added and the reaction stirred at 0 °C for 6 h. The reaction was warmed to rt, 
MeOH (1 mL) added and stirred for 5 min. Et2O (10 mL) was added and the mixture 
filtered, then concentrated under reduced pressure.  Purification by flash column 
chromatography (4:1 pentane:Et2O) gave cyclopropane 117 (52 mg, 54%) as a 
colourless oil. IR (film)/cm-1 2980 (CH), 2932 (CH), 1727 (C=O), 1424, 1370, 1325, 
1177, 1141, 855. 1H NMR (400 MHz, CDCl3) d 4.17–4.05 (m, 2 H, CH2CH3), 1.75 (ddd, 
J = 7.7, 5.1, 4.9 Hz, 1 H, Hc), 1.26–1.19 (m, 16 H, Hd + 5 ´ CH3), 0.98 (ddd, J = 7.7, 
7.3, 3.0 Hz, 1 H, Hb), 0.57 (ddd, J = 10.1, 7.3, 5.1 Hz, 1 H, Ha). 13C NMR (101 MHz, 
CDCl3) d 174.2 (C=O), 83.4 (2 ´ C(CH3)2), 60.5 (CH2CH3), 29.7 (C(Hd)), 24.7 (2 ´ 
CH3), 24.6 (2 ´ CH3), 18.5 (C(Hc)), 14.2 (CH2CH3), 13.0 (C(Ha)(Hb)). 11B NMR  
(128 MHz, CDCl3) d 32.58 (B(pin)). HRMS (EI) m/z Calcd for C12H2111BO4+ [M]+: 
240.1533; Found: 240.1528. 
 
(trans)-Ethyl 2-(triethoxysilyl)cyclopropane-1-carboxylate (118) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
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Chlorotriethoxysilane (157 µL, 0.80 mmol, 2.0 equiv) was added and the reaction 
stirred at 0 °C for 6 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added 
and the mixture stirred for 5 min. Water (20 mL) was added and the mixture was 
extracted with EtOAc (5 × 30 mL). The combined organic phases were washed with 
brine, dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by flash column chromatography (4:1 pentane:Et2O) gave cyclopropane 118 (55 mg, 
43%) as a pale yellow oil. IR (film)/cm-1 2976 (CH), 2934 (CH), 1722 (C=O), 1389, 
1264, 1166, 1100, 1073, 953, 776. 1H NMR (400 MHz, CDCl3) d 4.14 (q, J = 7.1 Hz, 2 
H, (C=O)OCH2), 3.91–3.81 (m, 6 H, 3 ´ SiOCH2), 1.74 (ddd, J = 7.7, 5.9, 4.3 Hz, 1 H, 
Hc), 1.28–1.18 (m, 13 H, Ha + 4 ´ CH3), 0.96 (ddd, J = 7.7, 7.7, 3.1 Hz, 1 H, Hb), 0.36 
(ddd, J = 10.8, 7.7, 5.9 Hz, 1 H, Hd). 13C NMR (101 MHz, CDCl3) d 174.6 (C=O), 60.5 
(CH2), 59.1 (CH2), 58.7 (2 ´ CH2), 18.2 (2 ´ CH3), 18.0 (CH3), 16.3 (C(Hc)), 14.2 (CH3), 
11.2 (C(Ha)(Hb)), 2.9 (C(Hd)). HRMS (EI) m/z Calcd for C12H24O5Si+ [M]+: 276.1393; 
Found: 276.1405. 
 
(trans)-Ethyl 2-formylcyclopropane-1-carboxylate (119) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
N,N-Dimethylformamide (62 µL, 0.80 mmol, 2.0 equiv) was added and the reaction 
stirred at 0 °C for 6 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added 
and the mixture stirred for 5 min. H2O (20 mL) was added and the mixture was 
extracted with ether (5 × 30 mL). The combined organic phases were washed with 
brine, with the aqueous being extracted with Et2O (30 mL). The combined organic 
phases were dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (5:1 pentane:Et2O) gave cyclopropane 
119 (48 mg, 85%) as a colourless oil. Rf = 0.17 (5:1 pentane:Et2O). IR (film)/cm-1 2984 
(CH), 2849 (CH), 2738 (CH), 1182, 980. 1H NMR (400 MHz, CDCl3) d 9.31 (d, J = 4.2 
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Hz, 1 H, C(O)H), 4.18 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.44 (dddd, J = 8.5, 5.8, 4.2, 3.9 
Hz, 1 H, Hd), 2.26 (ddd, J = 8.9, 6.0, 3.9 Hz, 1 H, Hc), 1.61 (ddd, J = 8.5, 6.0, 4.4 Hz, 
1 H, Ha), 1.51 (ddd, J = 8.9, 5.8, 4.4 Hz, 1 H, Hb), 1.28 (t, J = 7.1 Hz, 3 H, CH3). 13C 
NMR (101 MHz, CDCl3) d 198.1 (C=O aldehyde), 171.0 (C=O ester), 61.3 (CH2CH3), 
30.6 (C(Hd)), 22.2 (C(Hc)), 14.8 (C(Ha)(Hb)), 14.1 (CH3). The observed data (1H, 13C) 
was consistent with that previously reported.336,337 
 
(cis)-Ethyl-2-iodocyclopropanecarboxylate (107) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a −78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
solution of I2 (203 mg, 0.80 mmol, 2.0 equiv) in THF (0.5 mL) was added and the 
reaction stirred at −78 °C for 1 h. The reaction was warmed to rt, sat. aq NH4Cl (5 mL) 
added and the mixture was stirred for 5 min. Water (10 mL) was added and the mixture 
was extracted with CH2Cl2 (3 × 30 mL). The combined organic phases were washed 
with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (100% n-hexane to 10:1 n-hexane:Et2O) 
gave cyclopropane 107 (56 mg, 58%) as a yellow oil. IR (film)/cm-1 2981 (CH), 1726 
(C=O), 1396, 1380, 1248, 1175. 1H NMR (400 MHz, CDCl3) d 4.30–4.17 (m, 2 H, 
CH2CH3), 2.82 (ddd, J = 8.3, 8.1, 6.5 Hz, 1 H, Hd), 1.87 (ddd, J = 8.3, 8.3, 6.5 Hz, 1 H, 
Hc), 1.52 (ddd, J = 8.3, 8.1, 6.2 Hz, 1 H, Ha), 1.42 (ddd, J = 6.5, 6.5, 6.2 Hz, 1 H, Hb), 
1.32 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 169.9 (C=O), 61.2 (CH2), 
19.2 (C(Hc)), 16.3 (C(Ha)(Hb)), 14.4 (CH3), -14.6 (C(Hd)). HRMS (ES) m/z Calcd for 
C6H10O2I+ [M+H]+: 240.9726; Found: 240.9710.  The observed data (IR, 1H, 13C) was 
consistent with that previously reported.338 
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(cis)-4-Cyclopentyl-3-oxabicyclo[3.1.0]hexan-2-one (120) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Cyclopentanecarboxaldehyde (85 µL, 0.80 mmol, 2.0 equiv) was added and the 
reaction stirred at 0 °C for 1 h. The reaction was warmed to 25 °C, sat. aq NH4Cl 
(5 mL) added and the mixture was stirred for 5 min. Water (10 mL) was added and the 
mixture was extracted with CH2Cl2 (5 × 30 mL). The combined organic phases were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (2:1 pentane:Et2O) gave cyclopropane 
120 as a mixture of two diastereoisomers (dr = 61:39, 57 mg, 86%) as a yellow oil. 
Rf = 0.24 (2:1 pentane:Et2O). IR (film)/cm-1 2953 (CH), 2869 (CH), 1760 (C=O), 1452, 
1330, 1183, 959. 
Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 4.18 (d, J = 7.5 Hz, 1 H, 
CH(CHd)), 2.12-2.03 (m, 1 H, CH(CH2)2), 2.06-2.03 (m, 2 H, Hc + Hd), 1.88-1.76 (m, 
2 H, CH2), 1.69-1.53 (m, 4 H, 2 ´ CH2), 1.45-1.35 (m, 2 H, CH2), 1.28-1.19 (m, 1 H, 
Ha), 0.84 (dd, J = 4.7, 4.0 Hz, 1 H, Hb). 13C NMR (101 MHz, CDCl3) d 176.2 (C=O), 
84.7 (CH(CHd)), 45.0 (CH(CH2)2), 28.0 (CH2), 27.7 (CH2), 25.5 (CH2), 25.3 (CH2), 21.5 
(C(Hd)), 17.8 (C(Hc)), 12.2 (C(Ha)(Hb)). 
Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) d 4.28 (dd, J = 9.6, 4.4 Hz, 1 H, 
CH(CHd)), 2.21-2.16 (m, 1 H, Hc), 2.06-2.03 (m, 1 H, Hd), 1.97-1.88 (m, 1 H, 
CH(CH2)2), 1.88-1.76 (m, 2 H, CH2), 1.69-1.53 (m, 4 H, 2 ´ CH2), 1.45-1.35 (m, 2 H, 
CH2), 1.11-1.06 (m, 1 H, Ha), 0.96 (ddd, J = 4.7, 4.7, 3.2 Hz, 1 H, Hb). 13C NMR 
(101 MHz, CDCl3) d 176.3 (C=O), 84.1 (CH(CHd)), 42.2 (CH(CH2)2), 30.5 (CH2), 28.1 
(CH2), 25.4 (CH2), 25.1 (CH2), 20.8 (C(Hd)), 18.5 (C(Hc)), 8.8 (C(Ha)(Hb)). 
FTMS (APCI) m/z Calcd for C10H15O2+ [M+H]+: 167.1067; Found: 167.1068. 
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(cis)-4-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one (121) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a −78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Benzaldehyde (81 µL, 0.80 mmol, 2.0 equiv) was added and the reaction stirred at 
0 °C for 1 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added and the 
mixture was stirred for 5 min. H2O (10 mL) was added and the mixture was extracted 
with CH2Cl2 (3 × 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (10:1 n-hexane:Et2O) gave cyclopropane 121 as a mixture of 
two diastereoisomers (dr = 56:44, 48 mg, 69%) as a white solid. Rf = 0.59 (1:1 
pentane:EtOAc). mp = 33-34 °C. IR (film)/cm-1 3034 (CH), 3008 (CH), 2930 (CH), 
1762 (C=O), 1454, 1312, 1180, 969. 
Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 7.44–7.32 (m, 5 H, 5 ´ Ph-H), 
5.34 (s, 1 H, CH(CHd)), 2.31–2.24 (m, 1 H, Hd), 2.29–2.21 (m, 1 H, Hc), 1.37 (ddd, J = 
8.9, 7.6, 4.9 Hz, 1 H, Ha), 1.10 (ddd, J = 4.9, 4.7, 3.5 Hz, 1 H, Hb). 13C NMR (101 MHz, 
CDCl3) d 175.9 (C=O), 139.7 (Ph-C quat), 128.9 (2 ´ Ph-C), 128.8 (Ph-C), 125.5 (2 ´ 
Ph-C), 81.6 (CH(CHd)), 24.7 (C(Hd)), 17.8 (C(Hc)), 12.9 (C(Ha)(Hb)). 
Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) d 7.44–7.32 (m, 5 H, 5 ´ Ph-H), 
5.75 (d, J = 4.9 Hz, 1 H, CH(CHd)), 2.57 (dddd, J = 7.5, 4.9, 4.9, 4.9 Hz, 1 H, Hd), 
2.31–2.21 (m, 1 H, Hc), 1.14 (ddd, J = 9.0, 7.5, 5.1 Hz, 1 H, Ha), 0.89 (ddd, J = 5.1, 
4.9, 3.3 Hz, 1 H, Hb). 13C NMR (101 MHz, CDCl3) d 175.6 (C=O), 137.4 (Ph-C quat), 
128.5 (2 ´ Ph-C), 128.1 (Ph-C), 125.4 (2 ´ Ph-C), 79.2 (CH(CHd)), 22.2 (C(Hd)), 19.1 
(C(Hc)), 9.7 (C(Ha)(Hb)). 
HRMS (EI) m/z Calcd for C11H10O2+ [M]+: 174.0681; Found: 174.0674. The observed 
data (IR, 1H, 13C) was consistent with that previously reported.284 
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(cis)-Ethyl 2-[hydroxy(pyridine-3-yl)methyl]cyclopropane-1-carboxylate (122) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
3-Pyridinecarboxaldehyde (75 µL, 0.80 mmol, 2.0 equiv) was added and the reaction 
stirred at 0 °C for 1 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added 
and the mixture stirred for 5 min. Water (10 mL) was added and the mixture was 
extracted with CH2Cl2 (6 × 20 mL) then EtOAc (6 ´ 20 mL). The combined organic 
phases were concentrated under reduced pressure, dissolved in CH2Cl2, washed with 
brine, dried (MgSO4), filtered and concentrated under reduced pressure. Purification 
by flash column chromatography (3:1 EtOAc:toluene) gave cyclopropane 122 as a 
mixture of two diastereoisomers (dr = 57:43, 76 mg, 86%) as a colourless oil. Rf = 0.23 
(3:1 EtOAc:toluene). IR (film)/cm-1 3184 (OH), 2981 (CH), 2929 (CH), 2848 (CH), 1774 
(C=O), 1183.  
Major diastereoisomer: 1H NMR (400 MHz, CDCl3) d 8.62–8.45 (m, 2 H, 2 ´ Ar-H), 
7.80–7.63 (m, 1 H, Ar-H), 7.34–7.24 (m, 1 H, Ar-H), 5.72 (d, J = 4.8 Hz, 1 H, CH(OH)), 
4.16–4.07 (m, 2 H, CH2CH3), 1.90 (ddd, J = 8.3, 8.3, 5.8 Hz, 1 H, Hc), 1.70–1.62 (m, 
1 H, Hd), 1.26–1.09 (m, 4 H, Ha + CH3), 0.80–0.79 (m, 1 H, Hb). 13C NMR (101 MHz, 
CDCl3) d 173.2 (C=O), 149.4 (Ar-C), 147.5 (Ar-C), 139.8 (Ar-C quat), 133.6 (Ar-C), 
123.4 (Ar-C), 77.1 (CH(OH)), 60.8 (CH2CH3), 28.8 (C(Hd)), 19.0 (C(Hc)), 12.5 (CH3), 
9.7 (C(Ha)(Hb)). 
Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) d 8.62–8.45 (m, 2 H, 2 ´ Ar-H), 
7.80–7.63 (m, 1 H, Ar-H), 7.34–7.24 (m, 1 H, Ar-H), 4.81 (d, J = 9.2 Hz, 1 H, CH(OH)), 
4.16–4.07 (m, 2 H, CH2CH3), 2.62–2.57 (m, 1 H, Hd), 2.25 (ddd, J = 6.4, 4.1, 3.6 Hz, 
1 H, Hc), 1.46–1.36 (m, 1 H, Ha), 1.24 (t, J = 6.8 Hz, 3 H, CH3), 1.17–1.09 (m, 1 H, Hb). 
13C NMR (101 MHz, CDCl3) d 174.9 (C=O), 148.5 (Ar-C), 146.9 (Ar-C), 135.1 (Ar-C 
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quat), 133.4 (Ar-C), 123.7 (Ar-C), 79.1 (CH(OH)), 69.6 (CH2CH3), 21.6 (C(Hd)), 18.5 
(C(Hc)), 14.1 (CH3), 12.8 (C(Ha)(Hb)). 
HRMS (APCI) m/z Calcd for C12H16NO3+ [M+H]+: 222.1125; Found: 222.1124. 
 
(cis)-4,4-Diethyl-3-oxabicyclo[3.1.0]hexan-2-one (123) 
 
 
 
i-PrMgCl (0.32 mL, 1.82 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Pentan-3-one (85 µL, 0.80 mmol, 2.0 equiv) was added and the reaction stirred at 0 °C 
for 3 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added and the mixture 
stirred for 5 min. Water (20 mL) was added and the mixture was extracted with EtOAc 
(5 ´ 20 mL). The combined organic phases were washed with brine, dried (MgSO4), 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (2:1 pentane:Et2O) gave cyclopropane 123 (30 mg, 49%) as a pale 
yellow oil. Rf = 0.23 (2:1 pentane:Et2O). IR (film)/cm-1 2973 (CH), 2942 (CH), 2885 
(CH), 1766 (C=O), 1463, 1233, 1000, 941. 1H NMR (400 MHz, CDCl3) d 2.12 (ddd, J = 
8.9, 5.7, 3.1 Hz, 1 H, Hc), 1.99–1.95 (m, 1 H, Hd), 1.87–1.71 (m, 3 H, 3 ´ C(H)H), 
1.61–1.52 (m, 1 H, C(H)H), 1.11 (ddd, J = 8.9, 7.6, 5.1 Hz, 1 H, Ha), 1.01–0.94 (m, 
7 H, Hb + 2 ´ CH3). 13C NMR (101 MHz, CDCl3) d 176.0 (C=O), 87.7 (C(CH2CH3)2), 
30.9 (CH2CH3), 28.1 (CH2CH3), 24.7 (C(Hd)), 19.1 (C(Hc)), 9.7 (C(Ha)(Hb)), 8.4 (CH3), 
7.1 (CH3). HRMS (CI+) m/z Calcd for C9H15O2+ [M+H]+: 155.1072; Found: 155.1071. 
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(cis)-4,4-Bis(4-chlorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (124) 
 
 
 
i-PrMgCl (0.32 mL, 1.87 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min.  
4,4’-Dichlorobenzophenone (201 mg, 0.80 mmol, 2.0 equiv) in toluene (1.0 mL) was 
added and the reaction stirred at 0 °C for 3 h. The reaction was warmed to rt, sat. aq. 
NH4Cl (5 mL) added and the mixture stirred for 5 min. Water (20 mL) was added and 
the mixture was extracted with EtOAc (5 ´ 20 mL). The combined organic phases were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (2:1 pentane:Et2O–100% Et2O) gave 
cyclopropane 124 (83 mg, 65%) as a white solid. mp = 153–155 °C. Rf = 0.17 (1:2 
pentane:Et2O). IR (film)/cm-1 2968 (CH), 2932 (CH), 1644 (C=O), 1583, 1443, 1365, 
1087, 1020, 748, 691. 1H NMR (400 MHz, CDCl3) d 7.42–7.26 (m, 8 H, 8 ´ Ar-H), 2.75 
(ddd, J = 7.5, 5.5, 4.6 Hz, 1 H, Hc), 2.35 (ddd, J = 9.0, 5.5, 3.4 Hz, 1 H, Hd), 1.43 (ddd, 
J = 9.0, 7.5, 5.3 Hz, 1 H, Ha), 0.94 (ddd, J = 5.3, 4.6, 3.4 Hz, 1 H, Hb). 13C NMR 
(101 MHz, CDCl3) d 174.5 (C=O), 142.4 (Ar-C quat), 139.4 (Ar-C quat), 134.3 (Ar-C 
quat), 134.2 (Ar-C quat), 128.9 (2 ´ Ar-C), 128.8 (2 ´ Ar-C), 128.0 (2 ´ Ar-C), 126.7 
(2 ´ Ar-C), 87.6 (C(Ar)2), 27.9 (C(Hc)), 19.8 (C(Hd)), 13.1 (C(Ha)(Hb)). HRMS (ASAP+) 
m/z Calcd for C17H13O2Cl2+ [M+H]+: 319.0293; Found: 319.0290. 
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(cis)-Ethyl 2-[hydroxydi(pyridin-2-yl)methyl]cyclopropane-1-carboxylate (125)  
and (cis)-4,4-Di(pyridin-2-yl)-3-oxabicyclo[3.1.0]hexan-2-one (126) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
solution of di(2-pyridyl)ketone (147 mg, 0.80 mmol, 2.0 equiv) in toluene (1.0 mL) was 
added and the reaction stirred at 0 °C for 3 h. The reaction was warmed to rt, sat. aq. 
NH4Cl (5 mL) added and the mixture stirred for 5 min. Water (10 mL) was added and 
the mixture was extracted with EtOAc (3 × 30 mL). The combined organic phases were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (EtOAc) gave alcohol 125 (51 mg, 43%) 
as a white oil followed by lactone 126 (15 mg, 15%) as a yellow gum. 
(cis)-Ethyl 2-[hydroxydi(pyridin-2-yl)methyl]cyclopropane-1-carboxylate (125)  
Rf = 0.54 (EtOAc). IR (film)/cm-1 3339 (OH), 3058 (CH), 2982 (CH), 2935 (CH), 1728 
(C=O), 1587, 1432, 1187, 1083, 994, 769, 749. 1H NMR (400 MHz, CDCl3) d 8.54 (m, 
2 H, 2 ´ Ar-H), 7.89 (m, 1 H, Ar-H), 7.75 (m, 1 H, Ar-H), 7.65 (m, 2 H, 2 ´ Ar-H),  
7.14–7.10 (m, 2 H, 2 ´ Ar-H), 6.08 (br s, 1 H, OH), 3.96–3.82 (m, 2 H, CH2CH3), 3.00 
(ddd, J = 9.0, 8.7, 7.5 Hz, 1 H, Hc), 1.91 (ddd, J = 9.0, 8.7, 6.2 Hz, 1 H, Hd), 1.69 (ddd, 
J = 7.5, 6.2, 4.9 Hz, 1 H, Hb), 1.15 (ddd, J = 8.7, 8.7, 4.9 Hz, 1 H, Ha), 1.02 (t, J = 
7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 174.8 (C=O), 164.6 (Ar-C quat), 164.0 
(Ar-C quat), 148.2 (Ar-C), 147.9 (Ar-C), 136.7 (Ar-C), 136.2 (Ar-C), 121.9 (Ar-C), 121.8  
(Ar-C), 121.1 (Ar-C), 120.3 (Ar-C), 77.2 (C(OH)) 60.7 (CH2CH3), 30.9 (C(Hc)), 19.6 
(C(Hd)), 13.9 (CH3), 9.9 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C17H19N2O3+ [M+H]+: 
299.1396; Found: 299.1397. 
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(cis)-4,4-Di(pyridin-2-yl)-3-oxabicyclo[3.1.0]hexan-2-one (126)  
Rf = 0.22 (EtOAc). IR (film)/cm-1 3059 (CH), 3005 (CH), 2926 (CH), 2854 (CH), 1773 
(C=O), 1587, 1572, 1465, 1433, 1201, 1028, 948, 749, 675. 1H NMR (400 MHz, 
CDCl3) d 8.67–8.65 (m, 2 H, 2 ´ Ar-H), 7.73–7.64 (m, 2 H, 2 ´ Ar-H), 7.58 (d, J = 
7.9 Hz, 1 H, Ar-H), 7.45 (d, J = 7.9 Hz, 1 H, Ar-H), 7.24–7.20 (m, 2 H, 2 ´ Ar-H), 3.57 
(ddd, J = 7.7, 5.5, 4.7 Hz, 1 H, Hc), 2.27 (ddd, J = 8.8, 5.5, 3.3 Hz, 1 H, Hd), 1.36 (ddd, 
J = 8.8, 7.7, 5.1 Hz, 1 H, Ha), 0.82 (ddd, J = 5.1, 4.7, 3.3 Hz, 1 H, Hb). 13C NMR 
(101 MHz, CDCl3) d 175.2 (C=O), 160.1 (Ar-C quat), 159.3 (Ar-C quat), 149.6 (Ar-C), 
149.2 (Ar-C), 136.9 (Ar-C), 136.7 (Ar-C), 123.1 (Ar-C), 122.8 (Ar-C), 120.9 (Ar-C), 
120.7 (Ar-C), 88.8 (C(Ar)2), 26.3 (C(Hc)), 19.3 (C(Hd)), 12.3 (C(Ha)(Hb)). HRMS (ES) 
m/z Calcd for C15H13N2O2+ [M+H]+: 253.0977; Found: 253.0986. 
 
(cis)-Ethyl 2-benzoylcyclopropane-1-carboxylate (127) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
Benzoyl chloride (119 µL, 0.80 mmol, 2.0 equiv) was added and the reaction stirred at 
0 °C for 3 h. The reaction was warmed to rt, sat. aq. NH4Cl (5 mL) added and the 
mixture stirred for 5 min. Water (10 mL) was added and the mixture was extracted with 
EtOAc (5 × 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (9:1 n-hexane:EtOAc) gave cyclopropane 127 (73 mg, 64%) 
as a golden oil. Rf = 0.07 (9:1 n-hexane:EtOAc). IR (film)/cm-1 3063 (CH), 2983 CH), 
1727 (C=O), 1681, 1382, 1226, 1185. 1H NMR (400 MHz, CDCl3) d 8.05–8.02 (m, 2 H, 
2 ´ Ph-H), 7.58–7.54 (m, 1 H, Ph-H), 7.48–7.44 (m, 2 H, 2 ´ Ph-H), 3.99 (q, J = 7.1 Hz, 
2 H, CH2CH3), 2.79 (ddd, J = 9.2, 8.3, 6.9 Hz, 1 H, Hc), 2.31 (ddd, J = 9.2, 8.3, 6.4 Hz, 
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1 H, Hd), 1.92 (ddd, J = 6.9, 6.4, 4.8 Hz, 1 H, Hb), 1.37 (ddd, J = 8.3, 8.3, 4.8 Hz, 1 H, 
Ha), 1.05 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR (101 MHz, CDCl3) d 194.5 (C=O ketone), 
169.9 (C=O ester), 137.1 (Ph-C quat), 133.1 (Ph-C), 128.5 (2 ´ Ph-C), 128.3 (2 ´ 
Ph-C), 60.8 (CH2CH3), 26.2 (C(Hc)), 23.0 (C(Hd)), 13.9 (CH3), 11.5 (C(Ha)(Hb)). FTMS 
(+p APCI) m/z Calcd for C13H15O3+ [M+H]+: 219.1016; Found: 219.1014.The observed 
data (IR, 1H, 13C) was consistent with that previously reported.284,335 
 
(cis)-Ethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopropane-1-
carboxylate (128) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. 
2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (163 µL, 0.80 mmol, 2.0 equiv) 
was added and the reaction stirred at 0 °C for 6 h. The reaction was warmed to rt, 
MeOH (1 mL) added and stirred for 5 min. The mixture was concentrated under 
reduced pressure, dissolved in acetonitrile (10 mL) and extracted with pentane (5 ´ 
10 mL). The combined pentane phases were washed with acetonitrile (10 mL), then 
concentrated under reduced pressure to give cyclopropane 128 (79 mg, 82%) as a 
colourless oil. IR (film)/cm-1 2978 (CH), 2927 (CH), 2852 (CH), 1724 (C=O), 1380, 
1319, 1142, 854. 1H NMR (400 MHz, CDCl3) d 4.24–4.05 (m, 2 H, CH2CH3), 1.83 (ddd, 
J = 9.5, 7.8, 4.8 Hz, 1 H, Hc), 1.35–1.23 (m, 15 H, 5 ´ CH3) 1.12 (ddd, J = 8.7, 4.8, 
3.6 Hz, 1 H, Hb), 1.06 (ddd, J = 9.2, 7.8, 3.6 Hz, 1 H, Ha), 0.42 (ddd, J = 9.5, 9.2, 
8.7 Hz, 1 H, Hd). 13C NMR (101 MHz, CDCl3) d 174.4 (C=O), 83.5 (2 ´ C(CH3)2), 60.5 
(CH2CH3), 29.7 (C(Hd)), 24.89 (2 ´ CH3), 24.87 (2 ´ CH3), 17.8 (C(Hc)), 14.3 (CH2CH3), 
11.2 (C(Ha)(Hb)). 11B NMR (128 MHz, CDCl3) d 32.06 (B(pin)). HRMS (EI) m/z Calcd 
for C11H1811BO4+ [M-CH3]+: 225.1298; Found: 225.1302. 
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Synthesis of 129–136 through sulfoxide–magnesium exchange, Negishi 
cross-coupling 
 
(trans)-Ethyl 2-phenylcyclopropane-1-carboxylate (129) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. Bromobenzene (84 µL, 0.80 mmol, 2.0 equiv) was 
added and the reaction stirred at 25 °C for 15 h. MeOH (1 mL) was added and the 
mixture stirred for 15 min. The mixture was filtered through a pad of silica, washing 
with CH2Cl2 (200 mL). Concentration under reduced pressure followed by purification 
by flash column chromatography (30:1 n-hexane:EtOAc) gave cyclopropane 129 
(56 mg, 74%) as a colourless oil. Rf = 0.21 (19:1 n-hexane:EtOAc). IR (film)/cm-1 3086 
(CH), 3063 (CH), 3032 (CH), 2981 (CH), 2938 (CH), 2907 (CH), 1721 (C=O), 1178, 
755, 698. 1H NMR (400 MHz, CDCl3) d 7.31–7.28 (m, 2 H, 2 ´ Ph-H), 7.22 (m, 1 H, 
Ph-H), 7.13–7.11 (m, 2 H, 2 ´ Ph-H), 4.19 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.54 (ddd, J = 
9.4, 6.5, 4.2 Hz, 1 H, Hc), 1.92 (ddd, J = 8.5, 5.2, 4.2 Hz, 1 H, Hd), 1.62 (ddd, J = 9.4, 
5.2, 4.6 Hz, 1 H, Hb), 1.33 (ddd, J = 8.5, 6.5, 4.6 Hz, 1 H, Ha), 1.30 (t, J = 7.1 Hz, 3 H, 
CH3). 13C NMR (101 MHz, CDCl3) d 173.4 (C=O), 140.1 (Ph-C quat), 128.4 (2 ´ Ph-
C), 126.4 (Ph-C), 126.1 (2 ´ Ph-C), 60.7 (CH2CH3), 26.2 (C(Hc)), 24.2 (C(Hd)), 17.1 
(C(Ha)(Hb)), 14.3 (CH3). HRMS (ES) m/z Calcd for C12H15O2+ [M+H]+: 191.1072; 
Found: 191.1071. The observed data (1H, 13C) was consistent with that previously 
reported.339 
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(cis)-Ethyl 2-phenylcyclopropane-1-carboxylate (130) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. Bromobenzene (84 µL, 0.80 mmol, 2.0 equiv) was 
added and the reaction stirred at 25 °C for 15 h. MeOH (1 mL) was added and the 
mixture stirred for 15 min. The mixture was filtered through a pad of silica, washing 
with CH2Cl2 (200 mL). Concentration under reduced pressure followed by purification 
by flash column chromatography (9:1 pentane:Et2O) gave cyclopropane 130 (58 mg, 
76%) as a yellow oil. Rf = 0.27 (9:1 pentane:Et2O). IR (film)/cm-1 3028 (CH), 2982 
(CH), 2934 (CH), 1726 (C=O), 1382, 1179, 1157. 1H NMR (400 MHz, CDCl3) d 
7.29–7.18 (m, 5 H, 5 ´ Ph-H), 3.88 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.59 (ddd, J = 9.3, 
8.8, 7.5 Hz, 1 H, Hc), 2.09 (ddd, J = 9.3, 7.8, 5.5 Hz, 1 H, Hd), 1.73 (ddd, J = 7.5, 5.5, 
5.2 Hz, 1 H, Hb), 1.34 (ddd, J = 8.8, 7.8, 5.2 Hz, 1 H, Ha), 0.98 (t, J = 7.1 Hz, 3 H, CH3). 
13C NMR (101 MHz, CDCl3) d 171.0 (C=O), 136.6 (Ph-C quat), 129.3 (2 ´ Ph-C), 127.9 
(2 ´ Ph-C), 126.6 (Ph-C), 60.2 (CH2CH3), 25.5 (C(Hc)), 21.8 (C(Hd)), 14.0 (CH3), 11.1 
(C(Ha)(Hb)). HRMS (EI) m/z Calcd for C12H14O2+ [M]+: 190.0994; Found: 190.0988. 
The observed data (1H, 13C) was consistent with that previously reported.340 
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(trans)-Ethyl 2-(4-chlorophenyl)cyclopropane-1-carboxylate (131) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. 1-Bromo, 4-chlorobenzene (153 mg, 0.80 mmol, 
2.0 equiv) in THF (0.5 mL) was added and the reaction stirred at 25 °C for 15 h. MeOH 
(1 mL) was added and the mixture stirred for 15 min. The mixture was filtered through 
a pad of silica, washing with CH2Cl2 (200 mL). Concentration under reduced pressure 
followed by purification by flash chromatography (9:1 pentane:Et2O) gave 
cyclopropane 131 (76 mg, 85%) as a pale yellow oil. Rf = 0.31 (9:1 pentane:Et2O). IR 
(film)/cm-1 2983 (CH), 2938 (CH), 1724 (C=O), 1497, 1328, 1186. 1H NMR (400 MHz, 
CDCl3) d 7.27–7.23 (m, 2 H, 2 ´ Ar-H), 7.05–7.02 (m, 2 H, 2 ´ Ar-H), 4.18 (q, J = 
7.1 Hz, 2 H, CH2CH3), 2.50 (ddd, J = 9.3, 6.4, 4.2 Hz, 1 H, Hc), 1.87 (ddd, J = 8.5, 5.4, 
4.2 Hz, 1 H, Hd), 1.64–1.58 (m, 1 H, Hb), 1.29 (t, J = 7.1 Hz, 3 H, CH3), 1.28 (ddd, J = 
8.5, 6.4, 4.6 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 173.1 (C=O), 138.6 (Ar-C-Cl), 
132.2 (Ar-C quat), 128.5 (2 ´ Ph-C), 127.6 (2 ´ Ph-C), 60.8 (CH2CH3), 25.5 (C(Hc)), 
24.2 (C(Hd)), 17.0 (C(Ha)(Hb)), 14.2 (CH3). HRMS (EI) m/z Calcd for C12H13O2Cl+ [M]+: 
224.0604; Found: 224.0608. The observed data (IR, 1H, 13C) was consistent with that 
previously reported.110,341 
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(trans)-Ethyl 2-(4-methoxyphenyl)cyclopropane-1-carboxylate (132) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. 4-Bromoanisole (100 µL, 0.80 mmol, 2.0 equiv) in 
THF (0.5 mL) was added and the reaction stirred at 25 °C for 15 h. MeOH (1 mL) was 
added and the mixture stirred for 15 min. The mixture was filtered through a pad of 
silica, washing with CH2Cl2 (200 mL). Concentration under reduced pressure followed 
by purification by flash column chromatography (15:1 pentane:Et2O) gave 
cyclopropane 132 (77 mg, 73%) as a cream crystalline solid. Rf = 0.24 (9:1 
pentane:Et2O). IR (film)/cm-1 2988 (CH), 2953 (CH), 2911 (CH), 2837 (CH), 1719 
(C=O), 1516, 1252, 1186. 1H NMR (400 MHz, CDCl3) d 7.06–7.03 (m, 2 H, 2 ´ Ar-H), 
6.85–6.81 (m, 2 H, 2 ´ Ar-H), 4.18 (q, J = 7.1 Hz, 2 H, CH2CH3), 3.79 (s, 3 H, OCH3), 
2.49 (ddd, J = 9.3, 6.5, 4.2 Hz, 1 H, Hc), 1.83 (ddd, J = 8.4, 5.2, 4.2 Hz, 1 H, Hd), 1.58–
1.54 (m, 1 H, Hb), 1.29 (t, J = 7.1 Hz, 3 H, CH3), 1.27–1.24 (m, 1 H, Ha). 13C NMR 
(101 MHz, CDCl3) d 173.5 (C=O), 158.3 (Ph-C-OMe), 132.0 (Ph-C quat), 127.3 (2 ´ 
Ar-H), 113.9 (2 ´ Ar-H), 60.6 (CH2CH3), 55.3 (OCH3), 25.6 (C(Hc)), 23.8 (C(Hd)), 16.7 
(C(Ha)(Hb)), 14.3 (CH3). FTMS (+p APCI) m/z Calcd for C13H17O3+ [M+H]+: 221.1172; 
Found: 221.1182. The observed data (IR, 1H, 13C) was consistent with that previously 
reported.110,342 
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(trans)-Ethyl 2-[(E)-2-phenylethenyl]cyclopropane-1-carboxylate (133) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. b-Bromostyrene (103 µL, 0.80 mmol, 2.0 equiv) was 
added and the reaction stirred at 25 °C for 15 h. MeOH (1 mL) was added and the 
mixture stirred for 15 min. The mixture was filtered through a pad of silica, washing 
with CH2Cl2 (200 mL). Concentration under reduced pressure followed by purification 
by flash column chromatography (19:1 pentane:Et2O) gave cyclopropane 133 (73 mg, 
84%) as a golden oil. Rf = 0.46 (9:1 pentane:Et2O). IR (film)/cm-1 3027 (CH), 3000 
(CH), 2983 (CH), 2911 (CH), 1718 (C=O), 1650 (C=C), 1341, 1175, 1036, 964, 754. 
1H NMR (400 MHz, CDCl3) d 7.33–7.28 (m, 4 H, 4 ´ Ph-H), 7.25–7.20 (m, 1 H, Ph-H), 
6.55 (d, J = 15.8 Hz, 1 H, Hf), 5.77 (dd, J = 15.8, 8.7 Hz, 1 H, He), 4.17 (q, J = 7.1 Hz, 
2 H, CH2CH3), 2.19 (dddd, J = 8.9, 8.7, 6.2, 3.9 Hz, 1 H, Hc), 1.77 (ddd, J = 8.4, 5.2, 
3.9 Hz, 1 H, Hd), 1.49 (ddd, J = 8.9, 5.2, 4.4 Hz, 1 H, Hb), 1.29 (t, J = 7.1 Hz, 3 H, CH3), 
1.11 (ddd, J = 8.4, 6.2, 4.4 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 173.3 (C=O), 
137.0 (Ph-C quat), 130.3 (alkene CH), 130.1 (alkene CH), 128.5 (2 ´ Ph-C), 127.2 
(Ph-C), 125.8 (2 ´ Ph-C), 60.7 (CH2CH3), 25.5 (C(Hc)), 22.3 (C(Hd)), 16.0 (C(Ha)(Hb)), 
14.3 (CH3). The observed data (1H) was consistent with that previously reported.343 
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(trans)-Ethyl 2-(pyridin-2-yl)cyclopropane-1-carboxylate (134) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. 2-Bromopyridine (76 µL, 0.80 mmol, 2.0 equiv) was 
added and the reaction stirred at 25 °C for 15 h. MeOH (1 mL) was added and the 
mixture stirred for 15 min. The mixture was filtered through a pad of silica, washing 
with CH2Cl2 (200 mL). Concentration under reduced pressure followed by flash column 
chromatography (4:1 pentane:Et2O) gave cyclopropane 134 (46 mg, 60%) as a yellow 
oil. Rf = 0.17 (4:1 pentane:Et2O). IR (film)/cm-1 2981 (CH), 2930 (CH), 1723 (C=O), 
1595, 1476, 1330, 1179, 1049, 775. 1H NMR (400 MHz, CDCl3) d 8.46-8.44 (ddd, J = 
4.9, 1.8, 1.0 Hz, 1 H, Ar-H), 7.59-7.56 (ddd, J = 7.6, 7.6, 1.8 Hz, 1 H, Ar-H), 7.25-7.22 
(ddd, J = 7.6, 1.0, 1.0 Hz, 1 H, Ar-H), 7.11-7.07 (ddd, J = 7.6, 4.9, 1.0 Hz, 1 H, Ar-H), 
4.17 (q, J = 7.2 Hz, 2 H, CH2CH3), 2.59 (ddd, J = 9.0, 6.1, 3.9 Hz, 1 H, Hc), 2.25 (ddd, 
J = 8.3, 5.6, 3.9 Hz, 1 H, Hd), 1.65-1.57 (m, 2 H, Ha + Hb), 1.28 (t, J = 7.2 Hz, 3 H, 
CH3). 13C NMR (101 MHz, CDCl3) d 173.4 (C=O), 158.9 (Ar-C quat), 149.4 (Ar-C), 
136.0 (Ar-C), 122.5 (Ar-C), 121.3 (Ar-C), 60.7 (CH2CH3), 27.2 (C(Hc)), 24.3 (C(Hd)), 
17.3 (C(Ha)(Hb)), 14.2 (CH3). HRMS (EI) m/z Calcd for C11H13NO2+ [M]+: 191.0946; 
Found: 191.0941. The observed data (1H, 13C) was consistent with that previously 
reported.341 
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(trans)-Ethyl 2-(pyrimidin-2-yl)cyclopropane-1-carboxylate (135) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. 2-Bromopyrimidine (127 mg, 0.80 mmol, 2.0 equiv) 
in toluene (2.0 mL) was added and the reaction stirred at 25 °C for 15 h. MeOH (1 mL) 
was added and the mixture stirred for 15 min. The mixture was filtered through a pad 
of silica, washing with CH2Cl2 (200 mL). Concentration under reduced pressure 
followed by flash column chromatography (4:1 pentane:Et2O) gave cyclopropane 135  
(45 mg, 59%) as a yellow oil. Rf = 0.28 (1:2 pentane:Et2O). IR (film)/cm-1 2982 (CH), 
2938 (CH), 1725 (C=O), 1561, 1425, 1331, 1180. 1H NMR (400 MHz, CDCl3) d 8.60 
(d, J = 4.9 Hz, 2 H, 2 ´ ArNCH), 7.11 (t, J = 4.9 Hz, 1 H, ArNCHCH), 4.17 (q, J = 
7.1 Hz, 2 H, CH2CH3), 2.82 (ddd, J = 8.7, 6.2, 3.9 Hz, 1 H, Hc), 2.31 (ddd, J = 8.5, 5.7, 
3.9 Hz, 1 H, Hd), 1.71-1.64 (m, 2 H, Ha + Hb), 1.28 (t, J = 7.1 Hz, 3 H, CH3). 13C NMR 
(101 MHz, CDCl3) d 172.5 (C=O), 168.8 (Ar-C quat), 156.9 (2 ´ Ar-C), 118.6 (Ar-C), 
60.8 (CH2CH3), 28.0 (C(Hc)), 25.0 (C(Hd)), 17.7 (C(Ha)(Hb)), 14.2 (CH3). HRMS (EI) 
m/z Calcd for C10H12N2O2+ [M]+: 192.0899; Found: 192.0908. 
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(trans)-tert-Butyl 3-[2-(ethoxycarbonyl)cyclopropyl]-1H-indole-1-carboxylate 
(136) 
 
 
 
i-PrMgCl (0.32 mL, 1.85 M in THF, 0.60 mmol, 1.5 equiv) was added to a -78 °C 
solution of (trans)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 96 (95 mg, 
0.40 mmol, 1.0 equiv) in THF (4.0 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (9 mg, 0.01 mmol, 2.5 mol%), (t-Bu)3P (4.5 mg, 0.022 mmol, 
5.5 mol%) and ZnCl2 (82 mg, 0.60 mmol, 1.5 equiv) in THF (1.5 mL) was added and 
the solution stirred at 0 °C for 1 h. A solution of 3-Bromoindole-1-carboxylic acid 
tert-butyl ester (237 mg, 0.80 mmol, 2.0 equiv) in toluene (1.0 mL) was added and the 
reaction stirred at 25 °C for 15 h. MeOH (1 mL) was added and the mixture stirred for 
15 min. The mixture was filtered through a pad of silica, washing with CH2Cl2 (200 mL). 
Concentration under reduced pressure followed by purification by flash column 
chromatography (19:1 pentane:Et2O) gave cyclopropane 136 (119 mg, 94%) as a 
yellow gum. Rf = 0.15 (19:1 pentane:Et2O). IR (film)/cm-1 2980 (CH), 2934 (CH), 1722 
(C=O), 1451, 1369, 1345, 1254, 1152, 1079, 743. 1H NMR (400 MHz, CDCl3) d 8.12 
(d, J = 6.6 Hz, 1 H, ArNCH), 7.62 (d, J = 7.6 Hz, 1 H, Ar-H), 7.36–7.25 (m, 3 H, 3 ´ 
Ar-H), 4.23 (q, J = 7.1 Hz, 2 H, CH2CH3), 2.55 (dddd, J = 9.1, 6.6, 4.4, 1.1 Hz, 1 H, 
Hc), 1.92 (ddd, J = 8.4, 5.1, 4.4 Hz, 1 H, Hd), 1.68 (s, 9 H, C(CH3)3), 1.61 (ddd, J = 9.1, 
5.1, 4.3 Hz, 1 H, Hb), 1.34–1.29 (m, 4 H, Ha + CH2CH3). 13C NMR (101 MHz, CDCl3) d 
173.6 (C=O ester), 149.6 (C=O carbamate), 135.4 (Ar-C quat), 130.4 (Ar-C quat), 
124.6 (Ar-C), 122.6 (Ar-C), 122.0 (Ar-C), 120.3 (Ar-C quat), 119.0 (Ar-C), 115.3 (Ar-C), 
83.7 (C(CH3)3), 60.7 (CH2CH3), 28.2 (C(CH3)3), 21.7 (C(Hd)), 17.1 (C(Hc)), 15.3 
(C(Ha)(Hb)), 14.3 (CH2CH3). HRMS (EI) m/z Calcd for C19H23NO4+ [M]+: 329.1627; 
Found: 329.1635. The observed data (1H, 13C) was consistent with that previously 
reported.341 
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Synthesis of 137–144 through sequential scaffold functionalisation 
 
(trans)-[2-(Benzenesulfonyl)cyclopropyl](4-methylpiperazin-1-yl)methanone 
(137) 
 
 
 
mCPBA (24 mg, 0.14 mmol, 3.0 equiv) was added to a solution of amide 86  
(12.6 mg, 0.046 mmol, 1.0 equiv) in CH2Cl2 (2.3 mL) and the solution stirred for 6 h at 
25 °C. Solid Na2S2O5 (26 mg, 3.0 equiv) was added and the mixture stirred for 30 min 
before being concentrated under reduced pressure. The mixture was redissolved in 
acetone containing 5% Et3N, then filtered. The filtrate was concentrated under reduced 
pressure then purified by flash column chromatography (2:8 MeOH:CH2Cl2 + 2% Et3N 
to 3:7 MeOH:CH2Cl2 + 2% Et3N). The material was dissolved in CH2Cl2 and filtered to 
give sulfone 137 (14 mg, quant) as a cream gum. Rf = 0.13 (3:7 MeOH:CH2Cl2). IR 
(film)/cm-1 2958 (CH), 1640 (C=O), 1447, 1306 (S=O), 1150, 1088, 979, 745, 726, 
692. 1H NMR (400 MHz, CDCl3, 58:42 rotameric mixture, asterix denotes a rotameric 
signal) d 7.92–9.90 (m, 2 H, 2 ´ Ph-H), 7.71–7.67 (m, 1 H, Ph-H), 7.61–7.58 (m, 2 H, 
2 ´ Ph-H), 4.44 (t, J = 15.1 Hz, 1 H, NC(H)H), 4.22–4.01 (m, 2 H, 2 ´ NC(H)H),  
3.66–3.63 (m, 1 H, NC(H)H), 3.47–3.23 (m, 4 H, 4 ´ NC(H)H), 3.01 (ddd, J = 8.2, 5.6, 
4.3 Hz, 1 H, Hc*), 2.70 (ddd, J = 9.6, 5.6, 4.6 Hz, 1 H, Hd*), 1.70–1.57 (m, 1 H, Hb*), 
1.25 (s, 3 H, CH3), 0.90–0.83 (m, 1 H, Ha*). 13C NMR (asterix denotes minor rotamer, 
101 MHz, CDCl3) d 166.9 (C=O), 139.5 (Ph-C quat), 134.0 (Ph-C), 129.5 (2 ´ Ph-C), 
127.6 (2 ´ Ph-C), 65.3 (NCH2), 65.1 (NCH2) 60.2 (NCH2), 40.4 (C(Hc)), 37.0 (NCH2), 
29.7 (CH3), 18.1* (C(Hd)), 17.6 (C(Hd)), 13.4 (C(Ha)(Hb)), 13.1* (C(Ha)(Hb)). HRMS 
(ES) m/z Calcd for C15H21N2O3S+ [M+H]+: 309.1273; Found: 309.1278. 
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(trans)-[2-(Benzenesulfonyl)cyclopropyl](3,4-dihydroquinolin-1(2H)-yl) 
methanone (138) 
 
 
 
mCPBA (104 mg, 0.60 mmol, 3.0 equiv) was added to a 25 °C solution of amide 87  
(62 mg, 0.20 mmol, 1.0 equiv) in CH2Cl2 (10 mL) and the solution stirred for 6 h. Water 
(30 mL) was added and the phases separated. The aqueous phase was extracted with 
Et2O (5 ´ 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (1:2 pentane:Et2O) gave sulfone 138 (67 mg, 98%) as a 
cream oil. Rf = 0.29 (1:2 pentane:Et2O). IR (film)/cm-1 3040 (CH), 2950 (CH), 1642 
(C=O), 1581, 1492, 1402, 1306, 1148, 911, 727. 1H NMR (400 MHz, CDCl3) d 7.85 (d, 
J = 7.5 Hz, 2 H, 2 ´ Ph-H), 7.67 (t, J = 7.5 Hz, 1 H, Ph-H), 7.57 (t, J = 7.5 Hz, 2 H, 2 ´ 
Ph-H), 7.25–7.20 (m, 4 H, 4 ´ Ar-H), 3.80–3.71 (m, 2 H, 2 ´ NC(H)H), 3.14 (ddd, J = 
8.6, 5.7, 5.5 Hz, 1 H, Hc), 2.93 (ddd, J = 9.6, 5.7, 4.6 Hz, 1 H, Hd), 2.76–2.63 (m,  
2 H, 2 ´ Ar-C(H)H), 2.01–1.86 (m, 2 H, 2 ´ NCH2C(H)H), 1.73 (ddd, J = 8.6, 5.8, 4.6 Hz, 
1 H, Hb), 1.65–1.63 (m, 1 H, Ha). 13C NMR (101 MHz, CDCl3) d 168.2 (C=O), 140.1 
(Ph-C quat + Ar-C quat), 137.9 (Ar-C quat), 133.7 (Ph-C), 129.4 (2 ´ Ph-C), 128.6 
(Ar-C), 127.6 (2 ´ Ph-C), 126.7 (Ar-C), 126.0 (Ar-C), 124.8 (Ar-C), 43.3 (CH2), 41.3 
(C(Hc)), 26.7 (CH2), 24.0 (CH2), 20.1 (C(Hd)), 14.2 (C(Ha)(Hb)). HRMS (ES) m/z Calcd 
for C19H20NO3S+ [M+H]+: 342.1164; Found: 342.1174. 
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(cis)-[2-(Benzenesulfonyl)cyclopropyl](4-methylpiperazin-1-yl)methanone (139) 
 
 
 
mCPBA (28 mg, 0.16 mmol, 3.0 equiv) was added to a 25 °C solution of amide 89 
(15 mg, 0.05 mmol, 1.0 equiv) in CH2Cl2 (2.7 mL) and the solution stirred for 6 h. Solid 
Na2S2O5 (31 mg, 3.0 equiv) was added and the mixture stirred for 30 min before being 
concentrated under reduced pressure. The mixture was redissolved in acetone 
containing 5% Et3N, then filtered. The filtrate was concentrated under reduced 
pressure then purified by flash column chromatography (3:7 MeOH:CH2Cl2 + 2% 
Et3N). The material was dissolved in CH2Cl2, filtered and concentrated under reduced 
pressure to give sulfone 139 (17 mg, quant) as a golden gum. Rf = 0.29 (3:7 
MeOH:CH2Cl2). IR (film)/cm-1 3032 (CH), 2947 (CH), 1643 (C=O), 1446, 1290 (S=O), 
1147, 730, 690. 1H NMR (400 MHz, CDCl3) d 7.90 (m, 2 H, 2 ´ Ph-H), 7.72–7.67 (m, 
1 H, Ph-H), 7.62–7.58 (m, 2 H, 2 ´ Ph-H), 4.68–4.64 (m, 1 H, NC(H)H), 4.26–4.22 (m, 
2 H, 2 ´ NC(H)H), 3.80–3.76 (m, 2 H, 2 ´ NC(H)H), 3.52–3.48 (m, 1 H, NC(H)H), 3.42 
(m, 1 H, NC(H)H), 3.37 (s, 3 H, CH3), 3.35–3.23 (m, 1 H, NC(H)H), 2.83 (ddd, J = 8.6, 
8.6, 6.6 Hz, 1 H, Hc), 2.34 (ddd, J = 8.6, 8.6, 7.2 Hz, 1 H, Hd), 1.97 (ddd, J = 7.2, 6.6, 
6.1 Hz, 1 H, Hb), 1.39 (ddd, J = 8.6, 8.6, 6.1 Hz, 1 H, Ha). 13C NMR (101 MHz, CDCl3) 
d 164.1 (C=O), 139.8 (Ph-C quat), 134.0 (Ph-C), 129.5 (2 ´ Ph-C), 127.6 (2 ´ Ph-C), 
64.5 (NCH2), 64.3 (NCH2), 59.6 (CH3), 40.4 (NCH2), 40.2 (C(Hc)), 36.6 (NCH2), 23.8 
(C(Hd)), 11.4 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C15H21N2O3S+ [M+H]+: 309.1273; 
Found: 309.1270. 
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(trans)-[2-(Benzenesulfonyl)cyclopropyl](3,4-dihydroquinolin-1(2H)-yl) 
methanone (140) 
 
 
mCPBA (78 mg, 0.45 mmol, 3.0 equiv) was added to a 25 °C solution of amide 90  
(47 mg, 0.15 mmol, 1.0 equiv) in CH2Cl2 (7.5 mL) and the solution stirred for 6 h. Water 
(30 mL) was added and the phases separated. The aqueous phase was extracted with 
Et2O (5 ´ 30 mL). The combined organic phases were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (Et2O) gave the sulfone 140 (44 mg, 86%) as a cream gum. 
Rf = 0.19 (Et2O). IR (film)/cm-1 3030 (CH), 2934 (CH), 1655 (C=O), 1581, 1491, 1403, 
1321 (S=O), 1291, 1150 (S=O), 1086, 727. 1H NMR (400 MHz, CDCl3) d 8.00–7.98 
(m, 2 H, 2 ´ Ph-H), 7.63 (t, J = 7.5 Hz, 1 H, Ph-H), 7.57 (t, J = 7.5 Hz, 2 H, 2 ´ Ph-H), 
7.16–7.14 (m, 4 H, 4 ´ Ar-H), 4.34 (br s, 1 H, NC(H)H), 3.40 (br s, 1 H, NC(H)H),  
2.80–2.70 (m, 3 H, Hc + 2 ´ Ar-C(H)H), 2.41–2.39 (m, 1 H, Hd), 2.18–2.09 (m, 1 H, 
NCH2C(H)H), 2.02 (br s, 1 H, Hb), 1.85 (br s, 1 H, NCH2C(H)H), 1.39–1.34 (m, 1 H, 
Ha). 13C NMR (101 MHz, CDCl3) d 164.8 (C=O), 140.4 (Ph-C quat + Ar-C quat), 133.9 
(Ar-C quat), 133.6 (Ph-C), 129.0 (2 ´ Ph-C), 128.4 (Ar-C), 128.1 (2 ´ Ph-C), 126.0 
(Ar-C), 125.5 (Ar-C), 124.2 (Ar-C), 43.6 (CH2), 42.6 (CH2), 26.8 (C(Hc)), 25.6 (C(Hd)), 
23.8 (CH2), 13.3 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C19H20NO3S+ [M+H]+: 
342.1164; Found: 342.1163. 
 
(trans)-Sodium 2-(pyridin-2-yl)cyclopropane-1-carboxylate (141) 
 
 
 
NaOH(aq) (1.0 M, 0.29 mL, 0.29 mmol, 1.2 equiv) was added to a 30 °C solution of  
(trans)-ethyl 2-(pyridin-2-yl)cyclopropane-1-carboxylate 134 (46 mg, 0.24 mmol, 
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1.0 equiv) in EtOH (1.2 mL) and the solution was stirred at 30 °C for 24 h. The red 
reaction mixture was concentrated under reduced pressure, then filtered, washing with 
acetone (50 mL). The filtrate was concentrated under reduced pressure to give 
cyclopropane 141 (44 mg, quant) as a red gum. IR (film)/cm-1 1644, 1560 (C=O), 1420, 
1371. 1H NMR (400 MHz, DMSO-d6) d 8.36 (d, J = 4.7 Hz, 1 H, Ar-H), 7.59 (dd, J = 
7.7, 7.3 Hz, 1 H, Ar-H), 7.21 (d, J = 7.7 Hz, 1 H, Ar-H), 7.08 (dd, J = 7.3, 4.7 Hz, 1 H, 
Ar-H), 2.25 (ddd, J = 8.8, 5.4, 5.3 Hz, 1 H, Hc), 1.70 (ddd, J = 8.2, 5.4, 4.1 Hz, 1 H, 
Hd), 1.21 (ddd, J = 8.2, 5.3, 2.4 Hz, 1 H, Ha), 1.16–1.07 (m, 1 H, Hb). 13C NMR 
(101 MHz, DMSO-d6) d 176.1 (C=O), 161.7 (Ar-C quat), 148.9 (Ar-C), 135.9 (Ar-C), 
121.4 (Ar-C), 120.4 (Ar-C), 29.2 (C(Hd)), 25.2 (C(Hc)), 16.2 (C(Ha)(Hb)). HRMS (ES) 
m/z Calcd for C9H10NO2+ [M-Na+2H]+: 164.0712; Found: 164.0718. 
 
(trans)-[2-(Pyridin-2-yl)cyclopropyl](pyrrolidin-1-yl)methanone (142) 
 
 
 
HATU (49 mg, 0.13 mmol, 1.2 equiv) was added to a solution of (trans)-sodium 2-
(pyridin-2-yl)cyclopropane-1-carboxylate 141 (20 mg, 0.11 mmol, 1.0 equiv) in 
N,N-dimethylformamide (540 µL) and the resultant red solution was stirred at 40 °C 
for 10 min. Pyrrolidine (11 µL, 0.13 mmol, 1.2 equiv) was added and the solution stirred 
for 20 min. Diisopropylethylamine (56 µL, 0.32 mmol, 3.0 equiv) was added and the 
solution stirred for 24 h. H2O (10 mL) was added and the mixture extracted with EtOAc 
(5 ´ 10 mL). The combined organic phases were washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (1:2 pentane:Et2O) gave cyclopropane 142  
(19 mg, 82%) as a yellow gum. Rf = 0.27 (1:2 pentane:Et2O). IR (film)/cm-1 2954 (CH), 
2923 (CH), 2854 (CH), 1741 (C=O), 1596, 1460, 1375, 1220, 964, 803. 1H NMR 
(400 MHz, CDCl3) d 8.45 (d, J = 4.4 Hz, 1 H, Ar-H), 7.56 (ddd, J = 7.9, 7.7, 1.5 Hz, 
1 H, Ar-H), 7.29 (d, J = 7.9 Hz, 1 H, Ar-H), 7.09–7.06 (m, 1 H, Ar-H), 2.58 (ddd, J = 
9.0, 5.5, 4.3 Hz, 1 H, Hc), 2.41 (ddd, J = 8.9, 5.7, 4.3 Hz, 1 H, Hd), 1.58 (ddd, J = 8.9, 
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5.5, 3.4 Hz, 1 H, Ha), 1.48 (ddd, J = 9.0, 5.7, 3.4 Hz, 1 H, Hb), 1.34–1.22 (m, 8 H, 4 ´ 
CH2). 13C NMR (101 MHz, CDCl3) d 160.2 (C=O), 149.3 (Ar-C), 135.9 (Ar-C), 125.5 
(Ar-C quat), 122.9 (Ar-C), 120.9 (Ar-C), 45.6 (NCH2), 29.7 (NCH2), 25.8 (C(Hc)), 25.3 
(C(Hd)), 21.6 (NCH2CH2), 20.7 (NCH2CH2), 17.2 (C(Ha)(Hb)). FTMS (+p NSI) m/z 
Calcd for C13H17N2O+ [M+H]+: 217.1335; Found: 217.1336. 
 
(cis)-Ethyl 2-[1-(benzenesulfonyl)-1H-indol-3-yl]cyclopropane-1-carboxylate 
(143) 
 
 
 
i-PrMgCl (1.20 mL, 1.85 M in THF, 2.25 mmol, 1.5 equiv) was added to a -78 °C 
solution of (cis)-ethyl 2-(phenylsulfinyl)cyclopropanecarboxylate 97 (358 mg, 
1.5 mmol, 1.0 equiv) in THF (15 mL) over 10 s and the solution stirred for 10 min. A 
mixture of Pd2(dba)3 (35 mg, 0.04 mmol, 2.5 mol%), (t-Bu)3P (17 mg, 0.08 mmol, 
5.5 mol%) and ZnCl2 (308 mg, 2.25 mmol, 1.5 equiv) in THF (1.9 mL) was added and 
the solution stirred at 0 °C for 1 h. A solution of 3-bromo-(1-phenylsulfonyl)indole 
(1.00 g, 3.00 mmol, 2.0 equiv) in THF (2.0 mL) was added and the reaction stirred at 
25 °C for 15 h. MeOH (5 mL) was added and the mixture stirred for 15 min. The mixture 
was filtered through a pad of silica, washing with CH2Cl2 (200 mL). Concentration 
under reduced pressure followed by purification by flash column chromatography (5:1 
pentane:EtOAc) gave cyclopropane 143 (414 mg, 75%) as a colourless gum. Rf = 0.24 
(5:1 pentane:EtOAc). IR (film)/cm-1 3065 (CH), 2931 (CH), 1721 (C=O), 1447, 1366 
(S=O), 1170 (S=O), 1124, 1092, 980, 734, 684. 1H NMR (400 MHz, CDCl3) d 7.92 (d, 
J = 8.2 Hz, 1 H, Ar-H), 7.87–7.84 (m, 2 H, 2 ´ Ar-H), 7.59–7.57 (m, 1 H, Ar-H), 
7.52–7.48 (m, 1 H, Ar-H), 7.44–7.40 (m, 3 H, 3 ´ Ar-H), 7.30–7.26 (ddd, J = 7.4, 7.4, 
1.3 Hz, 1 H, Ar-H), 7.24–7.20 (ddd, J = 7.4, 7.4, 1.0 Hz, 1 H, Ar-H), 3.78–3.63 (m, 2 H, 
CH2CH3), 2.43 (m, 1 H, Hc), 2.18 (ddd, J = 8.8, 8.0, 5.5 Hz, 1 H, Hd), 1.65 (ddd, J = 
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7.2, 5.5, 5.1 Hz, 1 H, Hb), 1.42 (ddd, J = 8.6, 8.0, 5.1 Hz, 1 H, Ha), 0.73 (t, J = 7.1 Hz, 
3 H, CH3). 13C NMR (101 MHz, CDCl3) d 170.4 (C=O), 138.1 (Ar-C quat), 135.0 (Ar-C 
quat), 133.5 (Ar-C), 131.5 (Ar-C quat), 129.1 (2 ´ Ar-C), 126.8 (2 ´ Ar-C), 125.0 (Ar-C), 
124.7 (Ar-C), 123.1 (Ar-C), 119.4 (Ar-C), 118.9 (Ar-C quat), 113.6 (Ar-C), 60.1 
(CH2CH3), 20.7 (C(Hd)), 15.5 (C(Hc)), 13.7 (CH3), 11.1 (C(Ha)(Hb)). HRMS (ES) m/z 
Calcd for C20H20NO4S+ [M+H]+: 370.1113; Found: 370.1114. The observed data (1H, 
13C) was consistent with that previously reported.344 
 
(cis)-{2-[1-(Benzenesulfonyl)-1H-indol-3-yl]cyclopropyl}methanol (144) 
 
 
 
Lithium aluminium tetrahydride (1.0 M in THF, 1.35 mL, 1.35 mmol, 2.5 equiv) was 
added dropwise over 5 min to a 0 °C solution of (cis)-ethyl 2-[1-(benzenesulfonyl)-1H-
indol-3-yl]cyclopropane-1-carboxylate 143 (200 mg, 0.54 mmol, 1.0 equiv) in THF 
(0.68 mL) and the solution stirred at 0 °C for 10 min. The solution was warmed to 25 °C 
and stirred for 3 h. The reaction mixture was cooled to 0 °C, EtOAc (7 ml) was added 
and the mixture stirred for 15 min. The mixture was warmed to 25 °C, sat. aq. 
potassium sodium tartrate (15 mL) was added and the mixture stirred for 1 h. The 
organic phase was separated, and the aqueous phase extracted with Et2O (5 ´ 10 mL). 
The combined organic phases were washed with brine (20 mL), dried (MgSO4), filtered 
and concentrated under reduced pressure. Purification by flash column 
chromatography (1:3 pentane:Et2O) gave cyclopropane 144 (166 mg, 94%) as a 
yellow gum. Rf (Et2O) = 0.44. IR (film)/cm-1 3387 (OH), 3117 (CH), 3067 (CH), 2923 
(CH), 1447, 1366 (S=O), 1173 (S=O), 1124, 1096, 739, 685. 1H NMR (400 MHz, 
CDCl3) d 8.00 (d, J = 8.2 Hz, 1 H, Ar-H), 7.86–7.84 (m, 2 H, 2 ´ Ar-H), 7.65 (d, J = 
7.7 Hz, 1 H, Ar-H), 7.54 (t, J = 7.4 Hz, 1 H, Ar-H), 7.44 (t, J = 7.7 Hz, 2 H, 2 ´ Ar-H), 
7.37–7.33 (m, 1 H, Ar-H), 7.30–7.29 (m, 2 H, Ar-H), 3.51–3.48 (m, 1 H, CH(H)OH), 
3.12–3.07 (m, 1 H, CH(H)OH), 2.12–2.06 (m, 1 H, Hd), 1.64–1.55 (m, 1 H, Hc), 1.15 
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(ddd, J = 8.3, 8.3, 5.5 Hz, 1 H, Ha), 0.88 (br s, 1 H, OH), 0.75 (q, J = 5.5 Hz, 1 H, Hb). 
13C NMR (101 MHz, CDCl3) d 138.0 (Ar-C quat), 135.5 (Ar-C quat), 133.8 (Ar-C), 131.7 
(Ar-C quat), 129.2 (2 ´ Ar-C), 126.6 (2 ´ Ar-C), 125.2 (Ar-C), 124.0 (Ar-C), 123.6 
(Ar-C), 121.1 (Ar-C quat), 119.4 (Ar-C), 113.9 (Ar-C), 62.7 (CH2OH), 19.9 (C(Hc)), 10.8 
(C(Hd)), 7.6 (C(Ha)(Hb)). HRMS (ES) m/z Calcd for C18H18NO3S+ [M+H]+: 328.1007; 
Found: 328.1007. 
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4.3. Chiral HPLC Data for Enantiopure Cyclopropanes (1S,2R)-15, 
(1R,2S)-15, (1S,2S)-16 and (1R,2R)-16 
 
A.      Ethyl (1S,2R)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate 
 
 
B.      Ethyl (1R,2S)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate 
 
Figure 54: Chiral SFC traces for A. ethyl (1S,2R)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate and B. ethyl 
(1R,2S)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate post-separation. Absolute configurations were determined 
by X-ray crystallography of the corresponding enantiopure sulfone. Conditions: ADH column, 94:6 CO2:MeOH,  
flow = 5.0 mL min-1, pressure = 100 bar, temperature = 35 °C, UV detection at 220 nm. 
Date & Time: 28/04/2015 09:33:18
Chromatogram Name:  64J-E13842-021-355-4-AT1_2
Method Name:  64J-E13842-021-355-4
Operator:  AT Group
Instrument: SFC MiniGram
AT Portal ID: YEL11368-28/04/2015-09:41:51-64J-E13842-021-355-4
Vial Number: 8
Injection Volume: 10.000 ul
Sample Name: 64J-E13842-021-355-4-AT1
Column: AD-H
Mobile Phase: 6% MeOH (no additive)
Flow: 5 (ml/min)
Pressure: 100 (bar)
Temperature: 35 (C)
Wavelength: 220 (nm)
Comments: 6% MeOH, AD-H (4.6 x 100mm, 5u) 
CCP4760.tmp.DAT - Detector 1 Signal (UV)
Min
210
m
AU
450
400
350
300
250
200
150
100
50
0
-50
0.
78
Index
1
Total
Time
[Min]
0.78
 
Width 10%
[Min]
0.09
 
Height
[mAU]
446.59
 
Area
[mAU*min]
23.25
23.25
Area
[%]
100.000
100.000
Date & Time: 28/04/2015 09:28:37
Chromatogram Name:  64J-E13842-021-355-4-AT2_1
Method Name:  64J-E13842-021-355-4
Operator:  AT Group
Instrument: SFC MiniGram
AT Portal ID: YEL11368-28/04/2015-09:42:37-64J-E13842-021-355-4
Vial Number: 9
Injection Volume: 10.000 ul
Sample Name: 64J-E13842-021-355-4-AT2
Column: AD-H
Mobile Phase: 6% MeOH (no additive)
Flow: 5 (ml/min)
Pressure: 100 (bar)
Temperature: 35 (C)
Wavelength: 220 (nm)
Comments: 6% MeOH, AD-H (4.6 x 100mm, 5u) 
CCP4761.tmp.DAT - Detector 1 Signal (UV)
Min
210
m
AU
500
450
400
350
300
250
200
150
100
50
0
-50
0.
78
0.
91
Index
1
2
Total
Time
[Min]
0.78
0.91
 
Width 10%
[Min]
0.09
0.10
 
Height
[mAU]
8.30
489.30
 
Area
[mAU*min]
0.40
27.14
27.54
Area
[%]
1.451
98.549
100.000
S
Ph
EtO O
S
Ph
EtO O
  260 
A.   Ethyl (1S,2S)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate 
 
 
B.      Ethyl (1R,2R)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate 
 
Figure 55: Chiral SFC traces for A. ethyl (1S,2S)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate and B. ethyl 
(1R,2R)-2-(phenylsulfanyl)-cyclopropane-1-carboxylate post-separation. Absolute configurations were determined 
by X-ray crystallography of the corresponding enantiopure sulfone. Conditions: ADH column, 92:8 CO2:EtOH + 1% 
(2 M NH3 in MeOH, flow = 5.0 mL min-1, pressure = 100 bar, temperature = 35 °C, UV detection at 220 nm. 
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Cyclopropanes
Divergent Synthesis of Cyclopropane-Containing Lead-Like
Compounds, Fragments and Building Blocks through a Cobalt
Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide
Stephen J. Chawner,[a] Manuel J. Cases-Thomas,[b] and James A. Bull*[a]
Abstract: Cyclopropanes provide important design elements in
medicinal chemistry and are widely present in drug com-
pounds. Here we describe a strategy and extensive synthetic
studies for the preparation of a diverse collection of cyclo-
propane-containing lead-like compounds, fragments and build-
ing blocks exploiting a single precursor. The bifunctional cyclo-
propane (E/Z)-ethyl 2-(phenylsulfanyl)-cyclopropane-1-carb-
oxylate was designed to allow derivatization through the ester
and sulfide functionalities to topologically varied compounds
designed to fit in desirable chemical space for drug discovery.
A cobalt-catalyzed cyclopropanation of phenyl vinyl sulfide af-
fords these scaffolds on multigram scale. Divergent, orthogonal
Introduction
A limitation in examining new, challenging pharmaceutical tar-
gets is the availability of innovative, novel fragments and build-
ing blocks that possess desirable physicochemical properties,
and sample new regions of chemical space.[1] Recent years have
seen a focus on smaller, more polar compounds and less planar,
sp3-rich derivatives containing fewer aromatic rings, perceived
to be more likely to successfully progress through drug devel-
opment.[2,3] New synthetic strategies and methods can enable
chemical space to be probed more effectively by enriching cur-
rent lead-like and fragment compound libraries with com-
pounds that can present new design elements and novel bond
vectors.[1,4,5]
Late-stage compound attrition, particularly within phase II
and phase III clinical trials, is extremely costly to the drug dis-
covery industry, with the cost of ensuring appropriate molec-
ular properties at a much earlier stage of development being
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derivatization is achieved through hydrolysis, reduction, amid-
ation and oxidation reactions as well as sulfoxide–magnesium
exchange/functionalization. The cyclopropyl Grignard reagent
formed from sulfoxide exchange is stable at 0 °C for > 2 h,
which enables trapping with various electrophiles and Pd-cata-
lyzed Negishi cross-coupling reactions. The library prepared, as
well as a further virtual elaboration, is analyzed against parame-
ters of lipophilicity (ALog P), MW and molecular shape by using
the LLAMA (Lead-Likeness and Molecular Analysis) software, to
illustrate the success in generating lead-like compounds and
fragments.
significantly lower.[6] Hence, attractive screening collections can
offer significant value. Considerable effort has been expended
in developing guidelines to describe and influence compound
collections, which are frequently used to aid in the develop-
ment of a compound, aiming to predispose derivatives to fall
into regions of desirable chemical space.[3a,7] Relevant parame-
ters of interest include lipophilicity (Log P), molecular weight
(MW), number of rotatable bonds, polar surface area (PSA) and
the numbers of hydrogen-bond donors and acceptors (HBD/
HBA), and consideration of these has given rise to the terms
drug-like, lead-like and fragment to describe screening com-
pounds.[7,8]
The cyclopropane motif is highly significant in drug discov-
ery as the 10th most frequently found ring system in small mol-
ecule drugs.[9,10] It is also present in a variety of biologically
active natural products and other medicinally-important mol-
ecules (Figure 1).[11,12] Substituted cyclopropanes present a
well-defined 3-dimensional shape, conformational rigidity, and
electronic properties in between that of an alkene and a gem-
dimethyl group, for example, as a result of the small strained
ring structure.
The synthesis of cyclopropane derivatives has been exten-
sively investigated, exploiting numerous powerful synthetic
methods (Figure 2a).[13] Cyclopropanes bearing functional
groups have been generated through Simmons–Smith cyclo-
propanation,[14,15] transition metal-catalyzed carbene insertion
to alkenes using diazo compounds,[16,17] and the reaction of
sulfur ylides with electron deficient alkenes.[18] Furthermore, the
cross-coupling of cyclopropyl organometallic or (pseudo)halide
species has been exploited as a more divergent approach to
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Figure 1. Selected cyclopropane-containing natural products and pharmaceu-
tical compounds.
cyclopropane derivatives through functionalization of the
ring.[19] Most recently this has been extended to include power-
ful C–H functionalization methods.[20]
Figure 2. Strategies for the synthesis of cyclopropanes and designed bifunc-
tional cyclopropane building blocks.
We proposed that a divergent route to cyclopropane con-
taining lead-like compounds and fragments would present a
valuable approach to a novel screening collection. Furthermore,
this approach would provide interesting building blocks that
may be more generally applicable for the construction of cyclo-
Eur. J. Org. Chem. 2017, 5015–5024 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5016
propane derivatives. As such we targeted small bifunctional
cyclopropane-containing scaffolds (Figure 2b).
Here we report the development of (E)- and (Z)-ethyl 2-
(phenylsulfanyl)-cyclopropane-1-carboxylate as cyclopropane
scaffolds and extensive studies on the bidirectional functionali-
zation. Derivatization of these scaffolds affords a collection of
lead-like and fragment compounds as well as further building
blocks for the preparation of cyclopropane derivatives. High-
lights include a cobalt-catalyzed cyclopropanation of phenyl
vinyl sulfide, formation of amido-cyclopropyl sulfones, and gen-
eration of cyclopropyl Grignard reagent through sulfoxide–
metal exchange followed by reaction with various electrophiles
and use in Pd-catalyzed Negishi cross-coupling reactions. Fi-
nally, we present analysis on the physicochemical properties
and molecular shape of the compounds prepared, to illustrate
that these scaffolds afford medicinally relevant, non-planar
compounds that occupy desirable chemical space.
Results and Discussion
Scaffold Design and Hypothesis
We envisaged that a wide variety of medicinally-relevant cyclo-
propane-containing compounds could be prepared in a diver-
gent manner from a single central bifunctional cyclopropyl scaf-
fold. For this we required a low molecular weight scaffold that
could be easily derivatized to lead-like compounds or frag-
ments, and functionalized in two directions, ideally through
bond formation to the cyclopropane ring itself. The two scaffold
functionalities should undergo derivatization orthogonally,
granting access to a wide and diverse scope of functionality
on the ring. We considered (E)- and (Z)-ethyl 2-(phenylsulfanyl)-
cyclopropane-1-carboxylates would meet these criteria, and
provide suitable building blocks through functionalization of
the ester or sulfide groups (Figure 2c). Especially valuable would
be the potential to convert the sulfide to the sulfoxide and
exploit sulfoxide–magnesium exchange to form bonds directly
to the cyclopropane ring.[21–23] Both the E- and Z-diastereoiso-
mers were of interest, possessing very different bond vectors,
to increase the shape diversity of the compounds. Hence, the
first objective was to prepare these building blocks on a large
scale.
Cyclopropanation of Phenyl Vinyl Sulfide
To generate cyclopropyl scaffolds 1 and 2 we envisaged the
reaction of phenyl vinyl sulfide (PVS) with ethyl diazoacetate
(EDA) in a transition metal-catalyzed cyclopropanation
(Scheme 1). The only prior report of the cyclopropanation of
PVS with EDA was in 1962; an uncatalyzed reaction requiring
heating of the neat reactants at 100 to 170 °C in a sealed ves-
sel.[24–26] In search of less hazardous, lower temperature reac-
tion conditions suitable for multi-gram scale, transition metal
catalysts were investigated. Initially complexes of Pd0, Rh0, CuI
and CuII were explored for catalytic activity (see the Supporting
Information for further details).
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Scheme 1. Proposed synthesis of E- and Z-cyclopropyl scaffolds.
From the initial screening, only CuIOTf (0.5 mol-%) promoted
the reaction effectively, and a yield of up to 54 % was obtained
by running the reaction in CHCl3 at 30 °C with a slow addition
of the diazo compound. A mixture of trans and cis substituted
cyclopropanes were formed in a 1:1 ratio. These were readily
separated to single diastereoisomers. However, the relatively
low yield and exacting practical considerations detracted from
the reaction convenience and this approach was not suitable
for scale-up. Pleasingly on further investigation, CoII–(salen)-
type complex 3 was found to catalyze the desired cyclopropan-
ation (Scheme 1).[17,27] The use of 5 mol-% of the CoII complex,
in CH2Cl2 at 40 °C gave 40 % yield in 24 h (Table 1, entry 1). As
has been observed with other Co-catalyzed cyclopropanation
reactions using diazo compounds,[17] the reactions were facile
to set up and the catalyst was easily stored and did not result
in dimerization of the diazo reagent under the reaction condi-
tions, removing the need for a slow addition protocol.
Table 1. Effect of solvent and reaction scale on the CoII-catalyzed cycloprop-
anation reaction.
Entry[a] Solvent dr Yield 1 + 2
(trans 1/cis 2)[b] [%][c]
1 CH2Cl2 52:48 40
2 CHCl3 48:52 13
3 toluene 45:55 53
4 benzene 48:52 73
5 TBME 48:52 69
6 neat 46:54 93
7 H2O 47:53 100
8[d] Neat 53:47[e] 70[f ]
9[g] Neat 52:48[e] 46[f ]
10[d] H2O 45:55[e] 85[f ]
11[h] H2O 46:54[e] 89[f,i]
[a] Reaction conditions: EDA (0.3 mmol); PVS. (1.5 equiv.), catalyst 3 (5 mol-
%), solvent, 40 °C, 24 h. [b] Calculated from the crude reaction mixture by 1H
NMR unless stated otherwise. [c] Yields were calculated using 1H NMR by
comparison with an internal standard (dibenzyl ether) unless stated other-
wise. [d] 10 mmol scale. [e] dr from isolated masses. [f ] Combined yield of
separated isolated products. [g] 20 mmol scale. [h] 40 mmol scale. [i] Corre-
sponds to 7.9 g of product (1 + 2).
To optimize the promising CoII-catalyzed reaction a solvent
screen was conducted (Table 1). Cyclopropanes 1 and 2 were
observed under each set of conditions tested (Entries 1–7), but
the reaction was most efficient in the absence of a solvent (En-
Eur. J. Org. Chem. 2017, 5015–5024 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5017
try 6) or on water, which gave quantitative yield (Entry 7). Both
E- and Z-products were formed in approximately equal amounts
providing both diastereoisomers for further functionalization,
as was desired for a divergent strategy.
Excellent yields were observed both for the reaction without
solvent or run on H2O, up to a 10 mmol scale (Table 1, entries
6–8, 10). However, when the neat cyclopropanation was carried
out at scales greater than 10 mmol, an exotherm was observed
with concomitant gas evolution and a significant decrease in
yield (Table 1, entry 9). This was not observed when the reac-
tion was carried out on water, and under these conditions reac-
tion on a 40 mmol scale afforded excellent yields without indi-
cation of a significant increase in temperature.
Purification and separation of the diastereoisomers was facile
on smaller scales, but on larger scale, separation of a catalyst
derived impurity became problematic. This was resolved
through modification of the work-up procedure: bubbling air
through a diluted reaction mixture oxidized the remaining CoII
catalyst to a putative CoIII–peroxo-bridged dimer[28] which was
simply removed by filtration through a pad of silica. The rate of
CoII oxidation was highly dependent on the diluent due to dif-
ferent oxygen permeability, dissolution capability and coordi-
nating effects of the solvents, with isohexane performing best
(see the Supporting Information for further details).[29] This pro-
tocol, diluting the reaction with isohexane then bubbling air
through the solvent for 15 min followed by filtration through
silica, enabled facile removal of the catalyst and derived impuri-
ties and then separation of the diastereoisomers by flash chro-
matography. Approximately 4 g of each separated diastereo-
isomer was readily formed in a single run (Table 1, entry 11).
The enantiomers of both diastereoisomers were also readily
separated by preparative chiral supercritical fluid chromatogra-
phy (SFC) to afford all four possible stereoisomers, each in
Figure 3. Enantiomerically pure cyclopropyl sulfides were obtained by prepar-
ative chiral SFC and analysed by X-ray crystallography of the corresponding
sulfones.
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≥ 97 % ee. Whereas the sulfides were oils, the corresponding
cyclopropyl sulfones (vide infra) were crystalline. Absolute con-
figurations and structural confirmation of the sulfones and
hence precursor sulfides was proven through single-crystal X-
ray diffraction analysis (Figure 3).[30]
This separation approach provided highly enantioenriched
compounds 1 and 2, hence granting access to each derivative
as a single enantiomer. As an alternative approach to generate
the enantioenriched cyclopropane derivatives, chiral CuI and
CoII catalysts were investigated (see the Supporting Information
for further details). Enantioenriched catalyst 3 afforded moder-
ate ee values for both the trans and cis compounds (52 % ee 1
and 77 % ee 2, in H2O at 20 °C, 57 % overall yield). However,
this was not the focus of this study, and for the derivatization
reactions presented below the racemate was used to form a
racemic screening set.
Sulfide Oxidation and Ester Functionalization
With a practical, high yielding and scalable route to cyclopropyl
scaffolds 1 and 2, functionalization of the sulfide and ester
groups was examined. Oxidation of the sulfide to the sulfone
was readily achieved in quantitative yield using excess mCPBA
(Scheme 2). This provided a short route to the functionalized
cyclopropyl sulfone derivatives as single diastereoisomers,
themselves interesting motifs in biologically active com-
pounds.[31,32] Using 1 equiv. mCPBA at 0 °C gave sulfoxides 6
and 7 in high yields as a mixture of diastereoisomers at
sulfur,[33,34] and as important compounds for our envisaged
sulfoxide exchange strategy.
Scheme 2. Scaffold derivatization by oxidation, reduction or hydrolysis.
The ethyl ester was readily hydrolyzed to the carboxylic acid
using sodium hydroxide, for both diastereoisomers (Scheme 2).
Alternatively, reduction with LiAlH4 gave the primary alcohol-
cyclopropyl sulfide in high yields. To form the cyclopropyl
amides, the cyclopropyl carboxylate salt was reacted directly,
using a method described by Batey.[35] Under the same condi-
Eur. J. Org. Chem. 2017, 5015–5024 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5018
tions used for hydrolysis above, the reaction mixture was evap-
orated to form the carboxylate salt in quantitative yield, which
was itself characterized. This was applied directly in a HATU-
promoted amidation reaction to form a series of amides 14a–
14d from trans-cyclopropane 1, and 15a–15d from cis-2. Such
motifs are widely found in biologically active molecules (for ex-
ample see Figure 1). A selection of the resulting cyclopropyl
amides was oxidized to the corresponding sulfones to generate
further interesting compounds with desirable physicochemical
properties for drug discovery (16c,d and 17c,d). For compounds
16c and 17c, aqueous work-up proved problematic due to high
water solubility. This issue was overcome by an aqueous-free
work-up. Excess mCPBA was quenched by the addition of solid
Na2S2O5 to the reaction, which was followed by removal of the
reaction solvent, redissolution in acetone containing 5 % Et3N
and filtration. Under this procedure, after collection of the fil-
trate, all mCPBA derived materials had been removed, providing
the sulfones in excellent purity and yield. All of the transforma-
tions described were achieved without any epimerization to the
corresponding diastereoisomers, as indicated by 1H NMR
(Scheme 3).
Scheme 3. Synthesis of amide-substituted cyclopropanes through amidation
and oxidation. Yields for 14/15 quoted over 2 steps from 1/2.
Stability and Reactions of Cyclopropylmagnesium
Reagents Generated by Sulfoxide–Magnesium Exchange
A key aspect of our approach was that for increased diversity,
the position of the sulfur group should be functionalizable,
through its removal, in order to form bonds directly to the cy-
clopropyl ring. We intended to utilize cyclopropyl sulfoxides,
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and a sulfoxide–metal exchange strategy to allow functionaliza-
tion of the anion.
Sulfoxide–metal exchange has been used to generate three-
membered ring organometallics, in the form of cycloprop-
anes,[21,36] aziridines,[22] and epoxides,[23] for reaction with lim-
ited examples of reactive electrophiles or protonation. Knochel
has previously reported halogen–metal exchange to generate
cis-[2-(ethoxycarbonyl)-cyclopropyl]magnesium chloride,[37,38]
comparable to the Grignard reagent that would be generated
from 2 by sulfoxide–magnesium exchange. In the Knochel
work, coordination between the ester and the Lewis acidic
magnesium atom was proposed. Therefore, we concentrated
our efforts on optimizing the exchange for the trans-derivative,
where such a potentially stabilizing interaction would not be
possible.
Early investigation of this reaction showed that iPrMgCl
formed the putative cyclopropyl Grignard reagent 18 from
cyclopropane 6 efficiently at –78 °C, also generating isopropyl
phenyl sulfoxide. Trapping the intermediate using I2 gave cyclo-
propyl iodide 19a as a single trans-diastereoisomer. Impor-
tantly, the reaction proceeded with retention of configuration
for both the E- and the Z-cyclopropyl sulfoxides.[39]
To maximize the reactivity of the organometallic species
while avoiding degradation, we assessed both the time re-
quired for the exchange to go to completion, and the stability
of the cyclopropyl Grignard intermediate species. Sulfoxide–
magnesium exchange reactions were conducted on cyclo-
propane 6 using iPrMgCl and iPrMgCl·LiCl,[40] trapping with mo-
lecular iodine at –78 °C after different time periods (Figure 4a).
This study led to several observations i) the exchange was
complete in 10 min, ii) the cyclopropyl Grignard reagent was
stable for at least 2 hours at –78 °C prior to the addition of the
electrophile, and iii) similar yields were obtained for the reac-
tions using iPrMgCl and iPrMgCl·LiCl at each time point, indicat-
ing the addition of LiCl did not provide an advantage. Next, we
investigated the thermal stability of the Grignard intermediate
by conducting the sulfoxide–magnesium exchange with
iPrMgCl at –78 °C (10 min), then incubating the reaction mixture
at either –30, 0 or 25 °C for different time periods, prior to
trapping at this temperature (Figure 4b). Pleasingly, the cyclo-
propyl intermediate was stable for over 2 h at temperatures up
to 0 °C. However, at 25 °C significant decomposition was ob-
served, which corresponded to a reduction of product yield by
half after approximately 45 min of incubation, and <25 % yield
after 2 h. Following this study, various electrophiles were inves-
tigated, trapping at 0 °C to maximize the reactivity. Both the E-
and the Z-cyclopropyl sulfoxides could be trapped efficiently
with I2 to generate cyclopropanes 19a and 20a (Scheme 4).
With these exchange conditions in hand, a wide range of
electrophiles were examined, intending to generate varied
cyclopropane containing structures (Scheme 4). The Grignard
reagent 18 originating from E-cyclopropyl sulfoxide 6 could be
trapped efficiently with aliphatic, aromatic and heteroaromatic
aldehydes in excellent yields (19b–19d). Dialkyl, diaryl and di-
heteroaryl ketones also proceeded in good to excellent yields
(19e–19g). Electrophilic trapping of the cyclopropyl Grignard
was observed with benzoyl chloride to give the cyclopropyl ket-
Eur. J. Org. Chem. 2017, 5015–5024 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5019
Figure 4. a) The effect of using iPrMgCl or iPrMgCl·LiCl on the stability of the
cyclopropyl organometallic intermediate after various exchange periods. b)
The effect of temperature on the stability of the cyclopropyl organometallic
intermediate after various incubation periods.
one (19h). Trapping with phenyl isocyanate generated the
cyclopropyl amide (19i) and trapping with a disulfide gave the
corresponding cyclopropyl sulfide (19j). Finally, a series of po-
tential cyclopropane building-blocks were prepared. Trapping
with N,N-dimethylformamide allowed access to the cyclopropyl
aldehyde in an excellent yield (19k), an isopropoxy dioxaborol-
ane generated the corresponding cyclopropyl boronic ester
(19l) and trapping with chlorotriethoxysilane produced the tri-
ethoxysilylcyclopropane (19m). The Grignard reagent originat-
ing from the Z-cyclopropyl sulfoxide could also be trapped with
a similar series of electrophiles, generating diversely substituted
cis-cyclopropanes. Interestingly, it was observed that with cer-
tain aldehyde and ketone electrophiles initial electrophilic at-
tack was followed by lactonization to generate the bicyclic
product. Complete lactonization was observed to generate 20b,
20c and 20f, whereas alcohol 20g was the major product with
the dipyridyl ketone electrophile.
Next we explored a sulfoxide–magnesium exchange–Negishi
cross-coupling protocol to form (hetero)aryl cyclopropanes
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Scheme 4. Scope of electrophiles for the sulfoxide–magnesium exchange,
electrophilic trap protocol. [a] Trapping with I2. [b] From the corresponding
aldehyde. [c] From the corresponding ketone. [d] Using benzoyl chloride. [e]
Using phenylisocyanate. [f ] Using bis(4-methoxyphenyl)disulfide. [g] Using
DMF [h] Using (pin)BOiPr. [i] Using (EtO)3SiCl.
which are important pharmacophores.[12c] There are no prior
examples of cross-coupling between aryl halides and cyclo-
propyl organometallics derived from cyclopropyl sulfoxides.[21c]
We employed a protocol similar to that which we recently re-
ported for aziridine sulfoxides,[22e] and were delighted to ob-
serve the successful Negishi cross-coupling from both trans and
cis-cyclopropane derivatives with aryl bromides (Scheme 5).
The same sulfoxide–magnesium exchange protocol as devel-
oped above was used to generate the intermediate cyclopropyl
Grignard reagent. A mixture of Pd2(dba)3, (tBu)3P and ZnCl2
(1.5 equiv.) in THF was added and the mixture stirred for 1 h at
0 °C followed by the addition of the aryl bromide (2 equiv.).
The coupling of bromobenzene proceeded at 25 °C over 15 h
to give cyclopropanes 21a and 22a in excellent yields. Using
the trans-cyclopropyl sulfoxide, 1-bromo-4-chlorobenzene and
2-bromoanisole both gave high yields of the aryl-cyclopropanes
21b and 21c respectively. Cross-coupling with !-bromostyrene
gave an excellent yield of the corresponding vinyl cyclopropane
21d, which would be challenging to form through carbenoid
Eur. J. Org. Chem. 2017, 5015–5024 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5020
Scheme 5. Substrate scope for the sulfoxide–magnesium exchange–Negishi
cross-coupling protocol.
insertion to alkenes. It is notable that Lewis basic sites on elec-
tron-poor heterocycles as well as electron-rich heterocycles can
present difficulties in other cyclopropane strategies, hence
heteroaromatic bromides were investigated. Both electron-poor
and electron-rich heterocycles could be readily incorporated to
give pyridine, pyrimidine and indole cyclopropane derivatives
21e–21g respectively. cis-Cyclopropyl sulfoxide 7 also success-
fully underwent sulfoxide–magnesium exchange–Negishi cross-
coupling with a bromoindole to generate cis-cyclopropane
22h.
Finally, we chose to further elaborate compounds 21e and
22h through the remaining ester functionality (Scheme 6). From
pyridyl cyclopropane 21e, hydrolysis to give the E-cyclopropyl
carboxylate sodium salt 23 followed by amidation with pyrrol-
idine gave the corresponding cyclopropyl amide 24 in an 82 %
yield as a relatively complex yet low molecular weight frag-
ment. Similarly, reduction of indole-cyclopropyl ester 22h to
the primary alcohol 25 proceeded in a 94 % yield. Both 24 and
25 presented structural features related to biologically active
compounds shown in Figure 1, and were rapidly accessed as
interesting fragment and lead-like motifs.
Scheme 6. Synthesis of bifunctional cyclopropanes by utilizing both synthetic
handles.
Fragment and Lead-Likeness Analysis
The cyclopropane-containing compounds prepared in this
study were designed to possess desirable physicochemical
properties and sample new areas of chemical space for medici-
nal chemistry.[41,42] To illustrate the success of this approach the
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library was assessed against parameters of Alog P vs. MW, and
molecular shape through a principal moments of inertia (PMI)
plot,[43] calculated using the Lead-likeness and Molecular Analy-
sis (LLAMA) software, developed by Nelson and Marsden.[41] All
compounds prepared in this study were included with the ex-
ception of those considered reactive building blocks (iodides
19a and 20a, aldehyde 19k, pinacol boronates 19l and 20l,
and ethoxysilane 19m).[44] The molecular properties of the 50
included compounds were shown to explore efficiently lead-
like and fragment space (Figure 5).
Figure 5. The relationship between ALog P and MW for compounds prepared.
The PMI plot generated from the normalized ratios of princi-
pal moments of inertia calculated through LLAMA, showed that
Figure 6. PMI plot showing the shape distribution of the synthesized compounds. Some examples have been selected to illustrate the difference between
the E- and Z-diastereoisomers.
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the set of compounds possess varied 3-dimensional structures,
sampling chemical space away from the planar rod-like–disk-
like axis (Figure 6). The different 3-dimensional structures of
the E- and Z-diastereoisomers are exemplified by three sets of
compounds highlighted.
The powerful LLAMA software also executes virtual elabora-
tion of the molecular scaffolds and calculates the physicochemi-
cal properties of the resulting compounds.[41] This indicates the
potential of scaffolds to generate a much wider array of lead-
like or drug-like compounds through elaboration by common
reactions used in medicinal chemistry. The 56 cyclopropanes
prepared in this study, including this time those compounds
intended as building blocks, were examined as scaffolds in this
program. Given the presence of ester functionality in several of
the compounds in our study, a slight modification of default
decoration inputs was applied, by the addition of an ester
hydrolysis reaction option. Using the default set of 44 reactants
within LLAMA, and permitting up to 2 reactions on the scaf-
folds, 1187 cyclopropane-containing compounds were gener-
ated.[45] Of these, 392 examples had a molecular weight less
than 300 and 1033 examples had a molecular weight less than
500, indicative of fragment and drug-like space respectively. A
PMI plot of the decorated compounds shows that the full set
of elaborated compounds displayed highly varied topologies,
and were significantly removed from the often over-populated
region along the rod-like–disk-like axis (see Graph S2 in the
Supporting Information).[45]
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Conclusions
In conclusion, we have developed a strategy for preparing a
diverse range of cyclopropane-containing fragments, lead-like
compounds and building blocks from a readily accessible cyclo-
propyl scaffold. An operationally facile and scalable CoII-cata-
lyzed cyclopropanation of phenyl vinyl sulfide was developed
to prepare the bifunctional cyclopropyl scaffold. Divergent, or-
thogonal derivatization of the scaffold has been demonstrated
through hydrolysis, amidation, reduction and oxidation reac-
tions, as well as sulfoxide–magnesium exchange protocols. In-
vestigations into the stability of the cyclopropyl Grignard spe-
cies have led to successful trapping with a broad scope of elec-
trophiles. A sulfoxide–magnesium exchange–Negishi cross-cou-
pling protocol enables (hetero)aryl rings to be installed directly
onto the intact cyclopropane ring. Finally, we have presented
the calculated physicochemical properties of the synthesized
compounds and of potential derivatives which supports their
value as potential screening compounds.
Experimental Section
General Experimental Considerations: All non-aqueous reactions
were run under an inert atmosphere (argon) with flame-dried glass-
ware using standard techniques. Anhydrous solvents were obtained
by filtration through drying columns (THF, CH2Cl2, toluene, DMF).
Where applicable, room temp. denotes a room temperature of ap-
proximately 22 °C, and a specifically noted temperature e.g. “stirred
at 25 °C” indicates the stated temperature was accurately main-
tained. Flash column chromatography was performed using 230–
400 mesh silica with the indicated solvent system according to stan-
dard techniques. Analytical thin-layer chromatography (TLC) was
performed on precoated, glass-backed silica gel plates. Visualization
of the developed chromatogram was performed by UV absorbance
(254 nm), aqueous potassium permanganate, vanillin, ninhydrin or
p-anisaldehyde stains as appropriate.
Infrared spectra (ν˜max, FTIR ATR) were recorded in reciprocal centi-
meters [cm–1]. Nuclear magnetic resonance spectra were recorded
on 400 or 500 MHz spectrometers. Chemical shifts for 1H NMR spec-
tra are recorded in parts per million from tetramethylsilane with the
solvent resonance as the internal standard (chloroform: δ =
7.27 ppm, DMSO: δ = 2.50 ppm). Data is reported as follows: chemi-
cal shift [multiplicity (s = singlet, d = doublet, t = triplet, m = multi-
plet and br = broad), coupling constant in Hz, integration, assign-
ment]. 13C NMR spectra were recorded with complete proton
decoupling. Chemical shifts are reported in parts per million from
tetramethylsilane with the solvent resonance as the internal stan-
dard [13CDCl3: δ = 77.0 ppm, (13CD3)2SO: δ = 39.5 ppm]. J values
are reported in Hz. Assignments of 1H and 13C spectra were based
upon the analysis of δ and J values, as well as COSY, HSQC, HMBC
and NOESY experiments where appropriate. Melting points are un-
corrected. Optical rotations (α′) were recorded at the indicated tem-
perature (T °C) and were converted into the corresponding specific
rotations [α]DT . Commercial reagents were used as supplied or puri-
fied by standard techniques where necessary. Use of Diazo Com-
pounds: Although we have not experienced any problems in the
handling or reaction of diazo reagents, extreme care should be
taken when manipulating them due to their potentially explosive
nature. CoII-Catalyzed Cyclopropanation: For the CoII-catalyzed pro-
cedure, no special precautions were taken to exclude air or moisture
from the catalyst during storage or handling. After all reagents were
Eur. J. Org. Chem. 2017, 5015–5024 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5022
added the reaction vessel was sealed with either a crimp seal micro-
wave vial lid with a septum, or a suba seal and the reaction vessel
flushed with Ar(g). Ar(g) flushed, deflated balloons were attached to
the flask, so that the total potential volume of the balloons when
inflated was greater than the volume of N2(g) evolved from the reac-
tion. On scales where ≥ 10 mmol of diazo compound were used, a
precautionary blast shield was placed between the reaction flask
and the fume hood sash.
Supporting Information (see footnote on the first page of this
article): Further details can be found in Supporting Information.
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